<SEC-DOCUMENT>0000875045-16-000050.txt : 20160421
<SEC-HEADER>0000875045-16-000050.hdr.sgml : 20160421
<ACCEPTANCE-DATETIME>20160421165752
ACCESSION NUMBER:		0000875045-16-000050
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		117
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160421
DATE AS OF CHANGE:		20160421

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		161584562

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2016331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>10-Q</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s70F8917B3196D7C98183096EA209305F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><img src="biogenlogostandard.jpg" style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;height:61px;width:185px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check One):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:19%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;15, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219,051,491</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s658930F6A55ACA08ADA9096EF9F8CECA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s51769441E9AC4522CBBB096EFA490A9B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sE2D4E6932570102BD214096E9E6EA34A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2016 and 2015</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE2D4E6932570102BD214096E9E6EA34A">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s8C2EBB9AD40A594936E0096E9F9167A9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2016 and 2015</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8C2EBB9AD40A594936E0096E9F9167A9">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6D85D5DE968112216F7F096E9D794278"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2016 and December&#160;31, 2015</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s6D85D5DE968112216F7F096E9D794278">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7CDA4C4994B2C1996505096EA0DB3AB6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Three Months Ended March 31, 2016 and 2015</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7CDA4C4994B2C1996505096EA0DB3AB6">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s28328650E6EA9295CA27096EFB982531"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s28328650E6EA9295CA27096EFB982531">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s410FFC4A2135EACB9E2A096F00279A3D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s410FFC4A2135EACB9E2A096F00279A3D">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE9D56C6B63748AD0EF92096F043F46B2"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE9D56C6B63748AD0EF92096F043F46B2">51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9B4857CCE041A248105C096F04623CF8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9B4857CCE041A248105C096F04623CF8">53</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sBD70A944A8FF63ED79D9096F0493A193"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9CBB863A5D99D6E3A577096F04B4EFB8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9CBB863A5D99D6E3A577096F04B4EFB8">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s175A73AE66E90E27E209096F04E7CC15"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s175A73AE66E90E27E209096F04E7CC15">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s326DDEDCDE9029B8A667096EBD6A8AC7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s326DDEDCDE9029B8A667096EBD6A8AC7">67</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s597385CF13B0DDBE3D71096F0539639B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s597385CF13B0DDBE3D71096F0539639B">67</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3E6FAC4EB8D1AE033E7C096F055D3D0A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3E6FAC4EB8D1AE033E7C096F055D3D0A">68</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s9F463C8B9AB7E112602B096EFA28840F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities, and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filing and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, cost savings, and charges related to our corporate restructuring initiatives; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report, and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s9F463C8B9AB7E112602B096EFA28840F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Throughout this report, &#8220;Biogen,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries. References to &#8220;RITUXAN&#8221; refer to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, ELOCTATE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, PLEGRIDY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, RITUXAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, TECFIDERA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and TYSABRI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are registered trademarks of Biogen. FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and ZINBRYTA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. ENBREL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, REMICADE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and other trademarks referenced in this report are the property of their respective owners. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s51769441E9AC4522CBBB096EFA490A9B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><div><a name="s2C4F9176B0E73953001F096EFA7C9632"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE2D4E6932570102BD214096E9E6EA34A"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,309.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">330.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,726.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,555.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">313.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">312.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">437.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">460.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">497.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">560.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,348.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,437.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,378.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,117.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,325.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,102.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">356.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">969.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">820.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s8C2EBB9AD40A594936E0096E9F9167A9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">935.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">811.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">933.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">809.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s6D85D5DE968112216F7F096E9D794278"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2015</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,130.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,395.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,227.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">315.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">964.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">941.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">836.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,201.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,700.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,189.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,760.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,258.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,187.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,012.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,917.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,094.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,107.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20,674.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">496.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">208.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">271.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">267.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,003.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,776.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,577.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,535.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">117.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">124.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">905.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,346.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,129.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(259.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13,179.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,326.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,328.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20,674.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s7CDA4C4994B2C1996505096EA0DB3AB6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">969.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">820.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">149.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(160.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(128.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(88.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(180.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(205.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">225.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">154.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(69.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">963.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">733.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,181.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">373.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,914.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(323.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of business, net of cash acquired</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(198.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(126.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(97.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(300.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,203.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from issuance of stock for share-based compensation arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excess tax benefit from stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(192.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">311.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,204.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,130.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,478.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s28328650E6EA9295CA27096EFB982531"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="sF244DF33D2D2E62E1C0B096E9D1F6DFD"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, the FASB issued the following new standards, which we adopted on January 1, 2016:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have an impact on our financial position or results of operations. For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is expected to have a material impact on our financial position. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. We are currently evaluating the potential impact that this standard may have on our financial position, results of operations and statement of cash flows.</font></div><div><a name="s303FC104C7960E50666D096E9E22A29D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to previously accrued 2015 incentive compensation, resulting in net expected restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts have been substantially incurred and will be substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to the pipeline program terminations.&#160;We previously recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of restructuring charges in our consolidated statements of income during the fourth quarter of 2015. Our restructuring reserve is included in accrued expenses and other in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during the first quarter of 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s2DB352C45CB485D5A542096E9DFB02FD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">616.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(262.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(48.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(229.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(283.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">612.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sBCDFF779748A2794312F096E9D3941AA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">607.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">964.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory included in investments and other assets in our condensed consolidated balance sheets primarily consisted of work in process.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the FLIXABI program, which have been capitalized in advance of regulatory approval. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the FLIXABI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the BENEPALI program, which had been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s2AA3443CD7564430FAB3096E9E4D5995"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(510.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,578.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">427.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,331.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(561.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,769.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,662.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,650.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,012.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$88.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. In-process research and development amounts are adjusted for foreign exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$418.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,689.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in acquired and in-licensed rights and patents during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Samsung Bioepis, which became payable upon the approval of BENEPALI in the E.U. in January 2016. For additional information on our relationship with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="s2AA3443CD7564430FAB3096E9E4D5995"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">265.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">321.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">293.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">277.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">271.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">259.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,688.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">257.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,917.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="sB24A59809BFFD43D866D096E9E139D20"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,568.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,536.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">554.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sB24A59809BFFD43D866D096E9E139D20"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">603.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">563.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,543.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,058.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">992.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,880.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,053.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,521.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,506.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">461.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$303.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s6773516084128F992893096E9FA81965"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">488.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,225.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,222.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">507.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s6773516084128F992893096E9FA81965"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,023.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">163.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,181.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">373.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><div><a name="sAB54FADB4EA201EA333F096E9DAF50C1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,251.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,375.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. A net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts was recognized as a component of other income (expense), net, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to a net loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in the prior year comparative period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s249A4379E4E36C3F4D09096E9D522468"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,394.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,330.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$158.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><a name="s9E6867345B6DA5632DAB096EA07FE60B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$953.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$970.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s2FF3254D77A91772C057096E9D2D60E4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(26.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(70.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:47%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s9DEEA01B6BADA02776A9096E9D4BFD91"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="sDFD58235E95669AA5722096E9F8576FB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13. &#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Grants Under Share-based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">73,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">351,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><a name="sDFD58235E95669AA5722096E9F8576FB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,200,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares were issued under our 2015 ESPP, compared to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares issued under our 1995 ESPP in the prior year comparative period.</font></div><div><a name="s3F5E2D0ACE262BE89EE8096E9DF7F802"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate increased due to a state tax benefit in 2015, described below. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;In April 2016, we received final assessments for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$67.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;We are disputing the assessments for these periods, and believe that the positions we have taken are valid.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended March&#160;31, 2015, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;primarily related to the state impact of a federal uncertain tax item.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the tax authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, to reach agreement on the issue. In addition, we applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years. Over the past year, we have reached agreement with the tax authorities in the U.S. and Denmark regarding the tax treatment of these items for the years up to and including 2009. We have recorded the results of these agreements, which were not significant to our results.</font></div><div><a name="s2154E5022A86B6D46FAA096E9D3331EC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets includes prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$613.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">582.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">635.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,003.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL, our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In January 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only "the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months" of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013. We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recorded as accrued expenses and deferred revenue both included in our long-term liabilities in our condensed consolidated balance sheets for this matter as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s81706E2C7EC398B45E6F096EA042C687"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also consolidate the financial results of our other variable interest entities where we are the primary beneficiary. We may pay these variable interest entities up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments. We have provided no financing to these entities other than amounts provided for in the contract.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s5B1CDD5587704C414E12096EA0254354"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007, we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. We have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below, (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. For additional information on our collaboration agreement with Sobi, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA, the trade name for ELOCATE in the E.U., was approved by the EC in November 2015 and Sobi had its first commercial sale in January 2016. In March 2016, the EC approved the transfer of the marketing authorization for ELOCTA to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$165.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ELOCTA, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, are reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ELOCTA in the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, we and Sobi received a positive recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of ALPROLIX. The CHMP's recommendation was referred to the EC, which grants marketing authorizations for medicines in the E.U. If approved by the EC, upon the first commercial sale of ALPROLIX by Sobi in the Sobi Territory, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in expenditures for ALPROLIX, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, will become reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product. If EC approval for ALPROLIX is not granted within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months of the filing date, Sobi shall have the right under the collaboration agreement to require that the escrow payment be refunded and revoke its option right for such product.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table below over a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ten</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;year period, consistent with the initial patent term of the products. Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:35%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br>Revenue<br>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br>less 15%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;days of the six year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have made total upfront and milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which have been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make an additional milestone payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment, which has been capitalized in intangible assets, net in our condensed consolidated balance sheet as BENEPALI received regulatory approval in the E.U. in January 2016. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016. We reflect revenues on sales of BENEPALI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. Our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the Samsung Bioepis commercial agreement will be recognized in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in relation to these services as other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="sC200FB0D1C0DC06C61A4096E9FD5DEEF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv), the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025 (the '355 patent). Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. With respect to the '355 patent, the hearing has been stayed pending the outcome of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">opposition proceedings that we and others have filed in the European Patent Office, and with respect to the utility model the hearing has been stayed pending the outcome of those proceedings and proceedings in the German Patent Office.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ALPROLIX Patent Licensing Matter </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. </font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. All but one of the actions has been voluntarily dismissed. The pending action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States has not made an intervention decision in the action, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. We have filed a motion to dismiss, which is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for late 2016.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Petitions and Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. A hearing has been scheduled for late 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating multiple sclerosis and Crohn&#8217;s disease using specific formulations of natalizumab (TYSABRI). The USPTO has not yet decided whether to institute review.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 10, 2016, the European Patent Office revoked our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The decision was issued verbally and will be followed by a written decision, from which intend to appeal. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&#160;Subsequently, the same entity brought actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. A hearing has been scheduled in the UK action for late 2016 and in the Dutch action for early 2017. No hearing has yet been scheduled in the German action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016 we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="sD88B72610D648172C76C096E9DE0C4AC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2016, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales level related to the Fumapharm Products in the fourth quarter of 2015 and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="s410FFC4A2135EACB9E2A096F00279A3D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including a continuing reliance on sales and growth of TECFIDERA as we continue to expand into additional markets. In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products and assets originating from our research and development efforts, and successful execution of external business development opportunities. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products in disease areas for which there are inadequate treatments and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).</font></div><div><a name="s8288A60614D42B5E15EC096F005831CC"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="biib-2016331_finhighlights.jpg" style="height:426px;width:317px;"></div><div><a name="sD2B8D4027BF73D36A2C9096F007D0BFD"></a></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.43</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 26.9% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our income from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,726.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 6.7% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,309.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 6.3% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a 14.7% increase in worldwide TECFIDERA revenues as well as revenues from ELOCTATE, ALPROLIX and BENEPALI, </font></div></td></tr></table></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">partially offset by an 11.1% decrease in worldwide Interferon revenues. In addition, product revenues, net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by foreign currency exchange rate changes totaling $24.0 million as well as a $26.2 million decrease in gains recognized under our hedging program in the comparative periods.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$329.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 0.3% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled $87.9 million for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 69.0% from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by an increase in other corporate revenue.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,348.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in selling, general and administrative expense, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">7.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in the amortization of acquired intangible assets and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in research and development expense, partially offset by the recognition of a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge related to our corporate restructuring. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$963.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6,775.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapeutics or biosimilars of existing products and other technologies, such as gene therapies. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">health insurers and other organizations. Pricing of pharmaceutical products continues to be under intense scrutiny.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our competition and pricing risks that could negatively impact our products, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Key Pipeline and Product Developments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, we and Swedish Orphan Biovitrum AB (publ) (Sobi) received a positive recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of ALPROLIX for the treatment of hemophilia B. The CHMP's recommendation was referred to the European Commission (EC), which grants approval of marketing authorizations for medicines in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the EC approved the transfer of the marketing authorization for ELOCTA to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016, the EC approved Samsung Bioepis' marketing authorization application (MAA) for BENEPALI for marketing in the E.U. Under our agreement with Samsung Bioepis, we will manufacture and commercialize BENEPALI in specified E.U. countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2016, Samsung Bioepis received a positive recommendation from the CHMP for the marketing authorization of FLIXABI, an infliximab biosimilar referencing REMICADE. The CHMP's recommendation was referred to the EC.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved GAZYVA plus bendamustine chemotherapy followed by GAZYVA alone as a new treatment for people with follicular lymphoma who did not respond to a RITUXAN-containing regimen, or whose follicular lymphoma returned after such treatment.&#160;Follicular lymphoma is the most common type of indolent non-Hodgkin&#8217;s lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our relationship with Genentech (Roche Group), please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><br><div><a name="s08E182AAF8AE90927801096EB1F2FEE7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,663.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,533.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">646.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">638.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,309.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">84.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">330.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,726.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,555.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">945.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">41.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">824.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">670.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">754.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">477.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">107.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">75.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,309.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><a name="s702078C3B516588BF042096F00DADDAC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font><img src="biib-2016331_tecfidera.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 52% in existing markets and sales in new markets where we continue to launch the product and expand our presence around the world, partially offset by a pricing reduction in the first quarter of 2015 in Germany.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TECFIDERA revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by foreign currency exchange rate changes totaling $6.7 million as well as a $7.2 million decrease in gains recognized under our hedging program in the comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we continue to see a strong uptake of TECFIDERA in newly launched territories, total market growth and patient switch rates in our maturing markets, such as the U.S. and Germany, have returned to historical averages for MS therapies. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2016331_interferon.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volume, which was mainly attributable to a decrease in AVONEX unit sales volume of 21% due to patients transitioning to other oral MS therapies, partially offset by an increase in PLEGRIDY unit sales volume. The decrease in U.S. Interferon revenues was also due to higher discounts and allowances, partially offset by gross price increases. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. AVONEX and PLEGRIDY revenues totaled $400.0 million and $67.5 million, respectively, as compared to $478.7 million and $39.5 million, respectively, in the prior year comparative period. &#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to an overall decrease in Interferon unit sales volume primarily in Europe, which was mainly attributable to a decrease in AVONEX unit sales volume of 14% due to patients transitioning to other oral MS therapies, including TECFIDERA, partially offset by an increase in PLEGRIDY unit sales volume. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world AVONEX and PLEGRIDY revenues totaled $164.1 million and $38.8 million, respectively, as compared to $214.0 million and $22.3 million, respectively, in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world Interferon revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by foreign currency exchange rate changes totaling $9.1 million as well as a $11.3 million decrease in gains recognized under our hedging program in the comparative period.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="s702078C3B516588BF042096F00DADDAC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline as a result of competition from our own products, including TECFIDERA, and other MS therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="biib-2016331_tysabri.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to increases in gross price partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was due to a pricing reduction in the second quarter of 2015 in Germany, partially offset by an increase in unit sales volume of 6% primarily in Europe. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world TYSABRI revenues for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were also negatively impacted by foreign currency exchange rate changes totaling $7.3 million as well as a $6.6 million decrease in gains recognized under our hedging program in the comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We remain in discussions with the Italian National Medicines Agency (AIFA) about a resolution relating to a claim that sales of TYSABRI in Italy exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006 for the period from February 2009 through January 2013. If our most recent settlement offer is accepted, we could recognize approximately EUR40 million in revenue upon resolution of this matter. For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that TYSABRI revenues will continue to face competition from additional treatments for MS and certain other pipeline products, including ZINBRYTA and ocrelizumab.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Hemophilia</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ELOCTATE</font></div><div style="line-height:120%;"><img src="biib-2016331_eloctate.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ELOCTATE revenues was primarily due to an increase in unit sales volume of 93%. Rest of world ELOCTATE revenues primarily relate to sales in Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ALPROLIX</font></div><div style="line-height:120%;"><img src="biib-2016331_alprolix.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. ALPROLIX revenues was primarily due to an increase in unit sales volume of 54%. Rest of world ALPROLIX revenues primarily relate to sales in Japan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect continued growth of ELOCTATE as there remains a significant portion of the patient population that we believe can benefit from long-acting therapies. We also expect moderating patient additions for ALPROLIX.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><a name="s702078C3B516588BF042096F00DADDAC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BENEPALI</font></div><div style="line-height:120%;"><img src="biib-2016331_benepali.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our commercial agreement with Samsung Bioepis, we began to recognize revenue on sales of BENEPALI to third parties in the E.U. in the first quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s9ED53B189148EE0F3F00096EC06400AF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA operating profits are summarized as follows:</font></div><div style="line-height:120%;"><img src="biib-2016331_anticd20.jpg" style="height:236px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">974.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">956.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">173.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">799.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">782.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">312.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">309.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to price increases and increases in RITUXAN unit sales volume of 1%, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to 39% from 40% as GAZYVA was approved by the FDA in follicular lymphoma in February 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue on Sales in the Rest of World for RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN consists of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenue on sales outside the U.S.&#160;and Canada. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenue on sales in the rest of world for RITUXAN decreased as a result of lower pre-tax co-promotion profits on RITUXAN in Canada and patent expirations. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="s68B6BE07522BEB02A464096F0125B1B1"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty and other corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">86.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements which provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaboration partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues earned under our manufacturing services agreement with Sobi on shipments of ELOCTA to Sobi, royalties from Sobi on sales of ELOCTA in, essentially, Europe, North Africa, Russia, and certain countries in the Middle East (the Sobi Territory), and revenues from our license, technical development and manufacturing services agreements with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in revenues from collaborative and other relationships is primarily due to lower revenues earned under our manufacturing services agreement with Samsung Bioepis, partially offset by an increase in ELOCTA shipments made under our manufacturing services agreement with Sobi. For additional information on our collaborative and other relationships, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty and Other Corporate Revenues</font></div><div style="line-height:120%;"><img src="biib-2016331_otherrevenues.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our other corporate revenues include amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other corporate revenues was primarily due to higher contract manufacturing revenues related to services provided to a strategic partner.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="sF11EA2F277DDDE0DE0B6096F0154AF82"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of applicable discounts, allowances and other governmental allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves established for these discounts and allowances are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in same the period. To date, such adjustments have not been significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="biib-2016331_reserves.jpg" style="height:446px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by increases in gross selling price and contractual discount rates. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher Medicaid and other governmental rebates and allowances in the U.S., and managed care rebates as a result of an increase in contracted business, gross selling prices and contractual rates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return provisions increased primarily due to the first quarter of 2015 experiencing lower historical returns which reduced our reserve.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s072D93A0364B3DC15D7E096EA50C3419"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">313.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">312.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">437.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">460.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">497.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">560.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(70.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,348.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,437.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sC270246BDD2A8E7CE9B6096F01A97B1E"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2016331_cos.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily driven by favorable production costs and a favorable mix of products, partially offset by increased contract manufacturing production and higher unit sales volume related to PLEGRIDY, ELOCTATE and ALPROLIX. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by increased sales of our hemophilia products as well as the increase in royalty rates payable to Sobi.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Sobi, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="sDABA0DA2476E0BF4C02A096F01C9A6A2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="biib-2016331_rdchart.jpg" style="height:840px;width:317px;"></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="biib-2016331_rdpiechart16.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2016331_rdpiechart15.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Other research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs as well as depreciation and other facility-based expenses. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sDABA0DA2476E0BF4C02A096F01C9A6A2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily related to a decrease in milestone and upfront expenses and decreases in costs incurred in connection with our early stage programs and marketed products, partially offset by increased costs incurred in connection with our late stage programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with milestone and upfront expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to lower milestones recorded in relation to our collaboration agreements with Ionis Pharmaceuticals (Ionis) and the prior year milestone paid to AbbVie for the development of ZINBRYTA as our MAA was validated by the European Medicines Agency (EMA) in the first quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our early stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the advancement of our aducanumab program for Alzheimer's disease to a late stage program in the third quarter of 2015 and the discontinuance of development of anti-TWEAK in lupus nephritis and Neublastin in neuropathic pain, partially offset by the advancement of Raxatrigine in trigeminal neuralgia.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The decrease in spending associated with our marketed products for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the discontinuance of development of TYSABRI in secondary-progressive MS in the third quarter of 2015.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily driven by costs incurred to advance our aducanumab program for Alzheimer's disease and the nusinersen program for the treatment of spinal muscular atrophy. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where the drug candidate has the potential to be highly differentiated. Specifically, we intend to continue to invest in our MS pipeline, our aducanumab program, the BAN2401 and E2609 programs, the nusinersen program, the amiselimod program and our Raxatrigine program.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="biib-2016331_sga.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses reflects cost savings in connection with our corporate restructuring, which is described below under the heading "Restructuring Charges", a decrease in incentive compensation and an $18.0 million benefit to reflect the reimbursement of Samsung Bioepis' share of historical pre-launch costs pursuant to our commercial agreement with Samsung Bioepis, partially offset by an increase in corporate giving.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our commercial agreement with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="sC5B86AF1D632A0708AB4096F01FB87B3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2016331_amortization.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of 2015. Based upon this analysis, there was not a significant change in our expected rate of amortization for acquired intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily driven by a decrease in AVONEX revenues during the comparative period and the impact of higher expected lifetime revenues of AVONEX due to a slower than previously expected adoption of PLEGRIDY. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these and other variables and evaluating industry and market data regarding the productivity of clinical research and the development process and the estimated economics of our product candidates and those of our expected competitors.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The field of developing treatments for idiopathic pulmonary fibrosis (IPF) and forms of neuropathic pain, such as TGN, are highly competitive and can be affected by rapid changes to expected market candidates. There can be no assurance that we will be able to successfully develop STX-100 for the treatment of IPF or Raxatrigine for the treatment of TGN or other indications or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market.&#160;Changes to clinical development plans or life cycle management strategies are evaluated regularly. We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2015 resulted in no impairments.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s26eedee8272d4ba8b2e6e7bf5b41377f"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;"><img src="biib-2016331_restructuring.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in workforce. These changes are expected to reduce our annual run rate of operating expenses by $250 million.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to reinvest the savings resulting from the restructuring to support the advancement of our high potential pipeline candidates and to support key commercial activities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to previously accrued 2015 incentive compensation, resulting in net expected restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts have been substantially incurred and will be substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to the pipeline program terminations.&#160;We previously recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of restructuring charges in our </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidated statements of income during the fourth quarter of 2015. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during the first quarter of 2016:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><a name="sF5EF877CD544AB7887DE096F021ACAC6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="biib-2016331_contconsid.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular factor or factors. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in the loss on fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to changes in the discount rate, partially offset by changes in the expected timing related to the achievement of certain developmental milestones.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="sC0F02D471ED9621B2101096F024EEEAE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="biib-2016331_oie.jpg" style="height:236px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest expense as a result of our issuance of our senior unsecured notes in the third quarter of 2015, partially offset by an increase in interest income due to higher cash, cash equivalents and marketable securities balances and the impact of foreign exchange gains recorded in the first quarter of 2016 compared to losses recorded in the prior year comparative period.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="sD931679DBF6900D993C2096F027322BC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="biib-2016331_incometax.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions, and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate increased due to a state tax benefit in 2015.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 14, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="s309E3F3DD5685386D7F7096F029FEA6B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share in Equity in Loss of Investee, Net of Tax</font></div><div style="line-height:120%;"><img src="biib-2016331_equityinloss.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into an agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals. We account for this investment under the equity method of accounting. We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, our share of losses exceeded the carrying value of our investment. We therefore suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to this transaction, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="sEA32CF696D6A72F524ED096EB46004B3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,130.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,189.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,760.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,775.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,535.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,540.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,526.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,201.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,700.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,776.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,577.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,424.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,122.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sB03189EC5D00F8BD7014096F03478562"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$963.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$97.2 million in total payments for income taxes.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$733.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$198.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net cash paid for the acquisition of Convergence Pharmaceuticals (Convergence);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$97.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$69.7 million in total payments for income taxes.</font></div></td></tr></table></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. During 2015, we issued senior unsecured notes for an aggregate principal amount of $6.0 billion. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $3.7 billion was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside of the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to 20.0 million of our common stock, which has been used principally to offset common stock issuances under our share-based compensation plans. This authorization does not have an expiration date. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock remain available for repurchase under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity, and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is primarily due to net cash flows provided by operating activities, partially offset by contingent payments made to former shareholders of Fumapharm AG and holders of their rights.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The discounts are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, 5-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The increase in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects an increase in total current assets of $501.0 million, partially offset by an increase in current liabilities of $198.9 million. The increase in total current assets was primarily driven by an increase in marketable securities and accounts receivable. The increase in total current liabilities primarily resulted from an increase in taxes payable. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="sFB21B14A66AEDEE48F70096EAB4ED5A8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">963.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">733.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,203.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(41.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s339C044840A183E4CA72096F039A7628"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges and share-based compensation charges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in cash provided by operating activities is primarily driven by higher net income and an increase in income taxes payable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities is primarily due to an increase in net purchases of marketable securities.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows provided by financing activities is primarily due to a decrease in tax benefit from stock options.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="sD09773408B3C85C05989096F03BFCB94"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, capital leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no other material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $64.0 million of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $35.0 million on our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $495.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have planned clinical trials for our nusinersen and IONIS-DMPK</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;programs which are managed by Ionis. We have agreed to pay up to approximately $120.0 million in payments to Ionis as the trials for these programs proceed. If these trials advance and we continue with our Ionis programs, it is possible that we could make a significant amount of additional development payments in the future.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $2.6 billion as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate that we may pay approximately $80.0&#160;million of milestone payments during the remainder of 2016, provided various development, regulatory or commercial milestones are achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013, we acquired from Elan Corporation plc (Elan) full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013. Following that acquisition, we began making these royalty payments to Perrigo.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix), Biogen International Neuroscience GmbH (BIN) and Biogen Hemophilia Inc., formerly Syntonix, (BIH), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN, formerly Panima Pharmaceuticals AG, occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $1.3 billion in remaining milestones related to these acquisitions. </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIH, in January 2007, we agreed to pay up to an additional $80.0 million if certain milestone events associated with the development of ALPROLIX are achieved. In February 2016, we and Sobi received a positive recommendation from the CHMP for the marketing authorization of ALPROLIX. The final $20.0 million contingent payment will occur if prior to the tenth anniversary of the closing date, the EMA grants a marketing authorization for ALPROLIX. This payment will be accounted for as an increase to intangible assets if achieved. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2016, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2015 and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="sE83E48928278AD4FF6DE096F03EE74DE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s30EF6B7E57B4DEAFAA0D096F041064A6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7 &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K. There have been no material changes to these critical accounting estimates since our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K.</font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div><a name="sE9D56C6B63748AD0EF92096F043F46B2"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counter-parties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign exchange rates.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $210.0 million and $185.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $46.0 million and $43.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to constrain the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets and limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain </font></div></div><div id='pagebreak' style='width:4%; float:left;'>&nbsp;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><div><a name="s9B4857CCE041A248105C096F04623CF8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div></div></div><br><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><a name="sBD70A944A8FF63ED79D9096F0493A193"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><div><a name="s9CBB863A5D99D6E3A577096F04B4EFB8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Please refer to Note&#160;18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s175A73AE66E90E27E209096F04E7CC15"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products. We may be substantially dependent on sales from our principal products for many years, including a continuing reliance on sales and growth of TECFIDERA as we further expand into additional markets. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, due to a number of factors, including governmental or regulatory requirements, increased competition, or changes in reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Similarly, the hemophilia treatment market is highly competitive, with current treatments marketed by companies that have substantially greater financial resources and marketing expertise. Our ability to successfully compete in the hemophilia market and gain share in this market may be adversely affected due to a number of reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulty in penetrating this market if our therapies are not regarded as offering significant benefits over current treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction by other companies of longer-lasting or more efficacious, safer, less expensive or more convenient treatments than our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the hemophilia treatment market, which may impact our ability to develop relationships with the associated medical and scientific community; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if one of several companies that are working to develop additional treatments for hemophilia obtains marketing approval of its treatment in the E.U. before we do, our application for ALPROLIX with the EMA could be barred under operation of the EMA&#8217;s orphan medicinal product regulation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.&#160; </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products can vary significantly from country to country and as a result so can the price of our products.  Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the marketing of our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing, or reimbursement for our products would have an adverse effect on our business, revenues and results of operation, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to intense political and societal pressures which we anticipate will continue and escalate on a global basis.&#160;As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products. In addition, under the PPACA, as states implement their health care marketplaces or operate under the federal exchange, the impact on drug manufacturers, including us, will depend in part on the formulary and benefit design decisions made by insurance sponsors or plans participating in these programs. It is possible that we may need to provide discounts or rebates to such plans in order to maintain favorable formulary access for our products for this patient population, which could have an adverse impact on our sales and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases, and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market, and the imposition of fines or criminal penalties. Adverse safety events may also damage physician and patient confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy (PML), a serious brain infection, in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, inter partes reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, inter partes reviews or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events, or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm, or significant reduction in the commercial potential of the product candidate.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates, and compliance with extensive current Good Clinical Practices. If we or our third-party clinical trial providers or third-party contract research organizations, or CROs, do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is more limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations.  We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of several raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our manufacturing facilities in Cambridge, Massachusetts, RTP, North Carolina and Hiller&#248;d, Denmark for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third-parties for revenue, and the development, regulatory approval, commercialization and marketing of certain products, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative relationships for revenue, and the development, regulatory approval, commercialization, and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborator or third party devotes to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise with respect to ownership of rights to technology developed with our collaborator or other third party, and the underlying contract with our collaborator or other third party may fail to provide significant protection or may fail to be effectively enforced if the collaborator or third party fails to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborator or third party may not always be aligned with our interests and such party may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborator or other third party to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the market authorization of our products or to fulfill any responsibilities our collaborator may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may fail to achieve the expected financial and operating benefits of our corporate restructuring and the restructuring may harm our business and financial results. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We face significant risks associated with our corporate restructuring actions that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include loss of workforce capabilities, loss of continuity, decreases in employee focus and morale, attrition of necessary or key employees, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our corporate restructuring actions are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. If these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not manage our current growth and do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives, and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. The availability of high quality development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To manage our current and future potential growth effectively, we need to continue to enhance our operational, financial and management processes and to expand, train and manage our employee base. Our growth is also dependent upon our ability to attract and retain qualified scientific, information technology, manufacturing, sales and marketing and executive personnel and to develop and maintain relationships with qualified clinical researchers and key distributors in a highly competitive environment. We may face difficulty in attracting and retaining key talent for a number of reasons, such as the underperformance or discontinuation of one or more late stage programs or recruitment by competitors.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully manage our current growth and do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups and &#8220;hacktivists.&#8221; Cyber-attacks could include the deployment of harmful malware and key loggers, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place greater restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, we along with many other pharmaceutical and biotechnology companies have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations, or violations related to environmental matters. These risks may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have product distribution methods differing from those we currently utilize. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements, and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products, or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies which has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation.  Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures, and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a biologics manufacturing facility in Solothurn, Switzerland and acquired an additional manufacturing facility in RTP, North Carolina. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to incur significant investment to build or expand our facilities or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products.  If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions, or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies.  In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval, and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space, and manufacturing operations. For strategic or other operational reasons, we may decide to further consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges. If we decide to fully or partially vacate a leased property, we may incur significant cost, including lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements. Any of these events may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio, and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Board of Directors has approved stock repurchase programs and may approve additional repurchase programs in the future. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our stockholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, results of operations, financial condition, and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements, and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. &#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="s326DDEDCDE9029B8A667096EBD6A8AC7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011, our Board of Directors authorized a program to repurchase up to 20.0 million of our common stock, which has been used principally to offset common stock issuances under our share-based compensation plans. This authorization does not have an expiration date. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock remain available for repurchase under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock. </font></div><div><a name="s597385CF13B0DDBE3D71096F0539639B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="s3E6FAC4EB8D1AE033E7C096F055D3D0A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;21, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="s51EE951E11F5191C45F8096F058D1D88"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s658930F6A55ACA08ADA9096EF9F8CECA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2016, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2016331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA2E3A5B4B91E1C2BA1E4096EED9ACF7C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, George A. Scangos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;21, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2016331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s90C9396B670201B40231096EEE41B974"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Paul J. Clancy, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;21, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2016331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s608CA0B394808E89B9D0096EEEE552FF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2016 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;21, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">George A. Scangos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;21, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>biib-20160331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:521d390385cf4e9ab5d8c1d5082079e4,x:499f0a8b895f43a1aa290d0ae54c5361-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20160331" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrld="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20160331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A1995ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2009Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2009Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2007Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2007Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2011-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_OtherVariableInterestEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:OtherVariableInterestEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecHemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2007-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SwedishOrphanBiovitrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:SobiRateToBiogenOnNetSalesInSobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:SobiTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:RoyaltyAndNetRevenueShareRatesByTerritoryAxis">biib:BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementGeographicalAxis_country_CH">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SevenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EightbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EightbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:OneBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:ThreeBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q1YTD" decimals="-5" id="Fact-14BA519C5553797DAEC1BD9E4586409F" unitRef="usd">1400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-F8B02E547C638FA414EDBD9E4582E7BB" unitRef="usd">-1100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-2E0EBF90582A942CF66DBD9E457A610E" unitRef="usd">2600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-E0CC0F8D68168A49DE6BBD9E458077A6" unitRef="usd">-100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-57F1DEE5779E7695723EBD9E45899A49" unitRef="usd">185300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2016Q1" decimals="-5" id="Fact-9A163EFECA8632683156BD9E4585FFB9" unitRef="usd">163300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-8C0FDFA67DE4322691A9BD9E45888EC1" unitRef="usd">184500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2016Q1" decimals="-5" id="Fact-884FEFC12F6DD9E8997FBD9E4589871A" unitRef="usd">162900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2015Q4YTD" id="Fact-3A6D879AE2C251728716BD9E4588F2B3">P16M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2016Q1YTD" id="Fact-5AD288EDC2D0818627DBBD9E4588B9CB">P15M</biib:AverageMaturityOfMarketableSecurities>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-AAE3CEF352EDAD727E85C81EDD7E0C5C" unitRef="number">0.5</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-FB604C51D6E33AEEF34D2AC96A289892" unitRef="number">0.17</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-91FC1C922D54635822662AC9828B210E" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:BaseRateAfterFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" decimals="INF" id="Fact-C58EE1EECAE859A86A6F2AC9926FF803" unitRef="number">0.12</biib:BaseRateAfterFirstCommercialSale>
	<biib:CumulativeSalesLevel contextRef="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-9FAC503BA87BBB78406FBD9E4582E92C" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-5D5157A99368371457DBBD9E4581EEAE" unitRef="usd">8000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_OneBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-BF4A599DD1A079938027BD9E4585CD28" unitRef="usd">1000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-1BB4E97D8AE7D52AA0CCBD9E45876730" unitRef="usd">7000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2016Q1_biib_CumulativeSalesLevelAxis_biib_ThreeBillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-2306FCEB9A7C8A8163C1BD9E4588011C" unitRef="usd">3000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1ABB9B309048268BCD1FBD9E457AC3ED" unitRef="usd">616700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C34461751621BF714AB2BD9E4578ED73" unitRef="usd">480100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-5F00071CAC88606583A0BD9E4582EA78" unitRef="usd">127900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-F3F99FA68F91AE6109CFBD9E457DB2DC" unitRef="usd">8700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2015Q4" decimals="-5" id="Fact-AEC4A702F0AC1A4057D6BD9E457503D1" unitRef="usd">314500000</biib:DuefromantiCD20therapeuticprograms>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2016Q1" decimals="-5" id="Fact-04EBA3B723856D49EBD3BD9E4581275A" unitRef="usd">315100000</biib:DuefromantiCD20therapeuticprograms>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2015Q1QTD" decimals="3" id="Fact-B67CDE0372A28BD14385BD9E45860F22" unitRef="number">-0.016</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q1YTD" decimals="3" id="Fact-4B4CE3311440F29B06FCBD9E457BE22F" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:Employeestockpurchaseplanmaximumshares contextRef="FI2015Q2" decimals="0" id="Fact-A0A08DA491EDDE217849BD9E4573440D" unitRef="shares">6200000</biib:Employeestockpurchaseplanmaximumshares>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-001B16DDC6FFC1034699BD9E457D28A4" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-37765BAF123946F24281BD9E457ED8A2" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:Finitelivedintangibleassetsfutureamortization contextRef="FI2016Q1" decimals="-5" id="Fact-9CBD07CA4BDF5DA412A1BD9E457858F8" unitRef="usd">1688400000</biib:Finitelivedintangibleassetsfutureamortization>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2016Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-0307CCC424B3375672C7BD9E458256C1">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2016Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-CF4BFD8541B2883DAB13BD9E458216FD">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2016Q1YTD" decimals="INF" id="Fact-5567FF947C4C892E3B09BD9E45878EE3" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-CA904AA3E805323FD281BE409B342D10" unitRef="usd">933600000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-8B304924181E19EB2E06BE451D5E612B" unitRef="usd">1001500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2015Q4" decimals="-5" id="Fact-E8142563F699CB396D6ABD9E4578C92C" unitRef="usd">29200000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2016Q1" decimals="-5" id="Fact-ABE8CCE5950EDF4E079BBD9E45817131" unitRef="usd">38800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-F79F7F0A2E17F30B678ABD9E4578E85F" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-224FED3939912A725925BD9E45777CCF" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-F1782F450ACB8F8C3C14BD9E458050A9" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2015Q1QTD" decimals="-5" id="Fact-BF93148B80131048EF41BD9E45841642" unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q1YTD" decimals="-5" id="Fact-FB2DED9767E9E5EFABC6BD9E45817D3C" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2015Q4" decimals="3" id="Fact-92E13AE21F4F5C4D7924BD9E4587BBFD" unitRef="number">0.007</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:Overnightreverserepurchaseagreementspercentoftotalassets contextRef="FI2016Q1" decimals="3" id="Fact-2670B6C56AE25A37D0A2BD9E45873B3B" unitRef="number">0.004</biib:Overnightreverserepurchaseagreementspercentoftotalassets>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q1YTD" decimals="-5" id="Fact-3C84B54A348AEF221770BD9E45872FC4" unitRef="usd">262500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-FA5E2533D1CE89278551BD9E457B2CE3" unitRef="usd">187900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-2F6AFB29CD861C3F5C16BD9E45812A81" unitRef="usd">74300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-1735A2824CA27FDFDCF6BD9E458382FB" unitRef="usd">300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D3FA550BDE7BE796A359BD9E4583897C" unitRef="usd">283200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-E0E6EB5794259035682DBD9E4580BEC2" unitRef="usd">229700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-EB43080AE6212702FED4BD9E457D4995" unitRef="usd">48000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-DAF02FBB4CEFB4FA535BBD9E458598D5" unitRef="usd">5500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PeriodForGrantingOfApprovalByApprovingAuthority contextRef="FD2016Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-5D26393B7EB1520AD09AC88AFBF1C771">P18M</biib:PeriodForGrantingOfApprovalByApprovingAuthority>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-954AB8FE9533DBBF3628BD9E4584F2DB" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B02F9F394A83A1F34C36BD9E4579BF06" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9A2E45B11DA63C5DA016BD9E4585CAC4" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E50DFC619FE1504B5DF9BD9E4584B159" unitRef="usd">40100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0E389E6AD9B5006AD53ABD9E45776574" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2970E788E5833ED50B0FBD9E45748AA7" unitRef="usd">40400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2E11A186CCAE5FC4F316BD9E45753672" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-57EB1BAE7CEE915D86A6BD9E4574ABE5" unitRef="usd">40400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-C96FCF3DD1988A6CD0D7BE4AA2922391" unitRef="usd">18400000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-904C1574659A367274ABBE4A38E57154" unitRef="usd">24200000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-A38E90E6126C18FBE6B6BD9E4573FEE9" unitRef="usd">24700000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2016Q1_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-DA0720A4EB8377873BCCBE4730CD04A0" unitRef="usd">33800000</biib:Preapprovalinventory>
	<biib:Preapprovalinventory contextRef="FI2016Q1_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-7141D7C23FA9C9352485BD9E45736FB9" unitRef="usd">23500000</biib:Preapprovalinventory>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2007Member" decimals="-5" id="Fact-ACBE0ECBC311D115EBD5BD9E45778E7F" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2008Member" decimals="-5" id="Fact-E2143D2E4C0F0661BEFFBD9E45868FA7" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices contextRef="D2011Q4Oct_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2009Member" decimals="-5" id="Fact-320D836C1DC214EDD921BD9E4582AE3D" unitRef="usd">130000000</biib:ProposedDisallowanceByTaxAuthoritiesForPaymentForServices>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-409C04471AB39F93C4BAC81E5C85DF07">Base Rate
less 15%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-09B6852846B1FE359BC2C81CA0FF1219">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-619857CAFE1CCB8B5F1FC81C57F787C8">Base Rate
less 5%</biib:RateDuringReimbursementPeriod>
	<biib:RateDuringReimbursementPeriod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-1DB220E63E0CE7DF4082C80C0D3BBEFA">Base&#160;Rate
plus 5%</biib:RateDuringReimbursementPeriod>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-559E10AC5531B1152687C81DBCCEA44B" unitRef="number">0.1</biib:RatePriorToFirstCommercialSale>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-53EFBDB90402CC6D090AC81B9C9B9A00" unitRef="number">0.02</biib:RatePriorToFirstCommercialSale>
	<biib:RatePriorToFirstCommercialSale contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_us-gaap_StatementGeographicalAxis_biib_SobiTerritoryMember" decimals="INF" id="Fact-6F684ECE4441400709A6C818EB3A4E0A" unitRef="number">0.02</biib:RatePriorToFirstCommercialSale>
	<biib:ReimbursementCostAchievingPeriod contextRef="FD2016Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-D1D52B1199DFFA3862C0392796554761">P6Y</biib:ReimbursementCostAchievingPeriod>
	<biib:ReimbursementLimitStatedInResolution contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" id="Fact-75D074E3B0D9FCD3E455BD9E45873029">P24M</biib:ReimbursementLimitStatedInResolution>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" id="Fact-F8D754D4B6463F0770DBC808BC903820">Net
Revenue
Share</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" id="Fact-735B9C837145D84D7B33C808A972C1FE">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" id="Fact-8284D9C749A1D1203C16C8082DD065E7">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:ReimbursementUnderAmendedAgreementMethod contextRef="FD2016Q1YTD_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" id="Fact-8A97A881A87778691E12C804EAF5CD7F">Royalty</biib:ReimbursementUnderAmendedAgreementMethod>
	<biib:Reimbursementrecognitionperiod contextRef="FD2016Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-FC865BB6D36E2B1354B2392D1F99B528">P10Y</biib:Reimbursementrecognitionperiod>
	<biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement contextRef="FD2016Q1YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-DA2005032D6A46283229BD9E457FCA69" unitRef="usd">275000000</biib:RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement>
	<biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement contextRef="FD2016Q1YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-5C142B052C966B4BADF72AC2F992B85C" unitRef="number">1</biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement>
	<biib:RestructuringandRelatedCostExpectedCashPayments contextRef="FI2016Q1" decimals="-6" id="Fact-733D4988A5ABFBBA3635BE373DC0D096" unitRef="usd">120000000</biib:RestructuringandRelatedCostExpectedCashPayments>
	<biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="INF" id="Fact-E2FA06B0FAF00100CFA7BE29AC7B7218" unitRef="number">0.11</biib:Restructuringandrelatedcostexpectedpercentageofpositionseliminated>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2015Q1QTD" decimals="-5" id="Fact-C45A0D20E07CBE511727BD9E45875412" unitRef="usd">330600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F61B6D1ECA4BBB6BAA63BD9E4580786A" unitRef="usd">329500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2015Q1QTD" decimals="-5" id="Fact-5B0965D78F59F87CFE1EBD9E457275CB" unitRef="usd">87600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-BEEB80EEA7659E533FDFBD9E458953F5" unitRef="usd">51200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:StrategicInvestmentPortfolio contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-D0C4E6C579CC1777BE3BBD9E458897F9" unitRef="usd">96000000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-48ECA1738E7274807859BD9E45889738" unitRef="usd">102000000</biib:StrategicInvestmentPortfolio>
	<biib:TimePeriodForPayingRemainingBalanceDue contextRef="FD2016Q1YTD_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" id="Fact-9A929026E14FC6D59D813925805F0F09">P90D</biib:TimePeriodForPayingRemainingBalanceDue>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-4F5EE6BD6E169306C1FABD9E457FA197" unitRef="usd">1800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2016Q1" decimals="-5" id="Fact-43EACA3F2C86C1D0F674BD9E45810EFE" unitRef="usd">46000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<dei:AmendmentFlag contextRef="FD2016Q1YTD" id="Fact-F0ED70EAF4DBF57F012BBD9E457E928D">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q1YTD" id="Fact-9FEE87210FE906AF4579BD9E457850FC">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q1YTD" id="Fact-5D68ADFB3C5E3E369A30BD9E4575F7CD">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q1YTD" id="Fact-67F7758F4FFF15493C23BD9E457B42EA">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q1YTD" id="Fact-F76555C3DD5415A1E510BD9E45828A2F">2016-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q1YTD" id="Fact-F57D5E49E2E458488A36BD9E4572EBAC">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q1YTD" id="Fact-C914D3F014C88D35ED1CBD9E457F235E">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q1SharesOutstanding" decimals="INF" id="Fact-F4B73896399483B8F3F5BD9E457B602C" unitRef="shares">219051491</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2016Q1YTD" id="Fact-FE9728ED1F41AB04100ABD9E4578BED4">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2016Q1YTD" id="Fact-F73A97006A1F6EEABC7BBD9E45878168">BIOGEN INC.</dei:EntityRegistrantName>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F20D98428125D08B719ABD9E4577D6C5" unitRef="usd">76700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BADD36C03E832B25C6F0BEB122DD7593" unitRef="usd">80800000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B135E07A11BD0CEE6B04BD9E457666D3" unitRef="usd">945500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-81000BF17B4254CE1334BD9E4577235D" unitRef="usd">1103000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9BB61025C198D3AFB8E6BD9E457F8602" unitRef="usd">721000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-94996BEB96A5B69B5FB2BD9E457812D0" unitRef="usd">58300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-D8E82F9BE13E1B8A1CCFBEB02753FE93" unitRef="usd">65500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-160EDE195C5031DD49DEBD9E4577B2B2" unitRef="usd">1251300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-EE39A676CC5E14D02273BD9E4576676C" unitRef="usd">1375100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-08026DD46C26938ABE7BBD9E457E031B" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-8174DA0B89B53626ADB9BD9E457BAD7F" unitRef="usd">680800000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-9198F5E4BA9CD015AC5DBD9E4587E402" unitRef="usd">267400000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-DFC12E7C6009AC3CA6A8BD9E45880613" unitRef="usd">271300000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-42781C642A8CE73C3B84BD9E45822AAB" unitRef="usd">1227000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-2F0CF874248373CA1966BD9E457EC8D5" unitRef="usd">1395100000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-36C91915565FDBACCD76BD9E45819ED8" unitRef="usd">167900000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-507A66B044B423CEE75FBD9E45887010" unitRef="usd">161000000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-5" id="Fact-5F15BD51486D732919C3BD9E45808BEF" unitRef="usd">1330100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q1" decimals="-5" id="Fact-64DD52894B33C7D40D38BD9E4578974F" unitRef="usd">1394400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-5" id="Fact-E017D1443AB79024BDDCBD9E4581F610" unitRef="usd">-59500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-FC43716F621949F6AC35BD9E4587A8BF" unitRef="usd">-31600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-35E72891D86A31529F63BD9E457E71E4" unitRef="usd">71700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-73473D44D991A869E0DDBD9E457F3A98" unitRef="usd">-400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-62692EAC502376A298BDBD9E457726A1" unitRef="usd">-99200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q1" decimals="-5" id="Fact-BDD87B530B686EA012DABD9E457F9091" unitRef="usd">-70500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-948234C463A0D298584ABD9E4584D670" unitRef="usd">-30300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-66502758BC412C12F318BD9E4580DF32" unitRef="usd">159000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-F29D9814741A6E85DBD0BD9E457B954F" unitRef="usd">900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8469609439C646812DAFBD9E457C3549" unitRef="usd">-200100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-E6E7F5735C6B6D8416DCBD9E45806445" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-1453BC79217FA7BAF59DBD9E457DD819" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E40C82D3ADF664FEDFBEBD9E457C5E88" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-2D7899D22ED7629BDBB5BD9E457EA1E2" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-E533D92CADEC671D1B3ABD9E457CCF41" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1" decimals="-5" id="Fact-40849087E8DD06F7B022BD9E45788550" unitRef="usd">-259300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-F9E9F249B92C029FA124BD9E457D652A" unitRef="usd">-37600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B8770B839B81C1BFC945BD9E457D3F11" unitRef="usd">-37400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-DE7B088F7E8CA2D0376DBD9E457BC128" unitRef="usd">1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3C915005A64F5519FE64BD9E457BCA4F" unitRef="usd">-186000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q4" decimals="-5" id="Fact-5B70406228A5079EA437BD9E45778570" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q1" decimals="-5" id="Fact-BE27583C9B25B2118DABBD9E45782E03" unitRef="usd">18400000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-1E0FBAB9E01680616765BD9E457CDE43" unitRef="usd">60900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-B3F2F355B453C4D83F8DBD9E45882244" unitRef="usd">35400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-602F477D3A0AA3CF54C52ABB267494F8" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-7B4CF24F85D60FE40B18BD9E45893699" unitRef="usd">55600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-83FA1866E241CEE64551BD9E45727100" unitRef="usd">23800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-A848EAE2EC6F71CD5251BD9E45722893" unitRef="usd">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-FCC168976DC7D015CCF9BD9E4589DDB5" unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2913141E2CBCCC01A29ABD9E4573A417" unitRef="usd">31900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-CC8F0683E3CE1F792DC7BD9E457305E9" unitRef="usd">13200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-51F4772E47D699481C8EBD9E457B061B" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-F9068985210FBCDFBBD6BD9E4581A1DB" unitRef="usd">21400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-240B394CEB6EBB1D6FDA2ABA52E717BB" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-2272E850DCCA2C746F43BD9E457C06F0" unitRef="usd">34700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-C4046482A883CED4CDD8BD9E45735E57" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-51F40184D8C5859E2855BD9E45734E32" unitRef="usd">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-E6791C6F2D97AD8FA61FBD9E457744DF" unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-7187554C6A6210FD6F37BD9E4574B839" unitRef="usd">30100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-54B2BE15623C6F5EBFDFBD9E4573DF6A" unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-581E89C791E9BB5AB74FBD9E4572CBCD" unitRef="usd">91000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D1FF0081C6F46A5DFE28BD9E457358BC" unitRef="usd">54300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2015Q1QTD" decimals="-5" id="Fact-36AD1141922A27012484BD9E4577B7C9" unitRef="usd">95900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-BE7D83A9E886122B9044BD9E45862F7A" unitRef="usd">88800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2016Q1YTD" decimals="-6" id="Fact-2A6B6BCA6AC847AB276BBD9E457CD9B1" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-5" id="Fact-52A2FDA535ECC268DD9DBD9E458811D9" unitRef="usd">19504800000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q1" decimals="-5" id="Fact-A67BED41EF469CFA4552BD9E45825D8E" unitRef="usd">20674700000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-4CCEB44E01D21B05231EBD9E4573BC38" unitRef="usd">6700300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-2CD4C2C4FCCBFFE3047FBD9E45808A4A" unitRef="usd">7201300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-99099E666AAC6A25D229BD9E4585FACB" unitRef="usd">37500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3001747B691EF1D2F6D3BD9E4584D350" unitRef="usd">5857700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8952636EC0040363FFEDBD9E4588AAE6" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-93AAA0837549B331669EBD9E457A5B89" unitRef="usd">5895200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-92812B975307AA8B9CFEBD9E45761C68" unitRef="usd">32800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D38B6DDEFFFC08930D2CBD9E4576C9F4" unitRef="usd">6536100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-06AE096DCC56E3336040BD9E457609BB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5406AD9838F555B8F71CBD9E457497CD" unitRef="usd">6568900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2015Q4" decimals="-5" id="Fact-A0A41CEC9B72BF36FEE6BD9E45898FBB" unitRef="usd">4891200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q1" decimals="-5" id="Fact-B873C33705AE67675EBDBD9E458559FE" unitRef="usd">5641000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4" decimals="-5" id="Fact-29E50F7F28DAC7228ECCBD9E458536D8" unitRef="usd">4880900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF1A16CB2E48D8459007BD9E4578087D" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D02EAEF0985EEA161C81BD9E45834D94" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-968FB5FBA9034D091190BD9E4587CAE3" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2E35C33F81000E7A5B3CBD9E458485C7" unitRef="usd">494100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9AD214DFC9BBC2633A10BD9E45863DB8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-32A94E63DF15C0D3EF5FBD9E45854B95" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F97C16D735EB0B4F8ABDBD9E45835820" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1BB940D85529521E9CD9BD9E45886075" unitRef="usd">1510900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C73FEB25C911ABCB605FBD9E45857113" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-38BF25EF7DE68858D503BD9E4584FA4B" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-030790D378CCB4F36A6CBD9E4585EB53" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8F752DC2725D49A22C4EBD9E457AC2C4" unitRef="usd">2875900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-165256F7D43BE12CF937BD9E457FE9E1" unitRef="usd">394300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-40C02549315A7CDE63B6BD9E457F47B4" unitRef="usd">1116600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-2C2446A035E8E0453F61BD9E45801832" unitRef="usd">1723400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-8E70976FEDCF82F25171BD9E457FD9F9" unitRef="usd">1152500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0682EEAC16459670BA92BD9E4580CFA1" unitRef="usd">2800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-8AAD81FAB258357B4F7BBD9E457FC094" unitRef="usd">491300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-46D5676DF85803CD98C8BD9E4580E56A" unitRef="usd">37500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1" decimals="-5" id="Fact-FC35B7B3821FA53B86E3BD9E45892EE7" unitRef="usd">5644500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0BF2C6C101C712ECCCD3BD9E45762F73" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BBFC3C780AC08E0F48BFBD9E4575E194" unitRef="usd">509500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A85E2AA4141C2B36B451BD9E457641A1" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D239E08C9270671D4314BD9E4575C784" unitRef="usd">509500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-31110BBF21CC5D5D84FCBD9E457543C6" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-98BD471413EBF585AB31BD9E45764CEB" unitRef="usd">1855100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-51512B0F34493FBF6F7ABD9E4576E05F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C82AF56B0016286992CBBD9E45741019" unitRef="usd">1855100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-220633CE7E217419F5D9BD9E4576EB4F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4BBA3272D684CFC67875BD9E4575359F" unitRef="usd">3279900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-701778D9B0323883AF4CBD9E4575DF31" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-16474D1A39DB987D2E29BD9E4575EF9D" unitRef="usd">3279900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-702C46B3A8C1C0EBB017BD9E457A798E" unitRef="usd">629400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-9D1F1EAD8A7E04750833BD9E457B0638" unitRef="usd">1225700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-5EF129518E94AC48DBDFBD9E45799AEE" unitRef="usd">1823200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-0615A4287B7685228323BD9E457929B7" unitRef="usd">1456700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-D25A1EDBE5AE3D703783BD9E457B934D" unitRef="usd">2100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-727452AA793BDD3FCCADBD9E457AEB85" unitRef="usd">507400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-BED6A743B2D8009F9AFEBD9E457AFA03" unitRef="usd">32800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-069F820F1E5992CBBC70BD9E4580E2F2" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-5BB697F149BDDA7A04FCBD9E457F0520" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-42F9BA89AD07FDE424C2BD9E457FE35E" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-02F956E7B7223C890300BD9E4580F2B1" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-81F1DFA987BB62ABBF85BD9E45806F1D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-31709B6F131AF4C1CBE0BD9E457F6784" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-FD36D2199FD3DA96E085BD9E458074FD" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-2D20E637C5482E0C271ABD9E457F774B" unitRef="usd">9200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1" decimals="-5" id="Fact-B5D777EEA45A8FB155C7BD9E457903C1" unitRef="usd">6900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-F124AADBB926A4A6B2FBBD9E457A5739" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-F8FF7AEEF5CCBD348F02BD9E457AE3F2" unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-EFB716AC6757C7EAE73DBD9E45796E11" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9F424F7CCA09DE77C200BD9E457AB1CE" unitRef="usd">1400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-FE63EB56F81EA30F3D8DBD9E457A7B4C" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-C80B615363D74B49224ABD9E457BF4DD" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-E6EC36C63D2256017E54BD9E457BD196" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-5" id="Fact-1D08CD1A12188C9FF11FBD9E457F814E" unitRef="usd">10600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-7E10175ED62DCDED1515BD9E4580CED3" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-110F7B66A40CD03C09F3BD9E457FBD0B" unitRef="usd">4100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-2171B18517A789B4413EBD9E45807BE5" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-BAB294FFCD05D0741A2CBD9E457FC51B" unitRef="usd">3100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-C179A2E643FA028C298CBD9E458070A3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-990F18DC3F672B5F82EDBD9E45803CB7" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-729F321CBF626EE08F23BD9E457F0FC3" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1" decimals="-5" id="Fact-BE259790E4969A94C9B5BD9E457926DF" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-33ACD15579BD4AF6DEF3BD9E457A7C1E" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-5C4EB92AFBBDC1A3976CBD9E45791E33" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-795C03A089744C58A13BBD9E4579D39B" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-D7AEA90FFD73D45AE66ABD9E457B7622" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-EEFE2C396D106FCC72F2BD9E457A7A68" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-94692BA5E65ECAAAB4D0BD9E457A5D26" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-56E41DAF5FF66FA8C0FFBD9E457BF6FA" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-8855DCB7BD122987260DBD9E458049EF" unitRef="usd">4891200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-10C93765E9F76883DA07BD9E457F9262" unitRef="usd">394800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-86E236B161CC6C95E6DBBD9E457F124C" unitRef="usd">1120600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-1FB0A853E1607E0F9ADDBD9E4580A371" unitRef="usd">1724400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-594BCF35DC4578CC8745BD9E457FEEF2" unitRef="usd">1155600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-DAC5AE7965B736A26875BD9E457F07F6" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-B7EE17BB7A0038366530BD9E457F8418" unitRef="usd">493000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-B21C30C4634B5EC3392FBD9E457F659A" unitRef="usd">28300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1" decimals="-5" id="Fact-5F05D0B320DF19AC451EBD9E457A93A5" unitRef="usd">5641000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A1D7A2C1904797BBFDD1BD9E457A74EE" unitRef="usd">629500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-2F5E4CA966AE90F9F081BD9E4579111F" unitRef="usd">1222400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-E6EC0A685E5CFA2F6C7BBD9E457A82CD" unitRef="usd">1823000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9949A31F609D33E424ABBD9E457A6556" unitRef="usd">1456000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-EED1ED9FE9838549F5A7BD9E457921EC" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-87AA132EF5AC48496075BD9E457AB4FF" unitRef="usd">508000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-80DE2FCD9F0BD53C2334BD9E457A290A" unitRef="usd">33600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-3EEF8AAA33BF08BEAEEBBD9E4588E5E7" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-B874F675A756B3F16A05BD9E458118A7" unitRef="usd">2454700000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-E9992D4E010DA3FBFE63BD9E45857F3E" unitRef="usd">2583900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q1" decimals="-5" id="Fact-909382A41FF443E371B9BD9E45890D5B" unitRef="usd">3023100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-CAD4E743676BB36728FEBD9E4589E9DA" unitRef="usd">2575900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q1" decimals="-5" id="Fact-90AE52D933BFF4B5793CBD9E45893DEF" unitRef="usd">3026900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2015Q4" decimals="-5" id="Fact-38D48E0EC948E907B7D6BD9E45898963" unitRef="usd">2122000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q1" decimals="-5" id="Fact-8157C61D0CD7D77DCE22BD9E458972CE" unitRef="usd">2454600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-B0A4076A6FB6AA584A1BBD9E4589C7AC" unitRef="usd">2120500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q1" decimals="-5" id="Fact-B7ADD906276D28418B58BD9E458550F4" unitRef="usd">2454700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2015Q1QTD" decimals="-5" id="Fact-1B65727E4F9EBBCF84FCBD9E4586F107" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q1YTD" decimals="-5" id="Fact-95DC15463EAD6E8CFA86BD9E4587D7B6" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B781D834A1B8A896E522BD9E4586597B" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-117AF770FC189F491E30BD9E45872B59" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-41ACED28783B08C20281BD9E45839D5D" unitRef="usd">2760400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-8E8DF370AEC1F2352D0DBD9E457CF7E5" unitRef="usd">3189800000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2007Q1SD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecHemophiliaMember" decimals="INF" id="Fact-CA22142A80F2EE428C4CC87C2763E4DC" unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-3E00111A9ADA071DB56CBD9E457DD81B" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2014Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D18A3F3DECC1860CD11EBD9E45889D8C" unitRef="usd">215500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0509ADA04A1AFF305A0EBD9E45898FFA" unitRef="usd">461800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B8448280A4E42525F023BD9E45873ECB" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F89B4D82DAFE0C9E9375BD9E457A301D" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-467BF9EA5F1162D5EC56BD9E4579989C" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-818DC23EB02A75CE4C46BD9E457E901A" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AAFA8F931A09EF0C1ED1BD9E45759467" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8C1EC183EB872B9E20F6BD9E45754247" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F772F2B0BDE109F94706BD9E45759D05" unitRef="usd">508300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1242D068246ED9ED9611BD9E4586E321" unitRef="usd">508300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-E818F42D9C819E218892BD9E457C71BB" unitRef="usd">504700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-1A626DC970469F6F0A51BD9E4585CA2F" unitRef="usd">505100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-498DD894CE2D0FE92D20BD9E45895492" unitRef="usd">301300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-2A93178DAF2EFFA85993BD9E457BB043" unitRef="usd">303200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-5" id="Fact-8697A6D3A6C52871E5E7BD9E4577C505" unitRef="usd">1204900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q1" decimals="-5" id="Fact-8B10E071F9D910F8AA71BD9E45885DEA" unitRef="usd">1478100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-3E50CE613AD99D8854E3BD9E4585739A" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="-5" id="Fact-B5493638D3FB90BBF24CBD9E4574391E" unitRef="usd">1130700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-98310589B59D94EEF13EBD9E457A0E2A" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DFBE4B914F9809A29904BD9E45840EA1" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0714E91DB5136E07B02FBD9E457A07D4" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-78C4A7DA235F8D160BE1BD9E4588B56E" unitRef="usd">909500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0E6E54F92F3DCF58124CBD9E4575C65A" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1564C8E1E4D5820A78D2BD9E457528F2" unitRef="usd">820600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-91D371D23B2BA05CB4A4BD9E45761305" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-86CCA156EA72084DC4D0BD9E45760895" unitRef="usd">820600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q1QTD" decimals="-5" id="Fact-5924C15DA0728EDC2713BD9E4572A3D7" unitRef="usd">311000000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q1YTD" decimals="-5" id="Fact-857094D9C5F02D4D21DBBD9E45816EEA" unitRef="usd">-192400000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-4E7C9CF8F7B177BF38EBBE9B6B5E64BA" unitRef="usd">909500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-1A76DCB59746D8B80C73BE998A5AD2CB" unitRef="usd">21900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-F583B2637029B9A5FF93BE9B43C98718" unitRef="usd">79100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-1FD1F53254C139CB289DBE9AB2B47CD9" unitRef="usd">673800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-A647A03A17D4A7108EEABE9A41B37E4A" unitRef="usd">134700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="-5" id="Fact-F5AE66114304A48D9268BE98D888B60E" unitRef="usd">820600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-B623FB321229FB4899CEBE98478F18C0" unitRef="usd">7400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-2CFF11EC3CEA5AF46F48BE98C9312E43" unitRef="usd">234300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-2D1D1B0ABEDD4DB1C1BFBE98B8956BA8" unitRef="usd">488700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-87C4794F7429BE878AC5BE98A97C0B81" unitRef="usd">90200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-F922822DD3C0B243685BBD9E4584F98B" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q1" id="Fact-7061C88E7C750754A5C4BD9E45792894" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-0A22FAD5BFBA81DB1B2FBD9E457ED661" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q1" decimals="INF" id="Fact-DBC91FD631F14655595CBD9E457CA5B4" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-1BE3522F8B06394962B4BD9E45846BA8" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q1" decimals="-5" id="Fact-687F3FD1E2C9BFA719ACBD9E45752B25" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-4085CC2E46B450796DFBBD9E4582AEEF" unitRef="usd">811500000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-99C4C0CF38357B484851BD9E457E0921" unitRef="usd">935600000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2015Q1QTD" decimals="-5" id="Fact-78B826F87E899F086F51BD9E457E3625" unitRef="usd">2300000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-EA382E611D1AB75A5B67BD9E45891B0A" unitRef="usd">1700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2015Q1QTD" decimals="-5" id="Fact-18633C5657BE61E9C022BD9E457E9859" unitRef="usd">809200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-A9838B22E830F65C45E5BD9E45795467" unitRef="usd">933900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2015Q4" decimals="-5" id="Fact-74301C6FA0D6815D98B3BECEAB1A6DB0" unitRef="usd">99000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q1" decimals="-5" id="Fact-136FC9A5B221D94550FDBD9E45780A99" unitRef="usd">158000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:CostOfGoodsSold contextRef="FD2015Q1QTD" decimals="-5" id="Fact-7C35F37BB53FC0CD4FA3BD9E457EFAC9" unitRef="usd">312400000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1YTD" decimals="-5" id="Fact-7D5A7F6086442AB4B4D5BD9E4579DF1D" unitRef="usd">313000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q1QTD" decimals="-5" id="Fact-560D0532D2F28C8D583FBD9E45830332" unitRef="usd">1437100000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E6970D2FD399C0B6284CBD9E458831E4" unitRef="usd">1348400000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-0FD0D4D3441498F5C756BD9E45883209" unitRef="usd">4800000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-C9D82CD5E296625174D6BD9E4581ED15" unitRef="usd">4900000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2015Q4" decimals="-5" id="Fact-86E1ED57FF5EFB5778F8BD9E4583C4B7" unitRef="usd">6645900000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2016Q1" decimals="-5" id="Fact-A3851DCD1352D794C466BD9E45839DA6" unitRef="usd">7053400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-868773CC8BF9C7EE26CCBD9E458181EA" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-8B047B00B887667971F3BD9E4585B120" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-758AE6E5170DFFF6BF2EBE5E580E834C" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-F991C66071503F00432CBD9E45786AC6" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-19278F780046CC7509FFBD9E4577AF8A" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent contextRef="FI2016Q1_us-gaap_StatementGeographicalAxis_country_IT" decimals="-6" id="Fact-CFB38C492FCB7B507D6CBD9E458562DA" unitRef="EUR">75000000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q1QTD" decimals="-5" id="Fact-2F96A56CF5E64BAF109ABD9E457F7CC7" unitRef="usd">16700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E3BA675C708F62EA3E25BD9E45757D51" unitRef="usd">8900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-3595605C4BF0BF0A57F5BD9E45804927" unitRef="usd">124900000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-510B8F56B1EEE5E4DCA1BD9E4584984A" unitRef="usd">117800000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q1QTD" decimals="-5" id="Fact-8D694C4755A7BC6EF496BD9E4580E42D" unitRef="usd">147900000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q1YTD" decimals="-5" id="Fact-2FD855A5513141A3AE9FBD9E45830FB1" unitRef="usd">149700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-73242A7C86015E9E6370BD9E45828C4F" unitRef="usd">10300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-ED255E68E85848CF8513BD9E45819D2F" unitRef="usd">16600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-0EF84D012A19CB6F2BB0BD9E4580C6C3" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-269192872B434CA77E15BD9E45808DF7" unitRef="usd">16000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-0E3022D574B9EACD4CFFBD9E4589AC7C" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-42A82C136F85CDF39EA9BD9E457361C7" unitRef="usd">12800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-3DF252B8356F1ED97413BD9E45806F33" unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-906EEE7ABDE1B6916B10BEC0B8D8927E" unitRef="usd">10200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-3BCBB534ACB7085DD719BEC0E58EC131" unitRef="usd">2500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-D062C1F18E48CBCFF21EBD9E4585458E" unitRef="usd">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FD622FEDA0070EA8A8FCBD9E458198F4" unitRef="usd">35000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-86EB070D2CCFB4324F14BD9E458283CD" unitRef="usd">7100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-703B2563191156976D0DBEB313BEF716" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-98C142296525ADB8E81DBD9E45732EF9" unitRef="usd">35000000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-4EA9AF70A4312F74CB77BEB26F42B1C4" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-92FB6518D49E1B21B025BD9E4587C2AC" unitRef="usd">8800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-5FF69C7E07006994210ABEBEE9D63A16" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2015Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-79DC92F4F7475C1BBE8FBD9E45772623" unitRef="usd">2200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-067C59B6961AE34FF2D4BEBE0AB9F3B2" unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-30D55426514312B8B93FBD9E458521AD" unitRef="usd">1900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-C8C576ADBD47E8F969CFBEC4EC2B00E1">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-9C6081A7D6375D9CFC42BEC39419D9F3">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-12B8E39D0628EC033D11BD9E457F9BA2">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C01D66E7531F6E9C32F6BD9E457F0EC3">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q1QTD" decimals="2" id="Fact-2D15C21D445996F0BFC6BD9E45747046" unitRef="usdPerShare">3.50</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1YTD" decimals="2" id="Fact-ABA8A977B0A9CFB4ED1FBD9E4578619B" unitRef="usdPerShare">4.44</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q1QTD" decimals="2" id="Fact-50E0F71714C636D0B92FBD9E4585FBE3" unitRef="usdPerShare">3.49</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1YTD" decimals="2" id="Fact-94115CDE65E6B4356038BD9E45858979" unitRef="usdPerShare">4.43</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q1QTD" decimals="-5" id="Fact-3A56188E3DB372CAF36FBD9E4588FA17" unitRef="usd">-37800000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B5F9850884DF4C0611AFBD9E4580112B" unitRef="usd">15100000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q1QTD" decimals="3" id="Fact-5FBDAAE0DBF1B89E55D9BD9E4586940B" unitRef="number">0.256</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q1YTD" decimals="3" id="Fact-BB4C8C0D43CEDA7137D3BD9E457D6E75" unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q1QTD" decimals="INF" id="Fact-F64B1860BDDCA24B00E2BD9E457CE069" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q1YTD" decimals="INF" id="Fact-0C90C184F4F9F63D00E2BD9E457C0B38" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q1QTD" decimals="3" id="Fact-F1D91A799940ACC71D2FBD9E457DADBF" unitRef="number">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q1YTD" decimals="3" id="Fact-01498EC52269E0A71E2CBD9E457B1E86" unitRef="number">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2015Q1QTD" decimals="3" id="Fact-11558CF94900EBBBC08CBD9E457C1521" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q1YTD" decimals="3" id="Fact-F0E5666CBA3532E50317BD9E45869203" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2015Q1QTD" decimals="3" id="Fact-F2086B0CB443A8E42FE5BD9E457D1131" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q1YTD" decimals="3" id="Fact-69FC8EA132C00AFC16B9BD9E4589A553" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2015Q1QTD" decimals="3" id="Fact-D472324228AD07194C1EBD9E457DB977" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q1YTD" decimals="3" id="Fact-B7330B20BB081738A8BEBD9E457DAC7D" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q1QTD" decimals="3" id="Fact-76275E91CC985A6D301EBD9E457B1CD5" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q1YTD" decimals="3" id="Fact-2544DA71AECF8F7AE562BD9E457D881A" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q1QTD" decimals="3" id="Fact-2BD7311C16052746B8EABD9E457DB9D1" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q1YTD" decimals="3" id="Fact-6217DBD21AB496F08E67BD9E457D07D2" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-95C108D5C474C8700074BD9E4577756A" unitRef="usd">270800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-E93E5D73507CB3B182F0BD9E4577FBC6" unitRef="usd">180400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2015Q1QTD" decimals="-5" id="Fact-EF85A5E4E5D2544D88FABD9E4572DD8C" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1993EE382ADB7B5E66B6BD9E45899C8C" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-775B027374EF9E214D71BD9E4586804F" unitRef="usd">26700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-38F249ACEF8D42E167D0BD9E457E1A74" unitRef="usd">15200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2016Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-C287514C1079FE79A600BD9E4581A2E2" unitRef="number">0.09</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-24CD6F9B682747C17B79BD9E4585EF25" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-D97016F39F7CFDCDCCD2BD9E457D33E6" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-B577DE7FAD73E464CEC6BD9E45740553" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-59DBA0607D678420BEA7BD9E45862549" unitRef="usd">66400000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-EEE1F81875DDE468EA80BD9E458479EB" unitRef="usd">8300000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2015Q1QTD" decimals="-5" id="Fact-71E6ABB6271AAEE9FC9BBD9E4581790A" unitRef="usd">-7800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q1YTD" decimals="-5" id="Fact-82A03F7BCAB4E60C458BBD9E4581F7CF" unitRef="usd">-2300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A1DA9F654904B6EE8E84BD9E4578F222" unitRef="usd">238500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F3AE002B2FE966DC8DA3BD9E4586D14C" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2015Q1QTD" decimals="-5" id="Fact-D6EDEDAE21046556C5B8BD9E458944B8" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q1YTD" decimals="-5" id="Fact-91F8B19978EF784DEDF6BD9E4586D1DC" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2016Q1YTD" id="Fact-22C58DB0A3C27F9D278EBD9E4583F8D7">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-844B66BC2579FC99A5CFBD9E458297D9">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-DE60182FF73C11F5AC3EBD9E45828317">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-D794ADCE6C4DCD4EA2B1BD9E45832BC1">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-83266F3EC5AC61DEE1DBBD9E45832924">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-7011F5601C4B1F75D1CDBD9E45830320">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2016Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-AEF691ED688A54A7ADF8BD9E4582A001">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4" decimals="-5" id="Fact-BAD1A6BE9A8ADF84F3C3BD9E4575F265" unitRef="usd">3561200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-D6E98840CE5AE1144562BD9E45744C22" unitRef="usd">502300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-49EEEBBF69375C2AC223BD9E4575645B" unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-2ED1E0421F2D8CB1A3B6BD9E4576DC0E" unitRef="usd">2552900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-C9452687D61ED5532552BD9E45760A26" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-F54F89EB384A2DE31BEABD9E45762EE6" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1" decimals="-5" id="Fact-23E61586C5531298806CBD9E45766E4D" unitRef="usd">3650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-D122F2D70FE3E8F0C17BBD9E457544AD" unitRef="usd">561400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-A1FB351BEAC10110AF08BD9E4577593C" unitRef="usd">510500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-FA73D4CE776DB571CD8BBD9E45753BC6" unitRef="usd">2578100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-B1AA8B15DF6A607CD967BD9E4576D190" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-965ABCE6901CE4047EFCBD9E45755BF7" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2016Q1" decimals="-5" id="Fact-D9D14D5D7B7739881E74BD9E457868BE" unitRef="usd">321000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2016Q1" decimals="-5" id="Fact-FCC4364EED815FBB6362BD9E457739AE" unitRef="usd">265300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2016Q1" decimals="-5" id="Fact-6254B8CF66BBBA25EE70BD9E457878AE" unitRef="usd">259300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2016Q1" decimals="-5" id="Fact-AEF5041AA3806C7C45CFBD9E4577FBC3" unitRef="usd">271600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2016Q1" decimals="-5" id="Fact-30609FAE341ECDF8DF4DBD9E45779EBC" unitRef="usd">277600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2016Q1" decimals="-5" id="Fact-37F64BD6374EC7AE4822BD9E45770AC5" unitRef="usd">293600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-41856904420C788A12D4BD9E4575AA06" unitRef="usd">3303200000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-6D83A482DE55C48EFA31BD9E45752061" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-048FD75752A8383BF8AEBD9E45751289" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-BFF5A1BFD484A1C22A58BD9E45764E2B" unitRef="usd">3331100000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-909FE3CF5D46B91C800ABD9E4574B2A1" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-5373C285FF51F340B2A2BD9E45757C17" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-DC90AFF260A71E9791B9BD9E457582CD" unitRef="usd">2800900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-A8E3F96C9F98114554C0BD9E457581AE" unitRef="usd">37300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2015Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-6098235184104EFA5A81BD9E45747DB6" unitRef="usd">452400000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-EC2558554A160FBFEA09BD9E45803FED" unitRef="usd">2689200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-E3BA307B8D80FFCFB732BD9E4574BBF5" unitRef="usd">2769700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-B2B741814F4A594542B3BD9E4574A223" unitRef="usd">32800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-D8CD90E59F9072572936BD9E4576013B" unitRef="usd">427200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-1D66A7833F8A64F21A21BD9E457257A9" unitRef="usd">418900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q1QTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-1E6E75ACAEC9FC18EAF7BE5122B176C5" unitRef="usd">25000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C33A5AFEDAEDF400DC55BD9E45851119" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-53DB626846E7E6391BC0BD9E4579B326" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-790C18AACC4F44DFE9A9BD9E45796D86" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5DC788ABA0D89F38D945BD9E4583C7DC" unitRef="usd">27200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3EDB182A3B60F3181088BD9E45753A03" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DA4AA6882926650F0D28BD9E45767E4A" unitRef="usd">30600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5A76521EC567C9E19BF5BD9E457549BE" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-66B4F2462AF4C6FF3F94BD9E45745AEF" unitRef="usd">30600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B802EE882AB4B2BA6EF2BD9E45795A88" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB4113AAAF6E374DCB36BD9E457826D8" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C41AD26BB51B54DE96A2BD9E4585705E" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B0A36450754EEB13C1A3BD9E4585070E" unitRef="usd">14700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0C655758D6022E33EDBBBD9E4576F61B" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-42F74C6C934960697267BD9E457817CB" unitRef="usd">46600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-377EEEC54CF34AAEBDC4BD9E45764F01" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9AAA205D47BD52FFE7B0BD9E4575770A" unitRef="usd">46600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-9FF9F172A0A92AD3007FBD9E4587C3B1" unitRef="usd">-13000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-37E240BE3BB10B254310BD9E457EC9F3" unitRef="usd">2100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B604C65859AD932CA6C8BD9E4578E8E7" unitRef="usd">9700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-987582EAB63B8CFFCABCBD9E457F478D" unitRef="usd">2400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2015Q1QTD" decimals="-5" id="Fact-06626B0AA31B9411AD24BD9E45897CAA" unitRef="usd">-1700000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-78932339E39127D2C70BBD9E45778CBB" unitRef="usd">1600000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-5" id="Fact-6B37A5A37A20A29BB55FBD9E45816C0F" unitRef="usd">2663800000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q1" decimals="-5" id="Fact-F5F9EDD5D0DCF6D005F8BD9E45880139" unitRef="usd">2917900000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1D87AD4D608117FC1DC1BD9E45885A57" unitRef="usd">257800000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2016Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-C7B89A28C9392E42144FBD9E45818DD0" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2016Q1" decimals="-6" id="Fact-D8A62F4BDDB55E036D7FBD9E4581E122" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2016Q1YTD" decimals="-5" id="Fact-0EF780E835110ACB2111BD9E45882B94" unitRef="usd">-3700000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q1QTD" decimals="-5" id="Fact-6E0CCCDB2631D0C298CCBD9E45750437" unitRef="usd">1102900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-09C7E70AC1AC8F525114BD9E45866C40" unitRef="usd">1325600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q1QTD" decimals="-5" id="Fact-8CBB73E04EBD607970F5BD9E45881472" unitRef="usd">-800000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-C3BBBEF5764BD36ACEE2BD9E458536AA" unitRef="usd">-800000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-9C2A9AC7649CFBBB258CBD9E45786B75" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2016Q1" decimals="-5" id="Fact-9ABC01835B565A810457BD9E45849E0D" unitRef="usd">67000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q1QTD" decimals="-5" id="Fact-3F5DFF471A35A1048E3DBD9E4582EEDC" unitRef="usd">281900000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E80838768CF2157732B2BD9E457CD636" unitRef="usd">-200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-32EF0E4A915A2B48BAABBD9E457CEE99" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-17A3E8BADA7FB273597CBD9E45784AF0" unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8DCCF0EFAAD69CE454A8BD9E457ECDE4" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="-5" id="Fact-100BBF04B7223322AC44BD9E45847354" unitRef="usd">356400000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-A7BE3F77BD82E158615BBD9E45811C8C" unitRef="usd">42200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A25F2749622E6F962EA2BD9E457898C7" unitRef="usd">128300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q1YTD" decimals="-5" id="Fact-72751B4324D412D48E8BBD9E4588FDC0" unitRef="usd">160000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2015Q1QTD" decimals="-5" id="Fact-F35A3C3E2F9E56B00DAFBDB9EEB936EB" unitRef="usd">154000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q1YTD" decimals="-5" id="Fact-05538341148CD51F6FC1BDB9EECA16B3" unitRef="usd">225100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-EA93AF914E5FD045C355BD9E45882663" unitRef="usd">-205500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-57DC3E5CF6FF52686695BD9E457576FD" unitRef="usd">-180800000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2015Q1QTD" decimals="-5" id="Fact-57C4AE5EC2CAC39C5FC7BD9E458783E7" unitRef="usd">21500000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q1YTD" decimals="-5" id="Fact-45E8AC1D847514FF13B3BD9E45826962" unitRef="usd">88600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B4FCB370D3A814D5517ABD9E4580A4E3" unitRef="usd">69700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-67448EAA2F11884D0376BD9E45864EC1" unitRef="usd">-14800000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-193B33A844A12F82D114BD9E4573B2FE" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-13F96E657CC115E11385BD9E45738E55" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-276FB3D931B081280203BD9E45742228" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-2CD5536C313AF19E47EEBD9E45739331" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-DF83DDE5B3789978CBF4BD9E45743730" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-C48BBBE3F72E1ED623F0BD9E4574CA45" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-EFC579A2B778A847B8E8BD9E4574D8CA" unitRef="usd">730500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2015Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-E7FD94D2A4257F71445ABD9E45748B50" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-937F631A78B01037FC83BD9E4576592C" unitRef="usd">718500000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-C9F546086396811CF4E7BD9E45751862" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-ECDD716DA8057C7E1A67BD9E4576A674" unitRef="usd">7646300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2016Q1" decimals="-5" id="Fact-EAA9C05900B7129AE1CCBD9E4577CD77" unitRef="usd">7662200000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4" decimals="-5" id="Fact-33E6F6F8BE6B086BC1BBBD9E457A4827" unitRef="usd">4085100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q1" decimals="-5" id="Fact-8B43F432C9F159736A71BD9E45851D68" unitRef="usd">4012200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-FE1DA12FB054EC94A5F7BD9E4578D114" unitRef="usd">6700000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-5AFE202CF2944C319BB2BD9E4586AF21" unitRef="usd">63300000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-08067DD1484BE68A3A57BD9E4581B44F" unitRef="usd">143000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q1" decimals="-5" id="Fact-FCA83E54E907E3956A25BD9E457FC1C6" unitRef="usd">144100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2015Q4" decimals="-5" id="Fact-4C7825F4FDC5492EA0AEBD9E457B4859" unitRef="usd">893400000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2016Q1" decimals="-5" id="Fact-84C6AC2B778C1043D2A8BD9E4584818A" unitRef="usd">964600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-814C38B8CFA6B865140ABE448F70BFD8" unitRef="usd">40200000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-0002E6BA2662571FCC54BE4457F35E4C" unitRef="usd">36900000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-920BE94310E847969490BD9E4582B48D" unitRef="usd">213000000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q1" decimals="-5" id="Fact-9ED87BD2472C19F01559BD9E4589D3E5" unitRef="usd">249500000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2015Q4" decimals="-5" id="Fact-F12FF544E67393BDBA95BD9E45815177" unitRef="usd">577600000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q1" decimals="-5" id="Fact-7CD40C2C1F4A5A5DD0F3BD9E4587C308" unitRef="usd">607900000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q1QTD" decimals="-5" id="Fact-86C308BA1448733C4216BD9E45786685" unitRef="usd">3300000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-064BFA111C2A1CDCB5EDBD9E4574523A" unitRef="usd">11200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C8F360D2D3DC336C6A42BD9E45851EBD" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-32EE7FA215762A0421F3BD9E45845C19" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B81588D45234C8122E4ABD9E4589F087" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BF8AD39F29D60C50F7E5BD9E45799C77" unitRef="usd">37500000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-56CFEDFF5BBAD925439BBD9E45766371" unitRef="usd">32800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-87221346D1245FB8AA52BD9E4575B33D" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5669DA88AF696E09F942BD9E457668EF" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-725214D2D75F8953639ABD9E45766E20" unitRef="usd">32800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-5" id="Fact-8E167C73B44B7AA07DD4BD9E457E528C" unitRef="usd">10129900000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q1" decimals="-5" id="Fact-1C8C6255863C56448175BD9E4577AD3F" unitRef="usd">10346600000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-6F1EEA00D952FE487B0CBD9E458700BE" unitRef="usd">19504800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q1" decimals="-5" id="Fact-628897D007249B5CA4B4BD9E4589A8DE" unitRef="usd">20674700000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-9532A2AFEE3AB9586B4EBD9E45766ACB" unitRef="usd">2577700000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-08B9EDE501369529B0B6BD9E4573CE0B" unitRef="usd">2776600000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2ECB6B90BCDA330CC046BD9E45840339" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F7D1428DC04783BCD2E0BD9E45844A18" unitRef="usd">14700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-06AE3A0B4F48647FD958BD9E4579CED3" unitRef="usd">506000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1DE4725F4381043FEE27BD9E4579169A" unitRef="usd">520700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-821F3D10AB7C0BFD607FBD9E45742A1E" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2450FDF6D42C0F15750DBD9E4576D147" unitRef="usd">46600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-86F63A1A75A38D5CC71CBD9E4576713B" unitRef="usd">508300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-29831B0A841661B1E7AFBD9E457624D3" unitRef="usd">554900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LongTermDebt contextRef="FI2015Q4" decimals="-5" id="Fact-C8441E388087D3F85097BD9E4586EB24" unitRef="usd">6521500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2016Q1" decimals="-5" id="Fact-3169C2802656BCBF6C47BD9E458388D0" unitRef="usd">6535600000</us-gaap:LongTermDebt>
	<us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1 contextRef="FD2016Q1YTD" id="Fact-F063EE248C40BC204032BD9E457F46A2">P21M</us-gaap:MaximumRemainingMaturityOfForeignCurrencyDerivatives1>
	<us-gaap:MinorityInterest contextRef="FI2014Q4" decimals="-5" id="Fact-BD0F0C7586631BD8054ABD9E45845A31" unitRef="usd">5000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q1" decimals="-5" id="Fact-5DFA37360EBA3F7758E5BD9E4583AC8D" unitRef="usd">2700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2015Q4" decimals="-5" id="Fact-7A98EE51C3E269289B9EBD9E45753F0F" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q1" decimals="-5" id="Fact-A61AC745205C24FE82ADBD9E457A97AF" unitRef="usd">1300000</us-gaap:MinorityInterest>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-3F003384C6C9F72C4AD7BD9E457B9C5A" unitRef="usd">80800000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-80AF96AC8E1FCD0AE766BD9E457DC3F4" unitRef="usd">47400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-535171BA738663A2E214BD9E4587CB3F" unitRef="usd">-502800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-29020778E7B4B6359F47BD9E45862693" unitRef="usd">-1203200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-642927F0D86707ECEC41BD9E457AEDC4" unitRef="usd">733000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D8574B7C749E1101EE45BD9E458427AA" unitRef="usd">963400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A88347C5CCAA3948605DBD9E4582694D" unitRef="usd">822500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-2BF196C2CF1F4068F902BD9E457817F3" unitRef="usd">34700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-68C6218E81903A3ABD66BD9E457CDCA1" unitRef="usd">8700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-726A517B90E17EBE206CBD9E4586D3CF" unitRef="usd">970900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A7455BE84C5C8C8741DBBD9E45892FE7" unitRef="usd">-2400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-FD278A6D3A92E104B2A5BD9E457FC65E" unitRef="usd">-1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2015Q1QTD" decimals="-5" id="Fact-1A236A032629A752BBB62AB66C9F2CAC" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q1YTD" decimals="-5" id="Fact-125D3D2403840AF098A52AB54E46FC8E" unitRef="usd">900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-427DF01B7F419509364EBD9E457D6E84" unitRef="usd">-15000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-9AF9707E63CD379A0D93BD9E45788F20" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-612576132B7C5AB67B18BD9E457C9CA3" unitRef="usd">-100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-90C5907C9C259A1AF121BD9E457CD67D" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D6BB45F270E76A5786B0BD9E4578B5D3" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-73AEF849CA30811E1C6FBD9E4572E46F" unitRef="usd">-52800000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2015Q4" decimals="-5" id="Fact-FC734D64B7F51EED9C04BD9E458309F6" unitRef="usd">6506500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-9B54789AB5EB093C5D9CBD9E458385DA" unitRef="usd">9000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-BD11E7F8ADCE94BD55ACBD9E45826AD3" unitRef="usd">1721100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-54D2E5E653F8C7477E62BD9E45833BC2" unitRef="usd">1733400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-DD69788F84F8254F606EBD9E45842B35" unitRef="usd">565300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-C6EADD780CD4273BF994BD9E45827C49" unitRef="usd">992200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-97A8D4A6656D28796596BD9E45826097" unitRef="usd">1485500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1" decimals="-5" id="Fact-078A5071A49CF35F0648BD9E4582C022" unitRef="usd">6521100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-B334B0C283E1B31C1BE8BD9E45832298" unitRef="usd">9400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-60255E3C3BBC8478434EBD9E45830B83" unitRef="usd">1721200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-C2B0F68C99C733DCBC11BD9E45828068" unitRef="usd">1733700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-3858A88F9C80E98E9E34BD9E4583EEC8" unitRef="usd">563600000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-E4159532D35B36A6C2CEBD9E458348DE" unitRef="usd">992500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-F5F8DF28DC5FE25A7B4DBD9E45838B4F" unitRef="usd">1500700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-6619C0B89BE6D048B2FFBD9E45831E57" unitRef="usd">9400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-240F10518DEBB34916FFBD9E45839405" unitRef="usd">1757600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-4F343773878D31D2F21DBD9E4583C5A4" unitRef="usd">1764600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-E5922D246EC8D51A9E33BD9E4583950A" unitRef="usd">602600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-1CEF5BBC537A7D81412BBD9E4582B873" unitRef="usd">1014200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-5A659A11F0783B967BEEBD9E4583BD96" unitRef="usd">1497500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-E2BF2CBFF72226C87D24BD9E4583F95D" unitRef="usd">9700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-E79915BBCA36F66D21F4BD9E4583BDAF" unitRef="usd">1957100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-20FC3C627B0A78CE692CBD9E45825B1E" unitRef="usd">1880800000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-08D923731A15075868FABD9E458372C0" unitRef="usd">603700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-68C2CF73EA326C3A0987BD9E4582CFEB" unitRef="usd">1058700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-3B46A1EBEE7940C8DABBBD9E4582293F" unitRef="usd">1543400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2016Q1YTD" decimals="0" id="Fact-9496D6D7B49E9EFB0845BD9E458935BA" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-47C9652A95F586EC46FDBEDF8F0E489F" unitRef="usd">0</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A6DC87814E0B412D2749BEDF262F3CF4" unitRef="usd">100000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q1QTD" decimals="-5" id="Fact-42A0BEC3490A5AD592ACBD9E45817232" unitRef="usd">1117900000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-970942448095D0D4A1A8BD9E45880877" unitRef="usd">1378400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-63FDCB93506143AEEBBDBD9E4573888A" unitRef="usd">635300000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-D393D425C131F4E1EDA1BD9E4577D4E2" unitRef="usd">582000000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-059B26417803842C1C61BD9E45823F65" unitRef="usd">836900000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-E816E562C8AE7022F605BD9E457E5AF5" unitRef="usd">941100000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-BE43A5FB8FACD22A39E4BD9E45891995" unitRef="usd">1107600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-E4FDAD6E49BACAA98145BD9E45871312" unitRef="usd">1094600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2016Q1_us-gaap_StatementGeographicalAxis_country_CH" decimals="-5" id="Fact-D49274DA56A89807DFCABEFC4FDC2220" unitRef="usd">180000000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2016Q1_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_OtherVariableInterestEntitiesMember" decimals="-5" id="Fact-CEDEF08F913951F055C92AC53F9DC757" unitRef="usd">8000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-AE820DBCA8619DF95DFBBD9E4585AFD3" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-47F37EC55F6A4280692FBD9E45869593" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-ECAF0AD98F7C8CE0B552BD9E4578D593" unitRef="usd">23700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-3186C4C4EA16F96DB13BBD9E457E7C08" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-C9EB83109C435F8C0E7ABD9E457EBDFA" unitRef="usd">122100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-03A357C49F3012B514F7BD9E457F094E" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-0757CCAC7C8EB16581B0BD9E45866C49" unitRef="usd">-100900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-7CC9B7BC062EEF5AF8E1BD9E457859C4" unitRef="usd">-26600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-05240F6692C31617AAB0BD9E457EAD51" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BF3A49E6819037CD010BBD9E457B3E06" unitRef="usd">-38900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-EF113BA39CF015A35F7EBD9E457DB1F8" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-37148EC25EDC916C4EF3BD9E457E0321" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-AC91EBE9F80DF0936603BD9E457E6727" unitRef="usd">87300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-0A23353D135D24067D13BD9E457425CE" unitRef="usd">-47600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A8B4E2E0C9D8C012F03BBD9E45793BAB" unitRef="usd">-100900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F2277B24834E9523D9B7BD9E45865480" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-8DB6661FD77705C7354ABD9E457DE22D" unitRef="usd">-11100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-4219635FCFE7FFC8CDECBD9E4577D47C" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5293B0C47AE39E886CBCBD9E45779F69" unitRef="usd">87300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6DC087186C4196EF8383BD9E457F83D1" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-77DE20A9C423F1AFA257BD9E4585ABD4" unitRef="usd">-100900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-3E031FC942223D44D31DBD9E457971FA" unitRef="usd">-35300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-AFB154F6FD65E8202ACCBD9E457B21FB" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-F7CBE0D7FDC722195EEFBD9E457B45D0" unitRef="usd">-47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0F56D985EB197DC4E006BD9E457D6F5D" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-20618D0AFF3963E37E5ABD9E457B797D" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-800A22FA49DEA65BD2DFBD9E457F66E2" unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1E2FB9B7D283C453BCE1BD9E457DA040" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-1D5AEBABE9F0DCAD6B82BD9E45734519" unitRef="usd">2096800000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-6CD4D2E3A3038114DA41BD9E4582B42A" unitRef="usd">2003900000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-5" id="Fact-2D6074729F46E90A2FD6BD9E4583EC2C" unitRef="usd">905800000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q1" decimals="-5" id="Fact-FE5F3F8BD88F90A83F32BD9E45778246" unitRef="usd">916600000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-E7B3B2063A063882CCCBBD9E457D4D08" unitRef="usd">32900000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-518BC0D596DD6450D5BFBD9E4580274D" unitRef="usd">20200000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A769E23A7BD17C818E2ABD9E45891AB4" unitRef="usd">3100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E84AADE2716693E57F53BD9E45875AAA" unitRef="usd">-4400000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B3AF9A404C245244EA0BBD9E457E6EAE" unitRef="usd">52000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2015Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-994DADC80E848FD704BFBD9E457E682D" unitRef="usd">18900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-34923FEBCAFD4435BF74BD9E45782E2B" unitRef="usd">2700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-3618376F9FC67C174C29BD9E4574CB45" unitRef="usd">87900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B946D4BF907CD8769AA8BD9E4588845D" unitRef="usd">6700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-48F20E76D19363B496CDBD9E457E9D53" unitRef="usd">43000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q1YTD" decimals="-5" id="Fact-A76049F19B2DD14C2554BDDBFBB383F1" unitRef="usd">29700000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-C74CFCC4015A981B86BDBDDBEBC9630E" unitRef="usd">4600000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-DD04DCA3F5C84B30054CBDDBA5589416" unitRef="usd">25100000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-CF7B7C6762605D6F5F6EBD9E458101E3" unitRef="usd">323000000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6BDD1FAEC5D3DE07A946BD9E457C69B1" unitRef="usd">1914400000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-4B6FA956FED4D6A2E1D8BD9E45840A2D" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2016Q1YTD_biib_CumulativeSalesLevelAxis_biib_EightbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-9CC65981C0A6EF04609FBD9E45876DCA" unitRef="usd">300000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2016Q1YTD_biib_CumulativeSalesLevelAxis_biib_SevenbillionMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-B1942BEF86C2CD8BDC3EBD9E457D68A5" unitRef="usd">300000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2015Q1QTD" decimals="-5" id="Fact-CB661E9DFC73844BCB61BD9E45833E6B" unitRef="usd">198800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6E11A76032E154B864ADBD9E45870CAC" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2015Q1QTD" decimals="-5" id="Fact-C4BAF470287F18E81FA5BD9E45849C95" unitRef="usd">250000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-28AA172B55F69C471DD2BD9E45863630" unitRef="usd">300000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q1QTD" decimals="-5" id="Fact-EFA00DBE12D73D5ADE33BD9E45887401" unitRef="usd">97800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F05DA29BBF9F86B0FFC2BD9E45757036" unitRef="usd">126900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-F6A34000B20064F4D7A0BD9E457C4A7F" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q1" decimals="INF" id="Fact-05F9BB4448E3978DA9A5BD9E457786D5" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-F50461C808612ABD3894BD9E4587E47F" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q1" decimals="-5" id="Fact-652B3D0EAF9D898B7037BD9E45870FCD" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidTaxes contextRef="FI2015Q4" decimals="-5" id="Fact-923C43041E73797919CFBEE986684320" unitRef="EUR">550600000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2016Q1" decimals="-5" id="Fact-0BB8F1AA7F60E4C78881BEE951B3CC31" unitRef="usd">613200000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2015Q1QTD" decimals="-5" id="Fact-CD867D511682FF76E9E9BD9E45879997" unitRef="usd">25600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D6E1E9F265F648E7A612BD9E45887F4D" unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-BE5098B20E155D3BB95FBD9E4586D428" unitRef="usd">-11300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-4A725C353C47CCCD6718BD9E45878235" unitRef="usd">24600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q1QTD" decimals="-5" id="Fact-B999D76A0EDCAB4C95D2BD9E457DC327" unitRef="usd">373600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-4BE0F9FDCDA0352FE5E5BD9E457953C5" unitRef="usd">1181100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2015Q1QTD" decimals="-5" id="Fact-A25A024E232328164C41BD9E457D9428" unitRef="usd">820200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6BE3E9C85CA8A48F82CABD9E45865851" unitRef="usd">969200000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q4QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-FE6818C361A663FCCEF3BECCF6D42E54" unitRef="chf">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2015Q4QTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-0E8E7A7FAE28FB7E01F2BECBB100EE29" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-5" id="Fact-C623BF6949301EB7EE47BD9E458789B3" unitRef="usd">2187600000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q1" decimals="-5" id="Fact-084CCA1676455414A524BD9E45739D05" unitRef="usd">2258900000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q1QTD" decimals="-5" id="Fact-007A3E551EC920E4F92DBD9E4572FD28" unitRef="usd">-34700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-068E80F41CCDEE105A75BD9E457F90FD" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1754677D5A376AAB3004BD9E45784048" unitRef="usd">-34800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-FF8D56902A32898A2905BD9E457F3324" unitRef="usd">100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-C13254B727CAB8E469B7BD9E4581886C" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-798E752BFED8A211C6B8BD9E457D2528" unitRef="usd">-8700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-216F9E39A188ECD84071BD9E457B1DB1" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-013403C8CCDD8A3E7F1DBD9E457CED87" unitRef="usd">-8700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6BE841F09C97838BE605BD9E457A05BE" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-72A749B18D9FD77B3887BD9E457D11E5" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-19D734A2C6D52EE1BEE5BD9E457B4FA0" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q1QTD" decimals="-5" id="Fact-2B4505FAEAE4F0188ED2BD9E45893094" unitRef="usd">460500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q1YTD" decimals="-5" id="Fact-676251601D99AFD38361BD9E457CE794" unitRef="usd">437300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-8F6691EE8790DA49AC3DC8871B1896DB" unitRef="usd">135000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_TypeOfArrangementAxis_biib_SwedishOrphanBiovitrumMember" decimals="-5" id="Fact-FEA71173F495E826123EC87FE41602E6" unitRef="usd">165000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="FI2016Q1" decimals="-6" id="Fact-88DB2F68DB43AE58AA68BE3900A18E87" unitRef="usd">105000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringCharges contextRef="FD2015Q1QTD" decimals="-5" id="Fact-CB6C1CB69B8A95F33EFABDA93DACDDAE" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2015Q4QTD" decimals="-5" id="Fact-E958C7473E15B841FC98BE3BC215ED1A" unitRef="usd">93400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q1YTD" decimals="-5" id="Fact-375D78FC3A7C1D338E34BDA93DAF5A50" unitRef="usd">9700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-C718501F758A692D08CBBE3B499F39F0" unitRef="usd">8300000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-7378EE19CE01E37F74E5BE3ADB01DE0D" unitRef="usd">1400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCosts contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D8D56BF8385FA6E6A42EBDDA27ED0D33" unitRef="usd">10300000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-FCEF6E567714EAC24C28BDDA12714A6C" unitRef="usd">5400000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-D6E55421BF8C4BF3A2C4BDD99623194E" unitRef="usd">4900000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4" decimals="-5" id="Fact-715E65024727745E2B34BDD466060CD8" unitRef="usd">37300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-D3FD32DA48BD2898D8F8BDD45785E6AC" unitRef="usd">3600000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-985AB05DC30077C8791ABDD3C16EA840" unitRef="usd">33700000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q1" decimals="-5" id="Fact-5CDEC47B178BC51992F8BDD8A0A02BF9" unitRef="usd">17300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-FA06A0BAC2DF30BFC120BDD88A7B82A1" unitRef="usd">7300000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q1_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-1EBEA22FBFD28B7C2128BDD79122E1CA" unitRef="usd">10000000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2015Q4QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-F9A64D5C6A3E278A3665BE383A4397FB" unitRef="usd">15900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q1YTD" decimals="-5" id="Fact-0FF1F782491E1BD6A1F4BDDD407C6971" unitRef="usd">-600000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-5" id="Fact-6375BCA9C9B988CCF3F3BDDD30D3A36E" unitRef="usd">2900000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RestructuringReserveAccrualAdjustment1 contextRef="FD2016Q1YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" decimals="-5" id="Fact-D79C704F54F92428302EBDDCF954CD83" unitRef="usd">-3500000</us-gaap:RestructuringReserveAccrualAdjustment1>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-5" id="Fact-6B7723986BC6C0E53A6BBD9E45816344" unitRef="usd">12208400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q1" decimals="-5" id="Fact-2B756C076D049F66081FBD9E4589EEF9" unitRef="usd">13179300000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2015Q1QTD" decimals="-5" id="Fact-06A76B3E27E336053768BD9E457EF1EE" unitRef="usd">2555000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1YTD" decimals="-5" id="Fact-28A0707B41D5786349DCBD9E457738D6" unitRef="usd">2726800000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2014Q2QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-F8C733741B8605C81A75BD9E4584CA69" unitRef="usd">53500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q1QTD" decimals="-5" id="Fact-47F8FC0A51F8F717B227BD9E457B0B99" unitRef="usd">2172300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2015Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-F31CBDE71AA21FF00B6CBD9E457804E4" unitRef="usd">35000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-46485E6147167007ED8DBD9E45787D03" unitRef="usd">8800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-8F95C07111A8983DF368BD9E4587182A" unitRef="usd">2309400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2015Q1QTD" decimals="-5" id="Fact-4967F498A1342A84142FBD9E4579077F" unitRef="usd">560400000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-25BE3AE4222F332F077CBD9E45721D09" unitRef="usd">497300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q1QTD" decimals="-5" id="Fact-4E0FE6067574A6B320E0BD9E4586BE86" unitRef="usd">52100000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1YTD" decimals="-5" id="Fact-62FAE89348D510059197BD9E45887B0F" unitRef="usd">45300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="0" id="Fact-0FB0A05EA3F4424C78EEBD9E457AB09F" unitRef="shares">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="0" id="Fact-8AEE7DFF028A7A82878FBD9E45793833" unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="0" id="Fact-D082CF3C567C30B66A78BD9E45795E20" unitRef="shares">351000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2015Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-2B966A1B52DFCDB63E63BD9E457ABFE7" unitRef="shares">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="0" id="Fact-592366C9BBF8B3BF3850BD9E45790CD3" unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="0" id="Fact-DEE90D9A7A6EA9A4E6AABD9E457AD686" unitRef="shares">146000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="0" id="Fact-08616D1C0477D2EC7303BD9E457AEDB2" unitRef="shares">549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2016Q1QTD_us-gaap_PlanNameAxis_us-gaap_PerformanceSharesMember" decimals="0" id="Fact-EDE481042CDFD814A90CBD9E457927EE" unitRef="shares">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2015Q1YTD_us-gaap_PlanNameAxis_biib_A1995ESPPMember" decimals="INF" id="Fact-69E0F1F94CA995516BA3BD9E45743662" unitRef="shares">68000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q1YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-E763A229302BC1380593BD9E4577510C" unitRef="shares">65000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-910B85314D40406019F3BD9E4586E66E" unitRef="usd">9372800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q1" decimals="-5" id="Fact-463F514B7E7A29A6F3BCBD9E4588E1EB" unitRef="usd">10326800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-5" id="Fact-76053D13D44B398771E7BD9E4581EEFF" unitRef="usd">9374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q1" decimals="-5" id="Fact-1C9BC7A320CA2ED83247BD9E458191EE" unitRef="usd">10328100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityPeriodIncreaseDecrease contextRef="FD2016Q1YTD" decimals="-5" id="Fact-2E6040047821DACA6AA5BD9E45896104" unitRef="usd">953200000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
	<us-gaap:TaxesPayableCurrent contextRef="FI2015Q4" decimals="-5" id="Fact-516BAE9E02CB2563F4FFBD9E45821990" unitRef="usd">208700000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q1" decimals="-5" id="Fact-7884150D63DD36E140FDBD9E45845C1B" unitRef="usd">496500000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-5" id="Fact-272854FF977F1D98C69CBD9E4584DD61" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q1" decimals="-5" id="Fact-E1F8B106630E991CC3ADBD9E4586AE52" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q1" decimals="-5" id="Fact-CF285501C94F6E4CBCD2BD9E458230B9" unitRef="usd">16400000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-5" id="Fact-C01D209D39DF66B63AF5BD9E4581DBA2" unitRef="usd">662700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-D88062F21AD11BD154E7BD9E45773E75" unitRef="usd">144600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-AB5FBEA056D0E2A58CBCBD9E4577C8C2" unitRef="usd">518100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D5F30755E4A600A511DCBD9E45852A2F" unitRef="usd">548700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-DBB035F886570264EE28BD9E4581B6E3" unitRef="usd">56100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-D398C6C78E1A315F4EB5BD9E4580B8B8" unitRef="usd">57900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1" decimals="-5" id="Fact-4A64CBEDBFA22DBBFB46BD9E45879106" unitRef="usd">732300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-27F181C53F630E745D1DBD9E45774CB8" unitRef="usd">156900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-9599D04C9E72100A376BBD9E45786E59" unitRef="usd">575400000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-97D6EC1DD3EEDD6CDF9EBD9E458478CA" unitRef="usd">612300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-0763C22576AE687FB814BD9E45797F1F" unitRef="usd">59100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-E6C04CD08F7D7D365F32BD9E458296E9" unitRef="usd">60900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2015Q1QTD" decimals="-5" id="Fact-E91EA73A4F4FB5B3CE77BD9E45747139" unitRef="shares">600000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F488AB47D2A1D5767881BD9E4573E758" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q1QTD" decimals="-5" id="Fact-3BB05B68270C87081040BD9E4579E098" unitRef="shares">235600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F15D23CBAC7B5C51BA9BBD9E4581B73F" unitRef="shares">219300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q1QTD" decimals="-5" id="Fact-3AACD88F2DCBC69A44CFBD9E457903B9" unitRef="shares">235000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q1YTD" decimals="-5" id="Fact-CADBF93BBD687234DD03BD9E4584F3F1" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2016Q1YTD" id="Fact-94A16529A3F582F210EBBD9E4572D5FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;616.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(187.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(262.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(48.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(229.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(283.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;612.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;60.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;732.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2016Q1YTD" id="Fact-4817F17028C0931ED765BD9E45732F9E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2016Q1YTD" id="Fact-8DEB56A1554B7A3C14C6BD9E4581BBE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(510.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,578.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;427.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;718.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;718.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,331.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(561.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,769.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,662.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3,650.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,012.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-0012A3B761B80B0D4789BD9E4589026F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock>
	<biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock contextRef="FD2016Q1YTD" id="Fact-EF78F9E32A61B9291A8CBEF0A167BF45">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table below over a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year period, consistent with the initial patent term of the products. Under the collaboration agreement, cash payments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate prior to 1st&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;commercial sale in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the&amp;#160;Sobi&amp;#160;Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock>
	<biib:ScheduleOfRestrictedStockUnitGrantsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-BE9111821E04B3C529E0BD9E45742E32">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our equity grants to employees, officers and directors under our current stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;73,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;549,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;351,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfRestrictedStockUnitGrantsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-E51F71F0E644D5B967A8BD9E458853DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;732.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-4E055FECC16C9D8E8E78BD9E458584BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(63.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(52.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets includes prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$613.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;180.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;161.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;582.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;635.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,003.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL, our Italian subsidiary,&amp;#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In January 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only "the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months" of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013. We have approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recorded as accrued expenses and deferred revenue both included in our long-term liabilities in our condensed consolidated balance sheets for this matter as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2016Q1YTD" id="Fact-379A5FD85E66C5235064BD9E45884B67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,225.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,222.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,823.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,823.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,456.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,456.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;507.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,644.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,641.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2016Q1YTD" id="Fact-30159630367D63990A63BD9E45897C02">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2016Q1YTD" id="Fact-1A0DB7E1716BBAFFD664BD9E458800CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;90.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;488.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of total assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;629.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,225.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,222.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,823.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,823.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,456.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,456.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;507.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,644.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,641.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;394.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,116.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,120.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,723.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,724.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,152.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,155.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;491.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;493.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,454.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,454.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,023.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;162.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;163.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,644.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,641.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,181.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;373.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$102.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-E70E9F51B16E75402B93BD9E45803D01">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Swedish Orphan Biovitrum AB&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2007, we acquired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. We have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below, (the Biogen Direct Territory).&amp;#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. For additional information on our collaboration agreement with Sobi, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ELOCTA, the trade name for ELOCATE in the E.U., was approved by the EC in November 2015 and Sobi had its first commercial sale in January 2016. In March 2016, the EC approved the transfer of the marketing authorization for ELOCTA to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$165.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ELOCTA, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, are reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ELOCTA in the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016, we and Sobi received a positive recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of ALPROLIX. The CHMP's recommendation was referred to the EC, which grants marketing authorizations for medicines in the E.U. If approved by the EC, upon the first commercial sale of ALPROLIX by Sobi in the Sobi Territory, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$135.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in expenditures for ALPROLIX, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, will become reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product. If EC approval for ALPROLIX is not granted within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months of the filing date, Sobi shall have the right under the collaboration agreement to require that the escrow payment be refunded and revoke its option right for such product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table below over a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; year period, consistent with the initial patent term of the products. Under the collaboration agreement, cash payments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rates post Sobi Opt-In&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(3)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Royalty and Net Revenue Share Rates:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Method&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate prior to 1st&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;commercial sale in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the&amp;#160;Sobi&amp;#160;Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Base Rate following&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;1st&amp;#160;commercial&amp;#160;sale&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;the Sobi Territory:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rate during the&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reimbursement&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Period:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Sobi rate to Biogen on net sales in the Sobi Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base&amp;#160;Rate&lt;br clear="none"/&gt;plus 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen North America Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net sales in the Biogen Direct Territory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Biogen rate to Sobi on net revenue&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;from the Biogen Distributor Territory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Net&lt;br clear="none"/&gt;Revenue&lt;br clear="none"/&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Base Rate&lt;br clear="none"/&gt;less 15%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Net revenue represents Biogen&amp;#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If the reimbursement of the Opt-in Consideration has not been achieved within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; days of the six year anniversary date of the first commercial sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;Samsung Biologics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest is approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a loss on our investment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&amp;#160;Under the terms of this agreement, we have made total upfront and milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which have been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make an additional milestone payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we made the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment, which has been capitalized in intangible assets, net in our condensed consolidated balance sheet as BENEPALI received regulatory approval in the E.U. in January 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016. We reflect revenues on sales of BENEPALI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. Our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the Samsung Bioepis commercial agreement will be recognized in our condensed consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in relation to these services as other revenues in our condensed consolidated statements of income, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our other significant collaboration arrangements, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-BD2772B9BEB359B55F31BD9E457D054E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013, we paid this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2016, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales level related to the Fumapharm Products in the fourth quarter of 2015 and accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of Fumapharm Products during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We will owe an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment for every additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, until such time as the cumulative sales level reaches &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$180.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2016Q1YTD" id="Fact-D0D6845680B5AA2C79B4BD9E4585934D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(26.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(35.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(186.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;122.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(100.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(100.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;159.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(30.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(70.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2016Q1YTD" id="Fact-F046D52D65F14735D79FBD9E45893818">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-1A89732A82D4DF166582BD9E457F2C33">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,251.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,375.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$680.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$721.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. A net gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts was recognized as a component of other income (expense), net, for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to a net loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;12.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q1YTD" id="Fact-F41E343DF74990B004B1BD9E45749D43">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Grants Under Share-based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our equity grants to employees, officers and directors under our current stock plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;175,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;73,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;112,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;89,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;549,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;351,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,200,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares were issued under our 2015 ESPP, compared to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;68,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares issued under our 1995 ESPP in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q1YTD" id="Fact-E62B75CD42385BAF0E29BD9E45752C2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2016Q1YTD" id="Fact-4E84B0033D0345BB2846BD9E457C3731">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,855.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,855.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,279.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,279.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;509.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;509.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,568.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,536.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;554.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;603.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;563.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,543.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,058.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;992.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,880.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,733.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,957.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,053.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,521.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,506.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;461.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$303.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$301.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2016Q1YTD" id="Fact-CD731A7F6928E72A7DC8BD9E45846A6B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;461.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-02C3D6E84BD15B80AB3EBD9E4584E459">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(510.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,578.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;427.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,552.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;452.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;718.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;718.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;730.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,331.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(561.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,769.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,303.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(502.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,800.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,662.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3,650.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,012.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,646.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,085.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$88.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$95.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. In-process research and development amounts are adjusted for foreign exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$418.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,689.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in acquired and in-licensed rights and patents during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was primarily related to the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Samsung Bioepis, which became payable upon the approval of BENEPALI in the E.U. in January 2016. For additional information on our relationship with Samsung Bioepis, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;265.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;321.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;293.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;271.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,688.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;257.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,917.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-40FD752D4EB7A26303F9BD9E45820F16">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our effective tax rate increased due to a state tax benefit in 2015, described below. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&amp;#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&amp;#160;federal tax examination for years before 2013 or state, local, or non-U.S.&amp;#160;income tax examinations for years before 2004. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&amp;#160;In April 2016, we received final assessments for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$67.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including interest.&amp;#160;We are disputing the assessments for these periods, and believe that the positions we have taken are valid.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended March&amp;#160;31, 2015, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; primarily related to the state impact of a federal uncertain tax item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the tax authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&amp;#248;d, Denmark. We initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, to reach agreement on the issue. In addition, we applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years. Over the past year, we have reached agreement with the tax authorities in the U.S. and Denmark regarding the tax treatment of these items for the years up to and including 2009. We have recorded the results of these agreements, which were not significant to our results.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-1EBA094EF1090E8BA1C1BD9E4573DDDE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;607.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,001.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;964.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,001.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory included in investments and other assets in our condensed consolidated balance sheets primarily consisted of work in process.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$33.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the FLIXABI program, which have been capitalized in advance of regulatory approval. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our inventory included &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with our ZINBRYTA program, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the FLIXABI program and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with the BENEPALI program, which had been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2016Q1YTD" id="Fact-D4838F781F1928D0B1BCBD9E45887EF7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,454.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,454.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,120.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,122.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,026.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,023.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,575.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,583.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;162.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;163.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;184.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;185.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,644.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,641.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,880.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,891.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2016Q1YTD" id="Fact-34007C77CECCB1D29C32BD9E458661E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv), the parties&amp;#8217; legal theories; and (v) the parties' settlement positions.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Forward Pharma German Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&amp;#160;20 2005 022 112&amp;#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&amp;#160;extended its allegations&amp;#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025 (the '355 patent). Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. With respect to the '355 patent, the hearing has been stayed pending the outcome of opposition proceedings that we and others have filed in the European Patent Office, and with respect to the utility model the hearing has been stayed pending the outcome of those proceedings and proceedings in the German Patent Office.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;ALPROLIX Patent Licensing Matter &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&amp;#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&amp;#160;royalties on sales of ALPROLIX. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Italian National Medicines Agency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL&amp;#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&amp;#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &amp;#8220;the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months&amp;#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding this matter, please read Note 15, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. All but one of the actions has been voluntarily dismissed. The pending action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. The United States has not made an intervention decision in the action, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. We have filed a motion to dismiss, which is pending. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for late 2016.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Inter Partes Review Petitions and Proceeding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 22, 2016, the USPTO instituted &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. A hearing has been scheduled for late 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating multiple sclerosis and Crohn&amp;#8217;s disease using specific formulations of natalizumab (TYSABRI). The USPTO has not yet decided whether to institute review.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 10, 2016, the European Patent Office revoked our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The decision was issued verbally and will be followed by a written decision, from which intend to appeal. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&amp;#160;(&amp;#8220;Administration of agents to treat inflammation&amp;#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&amp;#160;Subsequently, the same entity brought actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. A hearing has been scheduled in the UK action for late 2016 and in the Dutch action for early 2017. No hearing has yet been scheduled in the German action.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated '755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 4, 2016 we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q1YTD" id="Fact-F8A16F42081647581472BD9E45725E0C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015, the FASB issued the following new standards, which we adopted on January 1, 2016:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have an impact on our financial position or results of operations. For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is expected to have a material impact on our financial position. We are currently evaluating the potential impact that this standard may have on our results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. We are currently evaluating the potential impact that this standard may have on our financial position, results of operations and statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-5650C83A3850B2F2E8A1BD9E457899C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,394.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,330.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 1, 2015, we purchased land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$158.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-C1E7A5698E2EA64AD0B9BD9E4588B401">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,181.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;373.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2016Q1YTD" id="Fact-CEC45E204AD5D7A5CA07BD9E458084AE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-EA4E28D119AD4498967DBDCCCF8112FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in workforce. We anticipate making cash payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this program, which includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to previously accrued 2015 incentive compensation, resulting in net expected restructuring charges totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$105 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These amounts have been substantially incurred and will be substantially paid by the end of 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized restructuring charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to our workforce reduction and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to the pipeline program terminations.&amp;#160;We previously recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of restructuring charges in our consolidated statements of income during the fourth quarter of 2015. Our restructuring reserve is included in accrued expenses and other in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the charges and spending related to our restructuring efforts during the first quarter of 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(29.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q1YTD" id="Fact-EACC6AAD876C555EBECFBD9E457DA607">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;504.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;180.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;270.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;161.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;582.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;635.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,003.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,096.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2016Q1YTD" id="Fact-6432C425E2E7166D7D57BD9E4580ACCF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(26.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(35.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(186.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(31.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(99.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(59.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;122.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(100.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(100.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;159.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(30.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(200.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(70.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-072804F293190A48F55DBD9E457B28D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;603.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;563.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;602.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;565.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,543.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,497.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,058.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;992.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,014.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;992.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,880.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,733.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,764.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,733.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,957.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,757.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,053.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,521.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,645.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,506.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-6B53A426EA154234A583BD9E4588D448">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;90.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;488.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;673.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;79.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2016Q1YTD" id="Fact-D42AF4E7C86DBABAA58ABD9E45740322">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2016Q1YTD" id="Fact-0BB7244F2722B00B2084BD9E45782931">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2016Q1YTD" id="Fact-93252663472194A9DABCBD9E45786B84">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;12.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2016Q1YTD" id="Fact-D3E690C24767D6358277BD9E45749B6F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;822.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2016Q1YTD" id="Fact-AB6CB2F375CD1E7D9F33BD9E4583C338">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q1YTD" id="Fact-D1EC7162FA516EDD59B1BD9E45740C20">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;87.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2016Q1YTD" id="Fact-B04E576C364233933D6DBD9E45834526">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;820.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,855.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,855.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,279.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,279.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;509.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;509.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,568.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,536.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;554.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2015 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;909.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,510.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,875.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;494.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,895.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,857.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2016Q1YTD" id="Fact-F2BDE4C4281E1F76D201BD9E4584B7D3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;257.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,917.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2016Q1YTD" id="Fact-A90C5A62B631EF144828BD9E45735A77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;607.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;577.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;143.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,001.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;964.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;893.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,001.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;933.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2016Q1YTD" id="Fact-5C31F0EEE4BA2DBB4FCFBD9E4578CC14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,251.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;945.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;76.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,375.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,103.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2016Q1YTD" id="Fact-132832B130F5099ABE83BD9E45828A81">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(63.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(52.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2016Q1YTD" id="Fact-0FC35461A810EC161342BDCF099694F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Workforce&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Pipeline&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;33.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(29.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to previous estimates, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring reserve as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-6CD508D155B8649CB2F4BD9E45790923">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;480.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;616.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(187.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(262.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(48.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(229.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(283.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;612.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;60.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;732.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;144.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;518.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;732.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2016Q1YTD" id="Fact-99971A36F8830CA6F1A1BD9E4581108D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;265.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;321.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;293.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;271.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,688.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q1YTD" id="Fact-EF996EBA4F5CDF1645DEBD9E4584E0F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2015, the FASB issued the following new standards, which we adopted on January 1, 2016:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have an impact on our financial position or results of operations. For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is expected to have a material impact on our financial position. We are currently evaluating the potential impact that this standard may have on our results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. We are currently evaluating the potential impact that this standard may have on our financial position, results of operations and statement of cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-50476FBA6E0BF7A46B4FBD9E4588627F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total equity as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$953.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This increase was primarily driven by net income attributable to Biogen Inc. of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$970.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Noncontrolling Interests&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2016Q1YTD" id="Fact-BD9F18DEC9E808A54E4CBD9E457A37B0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2016Q1YTD" id="Fact-6CA9EB6016D7BAEC3DEABD9E4580543C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&amp;#8217;s disease resulted from this collaboration. Based upon our current development plans for aducanumab, we may pay Neurimmune up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$275.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and are required to fund &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also consolidate the financial results of our other variable interest entities where we are the primary beneficiary. We may pay these variable interest entities up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments. We have provided no financing to these entities other than amounts provided for in the contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$38.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our investments in variable interest entities, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20160331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20160331" xmlns:biib="http://www.biogenidec.com/20160331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2119100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2419402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2419403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2319301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2125100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2425402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2425403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables">
        <link:definition>2325301 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails">
        <link:definition>2427401 - Disclosure - Commitments and Contingences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2127100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1">
        <link:definition>2427402 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2114100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2414402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2314301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2120100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2420402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2320301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2118100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2418402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2418403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2318301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2110100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2410402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2410403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2410404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2410405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2310301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2112100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2412403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2412404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2412405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2412406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2412407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2312301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2122100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2422402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2422403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2322301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2109100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2108100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2408402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual">
        <link:definition>2408403 - Disclosure - Inventory Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2308301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2124100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2424401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2126100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2426401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2123100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2423402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2423403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2323301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2116100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2416401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowances" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances">
        <link:definition>2107100 - Disclosure - Reserves for Discounts and Allowances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails">
        <link:definition>2407402 - Disclosure - Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2407403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1Calc2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2">
        <link:definition>2407403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesTables" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables">
        <link:definition>2307301 - Disclosure - Reserves for Discounts and Allowances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2106100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetails" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails">
        <link:definition>2406402 - Disclosure - Restructuring Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringTables" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables">
        <link:definition>2306301 - Disclosure - Restructuring Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2121100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2421402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2421403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2421404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2421405 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2321301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A1995ESPPMember" name="A1995ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BaseRateAfterFirstCommercialSale" name="BaseRateAfterFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecHemophiliaMember" name="BiogenIdecHemophiliaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" name="BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" name="BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeInstrumentsTextualAbstract" name="DerivativeInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EightbillionMember" name="EightbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Employeestockpurchaseplanmaximumshares" name="Employeestockpurchaseplanmaximumshares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Finitelivedintangibleassetsfutureamortization" name="Finitelivedintangibleassetsfutureamortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OneBillionMember" name="OneBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherVariableInterestEntitiesMember" name="OtherVariableInterestEntitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Overnightreverserepurchaseagreementspercentoftotalassets" name="Overnightreverserepurchaseagreementspercentoftotalassets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodForGrantingOfApprovalByApprovingAuthority" name="PeriodForGrantingOfApprovalByApprovingAuthority" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Preapprovalinventory" name="Preapprovalinventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" name="ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_RateDuringReimbursementPeriod" name="RateDuringReimbursementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RatePriorToFirstCommercialSale" name="RatePriorToFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" name="ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" name="ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementCostAchievingPeriod" name="ReimbursementCostAchievingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementLimitStatedInResolution" name="ReimbursementLimitStatedInResolution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" name="ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReimbursementUnderAmendedAgreementMethod" name="ReimbursementUnderAmendedAgreementMethod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reimbursementrecognitionperiod" name="Reimbursementrecognitionperiod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" name="RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" name="ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RestructuringandRelatedCostExpectedCashPayments" name="RestructuringandRelatedCostExpectedCashPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" name="Restructuringandrelatedcostexpectedpercentageofpositionseliminated" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" name="RoyaltyAndNetRevenueShareRatesByTerritoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" name="RoyaltyAndNetRevenueShareRatesByTerritoryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" name="ScheduleOfRestrictedStockUnitGrantsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfStockOptionGrantsAbstract" name="ScheduleOfStockOptionGrantsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SevenbillionMember" name="SevenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" name="SobiRateToBiogenOnNetSalesInSobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiTerritoryMember" name="SobiTerritoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SwedishOrphanBiovitrumMember" name="SwedishOrphanBiovitrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ThreeBillionMember" name="ThreeBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TimePeriodForPayingRemainingBalanceDue" name="TimePeriodForPayingRemainingBalanceDue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20160331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20160331.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20160331.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20160331.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20160331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20160331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20160331.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20160331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20160331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20160331.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20160331.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20160331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20160331.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20160331.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20160331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20160331.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20160331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20160331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20160331.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20160331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20160331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20160331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20160331.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20160331.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20160331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20160331.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20160331.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20160331.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20160331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20160331.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20160331.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20160331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_027121dc-d718-d921-ddd8-bd9e54985311" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_027121dc-d718-d921-ddd8-bd9e54985311" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="locator" />
    <calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4a851329-dac2-753a-9238-81894caa8647" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4a851329-dac2-753a-9238-81894caa8647" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1508a6a-babd-3ec7-9349-b4d44aab4c91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_11b1e641-cd86-3d66-b07d-893757bffb5e" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_11b1e641-cd86-3d66-b07d-893757bffb5e" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_260b0554-5407-84a9-0ddc-c064bbfac41b" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_260b0554-5407-84a9-0ddc-c064bbfac41b" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_441e5869-bd08-8d9f-f5d3-2febc2ab5a6e" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_441e5869-bd08-8d9f-f5d3-2febc2ab5a6e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41b443af-a326-4272-6fa8-602f7260ec05" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41b443af-a326-4272-6fa8-602f7260ec05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_36b3b152-325b-61f4-d066-1d3685b6c394" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_36b3b152-325b-61f4-d066-1d3685b6c394" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_10c80460-5b5e-7e81-facb-0d1ed91293c2" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_10c80460-5b5e-7e81-facb-0d1ed91293c2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ad66514d-dce4-49aa-3300-d457a5d4216a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ad66514d-dce4-49aa-3300-d457a5d4216a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df415662-e392-2016-38c7-6c4ddd8a9714" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_e3b09688-ae53-852c-5010-bd9e54dcfb80" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_df415662-e392-2016-38c7-6c4ddd8a9714" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="arc" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="biib-20160331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20160331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20160331.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20160331.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20160331.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20160331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20160331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20160331.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20160331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20160331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20160331.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20160331.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20160331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20160331.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20160331.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20160331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20160331.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20160331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20160331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20160331.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20160331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20160331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20160331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20160331.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20160331.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20160331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20160331.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20160331.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20160331.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20160331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20160331.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20160331.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20160331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:to="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:to="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F247D404926BD8CF76BBBEBB3BDAD0E5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F247D404926BD8CF76BBBEBB3BDAD0E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_8211EF6A7EF269659706BEBB3BDAA1E4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_8211EF6A7EF269659706BEBB3BDAA1E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:to="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:to="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:to="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:to="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:to="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4_default" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:to="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_210C44F256AB6C8CFA723916980A5EC1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_210C44F256AB6C8CFA723916980A5EC1" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Reimbursementrecognitionperiod" xlink:label="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_5E16080ACC4B13A1FA2F2A7B375C312A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:to="loc_biib_BENEPALIMember_5E16080ACC4B13A1FA2F2A7B375C312A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_F4B8646A3077B6F38E702A7B375D23CD" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_F4B8646A3077B6F38E702A7B375D23CD" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:to="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37_default" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:to="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:to="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:to="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:to="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:to="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:to="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:to="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:to="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:to="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:to="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:to="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:to="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:to="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:to="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:to="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:to="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:to="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:to="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:to="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:to="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_DEF338300912317352D22A7B379D1A98" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_DEF338300912317352D22A7B379D1A98" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_2052549A0DB2119FF62B2A7B379D85BC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_MarketStockUnitsMember_2052549A0DB2119FF62B2A7B379D85BC" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:to="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:to="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7777C1FF7C9F9A53DB0DBD9EA9312731" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7777C1FF7C9F9A53DB0DBD9EA9312731" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_FED29B5EC75DEEC9B0B1BD9EA8D7B12A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_FED29B5EC75DEEC9B0B1BD9EA8D7B12A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:to="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B73852436D781EF12342BE1E3146E756" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B73852436D781EF12342BE1E3146E756" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B578F9DA1CD12017DF1EBE1E314654A2" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B578F9DA1CD12017DF1EBE1E314654A2" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1DC179A834B45A75B31FBE1E3146AF74" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1DC179A834B45A75B31FBE1E3146AF74" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_687681095C2E88EE5B67BE1E3146AFBA" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_687681095C2E88EE5B67BE1E3146AFBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1CD49769208073CAC416BE1E3147104C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1CD49769208073CAC416BE1E3147104C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:to="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:to="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:to="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:to="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:to="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:to="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:to="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:to="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_11DD4442800B49BCDB1FBE517D3E85BB" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:to="loc_biib_BENEPALIMember_11DD4442800B49BCDB1FBE517D3E85BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:to="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:to="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:to="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:to="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_E01A3AD9A7CB85ED01EEBD9EAB9817A6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:to="loc_biib_TecfideraMember_E01A3AD9A7CB85ED01EEBD9EAB9817A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_C7A50C13374E86F97FBBBD9EAB9840E1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:to="loc_biib_FumapharmAgMember_C7A50C13374E86F97FBBBD9EAB9840E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_043619B18E87A3B71CB8BD9EAB98B2FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_043619B18E87A3B71CB8BD9EAB98B2FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:to="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:to="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:to="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OtherVariableInterestEntitiesMember" xlink:label="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:to="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:to="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:to="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:to="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:to="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:to="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_DBCD7FC5A4FECFA23B8A2A7B3771985C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:to="loc_country_IT_DBCD7FC5A4FECFA23B8A2A7B3771985C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_7C5077DD35E3C89ACF9E2AC086660969" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_7C5077DD35E3C89ACF9E2AC086660969" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E3E8CC4AB1F5503526AE2A7B37720661" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E3E8CC4AB1F5503526AE2A7B37720661" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:to="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:to="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:to="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9267EC0538473EF0317FBD9EA7F905A5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9267EC0538473EF0317FBD9EA7F905A5" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_57ACDE8E90E86A7AAC2039D762AE97CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:to="loc_us-gaap_EmployeeSeveranceMember_57ACDE8E90E86A7AAC2039D762AE97CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_112CA95209DA31898C1B39D762AF49B7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:to="loc_us-gaap_ContractTerminationMember_112CA95209DA31898C1B39D762AF49B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_551E05928CD7FB91259039D762AF1C94" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_551E05928CD7FB91259039D762AF1C94" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:to="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:to="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B29BAF7ED0CF473F82652A7B37952AF6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B29BAF7ED0CF473F82652A7B37952AF6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_348520E6B27C8DBADA492A7B3795B090" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_348520E6B27C8DBADA492A7B3795B090" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:to="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:to="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:to="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:to="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:to="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:to="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CB71467ED79D9C8FEB69BD9EACA0AF99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_MarketStockUnitsMember_CB71467ED79D9C8FEB69BD9EACA0AF99" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_0ECB3E82030C1343CF5DBD9EACA093D8" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_CashSettledPerformanceSharesMember_0ECB3E82030C1343CF5DBD9EACA093D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A8F0231E9B6B986764E2BD9EACA5EC53" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_us-gaap_PerformanceSharesMember_A8F0231E9B6B986764E2BD9EACA5EC53" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_C785F95349B3E75C2133BD9EACA57A71" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_C785F95349B3E75C2133BD9EACA57A71" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:to="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:to="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:to="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:to="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:to="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:to="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20160331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2_label_en-US" xlink:label="lab_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="lab_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:to="lab_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:to="lab_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:to="lab_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:type="arc" />
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87_terseLabel_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87_label_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:label id="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87_documentation_en-US" xlink:label="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements, percent of total assets</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:to="lab_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:to="lab_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:to="lab_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Workforce reduction</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:to="lab_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pipeline programs</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:to="lab_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:type="arc" />
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94_terseLabel_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94_label_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:label id="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94_documentation_en-US" xlink:label="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, expected percentage of positions eliminated</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:to="lab_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="arc" />
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF_terseLabel_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cash payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF_label_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:label id="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF_documentation_en-US" xlink:label="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cash Payments</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:to="lab_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to previous estimates, net</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:to="lab_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="lab_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:to="lab_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:to="lab_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6_label_en-US" xlink:label="lab_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:to="lab_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:to="lab_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:to="lab_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:to="lab_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:to="lab_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:to="lab_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:to="lab_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:to="lab_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:to="lab_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:to="lab_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:to="lab_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77_label_en-US" xlink:label="lab_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:to="lab_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:to="lab_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:to="lab_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B_label_en-US" xlink:label="lab_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:to="lab_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23_label_en-US" xlink:label="lab_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:to="lab_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:to="lab_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:to="lab_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:to="lab_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0_label_en-US" xlink:label="lab_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:to="lab_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:to="lab_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="lab_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="arc" />
    <link:label id="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D_terseLabel_en-US" xlink:label="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seven billion</link:label>
    <link:label id="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D_label_en-US" xlink:label="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:label id="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D_documentation_en-US" xlink:label="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven billion [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:to="lab_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="arc" />
    <link:label id="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016_terseLabel_en-US" xlink:label="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eight billion</link:label>
    <link:label id="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016_label_en-US" xlink:label="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eight billion [Member]</link:label>
    <link:label id="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016_documentation_en-US" xlink:label="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eight billion</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:to="lab_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="arc" />
    <link:label id="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C_terseLabel_en-US" xlink:label="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One billion</link:label>
    <link:label id="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C_label_en-US" xlink:label="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:label id="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C_documentation_en-US" xlink:label="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One billion [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:to="lab_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="arc" />
    <link:label id="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A_terseLabel_en-US" xlink:label="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three billion</link:label>
    <link:label id="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A_label_en-US" xlink:label="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:label id="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A_documentation_en-US" xlink:label="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three billion [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:to="lab_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9_label_en-US" xlink:label="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:to="lab_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:to="lab_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:to="lab_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667_label_en-US" xlink:label="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667_documentation_en-US" xlink:label="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:to="lab_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash portion of consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:to="lab_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:to="lab_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:to="lab_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="arc" />
    <link:label id="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3_terseLabel_en-US" xlink:label="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1995 ESPP</link:label>
    <link:label id="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3_label_en-US" xlink:label="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:label id="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3_documentation_en-US" xlink:label="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">1995 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:to="lab_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD_label_en-US" xlink:label="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:to="lab_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:type="arc" />
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE_terseLabel_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE_label_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:label id="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE_documentation_en-US" xlink:label="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan maximum shares</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:to="lab_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:to="lab_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:to="lab_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:to="lab_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085_negatedLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of stock for share-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D_terseLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess tax benefit from stock options</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:to="lab_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:to="lab_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:to="lab_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:to="lab_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C_verboseLabel_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity grants to employees, officers and directors under our current stock plans</link:label>
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C_label_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Restricted Stock Unit Grants [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C_documentation_en-US" xlink:label="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of restricted stock unit grants.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" xlink:label="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:to="lab_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:to="lab_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2015</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of March 31, 2016</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="lab_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:to="lab_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E_label_en-US" xlink:label="lab_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:to="lab_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:to="lab_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:to="lab_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="lab_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2007</link:label>
    <link:label id="lab_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF_label_en-US" xlink:label="lab_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2007 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:to="lab_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2008</link:label>
    <link:label id="lab_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814_label_en-US" xlink:label="lab_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2008 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:to="lab_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2009</link:label>
    <link:label id="lab_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8_label_en-US" xlink:label="lab_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2009 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:to="lab_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net benefit for a previously unrecognized position</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="arc" />
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA_verboseLabel_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proposed deduction disallowance by tax authorities</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA_label_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proposed Disallowance By Tax Authorities For Payment For Services</link:label>
    <link:label id="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA_documentation_en-US" xlink:label="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proposed disallowance by tax authorities for payment for services.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:to="lab_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B_label_en-US" xlink:label="lab_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:to="lab_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland land purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:to="lab_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC_verboseLabel_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option grants</link:label>
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC_label_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Stock Option Grants [Abstract]</link:label>
    <link:label id="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC_documentation_en-US" xlink:label="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of stock option grants.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:to="lab_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income loss before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:to="lab_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:to="lab_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="lab_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="arc" />
    <link:label id="lab_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB_verboseLabel_en-US" xlink:label="lab_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB_label_en-US" xlink:label="lab_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:to="lab_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="arc" />
    <link:label id="lab_currency_CHF_AA07138D2F258542768CBEBB1769ABF1_terseLabel_en-US" xlink:label="lab_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_AA07138D2F258542768CBEBB1769ABF1_label_en-US" xlink:label="lab_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:to="lab_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="arc" />
    <link:label id="lab_currency_CAD_BF65244D39936715E670BEB9AC9DBC33_verboseLabel_en-US" xlink:label="lab_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian Dollar</link:label>
    <link:label id="lab_currency_CAD_BF65244D39936715E670BEB9AC9DBC33_label_en-US" xlink:label="lab_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:to="lab_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8_label_en-US" xlink:label="lab_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:to="lab_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:to="lab_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:to="lab_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:to="lab_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:to="lab_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:to="lab_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:to="lab_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:to="lab_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:to="lab_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:to="lab_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:to="lab_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08_label_en-US" xlink:label="lab_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:to="lab_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A_label_en-US" xlink:label="lab_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:to="lab_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B_label_en-US" xlink:label="lab_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:to="lab_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899_label_en-US" xlink:label="lab_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:to="lab_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivatives designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294_verboseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="lab_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:to="lab_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected settlement time for contracts, in months</link:label>
    <link:label id="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC_label_en-US" xlink:label="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Remaining Maturity of Foreign Currency Derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:to="lab_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:to="lab_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:to="lab_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="lab_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D_label_en-US" xlink:label="lab_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:to="lab_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:to="lab_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:to="lab_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:to="lab_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292_label_en-US" xlink:label="lab_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:to="lab_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:to="lab_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:to="lab_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:to="lab_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="arc" />
    <link:label id="lab_country_CH_44F4EC842B19B2A2268DBEBB3B302681_terseLabel_en-US" xlink:label="lab_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
    <link:label id="lab_country_CH_44F4EC842B19B2A2268DBEBB3B302681_label_en-US" xlink:label="lab_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:to="lab_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:to="lab_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:to="lab_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3_label_en-US" xlink:label="lab_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:to="lab_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:to="lab_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3_label_en-US" xlink:label="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:to="lab_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="arc" />
    <link:label id="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F_terseLabel_en-US" xlink:label="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Variable Interest Entities</link:label>
    <link:label id="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F_label_en-US" xlink:label="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Variable Interest Entities [Member]</link:label>
    <link:label id="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F_documentation_en-US" xlink:label="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Variable Interest Entities [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_OtherVariableInterestEntitiesMember" xlink:label="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:to="lab_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:type="arc" />
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714_verboseLabel_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714_label_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Potential Development Milestone Payments And Royalties On Commercial Sales Under Terms Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714_documentation_en-US" xlink:label="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:to="lab_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="arc" />
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost in support of collaboration agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost In Support Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development cost in support of the collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:to="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional investments committed to if certain development milestones are achieved</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:to="lab_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:to="lab_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve as of December 31, 2015</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:to="lab_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:to="lab_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve as of March 31, 2016</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:to="lab_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D_terseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash reimbursement as an adjustment to the Base Rate</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Amounts Payable [Table Text Block]</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mechanism for reimbursement, under the amended agreement amounts payable.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:to="lab_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:to="lab_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:to="lab_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:to="lab_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:to="lab_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges and spending related to our restructuring efforts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:to="lab_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:to="lab_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="arc" />
    <link:label id="lab_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29_terseLabel_en-US" xlink:label="lab_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29_label_en-US" xlink:label="lab_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:to="lab_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:to="lab_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C_terseLabel_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C_label_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Limit Stated In Resolution</link:label>
    <link:label id="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C_documentation_en-US" xlink:label="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement limit stated in the resolution.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:to="lab_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="lab_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="lab_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs, net</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:to="lab_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:to="lab_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:to="lab_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:to="lab_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57_label_en-US" xlink:label="lab_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:to="lab_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:to="lab_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:to="lab_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:to="lab_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:to="lab_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:to="lab_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973_label_en-US" xlink:label="lab_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:to="lab_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:to="lab_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="lab_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:to="lab_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:to="lab_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:to="lab_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:to="lab_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:to="lab_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:to="lab_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Non Controlling Interests [Abstract]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">NCI, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:to="lab_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to NCI, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of net assets and liabilities acquired and assigned to NCI</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1_negatedTerseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment and other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">NCI, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:to="lab_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the changes in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in condensed consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity increase during the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:to="lab_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D_label_en-US" xlink:label="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:to="lab_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101_label_en-US" xlink:label="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:to="lab_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:to="lab_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:type="arc" />
    <link:label id="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D_terseLabel_en-US" xlink:label="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D_label_en-US" xlink:label="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:label id="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D_documentation_en-US" xlink:label="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-approval inventory</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:to="lab_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:to="lab_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:to="lab_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:to="lab_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:to="lab_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="lab_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:to="lab_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount reserved for this matter</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI product</link:label>
    <link:label id="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0_label_en-US" xlink:label="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:to="lab_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:to="lab_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:to="lab_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9_label_en-US" xlink:label="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9_documentation_en-US" xlink:label="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:to="lab_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:to="lab_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:to="lab_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2016 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:type="arc" />
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125_totalLabel_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125_label_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:label id="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125_documentation_en-US" xlink:label="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FiniteLivedIntangibleAssetsFutureAmortization</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:to="lab_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97_verboseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292_verboseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable interest entity, qualitative or quantitative information, ownership percentage</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:to="lab_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity minimum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4_verboseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share with Samsung Bioepis</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to technical development and technology transfer services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:to="lab_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:to="lab_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979_label_en-US" xlink:label="lab_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:to="lab_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:to="lab_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="arc" />
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A_terseLabel_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A_label_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swedish Orphan Biovitrum [Member]</link:label>
    <link:label id="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A_documentation_en-US" xlink:label="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Swedish orphan biovitrum.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:to="lab_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Hemophilia</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC_label_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia [Member]</link:label>
    <link:label id="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC_documentation_en-US" xlink:label="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen Idec Hemophilia.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:to="lab_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C_label_en-US" xlink:label="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:to="lab_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74_label_en-US" xlink:label="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:to="lab_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Axis]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4_label_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty And Net Revenue Share Rates By Territory [Domain]</link:label>
    <link:label id="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4_documentation_en-US" xlink:label="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty and net revenue share rates by territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="lab_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="arc" />
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6_terseLabel_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the Sobi Territory</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6_label_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Rate To Biogen On Net Sales In The Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6_documentation_en-US" xlink:label="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi rate to Biogen on net sales in the sobi territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:to="lab_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60_terseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net sales in the Biogen North America Territory</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen North America Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen North America territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0_terseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net sales in the Biogen Direct Territory</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Sales In The Biogen Direct Territory [Member]</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to sobi on net sales in the Biogen direct Territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:to="lab_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="arc" />
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635_terseLabel_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue from the Biogen Distributor Territory</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635_label_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Rate To Sobi On Net Revenue From The Biogen Distributor Territory Member</link:label>
    <link:label id="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635_documentation_en-US" xlink:label="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen rate to Sobi on net revenue(1) from the Biogen distributor territory(2).</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:to="lab_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="arc" />
    <link:label id="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07_terseLabel_en-US" xlink:label="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sobi Territory</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07_label_en-US" xlink:label="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi Territory [Member]</link:label>
    <link:label id="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07_documentation_en-US" xlink:label="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi territory.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:to="lab_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stock acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="arc" />
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13_terseLabel_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for granting of approval by approving authority</link:label>
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13_label_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period For Granting Of Approval By Approving Authority</link:label>
    <link:label id="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13_documentation_en-US" xlink:label="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for granting of approval by approving authority.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:to="lab_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="arc" />
    <link:label id="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A_terseLabel_en-US" xlink:label="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement recognition period</link:label>
    <link:label id="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A_label_en-US" xlink:label="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement recognition period</link:label>
    <link:label id="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A_documentation_en-US" xlink:label="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement recognition period</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_Reimbursementrecognitionperiod" xlink:label="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:to="lab_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0_terseLabel_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement under the amended agreement method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0_label_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Under The Amended Agreement Method</link:label>
    <link:label id="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0_documentation_en-US" xlink:label="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement, under the amended agreement, method.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:to="lab_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="arc" />
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5_terseLabel_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate prior to first commercial sale</link:label>
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5_label_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate Prior To First Commercial Sale</link:label>
    <link:label id="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5_documentation_en-US" xlink:label="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate prior to first commercial sale.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:to="lab_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="arc" />
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8_terseLabel_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base rate after first commercial sale</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8_label_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate After First Commercial Sale</link:label>
    <link:label id="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8_documentation_en-US" xlink:label="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Base rate after first commercial sale.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:to="lab_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="arc" />
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20_terseLabel_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20_label_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate During Reimbursement Period</link:label>
    <link:label id="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20_documentation_en-US" xlink:label="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rate during the reimbursement period.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:to="lab_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="arc" />
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF_terseLabel_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF_label_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Cost Achieving Period</link:label>
    <link:label id="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF_documentation_en-US" xlink:label="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement cost achieving period.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:to="lab_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="arc" />
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2_terseLabel_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2_label_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Period For Paying Remaining Balance Due</link:label>
    <link:label id="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2_documentation_en-US" xlink:label="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time period for paying remaining balance due.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:to="lab_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:to="lab_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20160331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:to="lab_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:to="lab_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20160331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20160331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:href="biib-20160331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:href="biib-20160331.xsd#CommitmentsAndContingencesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:href="biib-20160331.xsd#CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20160331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20160331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20160331.xsd#DerivativeInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20160331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20160331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20160331.xsd#EarningsPerShare" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20160331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20160331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20160331.xsd#Equity" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20160331.xsd#EquityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20160331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20160331.xsd#EquityTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20160331.xsd#FairValueMeasurements" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20160331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20160331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20160331.xsd#FinancialInstruments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20160331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20160331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20160331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20160331.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20160331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20160331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20160331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20160331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20160331.xsd#Inventory" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20160331.xsd#InventoryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20160331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20160331.xsd#InventoryTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20160331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20160331.xsd#Litigation" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20160331.xsd#LitigationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20160331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20160331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20160331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20160331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20160331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:href="biib-20160331.xsd#RestructuringRestructuringTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20160331.xsd#ShareBasedPayments" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20160331.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20160331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20160331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_7F49B6F1E24E91226857BD9EAD377CF5" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_7F49B6F1E24E91226857BD9EAD377CF5" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_3A6F089E105B66B96E88BD9EAD3744D6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_D082074D26424D736D31BEBB3BD985A9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_D082074D26424D736D31BEBB3BD985A9" xlink:to="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6312D7F1E03F656B6457BEBB3BD9E4B4" xlink:to="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F247D404926BD8CF76BBBEBB3BDAD0E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_F247D404926BD8CF76BBBEBB3BDAD0E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_8211EF6A7EF269659706BEBB3BDAA1E4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_8211EF6A7EF269659706BEBB3BDAA1E4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_327EBA83C0E8B30F9E07BEBB3BDA030A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_352EFCFEA660E3399411BEBB3BDAA6E3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_899188FC75CBB390D056BEBB3BDAD59A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18C1001F6A51AD837BA2BEBB3BD98A2D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C18190C387CF98A09CBEBB3BDA0CFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E6431F8D8482874B3D23BEBB3BDA2FA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3EF57A22413031B05503BEBB3BDA7691" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7349F214EA7A7BAF2909BEBB3BDAE428" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4591C559F4B1A6AB945FBEBB3BDA747E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B4B02889F3BF24CA05CCBEDE05ECEC19" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_9E1A99371F4D2591A3002A7B37A4F4DD" xlink:to="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22DFC594A71B041E74C32A7B37A40CC1" xlink:to="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_1296B5E94254C7E199932A7B37A4BB69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A0AC9E3FE386CABB9A992A7B37A437AF" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_5F3576E53A8B894EEC302A7B37A47052" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_8DCF6DFD5994626A81422A7B37A5E140" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_F64DFCAD06D820B7CD242A7B37A5C963" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_00A1F36A531A27A091A92A7B37A50047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3A757FB00948B5AAA0AE2A7B37A4DBC2" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_D725A99FE04D44B517412A7B37A5F661" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A4D37CEC57C4E1A34D9B2A7B37A55398" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7B150FFE00AD4152B9BE2A7B37A52E57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_OperatingExpenses_30B07D5B61A08B0408C12A7B37A5E017" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_AEF401FE24BCA9AD2E182A7B37A5CC08" xlink:to="loc_us-gaap_NetIncomeLoss_C446F571770D9E0815282A7B37A51633" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_3782F90BFE7F2472CE53BD9EAC73E162" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_3782F90BFE7F2472CE53BD9EAC73E162" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6A3D9B14987982797343BD9EAC736150" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_3782F90BFE7F2472CE53BD9EAC73E162" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_91B7A10F017BB52AAEC6BD9EAC7449C2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C7E929275BBE2D99F985BD9EAB4F501B" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5178764CC790C095FDA9BD9EAB4F78AD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9C6BB6D50BB84839B1639169809BE42" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F9C6BB6D50BB84839B1639169809BE42" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_826B27F20D7885FB8060391698098277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SwedishOrphanBiovitrumMember" xlink:label="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9EFD0AC82FC404AD966039169809F71D" xlink:to="loc_biib_SwedishOrphanBiovitrumMember_F1D716745AB736E6C75139169809416A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B529EB5FA65B274A129639169809CF78" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenIdecHemophiliaMember" xlink:label="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D7BE92B7EBFF28D9294139169809BDEB" xlink:to="loc_biib_BiogenIdecHemophiliaMember_3FE044DB21FE4E42BAC2391698091FFC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_8B16B895E4A2B198294C391698091D0E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:to="loc_biib_ELOCTATEMember_074F31524AA6A06728B039169809253C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_80C8285391A8287E224339169809DC79" xlink:to="loc_biib_ALPROLIXMember_9F92DAF4BC2CAE9548BB391698091B74" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain" xlink:label="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis_97A7B44C26A5B3F43A65391698090F27" xlink:to="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember" xlink:label="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember_31E004D35C0539D282D03916980911E6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember_3B4C68B8C6E3DD419344391698094B60" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember_2EC6D02EBAA201CD94163916980A8BA0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember" xlink:label="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RoyaltyAndNetRevenueShareRatesByTerritoryDomain_C7947A1564318DD8447E39169809EAB4" xlink:to="loc_biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember_F4225DDBF8ACE6F7C7B33916980AA635" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_564727FB97640D5254013916980A521A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SobiTerritoryMember" xlink:label="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_8844F901808F3DEEDBB93916980AF43F" xlink:to="loc_biib_SobiTerritoryMember_45CC6E810F50A02447B23916980A6D07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_392E693C4DE1F3938E3F391698096CB3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AD39B0D9910166B5C81E3916980AE479" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_210C44F256AB6C8CFA723916980A5EC1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_210C44F256AB6C8CFA723916980A5EC1" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PeriodForGrantingOfApprovalByApprovingAuthority" xlink:label="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_PeriodForGrantingOfApprovalByApprovingAuthority_36ED5023D04835DDB7A13916980A9A13" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Reimbursementrecognitionperiod" xlink:label="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_Reimbursementrecognitionperiod_86C16E108FDB7389C54B392D1EDBB46A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementUnderAmendedAgreementMethod" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementMethod_8AD24431F570C40583B93916980AB8F0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RatePriorToFirstCommercialSale" xlink:label="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_RatePriorToFirstCommercialSale_6CE4126501E564F735C03916980A3BB5" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BaseRateAfterFirstCommercialSale" xlink:label="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_BaseRateAfterFirstCommercialSale_383134968D6E13A2C50C3916980AD2E8" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RateDuringReimbursementPeriod" xlink:label="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_RateDuringReimbursementPeriod_DECF0B378F4AE64E61DD3916980A5E20" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementCostAchievingPeriod" xlink:label="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_ReimbursementCostAchievingPeriod_175FE4517DDB1FEB46993927962D40EF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimePeriodForPayingRemainingBalanceDue" xlink:label="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0A6239B1DB8C1A02456C3916980A9D2A" xlink:to="loc_biib_TimePeriodForPayingRemainingBalanceDue_B5C9F19AA977AC049A1339257FAD55F2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_378F6860B4DCCA97CE4F2A7B375C792E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_378F6860B4DCCA97CE4F2A7B375C792E" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_EBA8357915468D9F64032A7B375CF150" xlink:to="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_5E16080ACC4B13A1FA2F2A7B375C312A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_2BB4293067D8A001FC482A7B375CCECE" xlink:to="loc_biib_BENEPALIMember_5E16080ACC4B13A1FA2F2A7B375C312A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6F50AD12CA522A79D7182A7B375C1925" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_3CDD2E2BA12D90E729D82A7B375CDC99" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_15440395289CCCFB57BB2A7B375CAE91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_F15FE7681E1CFF8742902A7B375C3967" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_3700D94CED8EDB6B84422A7B375DEB97" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_38C04471CC9E10796E2C2A7B375D9292" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_EquityMethodInvestments_279CF679E3A9D5325E772A7B375D40E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_073AE65085FE8A71DD9E2A7B375D2BEF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_E9D98902F78869348A572A7B375D10B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_157D2BF4D0B5E4E85DFA2A7B375D9B92" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D628D543074B7785514F2A7B375D9195" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_F4B8646A3077B6F38E702A7B375D23CD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_F4B8646A3077B6F38E702A7B375D23CD" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_A1052D83F654B15DD56B2A7B375D1C76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_820ED0CABAC3D65976B42A7B375C8A72" xlink:to="loc_us-gaap_OtherSalesRevenueNet_213D78BA965B988B86A72A7B375D7B0E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_351669CDFD7338C853E8BEF037CB7B5A" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock" xlink:label="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_351669CDFD7338C853E8BEF037CB7B5A" xlink:to="loc_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock_D247783B0B7B60BABB09BEF0A1323D5D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C335EEDA61F1CB1D75BBBEBB3B7B801E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C335EEDA61F1CB1D75BBBEBB3B7B801E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_6B0851DB70D73F73F51BBEBB3B7B9FE3" xlink:to="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SevenbillionMember" xlink:label="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_SevenbillionMember_68D004F4A4F6AA01F9EBBEF8D88A5B9D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EightbillionMember" xlink:label="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_EightbillionMember_2FB2EC3288EBFBAA76C4BEFA080DC016" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_35F301030240C1EAAF64BEBB3B7C52CA" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OneBillionMember" xlink:label="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_OneBillionMember_CDB797B1BF21947CD345BEBB3B7C902C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ThreeBillionMember" xlink:label="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_2A7C991383711A370F86BEBB3B7CAD37" xlink:to="loc_biib_ThreeBillionMember_43C250F9D233A1F28CF1BEBB3B7CC98A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17AD020A74B0C5B91277BEBB3B7CF9B7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_516EE498C503640A9F77BEBB3B7C43BF" xlink:to="loc_biib_FumapharmAgMember_9F0CA47954CEDCFC781FBEBB3B7C2DB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_99D1FC60A96FB616AC15BEBB3B7CDDAA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_537FAD340A4ADF99E39FBEBB3B7CFC42" xlink:to="loc_biib_TecfideraMember_B07CB089761A72577722BEBB3B7C6667" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_D43E78097F22094E2B7FBEBB3B7B5CF9" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8028979125E611E764ECBEBB3B7CF533" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_3A08B0BC13D8E10737EFBEBB3B7D1876" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_02FA258840303AA7E021BEBB3B7C757A" xlink:to="loc_biib_CumulativeSalesLevel_5A2A3A8D5D4600366C72BEBB3B7D2093" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_729AF670807CAB006BA6BD9EA7E5CD00" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8ED963D06943DD773C33BD9EA7E5C673" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CDEBE3B2D635456AC59DBEBB3B3085B4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CDEBE3B2D635456AC59DBEBB3B3085B4" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:to="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_A8055E944F8A5F0ADD81BEBB3B308746" xlink:to="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_CH" xlink:label="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_4FDF718EE2AE1B388F02BEBB3B307535" xlink:to="loc_country_CH_44F4EC842B19B2A2268DBEBB3B302681" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_61EE9F2F573C6B128ADBBEBB3B305E1A" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_1567038990DC64C4830CBEBB3B30A263" xlink:to="loc_us-gaap_OtherCommitment_6117577E1A050C5594A4BEFC4FA3DBB4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_87A30D3E57300E1FD7942A7B393FB5FF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87A30D3E57300E1FD7942A7B393FB5FF" xlink:to="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5793D2DF08A81B7964C92A7B393FD239" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_52E1D2D9AA6A269B384B2A7B393FDE63" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5B203A8DDFE68DB8FCF32A7B393F8559" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_B81D71A05C56664405612A7B393F4A54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_InventoryNet_CB1BC738F0AAB4BA2A652A7B39405F78" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_OtherAssetsCurrent_316F25EAE2D49598D6092A7B39406B99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6B3F4E5B515B119CAB962A7B393F3DAA" xlink:to="loc_us-gaap_AssetsCurrent_7ABC4EE44C8C1F369F112A7B394086FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_A19949A939EE8185F9802A7B3940C587" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0EADA4171D9506E683C62A7B39408EB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_198717F45BA5BAC8F0D82A7B3940ED52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_Goodwill_725EC5C895820A1A85532A7B3940DC3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D0A8D3EC5B8526B6CD712A7B394048FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_445B9ECD7FEA93F2F1462A7B393FB6AD" xlink:to="loc_us-gaap_Assets_4CADE518CC9A9640F3952A7B3940AE57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_87A30D3E57300E1FD7942A7B393FB5FF" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="loc_us-gaap_DebtCurrent_A18601AA9FCCED25F6EA2A7B39458518" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="loc_us-gaap_TaxesPayableCurrent_46C8DE3E93630A0BAA2B2A7B3945E490" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="loc_us-gaap_AccountsPayableCurrent_24033843ABE4C9AD92822A7B3945DB3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_DAF0B7237DE80C7ABA7C2A7B3945FECE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1AFD0A5D023D9D978AE82A7B3940E1FD" xlink:to="loc_us-gaap_LiabilitiesCurrent_8DBFB348B710EA63E50B2A7B394660ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_LongTermDebt_602F80FA11CD8FC2311D2A7B3946982C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_2F82C51C4EC71C7D65BD2A7B394617C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_BE8A9B854E306E7D63ED2A7B3946A567" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_Liabilities_4BF31B07AA5037AC5C5E2A7B3946D973" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F2652E0EAE22024B7CE42A7B39462491" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:to="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_PreferredStockValue_9958A8D7CD3B5A4F7D7E2A7B3946CD33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_CommonStockValue_485C6C937ECB5B8F04FD2A7B3946C206" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3C9EF534833A80E205742A7B3946248F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_53F8FE1BA135E338127B2A7B3946C234" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_897BBBD59694BE5D3B522A7B394675EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_TreasuryStockValue_E972F6499B64CB2E9F5B2A7B3946362F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E56043A24FD8565C30402A7B394616B4" xlink:to="loc_us-gaap_StockholdersEquity_B98C698852A4BDAE37502A7B3946F54D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:to="loc_us-gaap_MinorityInterest_4E2A74900ED73FD586812A7B3946D7F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0B66C3CFC16D9CBBBC732A7B3946F152" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4C802F5D9571349618A92A7B3946D388" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8651612DC7B6D04E2A42A7B394082DF" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_34A27D4A3628B0AE65DF2A7B3946E099" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_667FD42515855AE23DB5BD9EA9389C82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B866045DF0827C881E8EBD9EA9383EC4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_BB3FCAC6C179242C31E3BD9EA9381B22" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:to="loc_us-gaap_ProfitLoss_3F149B1E028F5A708E622A7B390D1316" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_D1303F3867CB57B24E242A7B390862C6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_42C479B0F919912A4F2A2A7B390EE59C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_ShareBasedCompensation_A8E0CEDA3738F5CA91322A7B390EC918" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5A32B318E22AA60B4B002A7B390E9CCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_70E98EABF8474B66046E2A7B390E4176" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D525CC7608899B244F752A7B390E4FD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_95E29146426B05E04AA32A7B390EDAC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_D7B547E8D2B32F56E4E02A7B390EA56F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6431C19AA5DB4EE2C5B72A7B390EF061" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5E06391F863739E5B9FA2A7B390E4F14" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_AFE143D6B3B4E32EBB922A7B390E55F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_99866B183AD0BDD452C92A7B390E2F5A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_CE07AC4AA2D80EBF4F822A7B390EBBE0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_76DDD0D1EEFC41EE23FD2A7B390E46B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_EBC257157F5C356985FC2A7B390E3B10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_365E23B30CCA74261CFD2A7B390F27FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1D548AFA37C087B8588D2A7B390F888D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_834907ADFEEC95C5C0F12A7B390FF49E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_407779543A2F40BB7E282A7B390FA5D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20A5A07E68622F5C64012A7B390E8B9B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B29AD97F1B2BEA0F88C82A7B390F0140" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2C1C7E6A0C0360F6519B2A7B390F5085" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_05001D68F71F82D72C9D2A7B390FD09D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_E80F711813DEBF443E3D2A7B390FA212" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_837D3B74A1348C5D6E382A7B390F5B35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5971A58F487235EAB97B2A7B390FAAB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_710702AD50808825B1132A7B3914A8CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8062DF607340AC5812AA2A7B3914B464" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_386C715C3ABEA0DD24042A7B3914ED55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6E8B5C6576F5021D52D12A7B390823C9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FF2E517EDE435E16F7522A7B39141AD5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2FAAB0645E3D24155FF3BDA0CE05D418" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:to="loc_us-gaap_NetIncomeLoss_2FAAB0645E3D24155FF3BDA0CE05D418" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_689C8F891259D8A05453BDA0CE0555F0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0A4754679CC57AE6B9D0BDA0CE059D32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7CC475A697C47054B101BDA0CE05E5F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_393EE203A2511AE5D560BDA0CE052C55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_457F095598BB2D814013BDA0CE05B041" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_B0D653F2C6E5ABFB46D8BDA0CE05919A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0650D10A5938C86A4BC1BDA0CE05DA77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_AC6B88FBF89FE1C14B98BDA0CE06AADE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D618064AA450DA9C8640BDA0CE0583C3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5CFAD1458A7B4372E5FBBDA0CE06D854" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_3009B559E71728BCAD232A7B1C26F551" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_3009B559E71728BCAD232A7B1C26F551" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_2479C6E60EDAE8D5A2E12A7B1C272789" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:to="loc_us-gaap_OtherSalesRevenueNet_A88217A5F9588B2D5B3D2A7B1C27D591" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9BA3B166CE3F638751742A7B1C25C521" xlink:to="loc_us-gaap_Revenues_9CABCEBF534A23AF4D5C2A7B1C2724D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_CostOfGoodsSold_FC5CF5F54DE0066D93872A7B1C2794E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_D0468737D8F7E2EE4BF82A7B1C27189F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_96C6B29C87290FE221DA2A7B1C27CE0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_006342F25206213347D12A7B1C27F9B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B74AECF04EB5DE357AEB2A7B1C27B0EE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_RestructuringCharges_B74AECF04EB5DE357AEB2A7B1C27B0EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_575A49BC79458A5113C22A7B1C279CE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_18D001613E0AEAB3C5E52A7B1C274D6F" xlink:to="loc_us-gaap_CostsAndExpenses_ABD87D2A87E18FABDC652A7B1C28FD47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_OperatingIncomeLoss_00650849A5365722F0942A7B1C28FCB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3A6B54397F29D6A9EAAE2A7B1C285BBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F197471B6624994F45CF2A7B1C286DC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A4E8D12541E85BE7E84E2A7B1C2882A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2A56C2A399E607730AFA2A7B1C28FCC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_ProfitLoss_C212F67AF50EE1B545952A7B1C28D290" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_C0B8E7AE2B431123F97D2A7B1C28960A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_NetIncomeLoss_BA5FB418F8C20A9935602A7B1C286705" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:to="loc_us-gaap_EarningsPerShareBasic_96E8981B2CCE871A2D782A7B1C28D7C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_DE1BF7A25A55BDC1A2D22A7B1C28C964" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4BE93927C43272E948F82A7B1C28BBF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_DC144492CD00E3E337472A7B1C24E98D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07C8F20230CBE2AD45612A7B1C28F037" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56926A747C0455B5C53D2A7B1C2873D6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2180362A1862829B5B482A7B1C286013" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ECE17C6B62EC0E742401BD9EA9F9D395" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_2041784589128DF62EF1BD9EA9F956E7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9CD5D8A1A7FE49DEB099BEB9AC9C830A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9CD5D8A1A7FE49DEB099BEB9AC9C830A" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_231412101DB04785BD01BEB9AC9C5917" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_788806915BC0B9D320D5BEB9AC9D727E" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5989E9617FFFA16078BDBEB9AC9DF0F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_F75F285A3D1424DA7FB2BEB9AC9D37B9" xlink:to="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_EUR_E98F596FFF870908FF0BBEB9AC9D9AFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_CHF_AA07138D2F258542768CBEBB1769ABF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_247F58316BFD65573CD8BEB9AC9D9946" xlink:to="loc_currency_CAD_BF65244D39936715E670BEB9AC9DBC33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_794A00C4E0DEE2F9FB83BEB9AC9D5057" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_SalesMember_602EF1904470B301FC1CBEB9AC9EEDF8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_OperatingExpenseMember_07AE2A981AD85748DF67BEBBB357BE9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0C4C82D5A4FDC448905EBEB9AC9DEB06" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_4E561FD94960D5B9BB75BEB9AC9E23A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8EC6B7E57AA0AFCC25F8BEBD06035208" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:to="loc_biib_CashflowsrevenueMember_DBE9D440C584A7EB6D8EBEBD06607C01" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46299DF4AA836F98B779BEBD9BFD730C" xlink:to="loc_biib_CashflowsoperatingexpensesMember_3A2D0C7A171A70253CA3BEBEC6FF4DE9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_D73E5673A400C61ED576BEB9AC9E1F5C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:to="loc_us-gaap_ForeignExchangeContractMember_C0BD057DD5AEB211CFACBEB9AC9E1E2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_80B1F09C80966444C479BEB9AC9E920B" xlink:to="loc_us-gaap_InterestRateSwapMember_0A9ED546A76A4EB1C119BEB9AC9E38F4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6220377B06B24DFF9843BEB9AC9E9A2C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E354748B990DE353221EBEB9AC9ED626" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherInvestmentsMember_FEE9D88104BC81AC7507BEB9AC9F2163" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_FF2B730F5B245AB57F22BEB9AC9FBB60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7F5CB0E39D433DE3A7EDBEB9AC9EA346" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8155EA59C5E6E1A6C31FBEB9AC9FE60F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_511AD9B9B28816FE1DEDBEB9ACA068F7" xlink:to="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3264F50669F5982CB3E7BEB9ACA18E9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_30AA866EEC47994A2F22BEB9ACA1D273" xlink:to="loc_us-gaap_NondesignatedMember_A85EB7AAD005B626FA44BEB9ACA12C4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_59AE9E9F1609F186C5C3BEC2EF54ED08" xlink:to="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:to="loc_us-gaap_MinimumMember_A593A594F6A6F04A500BBEC30C10B05B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_153BC610B9241951E1BBBEC2EF5DFD0A" xlink:to="loc_us-gaap_MaximumMember_C37FE0597974D19B07AABEC496710899" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_5D4CE31585596474EDB5BEB9AC9C2AC5" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3B0BF5B7CA3CF8E2B121BEB9ACA13EBC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_063609B35F455DD2B9E3BEB9ACA13A7D" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_27BBF056B7477C107C84BEB9ACA2CAE9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_46BA5EFB438FFD5BB809BEB9ACA10652" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_B2CD0D4404C9F3852297BEC2BAF7467F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_invest_DerivativeNotionalAmount_6E27EA3E92A87AF6D9A0BEB9ACA290D9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_818E6322B70DAFBFEE9DBEB9ACA27EA5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1" xlink:label="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1_EDAB4423D200556B72DDBEB9ACA2E7CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_24339D5A97E60EF4C426BEB9ACA2D98D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_E1CC55A7B1DB19D5F340BEB9ACA25302" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5549CF680C66FF34DC53BEB9ACA291A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_1B6138BEBD0BB4A58343BEB9ACA2C294" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_43DBFAF037568C387E35BEB9ACA23EF8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D222FF8C8076DFAD3954BD9EA95B203F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D222FF8C8076DFAD3954BD9EA95B203F" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_7F7B1C1E06FD49BDC80FBD9EA95BD9F2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D222FF8C8076DFAD3954BD9EA95B203F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_50F57E6023F31FD68A64BD9EA95B0637" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_D222FF8C8076DFAD3954BD9EA95B203F" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_329A714600BBC21DD7EBBD9EA95C3876" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="biib-20160331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:type="locator" />
    <presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_EntityRegistrantName_8DCAD79F81B2DC9BC066BD9EA874EA77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_EntityCentralIndexKey_C8254FB3195E615A80D6BD9EA874E9CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:type="locator" />
    <presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_CurrentFiscalYearEndDate_D4FD8DC9EEEB3EB3BBB9BD9EA874921A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:type="locator" />
    <presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_EntityFilerCategory_4B9652BF3C42BA585E86BD9EA8741A6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:type="locator" />
    <presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_DocumentType_74DA475614C3135384F0BD9EA8741A23" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:type="locator" />
    <presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_DocumentPeriodEndDate_49019C9A27BDC0609353BD9EA8752C7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:type="locator" />
    <presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_DocumentFiscalYearFocus_0971A77EFD27E227E738BD9EA875155F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:type="locator" />
    <presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_DocumentFiscalPeriodFocus_306D25A88DBB5A8DC7FABD9EA87579A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:type="locator" />
    <presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_AmendmentFlag_AE8E005446CD0073E069BD9EA8753EF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:type="locator" />
    <presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_C1041970A57749C8CFCBBD9EA8743A1E" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_48978B3DEA9EC667CD6BBD9EA875DF82" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CDE11A84B38E9EB2050FBD9EA9EF367C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CDE11A84B38E9EB2050FBD9EA9EF367C" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DFCC6E42ED2C6A289A6CBD9EA9EFCAB4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60A4AA8A1BCD72DD63802A7B379CD399" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60A4AA8A1BCD72DD63802A7B379CD399" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8BC04FC9A47BD9226DF62A7B379D141F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_7910572582C40D2BE0FC2A7B379D7CA9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_DEF338300912317352D22A7B379D1A98" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_DEF338300912317352D22A7B379D1A98" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_2052549A0DB2119FF62B2A7B379D85BC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_D50FA7D30EE4864656BA2A7B379DDDDE" xlink:to="loc_biib_MarketStockUnitsMember_2052549A0DB2119FF62B2A7B379D85BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_69A547B0440B870A4FDC2A7B379DFA06" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_FB525AC17D01552DC9AA2A7B379D9CFE" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:to="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_3F3DED9DAD99383BE18A2A7B379DB583" xlink:to="loc_us-gaap_NetIncomeLoss_90E458561A98D00590802A7B379DDDC3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_E8665392A33E8E6362482A7B379D2853" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CCC17BFC83AE683EFFEA2A7B379DE7B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4A9CF8334C7BE971C9C22A7B379DF12C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_7E7C231B1CD6FBFCAFE92A7B379DC6ED" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_BF2E45E820DAF6388ECE2A7B379EA8A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_E219B2FF53AE132B6B6A2A7B379D2CD6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_401E013A9DDCC963C1862A7B379E8BF5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1B79210E930BB3032787BD9EAB6F9114" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1B79210E930BB3032787BD9EAB6F9114" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_A10EBB6C8AACD0219B8FBD9EAB6FA033" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_94222BE57FF638B26DDBBD9EAB735CFC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94222BE57FF638B26DDBBD9EAB735CFC" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_FEB6581228E869CB8740BD9EAB7385E1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9C7C87E42B91EC8144A62A7B37B0DC4E" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9C7C87E42B91EC8144A62A7B37B0DC4E" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="loc_us-gaap_MinorityInterest_C1EA2D90BA700C518BD12A7B37B14162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_96C5D702B2E50832A70E2A7B37B1D46F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C59B3B9208C6AAAAE5E02AB550833E8F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_9A1F7B93CE0F195437C22A7B37B1B9C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_473171840E8C023104C32A7B37B181C0" xlink:to="loc_us-gaap_MinorityInterest_5ED1C863B9684D241B8F2A7B37B1F8F2" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E60A0DB7D8A76671B4633916985783C9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E60A0DB7D8A76671B4633916985783C9" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_2E54739BCCB8A81CBFD0391698570556" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_87341AAF8753B40F914E39169857DEA4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E60A0DB7D8A76671B4633916985783C9" xlink:to="loc_us-gaap_NetIncomeLoss_87341AAF8753B40F914E39169857DEA4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0FA82C5A86DF42B73650BD9EAD32FB1E" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_2EE3911F5E8A297D0750BD9EAD32E9A8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FC2A49B2AF319DD9A738BD9EA8089FBD" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_74E2AD4AAD312EE60DF0BD9EA808D623" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DF1A032BE91B4247A24BBE1E3180029E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DF1A032BE91B4247A24BBE1E3180029E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_888793B1AFF80293A5CEBE1E31800B33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_AB6117D2BC86154C8ACEBE1E3180A070" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DE9D65723B46C4CEB616BE1E318042A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_DC10177B0798E9C7CF52BE1E31806B08" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A08A1C0555B02B55E8EEBE1E3180EDAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2267780CAB866F444C70BE1E3180C385" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1E468B2FB674E9A83762BE1E3180ECC8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57144538E8E99B8F6ABEBE1E3180DD33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1DACAE79FFA27818384FBE1E3180296B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0B204D31FC3FE7E6874DBE1E31818DD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_1AA740B29D5EC2F31F76BE1E31816253" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_86FA836C952493B7C982BE1E31818E76" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_52B16B32E4C562FB7647BE1E31812756" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DDB503BA7439552D6C46BE1E318097F0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3E84205F2828920B9611BE1E3181A528" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11629A2E298CA8EA1C5DBE1E3186CD20" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_AvailableForSaleSecurities_DDD5D86D3C35F4EB2090BE1E3186CBF6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_7531198A6ED869E97EB2BE1E318679F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_85554E38B33F38104F1CBE1E31867AD6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_DA98EDB0F878681EAABCBE1E318699A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_621C259BAC0EE77B7331BE1E3181DF1E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_262E5D3BC6D758F311C6BE1E3186C822" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_6807441CA28CF26324DBBE1E31814139" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_5D8FA84D07E5A6B86DFBBE1E31873313" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80259A0901537545328ABE1E31879E33" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_75C02D11705016CD4011BE1E31863DAA" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_082FB3202B4D807B4AC8BE1E3187E2D7" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C46E9E21B73B0A010A90BD9EA9310BF2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C46E9E21B73B0A010A90BD9EA9310BF2" xlink:to="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:to="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4F244D1D6C44DBAD0315BD9EA9311E55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_NotesPayableToFumedicaMember_DC67AF0D328589570DDABD9EA931F3C9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_7BBED2990A93B0CE5017BD9EA9310977" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7777C1FF7C9F9A53DB0DBD9EA9312731" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_7777C1FF7C9F9A53DB0DBD9EA9312731" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_788101D42DD133AC55B9BD9EA9316419" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_82DE3353922C771F5F07BD9EA9316113" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6406E5EC079A3BA71898BD9EA931AF5A" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_11470696087AFBCF5FD7BD9EA93189E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7634835FA1201D165C66BD9EA93119B9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_49EA1E5609D83D97B3FDBD9EA9311CFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_NotesPayable_A02C6497CDD50623632ABD9EA932A97D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_09B2F09E7D6A5F903866BD9EA931C9CD" xlink:to="loc_us-gaap_DebtInstrumentFairValue_A62DC5F60A620B413C31BD9EA932C1F1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9110C7D3D168EFDDCF26BD9EA8D6E490" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9110C7D3D168EFDDCF26BD9EA8D6E490" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C9782942053D4CD94573BD9EA8D72437" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_FED29B5EC75DEEC9B0B1BD9EA8D7B12A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_15E2EE37EC277D47353EBD9EA8D749C8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_FED29B5EC75DEEC9B0B1BD9EA8D7B12A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_1FDD1F7C2E6DA487878DBD9EA8D72A3E" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9A1097C57CD2052EB734BD9EA8D77947" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_EA69148A8E5AFC510107BD9EA8D7908F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F6CAE5A0D3EED440FE7ABD9EA8D70172" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1BEFAE3947705EE6F403BD9EA8D7E5C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_25D9B54B092DDA97DD56BD9EA8D7956C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10A5F085257EC9BC5437BD9EA8D7ADF1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54B0474668341E344D35BE1E3140BAB4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54B0474668341E344D35BE1E3140BAB4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:to="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B7B34D29CB515A2873EEBE1E3146527E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_B84647210D219A1F591BBE1E31469606" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B73852436D781EF12342BE1E3146E756" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B73852436D781EF12342BE1E3146E756" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B578F9DA1CD12017DF1EBE1E314654A2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B578F9DA1CD12017DF1EBE1E314654A2" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1DC179A834B45A75B31FBE1E3146AF74" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_1DC179A834B45A75B31FBE1E3146AF74" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_687681095C2E88EE5B67BE1E3146AFBA" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F9BC50A9CFFEBCE740D6BE1E3146CCC2" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_687681095C2E88EE5B67BE1E3146AFBA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_29A690BD94A8CE1A03DEBE1E3140AF90" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_AssetImpairmentCharges_9A13CAE8E208640C79CFBE5CD4E25E02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_860B9C9DD616517260DBBE1E31474BE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1CD49769208073CAC416BE1E3147104C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1CD49769208073CAC416BE1E3147104C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_15B95CB60DE16DA18631BE1E3147BE7C" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_937D03B0D9C31F323283BE1E31477C4A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_746726EA5A48698C47ECBD9EAA3F0EE9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_746726EA5A48698C47ECBD9EAA3F0EE9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_C2FF3314C1F646C587A3BD9EAA3F8805" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_746726EA5A48698C47ECBD9EAA3F0EE9" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_31853B4D9DAF5F2C1417BD9EAA3FCA02" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_746726EA5A48698C47ECBD9EAA3F0EE9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_4F11DF00E71DCE1816F5BD9EAA3F79BF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CE3A2F53E6B14BCD33E2BD9EABA83F71" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CE3A2F53E6B14BCD33E2BD9EABA83F71" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_502AD2EFF7E7800C5470BD9EABA84954" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_13C28DE1F807C943BDCFBE1E3105A2AF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_13C28DE1F807C943BDCFBE1E3105A2AF" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:to="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0AF9F07B8742CFCFC86CBE1E31051CD1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_CommercialPaperMember_ABB8465EA3636D02F127BE1E3105E4B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_C7BB83030A5FB6A7E29EBE1E31057BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4F3448E0C3D3A8537054BE1E3105CF8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_F24EA41F5B42B25FDCDFBE1E3105BF1F" xlink:to="loc_us-gaap_DebtSecuritiesMember_71B3801B2F3BCF4688E8BE1E31050D6E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_501083669D99EC486315BE1E31056C16" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_03C30C808450A49DA864BE1E3105BE8A" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_9693E24966B80C7FCE6BBE1E3105DC2D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A7B2281CC2BEB7F87544BE1E310590D1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1085F223DF665D339E7ABE1E311ACFAF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1085F223DF665D339E7ABE1E311ACFAF" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85BC91009D0B2422FDA3BE1E311ABDE2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_7321FAC928E5218497C8BE1E311B106D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7541C6D5EFFB1A5793CCBE1E311BDA6B" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_AA0BEC871AD62A590EB9BE1E311B3898" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_A7E142B268F21C4AB63ABE1E311B8620" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_C8FB6C222B77C04DABA2BE1E311BE450" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4F97975DA376FEA5FBE5BE1E311BAA6F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_70F8AE4B526CFF27AE78BE1E311B900F" xlink:to="loc_us-gaap_EquitySecuritiesMember_E3C2419868CFF9ABD5A2BE1E311BF369" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_DB60AED5ECDADAF615E0BE1E311A6A5E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_553329E8ECC96B738768BE1E311B962F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AA5D4C693140976CEB1ABE1E311B0F77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45FEDD823DB2533679CABE1E311BF210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_BDA3132922140C5F514BBE1E311B07A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6823CCBB266A9359240FBE1E311B3A8C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_274203437DAA9ED86B13BE1E311B0ECC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DE6FAB57E3A571C1BD9DBD9EAB0FB602" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DE6FAB57E3A571C1BD9DBD9EAB0FB602" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_46DB0524202DEB6D38ABBD9EAB0FFC1E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_DAE54409AC412062C25DBD9EAB0F6A16" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_28AF45CF933B724429D4BD9EAB0F3FC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_C6F373D8BE901D62FCBFBD9EAB0F1843" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_47ABB59C41735B4063A4BD9EAB0F9112" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_1008C86EB704A2800BC3BD9EAB0FEDA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleSecurities_E14548E865BE3BFD816FBD9EAB0F900A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_EEC61A035C44CE697999BD9EAB0F1B83" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_94E8B862400A49E79049BD9EAB0F2CCD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35CAA58C8552F41AE0D1BD9EA7EC9CDE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35CAA58C8552F41AE0D1BD9EA7EC9CDE" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D53A63FFACB2B00EC63DBD9EA7EC74B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35CAA58C8552F41AE0D1BD9EA7EC9CDE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_1242B482DCD619BDB45BBD9EA7EC827A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35CAA58C8552F41AE0D1BD9EA7EC9CDE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_5D22A45BF04B20A77054BD9EA7EC1C25" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_Overnightreverserepurchaseagreementspercentoftotalassets" xlink:label="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:to="loc_biib_Overnightreverserepurchaseagreementspercentoftotalassets_F68F5E43BF815C438ED1BE1E30E12C87" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B48D645A75EB86A78CFBE1E30E1E8C2" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_BB3E3AA3C12FC6384FE0BE1E30E1C35B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_17ACF616FD0661D451E1BD9EA8C5D906" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_275C4AC95956B8A4B81FBD9EA8C5ABC7" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_D70F6CBAE64F0C372DE9BD9EA8C57500" xlink:to="loc_biib_StrategicInvestmentsMember_A83C95158DF3505921DDBD9EA8C55971" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5500F01755CF503C2AB1BD9EA8C5C7FE" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B0C32C83EAF3A32E515FBD9EA8C57247" xlink:to="loc_biib_StrategicInvestmentPortfolio_66E1E1FCEFC98ACF437FBD9EA8C59DB1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_523BAB4F9F5216FC5B01BE1E31295E0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_523BAB4F9F5216FC5B01BE1E31295E0D" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_7C5FD944811D16817C64BE1E3129783E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_523BAB4F9F5216FC5B01BE1E31295E0D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_30EC7D8802B239215A4BBE1E31291C3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_523BAB4F9F5216FC5B01BE1E31295E0D" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_1D34551E5C881B7820A7BE1E3129C0F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_523BAB4F9F5216FC5B01BE1E31295E0D" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_7797AA70BA5D00F86603BE1E3129FC26" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FF87542FB4584F697922BD9EA9A5CEAD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FF87542FB4584F697922BD9EA9A5CEAD" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_B59D34929BCB2DBB75EBBD9EA9A5F386" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0169B596D8BEE50C5473BD9EAD0EFCF1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0169B596D8BEE50C5473BD9EAD0EFCF1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FBEC31BC411CB7E58436BD9EAD0FE52E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_EC07914723510EABBB69BD9EAD0F557A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_08027FCF7295C58008D4BD9EAD0FCB70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_BE920FC9FD4AEC820D46BD9EAD0F95BA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_2F660425F3CA0D5103AEBD9EAD0F35B4" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_255917384E280CD5023CBD9EAD0F2DD5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_4BEFDD28D493C5C1D744BD9EAD0F491D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_07FB9B60233EDBD154E4BD9EAD0F2224" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8812C422FE10B9910696BD9EAD0E3DDB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_DD7D94C8D1338717451CBD9EAD0F9288" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CBCF9184DCB603C74CE9BD9EAB44B7B9" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:to="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_97B2997B7B643C6F3F85BD9EAB44BA35" xlink:to="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2007Member" xlink:label="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2007Member_3CAEA1FF5D473E06AA96BD9EAB45CFAF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2008Member" xlink:label="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2008Member_10DCB3AF560B9F5E16FDBD9EAB45A814" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxYear2009Member" xlink:label="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_C18961D731F168403164BD9EAB452677" xlink:to="loc_us-gaap_TaxYear2009Member_97829E2C4E980A0EAF5BBD9EAB4586E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1A3400604B50F7A55288BD9EAB44D866" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_566C8D386805128BB45DBD9EAB455CCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9B2DD3773B60116754CBBD9EAB45AC96" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices" xlink:label="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0739BB414E6ED308BFBFBD9EAB45BD6C" xlink:to="loc_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices_047364173333AB6AF6F8BD9EAB4507AA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_929880464984A9DE7F22BD9EAB4A2D48" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_929880464984A9DE7F22BD9EAB4A2D48" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_E75E876F240F135B89FABD9EAB4A2EC3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_678A067E6EFBE0323DB1BD9EABA32225" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_678A067E6EFBE0323DB1BD9EABA32225" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_82ADE37D44EE654CE62BBD9EABA3D543" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8306BEEC2DCB5A88644EBE1E31CDD9EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14EC8AFBC7B3030F6196BE1E31CD6CF7" xlink:to="loc_biib_TysabriProductMember_CE0D8EBD43C74ED695A7BE1E31CD43E0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3078C3F382AD5410156CBE1E31CDC65D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2DE7601EA86FBBED4243BE1E31CD6957" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_925544E006FAC013DC0DBE1E31CD4563" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_ECC827A6C1751721EA4ABE1E31D291BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A9BA0DA507007F8F75DABE1E31D25A60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_biib_OutLicensedPatentsMember_639887BAA31AE6CDA5EABE1E31D2F0AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A6DCB14832418890BA94BE1E31D2152A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_42E87A4AAEB3E6A763B2BE1E31D248F4" xlink:to="loc_biib_InLicensedPatentsMember_F4BBB176AE98B8B70219BE1E31D28BDE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_2FC8223593AFC4B3074ABE1E31D39F4F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:to="loc_biib_AVONEXMember_DAE1B42068770520B1BBBE1E31D3DDF9" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_11DD4442800B49BCDB1FBE517D3E85BB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7B2A2C8C77E23350191DBE1E31D351F0" xlink:to="loc_biib_BENEPALIMember_11DD4442800B49BCDB1FBE517D3E85BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E8A8FF65F8F946998C9CBE1E31D342A8" xlink:to="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:to="loc_us-gaap_MinimumMember_193C271CA9DF71CBE78DBE1E31D3BDCF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B8DD3C99B0EF1C822FADBE1E31D353F6" xlink:to="loc_us-gaap_MaximumMember_4C1E3723F7FA1E82C283BE1E31D3196D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11281EDF80049322F39EBE1E31CCE2C9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_044B0D82E08244A603EEBE1E31D34D1A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_11FBD2D0024C34090EC9BE1E31D311EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4E5D8680246C919769B0BE1E31D3D911" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4A4D4D93B291760BAEAFBE1E31D3E71B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_B4D32ABF32C904201828BE1E31D3AD4D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75DCE39978AF2D300817BE1E31D31DA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_13A94065664A766FBAE3BE1E31D4115B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_5BD9A3C0EFFE95F95482BE1E31D3BB18" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_F6343CC7CFF48FF66F21BE1E31D4E6A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9234C39D1464594C5896BE1E31D3AABE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_7F4D6E080BB1C5BB1750BE51225834E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_EE2E74378BA0E5A37EBEBE1E31D4D275" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_EE2E74378BA0E5A37EBEBE1E31D4D275" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_DB4268FDDF6D669DC404BE1E31D42795" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_D831D225FBD4284FF8E2BE1E31D48167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1982F642F125D813DB74BE1E31D4E6F3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_15D2779A225B5DF540D2BE1E31D9E398" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3E201AA0F97BAFFB5F66BE1E31D996C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0CF228B87D77BA0A25B9BE1E31D9A000" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_94059F82FCB85F06067DBE1E31D9E5C9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_8E6ABB1D700BCAE6F8A2BE1E31D90E60" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Finitelivedintangibleassetsfutureamortization" xlink:label="loc_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_174E59C8E2601FB69FDFBE1E31CC4E07" xlink:to="loc_biib_Finitelivedintangibleassetsfutureamortization_B91EFE2BF3BBE627C5DEBE1E31D99125" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_AD20C1BDC1FF46B0A7B7BD9EAB982FB8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_E01A3AD9A7CB85ED01EEBD9EAB9817A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_7A604F3494DB3111932DBD9EAB985026" xlink:to="loc_biib_TecfideraMember_E01A3AD9A7CB85ED01EEBD9EAB9817A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_115588F56A70EA7DE559BD9EAB98216B" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_C7A50C13374E86F97FBBBD9EAB9840E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B743F658E6F783250B1FBD9EAB98A604" xlink:to="loc_biib_FumapharmAgMember_C7A50C13374E86F97FBBBD9EAB9840E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A1C227FFBFF11F3E923BD9EAB9859A5" xlink:to="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_043619B18E87A3B71CB8BD9EAB98B2FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_043619B18E87A3B71CB8BD9EAB98B2FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_6A340F20807770233FC6BD9EAB98C771" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_CF8AAD8BE39BDB43F64FBD9EAB982BC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D106A09678DD2A8064F7BD9EAB98FC86" xlink:to="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:to="loc_us-gaap_Goodwill_64A747C5C802A6A2BA23BD9EAB983A0E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_DC482D6F7D6655CF7140BD9EAB991618" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B221136A35A46CB92916BD9EAB98EB8D" xlink:to="loc_us-gaap_Goodwill_B6296293AEFE951FF799BD9EAB9960FD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D40D8ABEE06E236D4176BD9EAAFE993C" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D40D8ABEE06E236D4176BD9EAAFE993C" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_6E6190780BC8DEDAB0A7BD9EAAFEACA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D40D8ABEE06E236D4176BD9EAAFE993C" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_E2144BD02F22D8C11367BD9EAAFE3DD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D40D8ABEE06E236D4176BD9EAAFE993C" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_94E477A39C8740B5E36FBD9EAAFE8FD6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0F10FD2F00BC2962FF63BD9EAA36B94B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0F10FD2F00BC2962FF63BD9EAA36B94B" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_061FE391A07663CA470CBD9EAA37B5FD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9C500B3FCF5B1515A79DBE1E31FA9F49" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9C500B3FCF5B1515A79DBE1E31FA9F49" xlink:to="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_C6580F9B6A2CCB5568E0BE1E31FA104D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_52B7BD1C618A39A8D273BE1E31FA2F0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_F9CA21FE14A05E3C9829BE1E31FA28A8" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8D31B5134308DD2F1D7FBE1E31FA6774" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_E3CF351695D308027D5DBE4213FCCAA2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9C500B3FCF5B1515A79DBE1E31FA9F49" xlink:to="loc_us-gaap_InventoryNet_7D276650E38CAEEA41C3BE1E31FA26A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9C500B3FCF5B1515A79DBE1E31FA9F49" xlink:to="loc_us-gaap_InventoryNoncurrent_E79183C7F0137A28F403BE4457DA97DB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_EBEF1C1D891E711319C7BE1E31F24486" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_EBEF1C1D891E711319C7BE1E31F24486" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:to="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_269311619B24B1C1D4AEBE482C62CA21" xlink:to="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_ZINBRYTAMember_E5988837C0266F1F0A9BBE4880031B92" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_FLIXABIMember_BA327DB8F178327D3250BE49AA0B471D" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_5FEB21AD23D70CBF1317BE482C6643D7" xlink:to="loc_biib_BENEPALIMember_7C87FDBCC1EEDB233C25BE4B08E36101" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_6E73CFB78BAC01BD33BBBE47B397502E" xlink:to="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Preapprovalinventory" xlink:label="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1C1A703E7133479D56D9BE4909A5904A" xlink:to="loc_biib_Preapprovalinventory_963BBD18FBC115070E50BE4708774C5D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5C8E907CAFA8489FD57ABD9EAB1767C0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_FB1A38B1B3F74A040943BD9EAB17FF53" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_C78B2B6DB2CC51F299C9BD9EAB7D882D" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_CAF4232D0C876C9D6894BD9EAB7DEEF1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_113156C2720BAC1D752539D77AD1EACF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_113156C2720BAC1D752539D77AD1EACF" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_898B87896E0BEA36E6BC39D77AD1B976" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:to="loc_biib_NeurimmuneMember_FA9312A58C47B55014B039D77AD140D3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_OtherVariableInterestEntitiesMember" xlink:label="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_FBC9290BADA29CA2457339D77AD1AB77" xlink:to="loc_biib_OtherVariableInterestEntitiesMember_2195A63095A03C38217E39E15F36064F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_2D347948B73B6DB8F35739D77AD1947D" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement" xlink:label="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement_D0654A56CD6AD1545AA739D77AD1B714" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_9FC959E38FF86935460739D77AD11AAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_us-gaap_OtherCommitment_CAECB05FFD1E0A50E09C39D77AD1FD84" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_EE12123B114EEE3B064339D77AD1B6DB" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_BA99E0985C11BFF4F21839D77AD1C09A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C2A6633C10F60E030CE5BD9EABE8DE96" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_C2A6633C10F60E030CE5BD9EABE8DE96" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4D5F0932537E08EEBCB7BD9EABE86034" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_B2DE1992FB91FE5BD788BD9EA8F8ECEC" xlink:to="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:to="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_3955744457E7D7A27559BD9EA8F89898" xlink:to="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_B0F25719EEE5DD5FA5FEBD9EA8F897A7" xlink:to="loc_country_IT_1A328FBDBD9A3167315FBD9EA8F86B29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:type="locator" />
    <presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_F24E2D9FD501F1DDB5B5BD9EA8F89CD2" xlink:to="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_044CB4F6DB277C715B1BBD9EA8F8510A" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_F2A4D0D279814E89C770BD9EA8F89A3C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3F4F3C17AAE20C4905F6BD9EA9F4F9A2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3F4F3C17AAE20C4905F6BD9EA9F4F9A2" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_06763A05BFAE3D601C7DBD9EA9F4B52C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BCB14D50AD54DFA515163916981CB9E3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BCB14D50AD54DFA515163916981CB9E3" xlink:to="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_B312B5774236845FCBA03916981CFD5E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_E8553DDC06D530151FA83916981C3FA3" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_C72F830944A67922296E3916981C5A83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_89C564F3A995501F8C0D3916981CAA88" xlink:to="loc_us-gaap_StatementLineItems_940BDBA4DEF2E46BB9ED3916981C1AFA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BCB14D50AD54DFA515163916981CB9E3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_DAAD4A7A86557604822B3916981C42B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_EC582FFE49A17CA6E9283916981C0B1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_711228A3A143060AF2403916981DCEE1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_7E8192F1F198D70C66933916981D2729" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_846B66032536D18E3A823916981DCE8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_38E3A634438309BD632F3916981CCA82" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_70C2543D67A17C1B5A463916981D739E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_BCB14D50AD54DFA515163916981CB9E3" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_InvestmentIncomeInterest_A480141DC7C0D12CE3533916981DA9E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_InterestExpense_7DBCA6D07B8DA68F264D3916981DD292" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_7F32B76D9EA86301A7173916981D1B2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8545ED1C9204811CCAEF3916981DA35E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_B5B5057E08893544836C3916981D553C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_33815C54BA8B11A89E253916981D5375" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9052BD7B76284FA594F63916981D4807" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_BF614AC3506C6D6AE7222A7B3771E40B" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:to="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_E1A62650BAFDE0EFE8D52A7B37710354" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_DBCD7FC5A4FECFA23B8A2A7B3771985C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1D2C0A78E8E603F530A42A7B3771744B" xlink:to="loc_country_IT_DBCD7FC5A4FECFA23B8A2A7B3771985C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_18687CA6614CF21C17092A7B3771AAF1" xlink:to="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_PrepaidTaxes_65C3C8EC962125A40C982A7B377241EF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ReimbursementLimitStatedInResolution" xlink:label="loc_biib_ReimbursementLimitStatedInResolution_7C5077DD35E3C89ACF9E2AC086660969" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_biib_ReimbursementLimitStatedInResolution_7C5077DD35E3C89ACF9E2AC086660969" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E3E8CC4AB1F5503526AE2A7B37720661" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E3E8CC4AB1F5503526AE2A7B37720661" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_4BB660694E44775E0A752A7B3771000D" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_2F283310F7748274422F2A7B37724D44" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_990F3AC842CAD52DBBEE2A7B377A24C4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_990F3AC842CAD52DBBEE2A7B377A24C4" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F5F01A806138A70A97CB2A7B377BDA81" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_990F3AC842CAD52DBBEE2A7B377A24C4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A42DF1CD6846B0317C852A7B377B10A9" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91DD71759D1A07FFE4F9BD9EAD79897A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91DD71759D1A07FFE4F9BD9EAD79897A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_25740447FCB39D350659BD9EAD79863F" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D1447FFFD51F6440128ABEBB3BF46D2F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5182A305029C17275450BECC0034C783" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ADA46DB120A272B2FC89BECC00350D3F" xlink:to="loc_us-gaap_LandMember_FC73B4475E713624ABCCBECC27D1599B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4B43F6FB2519FFAFB1F0BEBB3BF55470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_054CEB0E07A5570A60B8BEBB3BF5EADE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_25433CB70C743BA3DC94BEBB3BF5483C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_80B0714DCE34D591ACC7BEBB3BF50788" xlink:to="loc_us-gaap_ConstructionInProgressGross_AA67D228D85EB1F805E8BECDBDDABD88" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_979E290C2F19F808FC95BD9EA9DB40AB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_979E290C2F19F808FC95BD9EA9DB40AB" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_848F357F96D48CEEB6CCBD9EA9DB1018" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BA233EF291C559D09112BE1E321F19FC" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_01367983A696D3F17DB8BE1E321FF2A2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_FAF28E74188869541284BE1E321F75FB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_biib_ContractualAdjustmentsMember_2A9976AAE74ED5C3A6EEBE1E321F4B22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_783AC5E2C98E1A29F715BE1E321FF5BB" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_2F6A5E7719405654A8E1BE1E322092EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_FEF8879F9E802F566CC2BE1E321F65D8" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_19B8E48FBAF19BA67D02BE1E3220FDFD" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_E0193CAC6FF9F6B83832BE1E3220E06C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_9A6C20BB8B9A8C543B37BE1E32203E28" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_65B7887FF68B207280E8BE1E3220DAE7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_4DF0C1C6BD26096ED3FFBE1E3220760C" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_22C34468AFE4B378F016BE1E3220BBFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_7AAE720082471E5DC473BE1E322089DA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2B1ED7D8E00285E12E89BE1E32204836" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_704279C712484BACC920BD9EA7F9E12D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_704279C712484BACC920BD9EA7F9E12D" xlink:to="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3A8AAA70E4C89AB15871BD9EA7F973D9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:to="loc_us-gaap_AccountsReceivableMember_6691CE2C80AF54FEABB5BD9EA7F9B2FF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9267EC0538473EF0317FBD9EA7F905A5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_69239C7B86B7C3E41275BD9EA7F94AF7" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9267EC0538473EF0317FBD9EA7F905A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76170CC1BB4DDA2F6460BD9EA7F9D16F" xlink:to="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_25044FE5570D6CE96BFFBD9EA7F9FFF5" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_F2D86B2E9944205E7300BD9EA7F9A65F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_16B00E604850ED26A3A3BD9EA7F92393" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BF5B5FD959DA359E49B1BD9EAB85E4B2" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BF5B5FD959DA359E49B1BD9EAB85E4B2" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_F617F13D94773AED4C36BD9EAB85AA40" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BF5B5FD959DA359E49B1BD9EAB85E4B2" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_A1439967F865462EAEAFBD9EAB855DB0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCD6E528A808693F2BEBDCC9FA695AF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCD6E528A808693F2BEBDCC9FA695AF" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_C15C05BF448B8AFA326EBDCCCF72CA41" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D9F42154374847877CF639D762AD9903" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D9F42154374847877CF639D762AD9903" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_7CCB318122C87158F9A939D762AEA2CC" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_57ACDE8E90E86A7AAC2039D762AE97CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:to="loc_us-gaap_EmployeeSeveranceMember_57ACDE8E90E86A7AAC2039D762AE97CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_112CA95209DA31898C1B39D762AF49B7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_F853DE37553EA552656939D762AE2E83" xlink:to="loc_us-gaap_ContractTerminationMember_112CA95209DA31898C1B39D762AF49B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_092678EE201E0174ED2A39D762AE5C91" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringCosts_97AA52DF5B4D873FB1B739D762AF67CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringReserve_7A2301DBC5C8043F689139D762AF88EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_PaymentsForRestructuring_FFEE7457AC6574F4456739D762AF3B4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_551E05928CD7FB91259039D762AF1C94" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_551E05928CD7FB91259039D762AF1C94" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_D1514971D0FD9A3FBE1B39D762AF5812" xlink:to="loc_us-gaap_RestructuringReserve_E0EF20C85799A489E5E339D762AF6E32" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_F86B5FE3DF69974637E439D77BCCF84A" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_BFD19FDA222A0EA0FA2C39D77BCCA693" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:to="loc_us-gaap_EmployeeSeveranceMember_C43EB02993636A14941639D77BCC6832" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C0D7633F993BCF36934E39D77BCC0EE7" xlink:to="loc_us-gaap_ContractTerminationMember_89027FD89D4DC397CEC839D77BCC147B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4A4C4E77B34423175C0C39D77BCC4AE8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated" xlink:label="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated_590118885371D008A34539D77BCC2A94" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_RestructuringandRelatedCostExpectedCashPayments" xlink:label="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_biib_RestructuringandRelatedCostExpectedCashPayments_963E8755CC6B7C40D57039D77BCC94DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_55E08D3A91F7D708785A39D77BCC5C0B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_311216DA88E65BC944A439D77BCCEFD1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_C441F464E64A19C2DED539D77BCC62BF" xlink:to="loc_us-gaap_RestructuringCharges_A975DEA433C28930255039D77BCC671A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18DEE8D65324D4EB90F2BDCC9FADE446" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_18DEE8D65324D4EB90F2BDCC9FADE446" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6527DF60B02A0B2C4888BDCF0977EB59" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6A8D98BF97ADAAC45FDDBD9EAB9E04E4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6A8D98BF97ADAAC45FDDBD9EAB9E04E4" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CC6870336001915EE711BD9EAB9EBFEF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DF3E9F51052CECB3DFD62A7B37946F6B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DF3E9F51052CECB3DFD62A7B37946F6B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_301DD8D40D0EB1182A1A2A7B37945E48" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F4B247E95B3CBA765142A7B37944E29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E2B49BFF764256FFD2822A7B3795AF01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_RestructuringChargesMember_EA8AB4A1EC274AB72D2B2ABA8ACD183C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8CA7C49E7D16C4F06D8D2A7B3794E815" xlink:to="loc_us-gaap_ParentMember_34D5B4101A6BEDD9892B2A7B3795E979" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5984909F677C9C8AC59F2A7B3794A9D4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0FA046031A5DD2D4DDF32A7B3795AE0C" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_E4B97369A16D4E9F699A2A7B3795F372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_21A1F2076436BC7B556C2A7B3795DA44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B29BAF7ED0CF473F82652A7B37952AF6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_B29BAF7ED0CF473F82652A7B37952AF6" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_348520E6B27C8DBADA492A7B3795B090" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_348520E6B27C8DBADA492A7B3795B090" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_A2F2B213A98D883851082A7B37956E2C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C7809EB4843903EFE142A7B37953B36" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5957E8157E95397F327BD9EAD6E8BDE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B5957E8157E95397F327BD9EAD6E8BDE" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:to="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4AD280A74B4AA1EA8A8BBD9EAD6EA3C8" xlink:to="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_MarketStockUnitsMember_A694281B618CD9C7ED16BD9EAD6EA819" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_281BB3F0FF27325EB860BD9EAD6E3484" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_CashSettledPerformanceSharesMember_068FB792C0941595A698BD9EAD6EE3DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_us-gaap_PerformanceSharesMember_4D69C1F0C231D5B6D784BD9EAD6E06A1" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_896C4C52CC795726567CBD9EAD6E0775" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_7D8B0B92B4A691E3DB83BD9EAD6E517F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_C98D7F0DC846766CF9ACBD9EAD6E649A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6ADD2F6FFDE65DB5637DBD9EAD6E2FC0" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EC0D1D91E3A9C27E3634BD9EAD6FCA9C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_8537C6CC56FBDBEEB786BD9EAD6F79BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C09F8E6714BCC3DAEB87BD9EAD6FABF7" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_ABC2C0D93362F2CF26EABD9EAD6E0951" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_E28CD9F05F3665859182BD9EAD6FBC1D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4C28F23E7DF5F12DB64DBD9EACA0646E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4C28F23E7DF5F12DB64DBD9EACA0646E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:to="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5C658BCB243946D0416BBD9EACA05672" xlink:to="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CB71467ED79D9C8FEB69BD9EACA0AF99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_MarketStockUnitsMember_CB71467ED79D9C8FEB69BD9EACA0AF99" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_0ECB3E82030C1343CF5DBD9EACA093D8" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_CashSettledPerformanceSharesMember_0ECB3E82030C1343CF5DBD9EACA093D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A8F0231E9B6B986764E2BD9EACA5EC53" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_us-gaap_PerformanceSharesMember_A8F0231E9B6B986764E2BD9EACA5EC53" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_C785F95349B3E75C2133BD9EACA57A71" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7F1DE08EB28611634DFABD9EACA0B3A3" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_C785F95349B3E75C2133BD9EACA57A71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6716249D051A760A8B2ABD9EACA03251" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ScheduleOfStockOptionGrantsAbstract" xlink:label="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A888A5DD8D8E36FF3CC3BD9EACA5B5CB" xlink:to="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfStockOptionGrantsAbstract_91BA7F370192D5870378BD9EACA52BCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_30AFFF29BB6815358F05BD9EACA5A44B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C4F18E99E9B56A90BBA6BD9EAA07D272" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:to="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6A527D61EBBA481A56B7BD9EAA0717DE" xlink:to="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_A1995ESPPMember" xlink:label="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:to="loc_biib_A1995ESPPMember_8CD791AF5E8FDFB922E3BD9EAA07D2A3" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9803346FFBAA04097D4EBD9EAA078A18" xlink:to="loc_biib_A2015ESPPMember_E4C3DFE501F853021702BD9EAA07E9CD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_A878B2EDB952874C4B77BD9EAA070AA6" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_Employeestockpurchaseplanmaximumshares" xlink:label="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="loc_biib_Employeestockpurchaseplanmaximumshares_1A3357F517D2D1B00782BD9EAA0712EE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_5AF53CAEF8010433F0B4BD9EAA073019" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6F4CFCB547D7CE00EAB9BD9EAA071277" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35FA7CD0849BD3654BFBBD9EABF1F98E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35FA7CD0849BD3654BFBBD9EABF1F98E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_02863B3192E2874F3C0BBD9EABF1B402" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35FA7CD0849BD3654BFBBD9EABF1F98E" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_22FAE81571C7F204C228BD9EABF1BE48" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock" xlink:label="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35FA7CD0849BD3654BFBBD9EABF1F98E" xlink:to="loc_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock_EB41CF77DDE5D2D6D0D8BD9EABF17D9C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_280B4A1A8935FADB546FBD9EAB7876AD" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17E79649BEF18654C2B0BD9EAB78793C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E0119C464ED8A639C38D2A7B38DD20A8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E0119C464ED8A639C38D2A7B38DD20A8" xlink:to="loc_us-gaap_NumberOfReportableSegments_FD4AF9B5B81627ACBDAF2A7B38DD9E66" xlink:type="arc" />
    <loc xlink:href="biib-20160331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E0119C464ED8A639C38D2A7B38DD20A8" xlink:to="loc_biib_InterestInSubsidiary_32CAE5C93D5F3213F57F2A7B38DD0B27" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:type="locator" />
    <loc xlink:href="biib-20160331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_277D9D9EE9E679732223BDA0CD97C0E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_C69B640815E0092F4E06BDA0CD97FE52" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_F454BC3FDEDE17431CE1BDA0CD979CB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:to="loc_us-gaap_UseOfEstimates_3F83DFF091CDEC8DBCBFBDA0CD97845C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8C43395F2F2ED7AAE5A2BDA0CD97E0A2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BC2BB7832838C1705F3BDA0CD975704" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-2016331_alprolix.jpg
<TEXT>
begin 644 biib-2016331_alprolix.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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MVJ0QV^I6#7$*2M9W\$,]S#%>6S.8;F.*XGB29'$<TJ!9& /FWXW_ +6OPT^
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MOV4\*_LPZEH6IZQK&O?$KXG^.KWXE>)M7U[]HBW\2:7\$8]'^/\ I%Y\&O\
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M3L?VI?\ LY7X_P#_ *M_QG7SU7\S8G-LR6(KI8W$)*M522F[)*;27RLON/\
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M3]I/X^NCJ<JZ/\7?&3(RGNK*00>X(-?/E?0O[7//[6/[4N?^CE?C_P#^K?\
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M ."W_P#)?U=^5OT;_B5CP^_Z"\[_ /"J/_R/]7?E;_1F;_@XF_80"DG4]5
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M65E8'XO>,R"K*2K*000RD@@@@D'-?/>QO3]1_C7^FE_PX$_X(X_](^OV??\
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M_P //XBU'Q3)!?6;7-D^IMJMO#<;[::"'Z>_X<"?\$<?^D?7[/O_ ()?$/\
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MU_XFU+58GT^6RDB6WNB$MKCX,\/_ +>'QL\??L@_LR_''0_ O@+PA\1_CO\
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MC:1^ /$4CZ:VAZ]X3Z_4_P!C[4;_ /:H\)_M36O[1GQ@T;4O!7@S6_AAX?\
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MY%I#=:YXL\9^)->\1ZJ;*RT[3(;W4YK;2-,TS2X+/3[;TRBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **;O3^\O_ 'T/\:4,IX# GT!!H 6BBB@
MHHHH **** "BBB@ HHHH **** "BB@D#J0/K0 44F1ZC\Q2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?JTDD6EZC+$[1R1V
M%X\;H2K(Z6TK(ZD<AE8!E/8@&M"L_5HY)=+U&*)&DDDL+Q(T0%F=WMI51% Y
M+,Q"J.Y(%)[.W9ET[<\+VMSQO?:UU>_D?Y6MS_P5._X*3I<7"K^W9^U&%6YN
M54#XK:S@*MQ*J@ J<!5  '0 8%?M-_P0#_;H_;+^/G_!1+P_\//C;^U'\<?B
MQX%N/@M\8-:G\(^/?'FI>(/#\NK:/%X4.EZC)IMR! UY8&\N6M)V!> S2;"
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-2016331_amortization.jpg
<TEXT>
begin 644 biib-2016331_amortization.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
MX*-^.OA)9^+?^%<Z7^T7J_A#]KKQI\,K2/X&^'9/VDXO@KX!_9MMKC6_$.E#
M]KCQ[I5MXF\*Z;JVC:;KE_!;RZ-XYMOB!<_%D>!(?A7\/O!J:;J7Q0U >9:+
M\2/%+?'_ $/5H/B1XEU#]JR^_P""C7C7X3^*OA'/\2O$K:9#^Q3967C2;0;T
M?!W^T1X5TSX;P_ 2V\$_'C2_B!:^%X%E^*>J0A/'ESJ?B6_T/4?VA\1_#7X>
M>,+N*^\6>!?!OB:]AACMH;OQ#X6T'6[J*WA:5HH8[C5-/NYDBC:>=HXED$:-
M-*54&1RW2KH^DIJ']K+IFGKJ@TY-(_M%;*V6_P#[*CG:YCTS[8(A<_V?'<.\
MZ6/F_94F9I5B$A+4 ?SI0?M)^(_"/PX_X*XZ3\)?VI=6_:&^(/@SX_? C4-$
M\06OQB\%Z[X]\/\ P=\4? ?]C.']HCQY\/;#P<M]HGPS\(_#G2?&WQ1\0Z?J
M'@;P5'X6^'^NZ7=ZHMCJ7B>QU26_^YOV+/BOI/A7PM^V!I]K?R>)?!WP,\06
MOB2T^(7@'XI_%?\ :9^#6MVNI?".Q\=:KHWPLN?%MWXF^($7B'PI#:Q'XC_#
M;PYXF\76=_XHUJQ\4>'9]*U[X@:IX0T'](_#_P -_A[X3OSJGA?P-X.\.:D;
M6:Q.H:#X7T'1KXV5Q/'<SVAO-,T^UN3:SW,4<\UN93#+,B2R(TB*PZ72])TO
M1+"#2]&TZQTG3;82BVT_3+2WT^QMQ--)<3>1:6<<-O#YL\LLTGE1IOFDDE?,
MCLQ /YU/!_\ P52_:1\4^-?"_P .]'O/A'JZ_$?Q=^PS?^%?B/<>'/"5Y86G
MA3]JKXP^//A1XXT2?PA\+?V@/BC8:=JOA&WT#0?$/A30_$7Q"A\;Z;>W%WI7
MCJWGLM1TO4HO._VIOV_/VAO'O[*_[;7@W5/BK\,?@EK_ ,&?@K^T[X0T/Q)8
M:#XA\,>./VH/'?PR_:(_:;_9PU75O@;=Z=\5+?5OAQK7@?3/@GX.\1^)-,\,
MGX@ZQH?CKXJ:.+J72_!MCIC^(/Z8;?PMX:M%B2U\/Z';)!=-?0)!I&G0K#>O
M?/JCW<2QVRB.Z?4I)-0:X0+,U](]V7-PS2%9O#'ARX\OS]!T6;R9M6N(O.TK
M3Y!%<:ZEQ%K4\8>V81S:O'=W4>J2IB344N)TO6G660, ?!'_  4#^(W[/GP^
MT3X;2?&_XC^+(=7\07WBO2_A)^SYX1^.J_ BY^/?CI--TJ\2YU#Q-9^+/A[?
MV^C_  QT^";6;_Q/K?CW0OAMX A\0-XK\6V^I^(;7P$MK^:?COQO\2?"7@#Q
MU;?%G]I?4O$_[0WP@_8/_9KU_P#8E\7^ /C-KT&B_M#?M*WEM\5K/Q?KW@K0
M_#MQIFB?M":MXX^+VE_#'X3^+=/UOP[XQFU+P%?:#+JWA[PU%\4-:?6?Z&/$
MO@GP=XSCM8?%WA3PUXHALO--G%XCT#2-=CM3.T#3&VCU6SO%@\UK:W:7R0GF
M-!"7W&*/;;M?"_ANQ@T2VLM T6SM_#09?#L%KI.GV\&@J]K+9.-%AAMDCTD/
M9S36C_V>MMNMI9+<YB=D(!^.&B_&;3-%_P""FW[1_P /+[]K*'7]2UO]A[P_
MJ.D_#[4OBEX7O]'^&7Q.@^,GQOM[OPKX#^%_A0VUPGB/PCX9TG3)?$%S_P (
MWKOQ3\0VUE;77B*[O(8M%TNPVO\ @FU>>&?!7CR]^%_A7Q#\)OC"GB;]GSX?
M_$OQ-\7?@K\7/C?\5])T'6]+U>'PU%X,^(=]\6_'/CRV7Q)XREUK6O%_A/Q!
MI2?#[6_$MCX>\9Q^)OAOHHT/2;R\_5V+X;_#V#7CXIA\#>#H?$IOY]4/B&+P
MOH,>N'4[I'CN=1_M=-/74OMUQ&[I/>?:OM,J.RR2LK$'I=/TG2])%X-+TZPT
MX:C?W.JWXL+.VLQ?:G>E#=ZC>"VBB%U?W1C0W%Y/YES.44RROM& #0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /E[XW_M:_#3X"_%_]F#X(>+].\7ZCXX_
M:W\=^-OAY\*AX>TK3KO18->\ ?#W5?B9KTGBW5+_ %G3#HFG'PWH]XMA<6MK
MJL]UJ7E6IM88F>YC^@AJNID CPY?8(!_Y"&BGK[C42/R)%?B_P#\%)_^4DG_
M  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!% &)_:NJ?]"Y??^!^B_P#RPH_M
M75/^A<OO_ _1?_EA6]10!@_VKJG_ $+E]_X'Z+_\L*/[5U3_ *%R^_\  _1?
M_EA6]10!@_VKJG_0N7W_ ('Z+_\ +"C^U=4_Z%R^_P# _1?_ )85O44 8/\
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M2_\ Y"I&^+7C_:V-= (5B#_9NE'!"DCC[%[4/Q7X>2O]2SG_ ,)\%_\ -_\
M5O2YN?6G]JZI_P!"Y??^!^B__+"K]C=W5SYOVG39]/V;-GG7%E/YN[=NV_8[
MBXV[,#/F;,[AMW8;"Z7-)<Z;IUQ,V^:>QM)I6P%W22V\;NVU0%&68G"@ 9P
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M_2ZXK(K^-\7_ +WBO^PBM_Z<D 4445S@&3C&>.N.V?6DP!G '/7CK]?6EHH
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ML_F;]W^J_>/OV[?GZ;<KUSQ_96%_W;#_ /7BC_Z;B(T****W **** "BBB@
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M .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 ? /B#_D/Z[_ -AG5/\
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M444 %%%% !1110!^$O\ P5T?XE^ OVG/^"4?[2WA#]G7]HW]HKP1^S;^T/\
M'GQ=\5- _9E^%&J?%_Q]HNA^,?V</$WP^\/WJ^&--O-.S;WGB77[.W:XN]0L
MX([>&]E626>&*UN.P7_@M%:JJK_PZN_X+2G:H&?^'?VOC.!C/_(_U^U6*3 ]
M_P S_C0!_-[JG_!3?5;W4]2O8O\ @E[_ ,%EQ%>:A>W40?\ X)_Z\'$=Q<RS
M1AA_PL4X;8XW#)P<C)JC_P /+M8_Z1??\%E?_$ ->_\ GBU_2A@>_P"9_P :
M,#W_ #/^-?GM3PRX9J5)U)?VCS5)RG*V+BES2ES.R]@[*[=M7;3>VH?S7_\
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M]3L;;3XK34&MQ&@@:\AF,.Q?**;1CM** &JJHJHH"JH"JH  4#@  8  '
M &    *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-2016331_anticd20.jpg
<TEXT>
begin 644 biib-2016331_anticd20.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M0ED" ?IA14<4B31I+$ZRQR*)(Y$(9'C<;D=&!(9&0AE8$AE(8<$5)0 4444
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M&\2V-O!'#:ZR+6%(8K=(UBM@+>,*$@'E!*\9_P"&V?CE_P!#GXV_\.=\0O\
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M:2XWR/'QP%/$5(PEB7@\/@X5L2J?,W[*G.,Y;)IW/[6:*P?[5U3_ *%R^_\
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M$Z3X;US5)]&>YU/XD:EXRT#XH:A<>'+Z[;2?#4/@9O#WBB:VUKQ/X@>W\-^
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M7>F-KMUJK1/:6D3R6UHAEFADN(1R \<?\' 04+_PSG_P2AP-N/\ C*3]JO\
MAQC_ )MZSV[D^^: /X?OVI?^3GOVD_\ LX7XY?\ JU?%U>$5^X/Q)_X("?\
M!93XD?$;XA?$6]MO^"=NF7GQ!\=^,O'5WIEG\=_V@)[33;KQEXEU3Q+<Z?:3
M7'P*-Q-:V4^J26MO+<$SRPQ)),3*SFN*_P"(=#_@L7_SU_X)Z_\ A\OCU_\
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M8[_Y0'_$(N.O^A70_P##EEWE_P!1/K]WF?CG17[&?\0Z'_!8O_GK_P $]?\
MP^7QZ_\ G$T?\0Z'_!8O_GK_ ,$]?_#Y?'K_ .<31_Q$W@[_ *&-;_P@QW_R
M@/\ B$7'7_0KH?\ ARR[R_ZB?-_=YGXYU6O?^/#4?^P=J'_I'/7[*_\ $.A_
MP6+_ .>O_!/7_P /E\>O_G$U'-_P;F?\%BIH)X#-_P $]E$\$\!8?'+X]943
MQ/$6 /P)P2H<D \$C!XIKQ-X.33_ +1K:-?\P&._^9Q/PAX[:?\ PET+M?\
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M:TN[4M;:AIFI6<DMK>V=PH+0W$$CQ2*,HQ%='0 4444 %%%% !1110 4444
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M0:7:N0=JY P#@9 ] >H'M0 *,*H/!"@$8 [>@X'T''IQ2T44 %%%% !1110
M4444 %%%% 'X;_ML^'=:^'6K_MYVGCOP-J'B[2?V[?A!\-_@?\ OB5./"D/@
M#P#XQM/A?X^\#:;\/_BIXR\2ZMI<'PC\,>%_B+J<WQJT3QAKF[1-4U7QCJ.F
M^"Y-2^*4.E>&-9['2M%G^'__  5(^&_CBP_9_P#CIK,=U^RW\2/@1\9/VC-.
M^">JOX4\:_%GQC\0OV3-5\%Z[K?CI+AYKSPG!X7^&GC*YGU.&'_A#O T]MJ-
MH!8ZCK5RM]^Q.I:9IVL6<VGZM866IV%P$$]EJ%I;WMI,(Y8YXQ-;74<L$H2:
M**9!)&P66..1<.BL+?EINW;$W9SNVC=GUSC.?>@#P/XW> /A-<Z%XP^(?CGX
M5:A\1[U/A_/X)UK3?"WAC5?%GC/Q-X"N/$FF>(K[P18Z!HUQ!?Z_IFH:W9VF
MH7^@Q[XM1B@N(;R*YL9+JUF_'_\ 94\&>*=._8>_9P\"^-O@-^VU\*M<_9Y^
M,'Q8U+5=+^%G@3PS\/\ QWX>TCXC:C\?H= N] TC6#=ZCKG@F3PE\1M-TB];
MX*LGC'P?JE_I$&+'P[:>*%M/W^(!!! (/4$9!^H--$<8!4(@4]0%7!^HQ@T
M?/\ ^RTGQ=3X'^$D^.#>('\?+?\ C4 ^,7\*2>.1X'_X3WQ1_P *I7XAR>!E
M7P?)\24^%?\ PAB?$5_#0.C-XT77&L6>,EV^@Z.G2B@ HHHH **** "BBB@
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MMO9W>M7-I'<VUJT>G6VH7VFV<MP9+J,A;B^MH]@<F4$ -^3[?\%Y?V2 2/\
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M^&GPDN?$GA'PMI7A3X>Z-XV_X5[>>%0#^FC(XYZG ]SSP/R.?0 GM7''XB>
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M:9#-#(NR2&6*QMTDB==S;7C=61EW-AE(W'&: -FBBB@ HHHH **** "BBB@
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-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-2016331_benepali.jpg
<TEXT>
begin 644 biib-2016331_benepali.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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MS:I93:+I[^'-'NTL+BTLM5EN=1,=L]O!"9+J/Z9!# ,.A (^A&:_$'_@I/\
M\I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"* 'T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2-C!R<#!R1U QU[]*6D/0X!/!X!P3QT![$^M 'X$?%/X2)\
M1_VQ_'LVC:7\6?B;I7A[]H7P'JMMXY\*?LZMKME\&OB1?ZQ^RIXE^(:3_%?Q
M9\6O#MI/KOA+X=? _P &^"? /C+X=^!8K;X6>$/B5\4-(UZ3QYJK7^B3?OLH
MPH&,8SQT'4]!V7^Z/3%?@3\6KWP]I7[</C/7%NK;1?B/)^T-\#] TK]F^U^)
M7[9FD_%SX_\ AF_M/AM92_'7PL/!O[1WASX(VW@OPEI]_K=S/I"_ KQ;\.(M
M ^''B32/BQXLT34-0U*+PG^^Z\@9]_7UZC/.#U [# H _#S_ (*7)+)_P4?_
M ."%B03_ &:5OVK/VG]DWE)/LQ^QW\0"?W4A"-N4%,DY3=O7+*!7[1)I^ME$
M/]O?PK_S"+$=AV$F!]!P.@K\8O\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]
M7'_N+_Z"* ,+^SM;_P"@]_Y2;+_XY1_9VM_]![_RDV7_ ,<KH** .?\ [.UO
M_H/?^4FR_P#CE']G:W_T'O\ RDV7_P <KH** .?_ +.UO_H/?^4FR_\ CE']
MG:W_ -![_P I-E_\<KH** .?_L[6_P#H/?\ E)LO_CE']G:W_P!![_RDV7_Q
MRN@HH Y_^SM;_P"@]_Y2;+_XY1_9VM_]![_RDV7_ ,<KH** .?\ [.UO_H/?
M^4FR_P#CE']G:W_T'O\ RDV7_P <KH** .?_ +.UO_H/?^4FR_\ CE']G:W_
M -![_P I-E_\<KH** .?_L[6_P#H/?\ E)LO_CE']G:W_P!![_RDV7_QRN@H
MH Y_^SM;_P"@]_Y2;+_XY1_9VM_]![_RDV7_ ,<KH** .?\ [.UO_H/?^4FR
M_P#CE']G:W_T'O\ RDV7_P <KH** .?_ +.UO_H/?^4FR_\ CE']G:W_ -![
M_P I-E_\<KH** .?_L[6_P#H/?\ E)LO_CE']G:W_P!![_RDV7_QRN@HH Y_
M^SM;_P"@]_Y2;+_XY1_9VM_]![_RDV7_ ,<KH** .?\ [.UO_H/?^4FR_P#C
ME:%A;WUOYOVR_P#MV_9Y?^B06OE;=V[_ %+-YF_*_>QMV\=36A10 4444 %%
M%% !1110 5C^(0QT'6@AG#'2-3"FVEU:"X#&QN-IMY]!237(9LX\J71T?58Y
M-KZ<C7JP*=BJM]:0W]G=V5P9Q!>6UQ:SFVN[JPN!#<0O#*8+ZQFM[RSF".QB
MNK2>"YMY-LUO-%,B.H!_/3X*^(OQ-\6?&/X=ZGK%K\6+07/C+X=:=<P:9XR_
MX+R:'X96STJ]T'1$>[\->*?@OH/PCF$MC8I-X@F\?/9^%O$.H2:EJWQ$U"2'
M4]>U%_Z'Q_4^OJ?7_P#5Z<8K\"_%VL:!_P -L:WX1?XS6_@3_A7OQ=^$/@O1
M_ TWC7_@IG\;=;\2Z99>%_AQ<:9>>)O$7PM_:=\-?L]^!_$7B(73V5WX*\>>
M!/$,MC:1V'C;XJIXE@\;7?VW]]!_4^OJ?7T_+TP,"@#\0?\ @I/_ ,I)/^"%
M/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_#[_@I=,+?_ (*/?\$+)FCFD"?M6_M/
MDI;PR7$QS^QW\0%^2&)6D?&=S;5.U S'A37[2IK]N$0?V?KW"J.="U0'@#J/
MLW!]1VH WZ*P/^$BMO\ H'Z__P""#5O_ )$H_P"$BMO^@?K_ /X(-6_^1* -
M^BL#_A(K;_H'Z_\ ^"#5O_D2C_A(K;_H'Z__ ."#5O\ Y$H ^(/^"E7[1'QD
M_9@_9:\:_%3X*^'[&]\0Z18ZZ^H^,-7\%>)_B3H7PTTZP\'>)M<M/%NM^ ?!
MMQ9^(?$5C>>(=(T7PBLT=Y9Z)X;NO$MOXH\57"^'-(U!).!UK]LCXQV^M_L
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MUK4;^=]\^U0#VFBL#_A(K;_H'Z__ ."#5O\ Y$H_X2*V_P"@?K__ ((-6_\
MD2@#?HK _P"$BMO^@?K_ /X(-6_^1*4>(;8\?V?KWXZ!JH_4VH% &]16%_;]
MO_T#]=_\$6J?_(U']OV__0/UW_P1:I_\C4 ;M%87]OV__0/UW_P1:I_\C4?V
M_;_] _7?_!%JG_R-0!NT5A?V_;_] _7?_!%JG_R-1_;]O_T#]=_\$6J?_(U
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MC5_X=GX@_P#S14?\-!_'[_HNWQJ_\.S\0?\ YHJ\AHK;ZKAO^@>A_P""H?\
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M[:HFI37O.";A!7J2M\%IP<_.O^&@_C]_T7;XU?\ AV?B#_\ -%1_PT'\?O\
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MCZ_9^_\ !-XB_P#FEH_X<!_\$<?^D?7[/W_@F\1?_-+5_P#$07_T*?\ R_\
M3_J"\G]_D9_\0LC_ -#Q_P#AM_\ PA_5WY6_F7^#OQ;U+X.>,['Q;I^@^$/%
MD$,U@^H^'/&6E6&K:3J4>FZA!JEDT-PW_$TT'4[._MH;BRUO0KNRU& >=;2/
M<V-U=6DW;:=^TQXB@G\?7_B'P/\ "GQIJ7Q)\.6/@KQ-J'B+2?$MF$\":2G@
MV+0O VA:=X2\=^%]'T#PQX>B\ >%;?0[>PT\:G9V>F+92:M<V\TT;_T9?\.
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M7$O]1*?\$!/^".1!)_X)\_L_ [G'_(&\1] [ 'GQ,>H /ISQ@8%._P"' ?\
MP1Q_Z1]?L_?^";Q%_P#-+5PXZIPFZD<F2J233G]?U?-[/FWP>\E2@I/=QA3B
MVU3@E$_#6K4IQHSX@DZ47%QA_9J45R<_*M,>M(NK5<5>T95JTHI2JS;_ )0M
MZ_WX_P#O[#_\<HWK_?C_ ._L/_QROZO?^' ?_!''_I'U^S]_X)O$7_S2T?\
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MZ+XDTRZCM[R&TU;2+K2M8LK6_C^(_P#AP#_P1P_Z1]_ #_P4^)?_ )IZ1O\
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M^):^'%\=MX&L]2M3XF7PB=;;PV-3.H:GJ/F#2#XCULVGE>3M.I7._P S<NP
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M#?'/P"\,JFD>!=+AO%\/>"Y+'XTGRM6\6:O8>+-6US1[Z"'PAI>A6=IK7B$
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M>ZG-;:1IFF:7!9Z?;>F444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-2016331_contconsid.jpg
<TEXT>
begin 644 biib-2016331_contconsid.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M% "T4F1[_D?\*,CW_(_X4 +129'O^1_PHR/?\C_A0 M%)D>_Y'_"C(]_R/\
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M?X4?\(QX>_Z ]A_X#I_A6[10!A?\(QX>_P"@/8?^ Z?X4?\ ",>'O^@/8?\
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M^C^RM4_Z&.^_\ -%_P#E?6]10!@_V5JG_0QWW_@!HO\ \KZ/[*U3_H8[[_P
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MJ":WN;:YA2XM[B">-HIH9X)5>.:&6)WCEBD5DDC9D=65B#8I#@ D],'/T[T
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MDI\=<*0G*$LXI*4).,E]7QCM*+LU=89K1Z:.V_9CL^S_ *_X=?>>N_:_$/\
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M9W;]V;.T\O;A<?ZS=N/W=O,>B_\ (&TG_L&6'_I+%6G7]E87_=L/_P!>*/\
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M$D4$<;@'_A'QD!E(!QR.:ZO1/$FE>(/M(TUK]OLGE>=]MT;6M)QY_F>7Y?\
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M  '    &    *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-2016331_cos.jpg
<TEXT>
begin 644 biib-2016331_cos.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M].U2&.WU*P:XA25K._@AGN88KRV9S#<QQ7$\23(XCFE0+(P!\Z?&;]K#X7_
MOXR_LN_ SQK;^*YO&G[7/COQO\//A7+H>C6VH:';:_X ^'FJ_$S77\6ZC-JE
ME-HNGOX<T>[2PN+2RU66YU$QVSV\$)DNH_ID$, PZ$ CZ$9K\//^"EL;R_\
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M_/:+_OXG^-?RM?#+Q]>?$7PE:^*Y=)L]"BO;W4+:TMM)^)'@OXH:==6UC*L
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M[M>U[7=C^E:%7VU"C6Y>7VM*G5Y;WY?:04^6]E>U[7LK[V1<HHHK,U"BBB@
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M8\6:)J&H:E%X3_?=>0,^_KZ]1GG!Z@=A@4 ?B#_P4G_Y22?\$*?^SK?VH/\
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MN[&[:V,X-?Q=B_\ >L1_U^J?^EL_TGP/^Y8/_L%P_P#Z9@7****YSJ"BBB@
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MU:S\#ZE\4-$ETS4=;^!+V?B.YCUSPW=6H\6^)]+C@\ ZUK]QX=M+?53R5O\
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M-KEZC,OV:+:60>'W"L1@E0[A3D!F R=ZTDU!_,^WVME;8V^5]DOY[W?G=O\
M,\[3M/\ +V_+MV^;NRV=FT;H-%_Y VD_]@RP_P#26*M.O[*PO^[8?_KQ1_\
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MS _LC4O^7VT)Y>SZ 3$G\!ZGH#7Q]_PX"_X(X?\ 2/K]G_\ \%'B/_YIJ/\
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M\7Z]1YN;V//_  X\O-RZ\O,P]H^TVW_/U9_^!MI_\?H^TVW_ #]6?_@;:?\
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MHH **** "BBB@ HHHHNN_P#7]- %%%% !1110 4444 %%%% !1102!U('UH
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M *R?V[FW]M_V[[#^R/W7]J_VC['VOUS"_P /ZY[GM>3F^'W^7FZ<QZ]378J
M1_>1>?1G53^0.1[TZD90PP?56_%6##]0,^U?B1_2Y^!O[.G_  5S\0>-+GPY
MXF^*_BO]G[4_"<L_[3FO?&GP%\+O!?Q<TOXB_LL_!_\ 9ZE^*B3?&3XA^(M<
M\5^,_#GCOPQ<ZMX%\%_#_4=/T3PYX/U>Z\=?%KPK:>%(=<>&?2Y_T*TO_@H%
M\'#K.M^%_&_A7XM?"7Q=X:\/>(_%/B+PK\3/!ECHVLZ-HFB_#J\^*^DW=U_8
M_B3Q!ILO_"<>!/#_ (^U?P?%8ZE=RW%Y\+?B9X<UU- \3^$;W1WAMO\ @G1^
MSC'\+OAW\'[VU\;:OX*^'>C?M$>$H;;4?%TZW_BSX?\ [4<7BD_&#X=^,M0T
MZRT^;4_"&MZGXBTWQ%IUIIPT?4M$\2> _A]K6GZK'=^'-UYQ'BO_ ()]Z-JN
ML>!&;Q/XA^(=U=?&KX._%7XP?%[XP^-M4UGXO:KHG[.=IJ,GPK^''AJU\*>&
M?#?@V\\(ZL=;\5^#_'.F:Q;Z79:KX/\ B%\2[S7+;QIXE\;ZC=Q@'EW[3'_!
M6+X??"3P/^T!I?A/PUJ&D_'WX9_ ?XR?&'P!X$^+I\,Z;9>+[GX,Z+;ZUXIT
MO7/#7@[X@:Q\4?",.F65Q_:6[QGX5\$KXHT6VO=3\#7_ (AM8%FE]#^$G_!2
MKPOXO\2_M :#\5/A#\0_@Q9?!OXU_M%?"K0/$VL-X;\1^'O'UG^SCX$T'XB^
M*+VVNO#FOW]WHOBG4?"&HZMXDTKPI?V'E7NB:'>RV&M7E_:ZGI^GT_&7_!);
M]F7QYHFM^%_$&O\ QD?PMJ%E^TSINAZ!9^.-*MK7P;8?M<V'B2U^-D&AWR^$
M6UW6+G7+WQ3J>LZ1K7C_ %?QMX@\.7WV>RTG5H/#T3:)+T_Q$_8%\.>(/&QD
M\+7\]I\.OB#^U1X-_:Q^+?A[7?$M_(FA_$+P'IEM'J,OPJTC2O#<%VUO\>5T
M^R\'?&_1O&WCF^\'2^!9M?MO#?A6.^\3ZQ'. ?H3I-^VJ:7IVIM8W^EMJ%A9
MWS:;JL,=MJ>GM=VT5PUCJ-O%-<107]H9#;WD,=Q/'%<Q2QI-*JAVT*11@ =^
MY QDGDG';)R?QI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBBBR[?U_20!1110 4444 %%%% !1110 4$ ]0#]:** $P/0?D*6BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-2016331_eloctate.jpg
<TEXT>
begin 644 biib-2016331_eloctate.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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MQKA:="%:57"KFE%6<<0M9.IHE9RO&-.-27NZ0K4I.RE!U/4P_P!'S-L3F-;
MT\+F\O8TZDW4C7RMZ4U@O?<N94O9U*N+K8>E)57SU\OQT(<\L/B(X?\ O _X
M;/\ V4?^CA_A!_X7.B__ "11_P -G_LH_P#1P_P@_P#"YT7_ .2*_P \+_AY
M9X&_Z)9XX_\ "B\,?_$4?\/+/ W_ $2SQQ_X47AC_P"(KE_U^P7_ #]PO3[&
M*\O[GF_Q[:^K_P 2T9U_T#YQ_P"#\F\O^GWG^#['^A[_ ,-G_LH_]'#_  @_
M\+G1?_DBNQ\"_M&_ CXG:^OA;X>_%SX?>,_$36-UJ2Z)X;\3Z;JVIG3[$PK>
M7@M+65Y3;VS7$ FEV[8S-&&(+C/^<C_P\L\#?]$L\<?^%%X8_P#B*_87_@AM
M^V3H?QT_;LL_ GAWP;KWAG47^"WQ2UH:IK]]I.KV M]+NO!J36QL]+N+*Z,\
M[7L1BE^T".,1R!XW+J5Z\!QIA<=C,-A(5,.YXBM"DE&&)4KS<5HY044]7;F:
M5]+Z:^)Q)X 9MP_D&;YW5H9I&GE> Q&.FZM;*Y4U&A3]H^=4:LJKC;=03D[-
M+4_M3HK&\CQ#_P!!31O_  17W_S1T>1XA_Z"FC?^"*^_^:.ON3^<C9HK&\CQ
M#_T%-&_\$5]_\T='D>(?^@IHW_@BOO\ YHZ -FBL;R/$/_04T;_P17W_ ,T=
M'D>(?^@IHW_@BOO_ )HZ -FBL;R/$/\ T%-&_P#!%??_ #1T>1XA_P"@IHW_
M ((K[_YHZ -FBL;R/$/_ $%-&_\ !%??_-'1Y'B'_H*:-_X(K[_YHZ -FBL;
MR/$/_04T;_P17W_S1T>1XA_Z"FC?^"*^_P#FCH V:*QO(\0_]!31O_!%??\
MS1T>1XA_Z"FC?^"*^_\ FCH V:*QO(\0_P#04T;_ ,$5]_\ -'5VTCU!/,^W
MW5E<YV^5]DL)[+9C=O\ ,\[4=0\S=\NW;Y6W#9W[AM +E%%% !1110 4444
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MR*** $P,," 0W# @$-T^\",-T'7/0>@I22>2<GU-%% !1110 5_03_P;.?\
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M5-4NKO\ SB_BO^T&FJ>#_@=\/M._:Z\>^(H_V:_@[=V_C;Q-X3\8_'CP]/\
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M4/\ H45>G_,9'RO_ ,P_K]WW_0?\2AX__HN<)_X8:WE_U-O7^M_]@#</1O\
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MGNTH5'S.K#2OQ+CZ6&S2:P26(PN92PF7PK83'TJ>/I?5:%6G%2Y91I2>*K+
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M/O\ X)?$/_S2T?\ #@3_ ((X_P#2/K]GW_P2^(?_ )I:\C_B%Z_Z'C_\-O\
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M?#W5O''AC2/$U]X3DNEU&+4OMJB@  P .>!CDY/XD\D^]%%% !1110 4444
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M SXU:-\>/!DOC70_#7BKPO91:Q=:.+3Q1_PB=X+UK:TL+Y-4T'Q)X \6^._
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MQOL==\*:ZVLV%_J'B)/A%X_\-^,(X+W1CI_AV"#6+;QA%IMZNE6FI^B_ O\
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' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-2016331_equityinloss.jpg
<TEXT>
begin 644 biib-2016331_equityinloss.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MZ7%?:-J*VGE_C+_@E%X5^)_B2S^(?Q>^+^H?&+XH>&O#'P;\+>"]:^)WP?\
MA#XK\$Z7IWP3'QZTGP\GB/X5W>A)X0\9?\)-X5_:%\;:?XU-\NGW<^O)IGBS
MP;>>";G3]-TW3]?Q=_P2N\ :YX"\3_##P?\ %3Q1\-/ _P 3?A7\-/AG\8]
M\&_#KX2:!I?CD_!_Q7KGC'P#XCTC2-!\&^'=!^'5Y%J/B76M*\3:3X*T>RT7
MQ#X=;3[9+72-=M+KQ)J8!^K"MN!.,89U]?N.RY_';GVSCGK3J:J[01G/S,W_
M 'TQ8C\"<4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *CD)"C!Q^\B'X&5 1^(X/M4E% '\@OBWXP_&;2_P#@FOXZ_9T'Q2^*
M,?BJ#X6Z5^WQHOQ4'C3Q4OBA?@AXC\=6>L#X<?\ "R&OO[<AO;#]K9=7\)'1
M9/$$5Q#\$DM-%^S?\(JWD'[!_:"_X*P?&_X5>*/CK<^!&\%^-_#6B>"O^"@Y
M\,:;KGA_PKX:U;X>>._V.?!'C_QIX0M/%/A+2/BGXR^*-MI_BZ?X=Z]X>UB\
M^*7ASX=S^+(6LO%_@;PSX<TE[?2M2_HH;2-*>W-H^FV#VK6XM&MFL[9K<VJR
M>:ML8#$8C )/G$)3RP_S!=W-0R:!H<KWLLNCZ7+)J3F34))-.LY'OG:R.FE[
MQW@+73G3V:Q+7!D8V9-J3]G)C(!^(?[1'[37QOT[2OVR?A1XR^.OPO\ "/B'
MX:_";XM>$O#WP^L/!>K>%OBS\8]/UG]B_P 3_'1?CU\*]9TSQUJ>I^$= \(^
M+[V_\#^&[Z32-3T"QM_@[XZD\7^*[;QUK.F)X8^E/^"?'QN^+_BO5_$'P/\
MBSK_ (<\8OX"_91_86^-_AWQ7I&@:KH6JBW_ &A/!WQ1T36_"7B"75/%'B:;
MQ+/HFN?!"?6[7Q;<-INIZLGBZ[L]3L#)ID%W<?I?<:3I=U<&[NM.L;BZ-E<:
M:;F>TMYISIUVR-=6'G21M)]BN6CC:XM-WV>=HT:6)V12)H+&SMI&EM[2V@E>
MWMK5Y(;>&*1K:S\W[);L\:*S06OGS?9X23'!YLOE(GF/N /PR^'WCSPGIW[8
M<4OPQ_:#NS\-?'GP1_:3U#Q-\0_#OQZ\2_%WQMH6NZ1!X-\0-\2?VN/A-\;=
M'@\!?LY6OP=U>+Q3X<^%<T&BW%I#J5W;?#GQ1H_AWPOY_AR;V7_@F)^T1\);
MCX&?$G1-5_:=\/?$^]T']NK]K#X7Z)XH\:_&C0/'GC'6K?Q7^UM\7= ^!FF7
MVLOK5S-=W?C[1=+@M_AQI]G!9:7K6GVL=AX&TR+1+*RL;;]6V\/Z&_\ :^_1
M]+?^WXO)UW?I]F_]M0_9VM!%JVZ$_P!IQBU9K8)??:%$#-"!Y;%3S\/PT^'U
MJ(!9^"O"]BMOJ>BZS$NG:%IFG+_:GAQYI= O9%L+6V6>;19;B:;2VG$HL)I#
M-:B*4!P ?E+_ ,%(/'?P8LO%_P#PKJW_ &A;KP;^UKXR^%^G)\$]*U/]I*/X
M*^ ?V9M/N/$FNZ<?VM_%UC#XG\+6-Y;6FMW4=C'I7B2V\>:Q\7&\#0?"SP/X
M2B\-7OQ7U*/S;1O'_B+_ (:'T75;;X@^(;K]K>]_X*,>-/AGXL^%4_Q&\2_8
MU_8<M=.\87'A[46^$+7H\,6/PIA^!%MX(^,VC>/[?PO#92?%S48%B\<S^(?$
M>H:;JG[7ZYX$\$^)KB.[\1^$/"^OW4,20Q7.M>'M'U:XCBC,A2*.?4+*YE2-
M/-DVHKA5\QR "[9W5TS3DO/[16QLUO\ [&NG?;5MH!=_V>DC3)8_:0GG_8DF
M9I5M/,^SK*QD6,.2Q /YR+']I/6_#WPZ_P""N^A?!7]J35/VBOB+X2^//P+U
MK0M<LOC%X3\2>/\ 2O@SXD^ W['%K^T9X]^'<'@B&^TCX>^$_AUIGBKXK:Q:
MWWPZ\&6OAGX<:_I=S>VNG/XFL;Z6[^[/V(/B9I/A?PI^U[I^DWMOXJ\!_!GQ
M7!XCT?XC_#+XB_%/]HGX->)+?4OA'IOC35]$^%S>+M9\7^,T\2^$/LD4'Q'^
M'_A/QAXGTS5_%FKVOBG1&T'Q+X\UOPEH7Z7Z-X&\%^';LW^@>$?#&AWQMI;/
M[;H_A_2-+N_LD\RW$]M]IL+.WG^SS7")/+#YGE23*LKJSJ&&[8:=8:5:16&F
M65IIUC!O\BSL;>&SM8?,D>:3R;:V2*&+S)I))7\M%W2N\C9=F8@'\YW@_P#X
M*B?M)^*/&/A?X>Z'JWPPUZ+XE^+/V%K_ ,+?$R3P_P"!]3LM*\.?M0_&CXA?
M"3XB^';OPG\*OC/\1]'T[6/"%GX?\-^)O#7A_7OB)/XUT&ZO;C2?&UQJEMJ%
MA?P><?M1_MZ?M&>./V5?VT?!.N_%7X>?![Q)\(/@=^T[X,\-^(--\+:QX;\:
M?M4_$/X7_M'_ +17[.FN:I\%Y++XEQZGX"UCP+H7P;\'^)?$>C>%5\8:KHWC
M#XJ:3J%Q+8>#+'3;36?Z;8/#^A6PC6WT;2H%BN&NXUATZRB$=T]Y)J#W*!(%
M"7#7\LMZTR8E:\DDNF8SNTA=+H.B3^7Y^CZ7-Y4NH3Q>;I]G((YM669-4FC#
MPL$EU%+B=+^1</>I-*MTTJRR!@#\^_\ @H7\1?V=OA_H7PUD^.OCW7SJ_B"\
M\9:;\(?V?M"^.D/P*C^.GCF/2-+NVU#5_$T?BGP)/8Z/\+-+BFUJ[\8:YXVT
M;P!\.T\0-XIURSUCQA#\/((?S3\?^,?'?AKP!XR@^*7[2=[XV_:"^%G[!W[-
M.N?L*>.?AY\8?$<NB_M"?M(W:?%"S\7>(_A]IN@SV6C_ !XUWQG\6],^%WPR
M\70:QH/C'4=6^&U]H5QXAT/1;'XE:^VL_P!$^O>%/#'BF."+Q+X<T'Q#%:EV
MMHM<T?3=7CMVD,32- FHVMRL)=H86<QA2QBC+9,:;9[?P]H-I#I%M:Z-I5M;
MZ "-#@M].LX(=&!@DM2-*BB@2/3<VLLML?L2P9MY)(#F)V0@'XS:!\9]!TO_
M (*A_M&_#B;]K"/Q)K?B7]A_P]/I'P\O?B=X>U;3_AU\5K#XS_'&WO\ P1\/
M/AAX12VG3Q5X1\,:?IMSK45MX8UGXL>(["SM;_Q+=:JD.BV-CN?\$U9_"?@G
MQS??#'P5KOP@^,5MX@_9Y^&_Q$\6_&+X(^//C!XYT[P_XGTK51X93P'\2K_X
MF^/?B!;7/BSQ:^J:UXW\.:]:0?"_Q)K5KI'B^#Q1\+])_LG3;^X_6J/P+X*B
MUC_A(8O"/A>/7C>S:E_;4?A[1TU?^T;B-H;B_P#[32R%]]MGA=HIKOS_ +1+
M&S(\C*2#O66FZ?IHN1I]C:6(O;N:_NQ:6T%L+J^N2#<7ER((XQ/=SE5,UU-O
MGF*@R2-@8 +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\J_'3]KOX=? 'X
MR_LI_ OQ5H?C/5_&O[8/Q$\;_#7X87'AVPT2?P]I.M^ /AMK?Q2UV]\;ZAJF
MOZ7>Z5I,GA[0KJUTZ;1=+\17USK$UK;36%M9M/?P?10U75V 8>'9\$ C_B9Z
M7T(S_P _%?C!_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 8?
M]IZO_P!"[/\ ^#/3/_C]']IZO_T+L_\ X,],_P#C];]% &!_:>K_ /0NS_\
M@STS_P"/T?VGJ_\ T+L__@STS_X_6_10!@?VGJ__ $+L_P#X,],_^/T?VGJ_
M_0NS_P#@STS_ ./UOT4 8']IZO\ ]"[/_P"#/3/_ (_1_:>K_P#0NS_^#/3/
M_C];]% &!_:>K_\ 0NS_ /@STS_X_1_:>K_]"[/_ .#/3/\ X_6_10!@?VGJ
M_P#T+L__ (,],_\ C]']IZO_ -"[/_X,],_^/UOT4 8']IZO_P!"[/\ ^#/3
M/_C]']IZO_T+L_\ X,],_P#C];]% &!_:>K_ /0NS_\ @STS_P"/T?VGJ_\
MT+L__@STS_X_6_10!@?VGJ__ $+L_P#X,],_^/T?VGJ__0NS_P#@STS_ ./U
MOT4 8']IZO\ ]"[/_P"#/3/_ (_1_:>K_P#0NS_^#/3/_C];]% &!_:>K_\
M0NS_ /@STS_X_1_:>K_]"[/_ .#/3/\ X_6_10!@?VGJ_P#T+L__ (,],_\
MC]']IZO_ -"[/_X,],_^/UOT4 8']IZO_P!"[/\ ^#/3/_C]']IZO_T+L_\
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M67?^$>'_ /E?E^?=GRW^L.??]#K-?_#ABO+_ *>^2/T9/_!6/]O, D_&NQ
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M_P#Y7Y?GW9Y'^L.??]#K-?\ PX8KR_Z>^2/T9_X>Q_MZ?]%JLO\ PV7PQ_\
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M3^?U]_8>E%% "Y//)YZ\]?KZTF2<9)..GM]*** "BBB@ JO>?\>=Y_UYW?\
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M.D^&-%U_3)[/7$MM.FU^_P!)O[;PLE[:6=EJEW]_#\NO\_Z]: /Q _X*3_\
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M_I3/ZRP_^[T/^O-+_P!(B%%%%9FP4444 %%%% !5/4!=FQO!8LJ7IM+D6CO
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M=;^+5_Z^3_\ 2F?UEA_]WH?]>:7_ *1$****S-@HHHH **** "BBB@ HHHH
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M.?0;NVL=62/3=:TS7K<VEU=V6H6\3->Z3:K*9+.8-;M-&H1W61 #\R&\?_\
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M  1M_P""R@!)\)_\$Y^ 3_R<?^T/V_[MTK^VND(R"#W!'YT?ZTY__P!#&?\
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M SPQH7B+P%\,-+T'Q#X>\6:/XGT?P?!H'AG4OAYX@\?Z[=@'[G44BC"J",8
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-2016331_finhighlights.jpg
<TEXT>
begin 644 biib-2016331_finhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS-;KYZH8F5S^]'_"2^'O^@WI7_@?;?\ QR@#;HK$_P"$E\/?]!O2O_ ^V_\
MCE'_  DOA[_H-Z5_X'VW_P <H VZXGXB_$?P)\)/!FN_$/XE^+-"\$>"?#5J
MMYKOB;Q'J$.FZ3IT$DT=M!YUS,1NGNKJ:"SLK2%9;N^O)X+.S@GN9HHGV_\
MA)?#W_0;TK_P/MO_ (Y7XG?\%UO"7C?XC_LH^$;_ .'#W/B71/ /Q7TSQ9\1
M- \.SOJ-_P#\(\WAOQ!HFG>(9M(L!-=:CIWAW7M4LIKYHHICI<5X-9EB2UL+
MBZM?I^#,CPG$O%619#C\?'+,)FF84<)7QKY+TH3N^2DZC5-5Z\DL/AW4O!5Z
MM-RC->[+YOB_.L5P[PSG6>8+ O,<5EF!JXJC@USVJ2ARISJ>S3J.A0C)XC$*
M%I.A2J<LH/WE]Z_ G_@HE^QS^TGXS/P[^$/QJT77_&\B7<VG>&=4T?Q-X0U;
M78+&&2YNYO#=OXNT71/^$B^S6L,UY<P:0UW=V]E#+>36R6T;RK]K;E(R""/]
MGYOY9K_/$_8O^'GQ'^*O[3GP6T+X376LV'B/3OB3X/UZZ\8^'I(8S\/='T36
MK74]<\97^KW%K?Z1HRZ+H]KJ$]JVLV]Q:ZE>^1HXT[5GOQIEU_;C'^S3\,M1
M\[_A.OCI\?\ XCI.7\ZV\0_M'>.O#NES!@ZXET#X7:O\/-!9"C -!_9GD$*5
M:,K),)?TSQ<\,^%?#W.L!@L%Q%CYT,9@/K,\#B,-A\QS;#RC5=/VLG0EE6%^
MKXA7=!570J<]*LDZL5S1_./"KQ&XFX\RC'8S&9!@85L'CEAH8W#XBO@,KKQE
M2C4]G%5EF>*>(P[:]NZ2K4^6K2;]E+W9?6FL:_H?AZS;4-?UC2]#L$R7O=8U
M"STNT0 J"7N+^:WA4 LH)+CE@.XSX!KO[9'[*WAY_L][^T!\*+R_S@:1X=\9
MZ/XNUQF(W*D>A^$KC7-7DD<8\N..R9Y"R*BLSJ#S^B?LJ_L9Z%,;J+X/?!S5
M]0)W'5O%VC:3X[ULOE296UOQN_B+56F9@6>9KPRNSR,SEI92_O\ H2_#OPQ:
M?8/#:>$/#UCD'['H4.CZ/:@AG8'[/IT=M#]Z1V^YU=CU9B?RC_C&Z+WSO,5=
M:6P&2M1TOKS9]=K6VD;^73]1_P",AK6_Y$V7Z:ZXW-[RTMI;)+)Z]96[O0\%
MD_; \"ZA'')X%^&W[1GQ*27B*?PI^SU\4=.TN9L*P\GQ#X_T'P-X;D0HX=95
MU<PNA5UD(DCWK+\;?VA-8DB_X0_]C[QI9V\Q'EWGQ8^+7PA\!P*NXH7GL_!F
MO?%S78%! 9E?2/.\O<R1,WEI+]*?\)'X=(P=;TH_[U_;-_.0TO\ PDOA[_H-
MZ5_X'VW_ ,<H_M#**.F'X?HUUK=YKF.88FIT^&665<D@OG2E^(?4,VJZU\]J
MT7IIEF P.'IW5KWCF-/.)M.SVJQL_N/FI[G]M[7)D:#2?V7?AI:2C=B]UKXK
M_&74+=6&0DL-GHWP4T]YDY5A%?/#NPR2.H *K\'OVEM8N&?Q1^US?:1:R#$M
MI\(_@=\-O" "-PZ0WOQ(E^--]$0I(282"1659 >"I^E/^$E\/?\ 0;TK_P #
M[;_XY1_PDOA[_H-Z5_X'VW_QRE_;M>G[N&R_)<+3M;D63X'&M:IIJOFM',,4
MFK:/V]_G9A_8E&;YL3C\XQ,[WY_[6QN"3VNG1RNK@,,T[:KV%K:'S7%^R5H%
M]([^-_C3^T]\0EDSYMOJ_P >_&G@[3YC_P!--(^#\WPRTG 8*ZQK9B-6 VJ%
MRK7=)_8J_95TJX^VS? OP#XEO^HU/Q_I<OQ+U4/DD2?VI\1+KQ3?F4$Y$IN/
M,! PW Q]#_\ "2^'O^@WI7_@?;?_ !RC_A)?#W_0;TK_ ,#[;_XY1+B3/VG"
M.<9A0I223H87%5<)A[*VBP^&E2H16FT::73;0<>'LC34Y93@*U2+NJV)PU+%
M8B^FKQ&)C5K2=U>\JC=V^Y5\.>#?"/@^S_L_PEX7\.^%[#:J"R\.:)IFA6JH
MH 55M]*M;.(*H "@)@  # K\N_VF/^"-G[*O[2WQ3UCXOZAJ7Q'^&OBOQ7>_
MVGXWB^'>L:#!HOBO5WVK=:]=:7XE\.^(8M,U[4$1!J5[H[V5MJ$R?;KRPEU*
M6ZO+C]3O^$E\/?\ 0;TK_P #[;_XY1_PDOA[_H-Z5_X'VW_QRM,CXJXCX;QU
M7,\CSG'9;CJ]*="OB*%9\]>C.492IUU4YX5H\\(32JQGRU(0J1M.,9+/.>&>
M'^(<%3R[.LIP688*C5C6H8>O27+0JPC*,:E!P<)T9\DI0<J4H.4)SA*\9R3\
MM_9[_9Z^%G[+_P +M!^$'P?T!M \(:$UU=$7-W/J6KZUK.HR+/J_B+Q!JMR3
M/J>MZO<*)KVZ810(JPV=A:V6G6MI9P>VUB?\)+X>_P"@WI7_ ('VW_QRC_A)
M?#W_ $&]*_\  ^V_^.5Y.,QF*S#%8C'8[$5L7C,76J8C%8K$5)UJ^(KU9.=6
MK6JS<IU*DYMRE*3;;=VSU<)A,+@<-0P6"P]'"83"TJ=##8;#TXTJ%"C2BH4Z
M5*G!1A"$(148QBDDDDC;HK$_X27P]_T&]*_\#[;_ ..4?\)+X>_Z#>E?^!]M
M_P#'*YCH-NBL3_A)?#W_ $&]*_\  ^V_^.5=L]3T[4?,^P7UI>>3M\W[-<13
M^7OW;-_ELVW=L;;G&=IQT- %ZBBB@ HHHH **** "BBB@ HHHH ^9OVE?V6O
M!O[4.G^ M-\:>,OBOX5M?AWXSM_'VC0?#7Q[=>$++4_$NG6LD&AW7B[2#8:K
MH?C*U\-W<@U[PYIGB72]1T_1/%-MIWBBPMHM>TC2=0L:,W[*^D:GI6D^'_$W
MQ;^/OBG0],^&U_X D34_C%XRT_6M4U*?Q_X?^(6E?$?4M=\*7_AJX/Q+\+ZG
MX;L-.\,>,;&"QU33=#FU+199+K2]1O+2?ZGHH ^/I/V(_@])X:_LYM3^*'_"
M<_\ "PX_BS_PN]?B=XH3XX#XBQ>"3\,QXC3XA)<K=10GX:O-\/SX6BL$\$#P
ME<3Z4GA=5E:4YNO?L _LV:UH7A3PQ:^'/%'A?P]X=\!7/PGUG2_!_P 0?&?A
MV/XF?"K4-9O?$NL_#SXO7=EK']I?$OP]K_B;5-;\0:[/XGOKOQ#JNI^)_&K7
M6O/:^//&UKX@^TZ* (H88;:&*WMXHX(((TBAAB18XHHHU"1Q11H%2..-%5(X
MT541%5$4* !(1GCG\"1^H(-+10!^'7CX8_X.(/V<.O\ RB;_ &DNI)_YNE^$
M/J37[BU^'?C_ /Y6(/V</^T3?[27_K4GPAK]Q* "BBB@ I" 1@]#_G_]?KTI
M:* ,71_#?A[P^;LZ#H6CZ*;^;[1?'2-+L=,^VSC=B:[^PV\'VF4;WQ)/YC@L
MQ#?,<[5%%5.<ZDG.<I3D[7E.3E)V22O)MMV225WHDD3"$*<5&$8PBMHQ2BE=
MW=DK+5ZON]0HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***BG#M#*L<GDN8Y DNQ9/+<HP63RV^5]C$/L;AL;3P30 _>F<
M;ESG&-PSGTZ]?:G5^,GQ0_:"\*>$/BZW@NUU7]J7Q;XBT'XN)X%^(?Q$LOC_
M !>$;'PEHL>K_LZ^$KSQSH?P7TY9_!'B:TB^)?[3?P[\':)X-O\ X9Z3+XFL
M-%^(6NZ5/JEAH>BVWC#]C=+M[JSTVPM+W4)M5O+6SM[:[U2X@M;:XU*Y@B2*
M:_GM[&"VL8)KN1&N)8K*VMK2.21EMK>" 1Q( 7J*0D#K^74GZ <G\*,C&<C'
MKGC\Z %HI-PQG/MT.<]<8ZYQSC&<<T;E&.1S^/'K[#W/'O0 M%%% 'X=^/\
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M!JMQ9_#KXBKHOQ.^/'P ^,VI?%/6O^"?OQXU_P".W@/5?#MA\)KS3/"'@?\
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M^A;U3_P+T+_Y;UN44 8?]J:E_P!"WJG_ (%Z%_\ +>C^U-2_Z%O5/_ O0O\
MY;UN44 8?]J:E_T+>J?^!>A?_+>C^U-2_P"A;U3_ ,"]"_\ EO6Y10!A_P!J
M:E_T+>J?^!>A?_+>C^U-2_Z%O5/_  +T+_Y;UN44 8?]J:E_T+>J?^!>A?\
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M#]G#_M$W^TE_ZU)\(:_<2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$M$_\$E__P#-!1Y/B/\ Z"6B?^"2_P#_ )H* -NBL3R?$?\ T$M$_P#!)?\
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MG*Y .#ZCT/TI:* "BBB@#\._'_\ RL0?LX?]HF_VDO\ UJ3X0U^XE?AWX_\
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M,T2#Q#X#U_PWKRVKEB+FQ74A97BA4N[>=$51U=% '\_VH_#CP_X*_P"#@_\
M9ZTO1]1\>7EM>?\ !*3]I&ZFE\6?%'XF>/-025?VGOA) $M=6\<>+?$.J6-M
MLD9FLK&\M[-YPER\#7*)*/WG_L&R_P"?C6O_  HM?_\ EG7XJ^/_ /E8@_9P
M_P"T3?[27_K4GPAK]Q* ,7^P;+_GXUK_ ,*+7_\ Y9T?V#9?\_&M?^%%K_\
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MX_MW-\7F?U6C@UB)KEHT8I6C"*C&=::2]MB)Q2=:LTN>=VHQBHQ7WO"'#O\
MJKP_E^2?7<1CWA*;Y\1B)-WJ5'SSIX>FY2]AA:<FXX>@I25.G9.4IN4I8O\
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M6)X8&BWL_P!DE?[%<3G3+OS-/N=EU;;%\Z-?,7/U%M'JW_?;_P#Q5 'XP?\
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M&_Z.SG_\1[_:H_\ G'5^S^T>K?\ ?;__ !5&T>K?]]O_ /%4 ?C!_P 1"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &2.(T>0AF"(SD(K.Y"J6(5%!9F(&%4 EC@ $D"O
M@T_\%#/A4"RGX/\ [8V59E./V./VA2"5)4D$>!\%3C*L.&&""017WK28'O\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129'O^1_PH 6BBB@
MHHIOF)NV[TW9QMW#=GTQG.: '4449 P"1D]!Z]^/7CF@ HHHH **** "BB@$
M'D$$<\CGH<'\CP?>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'#*P#*P*D @BOPK_ &E?BOXO_9I_;@^,?CN\^+/[0GC#X:?#7]CG1_VG=/\
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MX-3U*+6]/FLGMM574+XWZ7#7=PT@!^0_PN_;6^/W@#0]3^#.L^&/"OCCQ?\
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M2>P')/ KP8_M Z("1_PKSXWG!(R/@_XSP<'&0?L'(]#W'->]45UX6K@Z7/\
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M"_V1_P!JSQ6VN:-JUIXJ^(__  6(^%WP4\?Z9XHNS\:OA-XH_9ZTG]K7XO\
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MTZT^'FK:'XU\2>'=9T#1O WA:[OO&NCV=YX;\8ZG/=Z1JFM6/A?D/B;^U_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-2016331_incometax.jpg
<TEXT>
begin 644 biib-2016331_incometax.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MZ7%?:-J*VGE_C+_@E%X5^)_B2S^(?Q>^+^H?&+XH>&O#'P;\+>"]:^)WP?\
MA#XK\$Z7IWP3'QZTGP\GB/X5W>A)X0\9?\)-X5_:%\;:?XU-\NGW<^O)IGBS
MP;>>";G3]-TW3]?Q=_P2N\ :YX"\3_##P?\ %3Q1\-/ _P 3?A7\-/AG\8]
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M+[V_\#^&[Z32-3T"QM_@[XZD\7^*[;QUK.F)X8^E/^"?'QN^+_BO5_$'P/\
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M/_P)@_\ BZ +E%4_[1T__G^L_P#P)@_^+H_M'3_^?ZS_ / F#_XN@"Y15/\
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MX_AYILJ0*'G>.1)$@0D@/,Z:.RQ(2" \A520>>#4?_"Y-/\ ^A"T?_P)@_\
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M !(-=^XO_+O8>@_ZB=?C%_P4G_Y22?\ !"G_ +.M_:@_]8Y^(-?MY'_JX_\
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MEEZ5[.]KWM<ZJBN6_P"$AU7_ *$?Q3_W_P#"O_S24?\ "0ZK_P!"/XI_[_\
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M"(/-+'$ADD7=(Z1KEW53^P<?QA^%'EI_Q<SX??<7_F=O"WH/^HM0!\M>./\
MD<O%/_8=U+_TI>N6JKXT^)'PYF\7>)I8_B+\.V236]0=3_PG_@U25:X8@E7U
MQ67(/1@&'< US/\ PL3X>?\ 11/AW_X<#P7_ /+ZOY!S:$_[5S/W)?\ (PQG
MV7_T$U/+S7WH=GV?]?\ #K[SL**X_P#X6)\//^BB?#O_ ,.!X+_^7U'_  L3
MX>?]%$^'?_AP/!?_ ,OJ\_V<_P"2?_@+_P O-?>%GV?]?\.OO.PKRGQG\'_#
M7CG6O[=U:^UJWN_L5M8^787%I%;^5:F4QMMGL[B3S&\UMY\S:<#:J\YZ;_A8
MGP\_Z*)\._\ PX'@O_Y?4?\ "Q/AY_T43X=_^' \%_\ R^KV\@X@X@X6Q_\
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M6_@?XJ_#OPQ\-+[X _&/P+X%\-:!H7B.;Q;JS>&/&_[/7PD^-%C-XVUZ)8-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-2016331_interferon.jpg
<TEXT>
begin 644 biib-2016331_interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M?SV\,NH:OJMW:Z;I=DCM=:AJ%S;V5G%-<S11. :]%%% !1110 4444 %%%%
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MKX7UW_@H3\!O#VN:UX?O[/XA&^T'6-4T2]:W\+VDMNUYI%_<:==M;RG7(S+
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M (2R\O/S1/\ KYP;_P!%)E7_ (4Q/Q#_ &5?AC\:=0^ 7['.L>(_A;>_#O\
M9L\)^*/B;>^)O%OPY_9*U*_\:^(_%7C'X"^!++X<_'#6OV2[S0?B2/[:\&>(
M=.^*/P17XC:A\,_$&D^(+;Q%I/C>'X?>%X-0M_%&G_IAX"^$'BOXB_"S_@GS
M\*/B[^S#X+\'V]U9ZUXF^->F:-\(O#FE>&O"OPZ^!MO=:_\ "+X97>CSVOB:
MR^$Q^)'C+6?ACXMU;X367B*XT[0;+0/B#\++.YO]%MM5,OT7_P /(/V>O^?+
MXC]<Y_X1.TSG&,Y_M_.<<9STXZ4H_P""D'[/8P!9?$< #  \)V8 'T_M['^%
M'_$/.-_^B8S?_P )9>7GYH/]?.#?^BDRK_PIB?'O@SX5^-M+^-'PUTB#X3^,
M=*_: \#_ /!03]I?X\?&+X\R?";5HM \6?LN^.8?CW>>$(+;XR):RZ)XPLO%
M7PV\8?!#X0Z1\++#Q+JWB3P_XC\ V:WG@K2]+^&%EK-CQ/\ P4;LOVH/VD?
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MYM+6\U&\TV_MX;_@SX1W/C"R\*R'Q/I.BZM\0?$6M^%/A[HEWIVK7TOB;7-
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M_P"I?$^C7_"-CM;/_GS(^IX'E%\7\.6E%_\ "O@MFG_R^B?NUY7B7_G\T/\
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MWI_5GY7_ +POA]%XB/@+P28[O1!&?"/AK8&L-09@O]BV.T,1JB@L!C)55![
M=*[ZQ34U\W^T9K&8'9Y/V*WN;?;C=O\ ,^T7=UOS\NW9LVX;=NR,</\ !Z_E
MU7X2_##4YHXXIM1^'?@B^ECBW>5')>>%]*N9$CWLS^6CRE4WLS;0-Q)R3Z/7
M^9>8)QQ^-B]UBL0GUU565_Z['^BV!:E@L));/"X=KIHZ4&M HHHKC.H****
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M*<H2\%:.6%WAG1XYX'>">.5!'+'/"QBGCEC'$<L<J.DL8)"2*R D $MI ,
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MPU[PUX.TW5_%B6NKW<FFZ?\ )%-557(554$Y(554$^I"@ GWZTZOJ\LP2R[
M8;!*HJOU>#BZD:?L8SE*<IRE&@ISA0C*4FXT*+CAZ,;4L/2HT(4Z4/E\QQCS
M#&XC&.#I>WFI*G*HZTH1C&,(QE6E&$Z\E&*4J]92KUG>KB*E6O*I5F56O?\
MCRO?^O*[_P#2>6K-5KW_ (\K[_KRO/\ TFEKT([KU7YG#+9^C_(_T=?@;X@T
M&/X+?"))-;TA'7X7_#Y61]2LU96'A#1LAE:8$$=P0"*]@M-1T_4/,^P7]E>^
M5M\W[)=07/E[]VSS/)D?9NVMMW8W;6QG!KS;X%?\D4^$'_9+OA[_ .H?HU>J
MU_D)F?\ R,<?_P!AF)_]/3/]7<N_Y%^!_P"P/"_^F(!1117"=@4444 %%%%
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M_P"_L7_Q=?VJ_P##@3_@CC_TCZ_9]_\ !+XA/\_$M'_#@3_@CC_TCZ_9]_\
M!+XA_P#FEK^N<)]*J>%PN&PW^HL:BP^'HT.?_69QYU1IPI\W+_J_+EYN5OEY
MI6O;F>Z_E7%?1CAB<3B,0^-I0]O7JUN3_5M2Y/:5.?EYO[>CS<MVN;EC?>RV
M7\561_>3_O[%_P#%T9']Y/\ O[%_\77]JO\ PX$_X(X_](^OV??_  2^(?\
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MA0YN?V-&E2Y[<O-[.$8<W+>7+S<M[7=KVN]S[%HHHK V"BBB@ HHHH ****
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MQL/$>MW>L>,-5TT^5XL\0^([FWL+NS /LFBBB@ HHHH **** "BBB@ HHHH
M**** $P/0?D*,#T'Y4M% 67;^OZ2"BBB@ HHHH **** "BBB@ HHHH ****
M"@@'J ?K110 F!Z#\A2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-2016331_oie.jpg
<TEXT>
begin 644 biib-2016331_oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M7]HO_0L^(?\ O]H7_P MZ/\ A?VB_P#0L^(?^_VA?_+>OF*BC_B*'%'?+?\
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M\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!%?A]_P4N263_@H_\
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MN8U<RK&=4U<QK*>LJQF_V"4]Y  Y[L:#\*O K>;NT:1O/_U^=5U@^?\ -O\
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M\A_X$7G_ ,DUOT4 8'_",:+_ ,^0_P# B\_^2:/^$8T7_GR'_@1>?_)-;]%
M&!_PC&B_\^0_\"+S_P"2:OV.EV6F^;]C@$/G;/,_>32;O+W;?]=+)C&X_=QG
M/.>,:%% !1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\$*?^SK?VH/\
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M"PW7IVLZ'&D:R1N1BC8(T\@@," 5)4]5)!!H_P"$DTOUOO\ P3ZU_P#*ZMQ
M5!!.3N<_@SLP'X @?AQQ3J ,'_A)-+];[_P3ZU_\KJ/^$DTOUOO_  3ZU_\
M*ZMZB@#!_P"$DTOUOO\ P3ZU_P#*ZC_A)-+];[_P3ZU_\KJWJ* ,'_A)-+];
M[_P3ZU_\KJ/^$DTOUOO_  3ZU_\ *ZMZB@#!_P"$DTOUOO\ P3ZU_P#*ZC_A
M)-+];[_P3ZU_\KJWJ* ,'_A)-+];[_P3ZU_\KJ/^$DTOUOO_  3ZU_\ *ZMZ
MB@#!_P"$DTOUOO\ P3ZU_P#*Z@^)=+ )+7V ,G_B3ZUT'_<.K>I""00#@D$
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M_%*'Q)\"+7X4_%#Q)-\7V\5^"_A?\8?&L.N?'G3=9\+ZII_AFPO;;PQNUGP
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M=YX1\3:-+/J>K*4U2\^J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-2016331_otherrevenues.jpg
<TEXT>
begin 644 biib-2016331_otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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MECJWBCQSX4\=>'(-8T>-]%U5@#]G**^%_P!E3X^:QK?A+XZV'QL\?3?\)1\
M/&-U:^/4^(GPUT3X+^,?A[X0O/ 6@?$+2K_XDV_AKQMXW^&FM6%UH6I7_B71
M_B%X"UFR\+W'A1[;0]:TO3_''A3Q@)?$/V)?VYK_ /:B_:I_:5\&I\1OA-KO
MPRLO@E^S/\:/@/X'\(:SX4U;QUX;\+?$?Q3^T/X7\33?$#4=$\1ZK=ZCXDU7
M3OAY\-_&FM^''T^P'PLB\>Z%X0U4SZM/->WX!^J]%%% !1110 4444 %%%%
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M_P#_  .T;_Y85\5:]JNJ)KNMHFIZDJKK&IJJKJ%ZJJHOIP%55G"JJC 50
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MSP]X8\2Z3\/_ !R?B?\ $+P/HWQ&\ Z.!\0S/)X?G\7VMWX>\-:;<6'ZN?\
M"[?!>,^7KF-Q7/V!,;@,E<_:\;@,$KG('.,4?\+M\%\GR]<P "Q%@A"@G:"Q
M%WA06.T$X!/'6C_7'A=_\SS+O_"B'EY^:_$#T"+Q3X>>*-QJ]FH:-&"R2>5(
M R@@/'(%DC< X9'571LJP# @2?\ "3^'O^@Q8?\ @0G^->=_\+M\%_W-;_\
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M6Z0+_HTYCI?1'P[]E;Q*HOVZO0MPS3;KI)-NC_QDW[U)/F;I\WNV;LG=9_\
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M>(<*5.O)*,U0I0PV'G0P[J4I_#OPY'CK2OB3\2?'.K^ O$MAIW[0'Q-T6_\
M[/OO%7P[FOOA7X?^''P2T/PC9>-?B';:=XJU&.YUCXG>(/#7]EKHO@K5/&FI
M:.C>%+GQ!<VMK%JKZ9W_ ,+M*\0VEU\4/%7CAEB\4>.OBKXMO;:.XUJRU-K3
MX;>%+Q_!OP@TRWGBO;B.WLAX+TE/%1L%:.2WUOQIX@FO88=3O+Y!^H:?\$ _
M^".)!)_X)]?L_@[G'_('\2= [ 'GQ.>H /ISQ@8%._X<!?\ !'#_ *1]?L__
M /@H\1__ #35WT?%:-)TV\AJU?9U<17BJF;T[>VQ3E*K4M#*(+FYJF(<>D%B
M:L$O9JG&GY6(\!IUU52XIH4?;4,'A9NEP_6O]6P,80P]%.KQ#5]U4Z&$C-[U
M)8.A5DW5=:=;X0\^#_GXMO\ P*MO_CU'GP?\_%M_X%6W_P >K[O_ .' 7_!'
M#_I'U^S_ /\ @H\1_P#S34?\. O^".'_ $CZ_9__ /!1XC_^::NO_B,7_5._
M^9?_ /!9YW_$NJ_Z+!_^(_\ _AOU_I:_"'GP?\_%M_X%6W_QZOL;]A:ZM8_C
MQ"SW5JJ_\(3XI&3=VPY,VBX _?<GZ=LGH":ZG_AP%_P1P_Z1]?L__P#@H\1_
M_--1_P . O\ @CAT_P"'?7[/_P#X*/$G\_\ A)LUYV;^*7]JY9CLN_L+V'UW
M#5</[;^T_:^R]I%QY_9_V?3Y^6]^7VD+[<RW/9X>\#%D.=Y7G/\ K1]:_LW&
MX?&?5O[$]A[?V%2-3V?MO[7K>SYW&W/[*IRWORNVOZ\_VC8?\_MI_P"!5O\
M_':/[1L/^?VT_P# JW_^.U^0O_#@'_@CA_TC[^ '_@I\2_\ S3T?\. ?^".'
M_2/OX ?^"GQ+_P#-/7Y(?OYZA_P45O;26R^$?EW5JVV\\;9Q=6_&;7PUC_EK
M[&OS!\^#_GXMO_ JV_\ CU?=_P#PX!_X(X#_ )Q]?L__ (Z1XD/\_$]'_#@+
M_@CA_P!(^OV?_P#P4>(__FFK]0X<\2?]7\FPF4_V+];^JO$/ZQ_:/U?VGM\5
M6Q/\+ZC7Y>3VW)_$ES<O-I?E7X=QCX,KBWB/,,__ -9'E_UY81?5/['^M>R^
MJX+#8/\ C_VIAN?VBP_M/X,.7GY?>Y>:7PAY\'_/Q;?^!5M_\>H\^#_GXMO_
M  *MO_CU?=__  X"_P"".'_2/K]G_P#\%'B/_P"::C_AP%_P1P_Z1]?L_P#_
M (*/$?\ \TU>Y_Q&+_JG?_,O_P#@L^8_XEU7_18/_P 1_P#_  WZ_P!+7\-O
M^"@'A2\\8?L\>(O[#\-^-O%&NZ#%J^IZ+-\-I_">K>(] O;_ $&_\/R7TG@G
MQ-YUOXXT?4M/U6^T74--T>)_$VBO>6GB#1?+%E?7$'D?CG2_%&E^*OV*_%OB
M?]GKQ7J?Q)^&'Q3U?Q'\1M<^"7PCM-;\/>%?A?/X%_:1\,:)I5C'X7UN\\+>
M'O$.JZQXT\%Z]X]^'?@*[U#2['Q)KE[);:GKOAS0-)O;;^B7_AP%_P $</\
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M'U^S_P#^"?Q'_P#--37C%9I_ZN;._P#R-_\ \%@_HZIIK_7!ZJW_ "3_ /\
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M/PPU+Q?X:CO/%7C&STW7[Z'A/V=_^"MTGQ*N=&\1_%WX'>+OA5\.?%/[//\
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' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-2016331_rdchart.jpg
<TEXT>
begin 644 biib-2016331_rdchart.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -( 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M_EA6]10!@_VKJG_0N7W_ ('Z+_\ +"C^U=4_Z%R^_P# _1?_ )85O44 8/\
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M/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\
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M4YC\Z-X\_>4CBOU2'(!]0* %HHHH **** "BBB@ HHHH **** /Q _X*3_\
M*23_ ((4_P#9UO[4'_K'/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:_;R/\ U<?^XO\ Z"* 'T4F1ZC\Q1D>H_,4 +2$X[9Y []R!G@'
MIG/IZD#FC(]1^8IKA)$9&/RNI5L,5)5A@@,I#*2"1E2&'4$'F@#\F/V8O^"C
M^M_%+Q9^ULGQC\/_  P^'/AO]GJ_LKH> M)\5>+[C]I#P98S_#SX5>((_"GQ
M+^#OB7P9H6J:[XFU?Q7XVUWPIH?B'X?/=^&]7\;:1_PKSPO!XMCD\/>//%VA
MX*_;>^.WC+X"?%[XHZYX#^"?P>U/X2_M2?&CX*^-M6^(/C?QMJO@OX?>!OAW
MXB31_#FO:G:^%?#<_B#QUXVU6^U/P]X3U[1?#EUH'AC3M=NM9UK3O$E]H^E6
M-CK?8>&?^"77[/J>-_BSXO\ C!JGC?\ :0MOB%K4-UX6\.?''73XOL/AGH \
M.?L_Z9=:/I.J".T\1>*]:N==_9N^%^OQ^//&VKZWXQLD\(^%["UU);[3-7U[
MQ+O_  E_X)Q?"/\ 9VT7Q=IG[-OQ ^+WP&O?&7QI\=?&W5=6\"^(/#-_#/J_
MCVT>QOO"6H^$O'/A+QAX$\1^"=#M3&/"=EXE\,:KKOAVZ@CU"P\0K>O=370!
MY@W[5W[6'C_X3?LO?%WX7^&OV?/#$_[1K^$/#&A_"WQ])\3/%^NZWXNU?5/$
M^J:[XA\,>-_ ^HZ/I-K\-;'X1>%]8^,,%]XE\)6OBNP\*:3=V/B'0]/\77-O
MX6C^Q_VH/BGXY^$'PX;QMX2?X6:+I6FZC#_PFWCOXO:UXKLO"7@+P],C06NJ
MMX?\%:+J?B7Q?JFJ:_<:+X=M=%M+[PY!9)JMSKUWK,D>DIH^JX7P\_8[^%7P
MRF^!DOAS4/&$P^ B_&Z_\.)K&M66I#Q'XP_:$UA_$/Q.^(/B\G2H!>>,-7U[
M4?%6J6L^B)H.BZ6WC;Q/8:?HEMI%QI^G:=N^)/@%XHUN[U?5=._:9_:"\+ZW
M<_$;6O'?AR_T35?AK)I_@W1==\'Z%X3NOA;8>$=:^&>K>"_%'P\M)]%G\7:,
MOQ$\/^,/&VA^+]<UC4=)\:6EA)::5:@&I^RU\9=6_:$_9^^%?QGUSPC#X'U+
MXA^%;;Q%-X>M->@\3:;#%/=7EO9ZCHVN16UA-?Z#X@L;:V\1Z ^J:9HVOPZ+
MJ]A:^)-#T3Q!!J>DV?O]>3? _P"#7@WX ?#/0?A9X%;5IM!T.[\3:O-J'B#4
M5U37M=\2^-_%NN^/?&WBC6[Z.WLK676/%?C7Q/XA\2ZFFG:?IFD6][JL]MHV
ME:7I4-GI]MZQD>H_,4 +129'J/S%&Y?4?F* %HHHH YWQ?\ \BIXF_[%_6O_
M $V75?S"0?ZB#_KA#_Z*2OZ?/%P)\*^)0 23X?UH  $DDZ9=8  Y)/8#DU_,
M=!I]_P"1!_H%_P#ZB'_EPO/^>:?],* (:*M_8+__ )\+_P#\ +S_ .,4?8+_
M /Y\+_\ \ +S_P",4 5*^.M0_:1\5VG[65O\ /\ A&O!MAH#^"M<UNSC\3^*
M-1\+_$7QO?:=-X0GMM:^&<.J:+'X+\6:1-;Z_JNFP^&;777UZ:7PYXDUK4]1
M\/#0UT+4?M#[!?\ _/A?_P#@!>?_ !BOFSQ7^ROI?C'XQZ/\7-9\2_$ZXCT'
M3#+I'@&>Y?4/!NE^.+/Q7X8\8>'/'.EVVIZ9>7U@?#FN^%=,UZT\%Q71\%WO
MBF"#7K[2Y(3J>D:N 0>&/BO\46\>:E\.?%_PZ\,:IXM7X3Z3\5[70OA9XNEU
M"?P]/K?BVU\)Z7\-?&VL>-H="T*W\1:R]Q>ZOX9\9V=Q8>'/$>C^%?&VH6F@
MV]GHNFSZYT7[.7Q4U;XV?!/P)\4M?T'2_"^L^*XO%1U+0-$U*]UO2M+N?#?C
MSQ;X->WT_5;^ST^]U.&1/#*W0NI["Q>XEN'*6=I%Y<,>-\+_ -F_Q;\*=)\2
M:;HWQO\ C!K-[XD:74[KQ/XD\$?!^_\ %C>-)[W3[F7XA:QKUO\ "NTN_&?B
MMK2Q_L6,>,_[<T&ST69--TS1;"STW1K?3I/@_P#LUZS\&O"G@SP/HGQ;^,>M
M^&/!'B'7]<L=,UK1/AY:)K%CXD7Q?>ZEX5\23^'OAQI%UJGA\>*_&-QXULVB
MFL]:M==TC1;--6/AV&]T6^ )?@E\7O$_Q0U_XZZ'XI\"0> +OX2?%'1O EAI
M1\06OB/5[S2M:^$_P]^)=IJ'B2ZTP/H5EKY'C@V=YI'A^]UC2M-2UBMDUS5K
ME;F\?WVO"?A-^SSKWPL\9?$CQG-\5/BGX_N/BMK5IXG\7Z1XM\*?#?3M*G\4
MZ=X4\)^!M-UW3W\$_#KPOJFGR67A3P9H^DKI<6H-HUPYO-3N[&?4YQ<Q_0/V
M"_\ ^?"__P# "\_^,4 5**M_8+__ )\+_P#\ +S_ .,4?8+_ /Y\+_\ \ +S
M_P",4 >L?L\?\EX^#W_91?#'_I<M?T:+T'T'\J_G4_9[LKU/CM\'W>SO45?B
M)X99F>SND15%\N69WA554=26( '4U_16O0?0?RH 6BBB@ HHHH **** "BBB
M@ HHHH _$#_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"*_$/_
M (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@B@#\NOB;;_M-M\1?'+>
M&OCA/HGAX^*=7.B:.LDH73-,-RWV2Q &AS@"WCP@ FE''#L.:X?[+^UM_P!'
M"7'_ '\E_P#F>KZ7\;?\CCXI_P"P[J/_ */:N8H \/\ LO[6W_1PEQ_W\E_^
M9ZC[+^UM_P!'"7'_ '\E_P#F>KW"B@#YV\0ZQ^TOX2T/5?$WBG]IZS\.>'-#
MLY-0UK7M:OS8Z5I5A$R))>7]W)X>*PPJ\D<:A5DFGGDBMK:&>ZGA@D^;_"O[
M9VL>-?AGX4^+7AG]M4ZQX3\:ZI?:#X=LM-\+_$'5_'EYXATK21XAUCP_)\+=
M!^&NL?$FUUC1?#3P>)]9MIO"PCTSPS=V&OW<\>EZC87-S]H?%_PI+XX^&WBG
MPK!X5T3QO)JT.D;?"GB#QCKGP[L=8;3/$FBZVBVOQ!\-VE]KG@3Q%ITFEIK/
M@WQCIUK)+X:\9Z;X>UB5[:VLY[NW_-+]E'X:_MD?#K]E'P?X!^*/A+XN:I97
MRZ98Z5X<\#_M$^"/AM^UW\$_#6G:'H4LVG#XMR6?A'PGX@TWQ)X_M/$MRV@W
M'C67QEX$\"WVAZ?<>)?B#Y]SI7AD ^P)/BK\8XOA:OQO;]L3PZWP@D\*6WCB
M'XD1:PUQX2N/"5['#)8ZY:ZE;^&Y6N[:^-S;6UA;6L$VI7NI7$&CVMC+K$T=
M@USX>_$'X_\ Q4T.Z\0^!/VH)]:T[3];U/PSK$5QIWB/P[K?A[Q-HWV<ZOX9
M\4>%O%?@G0?%7A;Q%IL=Y8W%WHGB+1-+U)+*_P!/U!+=]/U"QNKCY[LO@7\?
MH_V3?AA^S?<> ?"%MXI^#7AG]G?XJ:/XET+QKX7T/X:^,O'WP4_:6TKXH0_L
M]WNG6&EQ:UI]_?>!/!.A)XO^,<OAFV\ >*/'GB&\\26>EVRC4K6#Z:^ _@OQ
MO8^./VD/C!X[T"Z\#WWQ]^(W@3Q#HOPZO_$F@>*]7\*>&_AE\'O!_P )]-U'
MQ1J_A.\U3PHWC'QK/X>O==UFQ\.ZUK]AI6CP>%M,EUR^U&TOH[4 Z3[+^UM_
MT<)<?]_)?_F>H^R_M;?]'"7'_?R7_P"9ZO<** /#_LO[6W_1PEQ_W\E_^9ZF
MR6O[6YCD"_M"W"MY<FT^9+PVQMI_Y%[L<&O<J1ONO_N/_P"@&@#[^T;[3_9&
MEB\F^TW8TZQ%U<'K/<?9(?/F/RK_ *V7?)]U?O?='0:=4=,_Y!UC_P!>=I_Z
M3Q5>H HZG_R#[[_KSNO_ $GEK\_E=]J?,WW$_B/]P>]?H#J?_(.OO^O.[_\
M2>6OS\7[J?[B?^@"@!^]_P"\W_?1_P :-[_WF_[Z/^--HH =O?\ O-_WT?\
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MONO_ +C_ /H!I:1ONO\ [C_^@&@#] ],_P"0=8_]>=I_Z3Q5>JCIG_(.L?\
MKSM/_2>*KU %'4_^0=??]>=W_P"D\M?GXOW4_P!Q/_0!7Z!ZG_R#K[_KSN__
M $GEK\_%^ZG^XG_H H 6BBB@ HHHH **** "BBB@ HHHH ZCP1_R.7A;_L.6
M'_HT5]T5\+^"/^1R\+?]ARP_]&BONB@ HHHH **** "BBB@ HHHH **** /P
MZ_X*7221?\%'O^"%DD4#W,B_M6_M/[8$DBB9\_L=_$ '#SO'$-JDN0SKN"E5
MRQ4']I4U35 B#_A'+[[J_P#,0T4]AW&H8/U'![5^,'_!2?\ Y22?\$*?^SK?
MVH/_ %CGX@U^WD?^KC_W%_\ 010!\*^,'>3Q9XDDDB:"1]:OV>!WC=XF:8DQ
ML\+R1,R]"8W=">C$5SE=/XV_Y''Q3_V'=1_]'M7,4 %%%% !1110 4444 %%
M%% !2'[K_P"X_P#Z":6D;[K_ .X__H!H ^Y]/U/4UL;-1X=OF"VML PO]&PP
M$$8# '4 0"!D @'!Y Z5<_M75/\ H7+[_P #]%_^6%:&F?\ (.L?^O.T_P#2
M>*KU '*ZAJ>IM8WBGP]>J&M;D%C?Z-A08) 6(&H$D*#DA03@< ]#\,#[J?[B
M?^@BOT#U/_D'7W_7G=_^D\M?GXOW4_W$_P#0!0 M%%% !1110 4444 %%%%
M!1110!TG@YWC\6>&Y(XFGD36;)D@1XT>5EDR(U>9XXE9N@,CH@/5@*^SO[5U
M3_H7+[_P/T7_ .6%?&O@C_D<O"W_ &'+#_T:*^Z* *EG//<0F2XLI;&3>RB&
M:6VF<J,8D#VLT\6ULD!2^\%3N4<9MT44 %%%% !1110 4444 %%%% 'X@?\
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M_P#1[5S% !1110 4444 %%%% !1110 4C?=?_<?_ - -+2-]U_\ <?\ ] -
M'Z!Z9_R#K'_KSM/_ $GBJ]5'3/\ D'6/_7G:?^D\57J *.I_\@Z^_P"O.[_]
M)Y:_/Q?NI_N)_P"@"OT#U/\ Y!U]_P!>=W_Z3RU^?B_=3_<3_P! % "T444
M%%%% !1110 4444 %%%% '4>"/\ D<O"W_8<L/\ T:*^Z*^%_!'_ ".7A;_L
M.6'_ *-%?=% !1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\$*?^SK?V
MH/\ UCGX@U^WD?\ JX_]Q?\ T$5^(?\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-
M?MY'_JX_]Q?_ $$4 ?#/C;_D<?%/_8=U'_T>U<Q73^-O^1Q\4_\ 8=U'_P!'
MM7,4 %%%.1@CHY0RA)$<Q*%+2A7#&)5965FD V*K*RLS!65@2" -R "20 .I
MR,#Y$DP?0^7)')@X/ER1R8V2(S6([2\FD>*&SO)IHQNDAAM+B6:->/FDBCC:
M2-3D89U .1SR,_@5^P_XX\-Z5\>/VR_"/BGXV>+(='U/6=(UGX@_M<:;\4?'
M7@2#P<=*\ _LJZ7-)\=OAW^T%8ZGX,^!7QN\62^)M5T/PCXCL;D7^D:OH_Q<
M\)Z#X2\(>%/#'P\FLNJ^!7BOX4?%'_@DE\'M3U!O!7[1OCGP3HNE^"/#>G>)
MO&VJ?$6ZT#XZ_%3XW:Y\)OAA<?$2]TWQ5-XEGU"T?QSX?\0ZK;^+M1DU+6O"
MMG<7$QDBODO2 ?N4;:Z'G9M;H?9@#<YMIQ]F!&0;G,8^S@CD>=LR.1Q4(!8A
M5!9F(554%F9F("JJ@$LS$@*H!))  )-?@]^V+X'N/V>+#QE\-OAEXEM?$?B[
MPQ^RA\-O"G[#]I??'/QGX1^+'PC^-WA7Q+X^T^7QOX.^&5N9M0^/_BCX_P#Q
M"U#PA<ZQ+X3E\3:IHZZ/=> /B5I7A3X+W5OJUQ]]?M-_%K6O$?@/7?A_\+O#
MWQ!^)SQ^*O%WPK_:=U?]F^/0_$?BSX(-X:^&UCXU\8^!Q#=>,/!U]X>\6>/(
M_$GAKPMI.NZ3>W-SX*\%^)-9\90>5K5KX76Y /NAE9&9'1XW1BKI(K(Z,I(9
M'1@&1U((96 92"" 013:^-/^"=7B/4_%?[ _[&.NZSIWBW3-6N_V8O@A#J$?
MCB%X?$=_=V/PX\.64VNW#S:MK=U>V/B)X&UO1M4O]0DU+5M(OK+4=2@L[ZZG
MM(?LN@ I&^Z_^X__ * :6D;[K_[C_P#H!H _0/3/^0=8_P#7G:?^D\57JHZ9
M_P @ZQ_Z\[3_ -)XJO4 4=3_ .0=??\ 7G=_^D\M?GXOW4_W$_\ 0!7Z!ZG_
M ,@Z^_Z\[O\ ])Y:_/Q?NI_N)_Z * %HHHH ***3(QG(QZYX_.@!:*,@8R0,
M]/?Z4F1G&1GKC/./7% "T4A95QN91GID@9^F:6@ HHHH ZCP1_R.7A;_ +#E
MA_Z-%?=%?"_@C_D<O"W_ &'+#_T:*^Z* "BBB@ HHHH **** "BBB@ HHHH
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MD\57JHZ9_P @ZQ_Z\[3_ -)XJO4 4=3_ .0=??\ 7G=_^D\M?GXOW4_W$_\
M0!7Z!ZG_ ,@Z^_Z\[O\ ])Y:_/Q?NI_N)_Z * %HHHH **** "BBB@ HHHH
M**** .H\$?\ (Y>%O^PY8?\ HT5]T5\+^"/^1R\+?]ARP_\ 1HK[HH ****
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M -&BONB@"I9SSW$)DN+*6QDWLHAFEMIG*C&) ]K-/%M;) 4OO!4[E'&;=%%
M!1110 4444 %%%13^<(9C;^5YXBD,/G[Q#YNQO+\TQ_.(]^WS"GS!-VT%L4
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MU_\ <?\ ] -+2-]U_P#<?_T T ?H'IG_ "#K'_KSM/\ TGBJ]5'3/^0=8_\
M7G:?^D\57J *.I_\@Z^_Z\[O_P!)Y:_/Q?NI_N)_Z *_0/4_^0=??]>=W_Z3
MRU^?B_=3_<3_ - % "T444 %%%% !1110 4444 %%%% '4>"/^1R\+?]ARP_
M]&BONBOA?P1_R.7A;_L.6'_HT5]T4 %%%% !1110 4444 %(<8.0",'(.,$8
MZ'/&#[\>M+5:\N[6PM+J^O;JWL;.SMY[J[O;R:*WM+2VMHGFN+JYN)F2&"WM
MX4>:>:5TCBB1W=E120 ?@/X^U;X-:[^W/\5?#>J>/_V2?AGJL'QQ^$7A_6?A
MI\6?C?\ &+4/B)X\O$U+X,?$I/$/@KP#X>\?^&_AIX)N_BCXP\'^!(M<\&6&
MB:R?B+K7PN\&7GQ3&IB2;PVG] "\#'!P3T^IZ^_]X^N:_![XE?&F&?\ :WO-
M#T3]I7P=/X\\5_&SX'ZS\'O&UA_P4#^'?A?X3^"O@CK-G\-+[6_A9XE_9%/Q
M:L;_ ,?>+O'VDIXH_L#[/\(_'=S\2+KQ_P"#/$NF_$_P.EKH\/A']X5Z#)SU
M'7/0]">Y'0GUS0!^(/\ P4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_
M $$5^(?_  4G_P"4DG_!"G_LZW]J#_UCGX@U^WD?^KC_ -Q?_010!\,^-O\
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M*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\ Z"* /Y\/C[X[\;6/QO\
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M %YW?_I/+7Y^+]U/]Q/_ $ 5UEBT444 %%%% !1110 4444 %%%% '4>"/\
MD<O"W_8<L/\ T:*^Z*^%_!'_ ".7A;_L.6'_ *-%?=% !1110 4444 %%%%
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M]7'_ +B_^@B@#^<7]H?_ )+Q\8_^RC^*?_3@]>.5['^T/_R7CXQ_]E'\4_\
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M;5O".B>$[3P9X?N-8\ ^#/AQ=:5XW\9^%_&$OA?P/JGP^\.:+<:=XJO-*F7
M+ABLYPU7'8["K*LLJX_FQV3O"R=7#Y<\?B<+BW]?J87#RPLYX'!XEX7&9A7A
M5S/!SCA9QCB50'@K2JISG'V=-S7/2<6VJ?/*,_?<8N+Y(/EG.5ZD&HM<W+^F
M5%(,X&>N!G'3/>EK\Z.$*CF_U%Q_U[W'_HEZDJ.;_47'_7O<?^B7I2V?H_R
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M_P#BJ-Z?\](_^_B?_%5^.GF2?\]'_P"^F_QH\R3_ )Z/_P!]-_C1_P 3Q_\
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M -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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ME?R_0_ZBW_Z][?\ ]$I7]0/B_P#Y%7Q)_P!@#6__ $U7E?R_0_ZBW_Z][?\
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MMM,Y48Q('M9IXMK9("E]X*G<HXS;HHK^UCZP**** "BBB@ HHHH **** /Q
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M_P!8Y^(-?MY'_JX_]Q?_ $$4 ?"?CC_D<O%/_8=U+_TI>N6KJ?''_(Y>*?\
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MJNHAI[NZT;5[R&Q;0/#OBG6]"TF_:'\)V_Q<T;X+ZEX&^.6A^)?$6H^+]/\
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M>#W'7%%>,(*1ONO_ +C_ /H!I:1ONO\ [C_^@&E+9^C_ "''=>J_,_0S3?\
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M62Q;A4A&I3FD\]3<:E.<:D);3A*,HMQ:;?\ Q+]Q7_T-^'?_  HS3_YT^O\
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M@)XF<(PCAJ5%QJ/$X;#24W*FVE&,ERM>]?0****\D_3PHHHH **** "BBB@
MHHHH _#K_@I=))%_P4>_X(6210/<R+^U;^T_M@22*)GS^QW\0 </.\<0VJ2Y
M#.NX*57+%0?VE35-4"(/^$<OONK_ ,Q#13V'<:A@_4<'M7XP?\%)_P#E))_P
M0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% 'P?XR=Y/%OB222)H)'UJ_=X7:-
MWB9IW)C9XGDB9D/!:-W0D?*Q%<U74^./^1R\4_\ 8=U+_P!*7KEJ_C_-O^1K
MF?\ V,,9_P"I-4 HHHKSP"BBB@ HHHH **** "D/W6YQ\C\^GRGFEI&^Z_\
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MX3"XA1]FZ])/G<;\_NIV=OVHHK\6_P#A]3\*_P#H@?Q0_P#"P\#_ /QFF_\
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MHEA;ZI)HNIR6KW\-C/X9N9K2.Y*F1+>2XG>($*TKGYCXI_P^P\)_]&Y>+/\
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M_P!/TU?)5?6O[?'_ "?!^UQ_V<'\2_\ T_35\E5_K7PM_P DQPW_ -B#)O\
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MW/"?]@U#_P!-0. ^*W_),/B+_P!B)XQ_]1O4Z_S7;+_CRL?^O*S_ /2:*O\
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M/POOO"'C'6]O[1,>LZ/J(U7XU:_XFG\-^%_"E]8Z-J^NZ3?WGBC3M5\0:?\
M#V[T-;3A_#_BSX;>%_@!\8=*O?B+X"\2>(OB;\'/!OAG0=3TBW^*$/[0B:SI
M7B[P'XE@^"_CK2O$B:I\.M*^"OA)O#U]'>:EH6HV\^I1>'?"$_A'4W2[O/#\
M?P_D\<GCIST^GI29.,9./3M^594.%:%#"83 K,LSGAL)B<'BH0J3PKE.I@L1
M1Q-*,ZJPL:GLI3PV']K2A*-*?)*?(JL_:1UK\3UZ^+Q6-EE^70Q.*PV*PLYT
MX8E1C3Q>'J8:HXTWB73]I&G7Q'LZLHRJQ52-/G]E#DDIQDXSC)QGKCW]_6DH
MHKZD^9"JU[_QY7W_ %Y7G_I-+5FJU[_QY7W_ %Y7G_I-+3CNO5?F*6S]'^1_
MI2_"W_DFGP]_[$?PC_ZCNFUWE<'\+?\ DFGP]_[$?PC_ .H[IM=Y7^0&._WS
M%?\ 816_].2/]8,%_N>$_P"P:A_Z:@<!\5O^28?$7_L1/&/_ *C>IU_FNV7_
M !Y6/_7E9_\ I-%7^E%\5O\ DF'Q%_[$3QC_ .HWJ=?YKME_QY6/_7E9_P#I
M-%7]B_10_P!QXW_["\@_],YN?R3]*#_?N#?^P;/?_3F4%FBBBOZY/Y6"C^?3
M/?'7&>N,\X]<>E%% "Y/!R<C@')X'H/2@DGJ2>,<DGC.<?3//UI** #)/4].
M![#THHHH **** /KC]@3_D]_]DG_ +."^&O_ *>TK_0?7H/H/Y5_GP?L"?\
M)[_[)/\ V<%\-?\ T]I7^@^O0?0?RK^'?I4_\E/PQ_V(:_\ ZL*Q_9WT8_\
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M $FEIQW7JOS%+9^C_(_TI?A;_P DT^'O_8C^$?\ U'=-KO*X/X6_\DT^'O\
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MZM6?)3S6,(\]1N7+",81NU&,8I)?P'?\.?O^"Q__ $:;^SU_XF=H?_SK*/\
MAS]_P6/_ .C3?V>O_$SM#_\ G65_?C16_P#Q'KQ9_P"BME_X9.&_+_J3^7]6
M5L/^('>%O_1+1Z?\SKB'I;_J;_W5^)_ =_PY^_X+'_\ 1IO[/7_B9VA__.LI
M#_P1_P#^"QPY/[)O[/74#_D\_0QR2 .OPL'<].IZ#)P*_ORIK*&&#_>5OQ5@
MP_,C!]J/^(]>+/\ T5LO_#)PWY?]2?R_JRL?\0.\+?\ HEH]/^9UQ#TM_P!3
M?^ZOQ/\ /.^%'_!,O_@K-\9OAQX-^*?@G]E/X"7'A/QWH-GXCT">^_;%T.RO
M)--OU9K=KJS_ .%8SFVF(4B2!I6:-@4<AU91Z%_PY^_X+'_]&F_L]?\ B9VA
M_P#SK*_N6^ _PAT7X!_!_P"'GP;\.ZIJVM:'\.?#-AX7TS5==^P_VO?VE@9/
M+N=0_LVULK'[2_FG?]EM((N!MC'->MT?\1Z\6?\ HK9?^&3AOR_ZD_E_5E8_
MX@=X6_\ 1+1Z?\SKB'I;_J;_ -U?B?P'?\.?O^"Q_P#T:;^SU_XF=H?_ ,ZR
MC_AS]_P6/_Z--_9Z_P#$SM#_ /G65_?C11_Q'KQ9_P"BME_X9.&_+_J3^7]6
M5C_B!WA;_P!$M'I_S.N(>EO^IO\ W5^)_ =_PY^_X+'_ /1IO[/7_B9VA_\
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MMNQCKH\8]?S)_F:6B@ QG_\ 61_*DV@]0#P1SSP>H.>H/<'CIZ4M% !1110
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MA2;3?B3XFU[X6?&/P_\ M8?LPR^ K#PMXV\9>(+KX9^+%G^"FL_&T"]_9_\
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MDZI8VNHZ9J-C=1F*YL[[3[V&>SO+2XB9HY[:YAE@FC8I)&RDBM$*J]%48Z8
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M@9&!@8.,C X^G%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQRZSXBU8:=;6PU+7=6EBBDU/5[WS]1OY(T>[N9F12 #^?W]J+X7?M;_%F?\
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M\\9_M3^%?A+XQT#2=>^(?@OX<:=X>\/_  Y\5^)-:^"6A:I\-+G5O#UEX?\
MA7'IW@7Q!\2M<T[^F$*J_=4#KT '4Y/3U/)]3R:XWQU\./A]\4/#\WA+XE>!
M?!WQ"\*W%Q!=W'AKQQX7T+Q;X?N+FV#BWN)]&\06&HZ;+/ ))!#,]L98@[B-
MU#MD _GK^#/_  U+;?#'XD:EX5\1_M)?&?P%X1^'O[%_PV\'>+/!6H_%?P+H
MFI>,+WQ=XV\%_MU?%FV\%6\<OQC\<^)O!/BOPL[_ !-\%^&I(/BC=:C%K=W\
M/K_P=XG\72^(;',L[+_@IU>^!OC?I=[J/[44%Y\+OV=?^"D?B3]GK6- T[QM
MX<U#QS\2O WB']E'QW^PY;ZMI_B_Q5\0O%_BS6M:DU_XQZ#X=\%?$OQ;XJUW
MQOX9TKQ%X,^))U3^R]2TBW_I$T/0=#\,Z/IOA[PYH^E:#H.CV=OIVDZ)HNG6
M6E:1I>GVB".UL=.TS3X+>QL;.VC58[>UM8(H(4 6.-5 %:H50,!0!@C  Q@]
M1CT.!F@#^?[XDZ/^VIIWBKXN>'9?%?[75O\ "W0?C%X+\5>!KC2M"^+_ (L/
MC2/Q]^RIX*U3Q=X;N/'WP2OX?COX2\%^$?CN?%%_X23PCX;\>?#'PQXRN-8\
M&?$'P=!X @\+Z;I?[:?!35O&.N_![X5ZU\0O"VO>"/'FK?#KP5J/C3P;XJUW
M0O%'B;PKXKO/#>FS^(/#WB'Q)X7T_2?#>OZWI&JO=6.JZSH.E:9H^I7\-Q>:
M;IUA:2Q6D/IA53U53WY /.,9Y'IQ].*=TZ4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45\Y?&3]J'X;? S7]+\-^-+?Q
M1+J&KZ/_ &Y:MH6C0ZE;"R^W7&GXFEDU&S:.?S[:0^6(W'E[7W\D#R!O^"AW
MP%568V7Q$(16<X\*VN<(I8XSK@YP#7YQF_B]X99!F6,R?.N-^'\MS3 5%1QN
M!Q>.ITL1AJKA"HH5:;UC+DJ0G9_9=S@JYIE]"I.E6QE"G4@[3A*:4HNR=FNF
MC3^:/NRBLK0M8M/$.B:/K]@)EL=;TO3]7LUN(Q%<"TU.SAO;<3Q!W$<PAG02
MQAW"/N4,P&3JU^ATJM.O2IUZ,XU*5:G"K2J1=XU*=2*G"<7UC*+4D^J:9W)J
M24D[II--;--737J@HIDDD<2/+*Z1QQHTDDDC*B(B*6=W=B%5$4%F9B J@DD
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MI^(6@^$+VVL-634&GNK7[7$;.U2>,1>:\.'9IXBK[T;Y=I&W!SSBN8/QN\&
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MMQ.-.O9(+TPG_6^1LP=V*_F]^(G[)OQC^,_[*/@'X ?#OX!_$KX5_%;X)_\
M!.S]JWX#?'#6[G2E^%]K\3_BIXZ^ %CX&T#X8^$?B=IFI6$'QBTCXL_M :/:
M?&G5O&^BZQJWA2^TO1&E^(FJ:=K_ (VO= N?Z7Z3:HSA0,]>!SGKGUZGKZT
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M::WX8^&>L&VL#<?';2O&-S?^8_%[7_\ @I_-<?%;Q!\*/#O[4'AG4/%7PO\
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MZ]?3O0 M%)N7.-RY],C/3/3KTY^G-)O3^\O! /S#J>@Z]3VH =13=R\?,OS
M$<CD'H1SR#VQUI0RDD!@2.H!!(Y(Y Z<@CZ@T +1110 4444 %%%% !1110
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M\J\8 ^4< = ..,9.,=,TH5020J@GJ0 "<G)SCU//UYH 6BBB@ HHHH ****
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M^M^*_&=EX#\<?$?0K;QQ;6FG:%L_'.V_;4N7\ P_ +7_ -J_PS\#F\%_&D>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-2016331_rdpiechart15.jpg
<TEXT>
begin 644 biib-2016331_rdpiechart15.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MP7\(+/7K.]B<7<>N:_J,9/V.ULP/)+7_ () ? N'X?V?A:Y_X5S>Z_X8\;>
M_&?@K61^R_\ LX:9X8^T_#CP=X^^'^C0_$[X>:)X$TS0_C!-KOA7XG>,H?%]
M[XIOK4G6M0M_$?@"U^'.J62O, ?5'[0O[7UG\./V0/%?[5/P0\)V_P ?I+*P
M\/'P'X%BU^]\ S>-_$?B+XBZ!\-+?PA<ZGJ?AK5]4\)>(;;Q-K,VBZEI6L^%
MSJNC^(M.NO#^M:;IU_#=K:>2>-/^"E'PZ\.?&K]E+P-I>AV5[\)/VA_@K\1_
MCIXQ^-VO>*H_#.D?!WPCX9^$?B#XQ>"UUG1FT?4H-5N?%7A?P)\1KSQ"MUKV
M@'P/8>%%OKE-7_M2*"#W;_AD7P;;?LS^%OV9M'U=O#OAKPMK7@#Q%:ZKX7\'
M^ O!Z#5_ _Q@\._&EYK#P=X)\.^&/ V@VNM>*=!>.XL=#T&R@M;74)YE^TZD
M)+ZX^9=8_P""47P3\0)J&CZSXV^(5[X1U?Q_^UAXLU/PV3H$2V_A3]JWX,>*
MO@CJGPM\.:I'I(N/#O@CX8^%_&&LW'PRL+>&\DT.\N9!,)X+B=) #WL?\%!/
MV7S;Z2#XJ\;1:]K_ (PB\!Z%X!N?@M\:+3XI:SXHOOACXI^,N@:?IOPLO/ -
MO\0;N+Q?\-/!7BOQ3X,U*'PXVE^*[?P]K5AHMY=:OI.IZ?9_-/Q#_P""N?P9
M\/W?Q+C\ >"?'7Q T/X=^#OV%_B1%\1)?#OB_P .?"[Q;X#_ &V/V@;#X(Z7
MJ?AWQC-X/U"*76? ]M<7_B)_#=Q:QZKXLUG1/$7@72(+;7_!_C4^'O7O"G[!
M=I!\:/AE^T/\1/C-XT^)OQC^'?C[1/%D_BO5/"W@[PO;>(_#W@_X!_'CX">"
M_!5SH?AG3K#3=-LM,L_VAOB#X^UC5[(2:EKOCC5)C&FC^%(M(\,:-XQH'_!)
MGP=X7\)^&? VA?&OQQ!X:L_ ?[,'@?QM:77ACPE>77C!?V0?VJ==_:L^#&M6
M]]B&?PO?V_B7QEXT\*>*[>Q^WZ?XB\.:KI=Q';Z9K.AK>WX!]3_\-^?LQ21Z
M8MGXL\9:KJM]??$6RU#PGHOP8^-.M>//!T?PE\0Z#X6^(VJ?$?P!I?P_N_&G
MPWT/PCKGBKPM::MK?C?0M#TY8O$>C:C:SW.EWJ7H]D^+WQ_^&/P/7PS'X\U3
M6SJOC.[U2T\*^%_!W@OQI\2/&>OIH&F_VSXDU'3/!GP]\/\ B?Q1<Z)X8TC9
MJ/B/75TH:/HEO<6*7][#=:GIEM>_#7Q'_P""8/A;Q[/\36A^*^KZ0GQ4^,OQ
M@^,&J7-S\,/A7XE\1>"=8^,OACX:>%=4UKX/>.M<T&7QS\*?B/X0L_AGI\W@
M7XB>%/$<#Z9=:E=76M^%_$%YI^@W>F>S?M1?L,?#C]I]/@]J'B:ZTZY\7?!&
MT\6:-X1UOXD?#KP)\<-'N]#\?Z1X<T;QG%X@\'_%/1]5T#5M>O\ _A$?#6NZ
M5XLC%IK6D>)-&BNFDU'1-2\0^'M: .EM/V]?V5=0\:6?@33?B@FJ:K>:M\*=
M$_MC2_"?C;4? MEJ'QU\':;X[^#$>K?$:S\.3>!-&@^*?A[5M/?P)>ZMXALK
M+Q'JMPGA_3YY==(T\^(6O_!43X$ZA\9-(\"Z?;>)+CX;Z]^S_:_&SP]\3)/!
M7Q4L]4\;WOB/XU>%_@U\./"WPN^'%Y\.+?Q+\5K+XHWGB1=9\ ^*_A^WB#3O
M$]K!&='M[S3[A]4MR^_X)A_"6]T[QSX>;Q9XA3PIXY^)'[%'CF]\-V^@^$-)
MTNTTK]BK1_ASX?\ #/@JQT_PSI7A[1].T#QUHOP[MM/\11:'I&AV^AP:M>P^
M$=/TFVM=.M[?R_Q%_P $AOA]XWMO!<'Q#^+GB;XC)\'_ (5^"/@_\$K#QS\.
M_A9X@\.^#?"7PH^(7AKQW\,QXI\*W/A]?#_Q/O;*T\/R>#?&;^)["&U\9>'=
M2DN[6T\*>)[.SU] #W+]H+_@I/\  3X+_ KXC?%G0;C7OB'XF\&_ OXX?&K3
M_AO8>"_B7I^K0V_P0A\4:3KND?%:YM_ 6KW?P&@;XC>%M1^&=_JWQ1TC0_[+
M\6V6LZ<+&]NO#^KV]KTW[0G[:'_"@O&7[(>BZC\//[;\*_M'^.I_"_CKQ8/%
M"Z8WP:T";PSI3Z3XSN-,DT.[B\4Z4_Q"\6>!_!^N12:EX;&AZ/KUYXL:ZNX]
M&DTJZ\3\1_\ !++P1??#7Q3\-_!7Q0U7X3Z=\6/V?/B+^S9\<_\ A6?PK^#?
MA#1OB!\/?'^O_$KQ?'_87@[0/"6E^&/ASK/A;Q)\6/'$&B:KX>L;F\O_  QK
M]]IWBJ?Q#XGCTSQOIGTW\<_V0?!OQYL/!>E^*O$6O66G>$/AG\7_ (9>3I5O
MIRRZCIWQ>^'>G_#Z_P!6\^XBG?3]8\.IIMIX@\/7%HC?9=<M[:X;_CVB( /(
M?!W_  4+\.:Y\?\ ]K3X1:_\./%NG^%_V<]5^"WA_P '>+_!FB^.?BKXI^,>
MN?$L?&G2/%5MI?PR\"> M3UW0+'P%XW^!7COPH=7:\UG3=6.BZGJU]<^'[6V
MACNO0A_P4/\ V0GACN8/BU'>6W_"MM.^+=W<6/@WQ_?1:1X%U;Q9X^^'NF7^
MO?9/"TTNA:O?_$KX:>+OA?9^$=6BM/&%W\3[*R^'EKH,_B_6=(T>\^>]5_X)
M7>"[I]/O;/XN^+[O4;'P=^S3X5U.W\;^$? OQ"\)?$2?]GO2OVB;&[USXP^!
MO$.G#PW\3;[XCZW^TIXQ^).N0ZQ;6UOH7Q:T3PGX^T$1WVER6=Q!\._^"2?P
M>^&W@GQUX#T+XB>/(=*\4^!/ 7A/P]=6>E^!]'O? 6L_"O\ ;&^/?[;/PX\8
M^'['3/#T/A5K[PI\5_CB(+/P[+X9C\'R:!X)T/3#H45E>ZA9T =MX@_X*=_!
M/PM\7+3P=XATSQ7HWPV3]GWQQ\</$_Q%U+P/\4K?Q#\/I?AU\9?#GPD\::'\
M2/A4/AT_C#X>Z%X0'B"+Q5XP\=>-4T+0O#.A"TU+4 -#U.RUN7ZD_:,^,?B#
MX,^!+7QMH6F_"PZ(FH*/%?C[XV_&C1_@=\'_ (=^'WLIVM?$'B_QQ=:#XOU,
MKK.N/H_AC0K'1/"VI+<ZIK5O<:E?Z3I\#3S_ #%X]_X)YQ?%FU^*U[\4_CMX
M[\7^,/C%^QY\=_V0?%?B@>&?".DI8^&_CKXJ/B>_U[PUH6G6XL]+'@L"'1O!
M_A^ZFU6)=,A$NOZQK>JS76HS_5'Q.^$_C7Q-H?@NT^'?QC\2_"S6?!J-;+-;
M>%_"WC;PMXJL9=-L]-:S\9>#_$MDT6H&P>SM]7T&_P!(UKP]J.CZO&7-W?:7
M<ZAI-Z ?+&A?\% -:U^\_8+6/]G+Q[HFA_MIZ[%H5_XM\1^(?#^G^&_AK>WO
MP?\ CI\5=&L])EB2XUKXF7?B"S^"%]?:/-8:%X8T8> _$_AKQIJNJ:9J.L:7
MX0O?T#\4ZS?>'_"WB+Q!IGAW5_%VHZ+H&KZQI_A/P^^F1Z]XFOM.TZXO;3P]
MHDFM7^E:,FK:U<0QZ;ITFKZIINEI>7,+ZAJ%E:+-<Q?FKXA_X)U^,;32OV6?
M#?PB_::UGX=^&/V4?&.L?%7P59:S\(_ _C[4?$'Q<\4:+\;/#?BWQ7XCU"75
M/"UA::#JNC?'CQG!IOP_\*:%X=\,>%)8-$B\-QV&D:7!HX^Z%\'_ !5GT#XV
M:7/\69;/5_&NK>(9/A!XBMO!WA6[N/@SHVH^ O#GA_0[6WTJYL8]+\<S:!XV
ML/$/CV!O&2ZDU^^O)X;U2XNM$TVVA4 ^+=6_;R^(/@SQ?K7P8\?_  3\':;\
M?[V^_9QTOX=>$_"OQIF\5?#[5]7_ &F/$'Q1TCPYH'CGX@7'PQ\/:OX+USP'
MI/P<^(/C?QO::7X%\8+JO@;1[?6O #>)KW4/[&LZ'Q(_X*,:S\-O@OXB\>7/
M[/\ K7B7Q]\-/VC?#W[-WQH\,>'?'&DMX ^&WB'5/BK\'O <OBJ?XCZQI.DZ
MIK?A_6?"WQM\#^/_ (?Z/8?#]?&?B>UU:/1M;T#PB-,\2ZUH<WP__P"">?BC
MPYX#U3PEXS_:(O\ QGXI@^(/@7XW>#_B_9?"+P?X8^*EI\?O!%U(TGQ>^(/B
M.76O$]M\6-:\5Z(R^"?$6A^(K#3]!MO $UUX,\(6?A708- M?#S_ (N?\$\-
M?^(WP+U3X,Z)^T1KOA2]^(OQ@A^/'QX^(5Y\,_!_BKQ)\4_B7IGCWX<_$3PW
M?VEA/J6BZ%X&T3PUJ?PN\'^&M,T+2;/4D;P'HVGZ#>7MSJL$WB6[ .K\;_MJ
MZ[X;_:SE_9]@L?@5H7A'1?$GPG\+Z_XH^(GQ6\>>'_&U]J?Q/TZ/5;.V\.>&
M/#WP:\5>!K2YU 7NG>'/ -KX_P#BAX)E^(?C,ZCX>T0+/9Q-=_H?7Q+XR_91
M\?\ Q2@TW0/BG^TAXP\4?#_5O^%<:E\5/A_IO@3P%X<T?QKXC^&^J:'KD,WA
MS6(K/4O%?PZ\,>,M9\.Z9?>-O#&GZYKT]PR7*^%/$/@]M1U*6Z^V0 !@>I/X
ML23^I- "T4$@=3CH.?4G 'XG@>]% !1110 4444 %%%% !1110!\7?MQ_'_5
M/V?OAEX.U/0O$VG>$-=^(7Q2\/?#;2O$&L:'X3U#2+&;4] \5^)+HWWB#XB?
M$7X8?#7P*TNG>%;R/3_%/CSQ#?:2^IFT\.:3X5\6>*_$'A_1+C\L?!/_  5'
M^.>LZ+\%_''Q!USX3^!=!DN=>\.>/?"/A?0_"GCOXD^*=?\ !/[87Q9_9O\
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MX(A860CMKN34+>-;6!4M[Z66>:6]A01A8KN2:ZN97N8PL[2W$\C2%Y9&8 _
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M>*_AKKGQ"^'VJZWX6\->'YO!^M>$OVO/V6/@4?!_B[X?^#OC#\0?'7A >(/
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M$T;2-:\3>*/$$]CX:\')X4TH>(F^I[O_ (**Z)8^/M"^"=U^SS\<(/VA=?\
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M1&+/7[CF/T;/$K!4G4PU/(\WDE?V679HZ=5[:+^U,-EE.3\E4UZ7>B_%\O\
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M=&C0I:QZG+?:>.W]G:J!J5GMZ<(ER8,=C"1U!Q\N?M#_ /)"OBS_ -B/J_\
M."OHN$/^2MX5_P"RDR+_ -6F$/ XK_Y);B;_ +)[._\ U68H_"1NI^I_G24K
M=3]3_.DK_66.R]%^1_EL(0&#*P#*P*LK ,K*>"K*00RD<%2""."#7W1^R/\
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MHUJN'K4L1AZM2C7H5(5J-:E.5.K2JTI*=.K3G%J4*E.<8SA.+4HR2:::3/\
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M;0O"::AJ-KI.JZ?;:MXHGU?3_"NBZKK-GXO-_P %-/ABOQ/\-V*6QD^$6I_
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M/X@]O04ZB@!I0'NW&>CN#R<\D,"1Z \ <# XI2H/KVZ$CIG&,$8ZGI^-+10
M4444 5;ZSM]1L[NPNT$EK>V\UK<1G^*&>-HY #S@[6.UNJG!'(%?"OB/0;OP
MUK-[H]X&+VLI$,Q!"W5J^6MKI">"LT6"V#\DJRQG#(17WI7F'Q-\#_\ "5Z8
MMY81I_;NFHQM<D)]MMB2\M@[D8#,29;1F(5+@;&*QS2, #X^HIS(\;,DBLCH
MS(Z.I5T=&*.CJ<%71@592 58$$ @TV@ HHHH *\Z^+O_ "3#Q[_V+&H_RBKT
M6O.OB[_R3#Q[_P!BQJ/\HJ^3X]_Y(7C7_LD>)?\ U2XTYL;_ +GB_P#L&K_^
MFIGY:MU/U/\ .DI6ZGZG^=)7^&9^0%JUN6MI PR4/#J/XE_^*7JI]1@Y4FND
M1UD19$.Y'&5/\P1V(/##J",5R-7[*[,#E7),+GYO5#T\P#Z8W@=5&<;AD_W_
M /0I^E5+PFSFCX;\>9A+_B&G$&-?]GYAB9MPX)SS&5$GC.>3:H\.YG6DEG%'
M2C@,5-9W2]BI9O\ 7_SCCOA#^V:$LTRZFO[5PU-*I2BM<PP\%I3LM\31BOW$
MOBJ07U=\W[GV?0T4<'!!!! ((Z$'D$>H(Y!]*]<^"OP@U_XT^-K+PKHXDMM/
MB\J]\3:V$#1:#H7G"*>[&\>7+?W!#VVDV9YNKS+.%M+:[EA_W(Q&-PN%PE7'
MXBO2IX.C1=>>(<DZ2HV4E-2C?G4TTJ:AS.HY1C!2E**?X5@,!C,SQN&R[ X>
MIB<;C*T,/A\/35YU*LW91ULHJ.LJDY.,*<(RG4E&$927U[^P5\(9M0UO4OC!
MK-J5T_14NM!\(&5<"ZUBY0PZYJL((^>+3;)VTJ&4 H;N]OT4B2S;'ZKU@>%?
M#&B^#/#NC^%?#EDFG:)H5C#IVG6D>3Y5O"/O2.<O-/-(7GN9Y"TEQ<2RSR,7
MD8G?K^4>*,^J\1YSB<RFI0HNU'!T9--T<)2NJ4':ZYYMRK5;-KVU6IROEL?W
MMP/PM1X/X<P634Y0J8B*>)S#$034<1F%=1>(J1NDW3ARPP]!RBI?5Z-+G7/S
M-_,7QV_:E\*? OQC\._AU=^ _B=\2?'_ ,4_#/Q8\6>"?"'PQT3PWJNJ:KI?
MP7T[PGJ_CE&G\4^+?!VD6=[!I?C#3KO2+:ZU2)M;FM[C1].:;7[K1=*U;PK0
MO^"F/P%\:RM'\-/#/Q9^)D=]XI^$G@/P9<^%/"WAZVM/B/X_^-OP3\&?M'?#
M[P9X,G\7>,O"R?VK=_!#Q;<_$3Q%J'B?_A&?#7@+1/!WBM?'6N^'M03P[8^(
M^Q_:6_9!U+]H7XY?L\_%.W^*?BOX9Z?\%_!G[1OA74)?A_?RZ'XYU)OCIH/P
MZT"*;1/$$MMJ>E:=!IEGX.U1+U=1T;4+@3ZIIVKZ#-I6OZ)IVJ6L.G?\$\_V
M>O#7A_5M!\ P>-/APS_$WX3_ !=\$ZSX-\4FTUGX4>./@O\  ;P1^S5X&OOA
M[-JVFZS8PV$/P=\#6OA+7M%\7Z?XQTGQ99Z_XMC\26FI0:_<6\7SQ]<<!=_\
M%,?A'J=SX.TGP-X!^)?BG5=?\5_!GP5XN;5-.T#P9H_P7\7_ !H_:'\6?LQ>
M&?"WQ7N=9UZ;7[?Q+:_%WX>?$+PGJ6F?#GPM\24TS4_#$4NK7NEZ!XC\/^(;
M["\2?\%9?V=O"?P@L?CYXB\)?%30/@[?P?$*_B\=^)A\(/!VFRZ-\*M;O?#?
MQ!U32K+QK\8O#FM>+;GP[K6DZU9IX1\$Z7XE\?\ B.'2KC5O"/A+7]#N-*U3
M4_+=;_X)I>/O"OQY\*?$CX)>/_#^AZ;X4T[P=8^"O%OBW4-5USQU\.+I?'?B
M_P"(OQH\0ZQH/B'P9XZTOXX>*OCIXQ^(/COQ'XH\07'C7X*7EC>>)Y;,_P!I
M0Z1H]U:>Y7/_  2U_9N;P:G@/3-4^+/AWPY>_!GXN?L]>+X- \?"SNO'GP7^
M,OC;Q?\ $/Q1X"\27]QH=Y=VEC;>+?&^N:GIFK^#YO"?B5X7M]'US6M<T*'^
MS6 -B;_@I'\'KCQE<^!O#'P]^-?C?6Y?B)\6_@_X4/A;PWX*FL?'_P 6?@SX
M#L/BMXI\ >$[W6/B'HL<>IW_ ,*[NZ^(/AS7O%*^&?!&J:-H^KZ/)XJL_&<%
MOX7N]3X4?\%#O@/\=OB)X(^'OPRTGQ[XKC\<>#OAGX]TWQ6FE^$[#1['0?BO
M\+=/^,?@C4[WPIJ_C6R^+%UHEUX1U/34U'QWH'PUUSX=>&O%,T_@W7?&6G>*
M=*UK3=-Z+P9^P5\"O OBKP?XPT3_ (30ZOX(^-_Q(^/^B_;/$D-Q:'Q[\4_@
M=<_L_>*/MENFDP"?0SX!NI3INE(\)LM<V:G]JFC46=<MX0_X)Q_ WP=;_L_Z
M):^)/B[K/@?]FJ#X03_#'X?>)O'D.N>&-)\2_ SPM9^$?A[XMMY[GP^OBO0=
M1M--L+:Y\0>'O!/BCPE\._&FL->ZSXO\$:U?ZGJLM\ ?3.B_$SQ;XJ^#MM\1
M_#_P:\>:+XPU33)KC2?@_P#$^[\+^!?&=KJ8U:;2+73O%E_8ZWXQ\/>'XI!$
MNL7-[8ZCXDFBT*5+BTT[4M6>+19?C/X&?MM?$#XF?L3?!KXUZYX3\#G]HGXY
MW_B_P+X#^&OAB[\0)X'U7XDZ!XS\?^'I9(]1UB63Q!!\/O"'AOP-JGQ!\>>(
M;XVE]9^#M!UR]@LK35;K2M$;[&T;X.W^@_!>W^$&G_&3XSR:A9Z5-IMK\8M9
M\2^'/$_QDCFEU>;5DU>?Q%XH\':SX:U+5;83?V9;R:MX-O[)=)B@M);&5HA-
M7S=\*/\ @F[^S?\ #WX2:-\$?'.DW7[2WP]\(:OKNM?#K2OVFO#GPG^*$WPT
MNO%4^L7OBD>"+V'X8^')]./B+4=?U6^U6ZOSJNHR-<K807T&CVMIIL !D>#O
MVK/BWX[_ .":WP@_:WT+PWX9E^,7Q1_9Z^"/Q.FT31O WQ!\<^$-'\3?%&Q\
M%/KU_I_PY\*:S=?$KQ)X:\+_ /"2ZGKD/A/3/$;^)K_3=)&F-X@2Y:75$\XE
M_;0^-/A_P3?ZO<VOA_XB:W\.O%'C"/XU"#]G?XL_ _4? =EHVE?#OQ-X2\"^
M(/AUXJ^*?Q*UGPC<^// OB;Q?X[T7X[ZIXJU;X5_V?X2@T)M'.N:KY-O[W\+
MOV!_A#\%OA9X5^"?PM\6?&/P#\*O!/P0\+_!7PQX)\%?$6Y\%:3I,OA7Q2_C
M&V^+ML_@_3-!OE^-FLZT8V\6>./M?V;Q991OIOB#0+^QO=3M[[N/#_[(WPYT
MG1]8T_6M>\?^.]6\7_$OP3\5/B1XM\:>([/4/$?Q-\0?#B/2(_!&E>,/[+T3
M1= 3P7X>_P"$<\.O9^"/"V@>&/#+R:0'N].N3K'B3^VP#O?@)\58OC%X"3QB
M-0\,3W<VMZW;WFC>&M3@U2;PA"U_+>Z!X5\62V]]?1VWCO3/"MYH,GC*QC>.
MVL=?NKVTL8WL8+>XG]JKP_X(?L^_#WX :7K>D^ HM8%OKEWHSS2:WJKZM<VF
MD>%O#FF^#_!WAJQG:"W9-#\)>%M(T_0]'6Z%WJLMM ;G6M5U?4Y[B_E]PH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /%OB/\,5UYI-;T".*'6,%KRT
M)6*'5,+Q(K<)#J P%$C[8KH86=HY%68_+L\$UM-);W$4L$\+F.:":-HIHI%X
M9)(W"NCJ>JL >A&003^A=<-XN\ :'XOC,EU&;/4T7;!JMJJBX4 ?+'<(<)>0
M @8BF(>,9$$T!8D@'Q117?\ B7X:^*/#9DFDLSJ6GIEO[0TU7GC1!SNN;?!N
M;4@$;BZ/ ISBX8 FN ]QR,XR.1GT^OJ.HH *\Z^+O_),/'O_ &+&H_RBKT6O
M.OB[_P DP\>_]BQJ/\HJ^3X]_P"2%XU_[)'B7_U2XTYL;_N>+_[!J_\ Z:F?
MEJW4_4_SI*5NI^I_G25_AF?D 45J:-H>L^(M4M=$\/Z3J6N:Q>R"*STK2;*X
MU#4;F1N0L5I:QRS-QEF<H(T4%Y'5 6'Z ?!3]@+Q?XCFM-<^+]RW@[0 T<__
M  BUA<0W'BO4X^'\B^O(&FL/#<,BLOF>7)J.K;?,C$6FSA9E^XX)\..-/$/'
MPP'">18S,?WBIXC'^SE0RK 7Y7*>.S.JHX3#<D)>T5*51XFK%<N&H5JKC3EU
MX3 8O'3Y,-1G4UM*=K4X;:SJ.T8V3O:_,U\,6]#Y:^"7PC\<_&CQ%_PC7A2Q
M!M;14FUCQ#?++'HOAZU=PNZ^N41C/<R@EK'2K;=?W;*Q58+19KN#]W?A!\(/
M"?P9\)V_ACPQ;EY7*7.MZW<I&-4\0:H(PDE_?R(,*JC,=E91G[+IUKBWMP29
M99NJ\&^"_"OP]T"R\+^#M$LM T/3TQ!8V,)1&D*JLMW=3-OFO;^XV![O4+V:
M>]NI/WEQ/(W-=57^R_AIA.,^$?#'AGP]XHXLK<3KA^E*E1KNFZ=/#X6\7@LG
MI5Y_[7C<OR6">&RRIC7[6GA^2E3I8;#4<)A,+]1P_P "Y'D.98O.Z6%I2SG'
M1M7Q27[NCS+]]]4IO2C+$.TL35BE4KR3E+E4YQD4445]2?:A1110 4444 %%
M .>?Y@C]#S10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7):QX%\*:Z[2ZCHMH]PX(-U 'LKHDG.YI[1X7D8'HTF\CIR.
M*ZVB@#Q"^^!F@S,S6&K:K8[@-J2K:WT2-GGEXX)V4C@ S;@>=QZ5YYXT_9GN
MO%/A7Q#X<@\806;:WIL^FI=RZ'),MNMPT8,SQ)JD9E*(I(C#QAWP"Z+EA]94
M5QYA@,+FF7X[+,=3=;!9E@\5E^,I*<Z;JX7&T*F&Q%-5*4H5:;G1JSBJE.<*
MD&^:$HR2:F<(U(3IS5X5(RA)7:O&2<9*ZLU=-JZ::Z'Y9V/_  33B$^[5/B_
M.]L&0F/3?!4,%PZ[B9%$U[XBO(HF*X$;FWE56)+QN!MKVKPG_P $_P#X%Z"\
M4^NGQ7XUF5MSQ:WK?]G:>V""H-CX;M](:1>/F6>[G5N>,?+7W%17Y%E'T=_!
MC):L:^$X"RJO4C+F7]K5\RSVE>]_]WSK&X_#:?\ 7G8\NED>547S0P5.36O[
MV52LO_ :LYQ_ \C\/> ?!?PLU;1;?P5X6T/POH^LV]SH-[#HUA:V/G7\1DU?
M1[B\G1#=7<CB+5K,S7<\SO)<6D9?B-:]<&,<=.V.F*R]9TM=7L6M//:UE6>S
MO+6Z2-)'M;RPNX;VTG"/@.$G@021[D\V%I(BZAR0EO!K*3HUUJ6GS6X+%X8-
M(FMI&!5MJI.^K7(0*Q4DM#(652O!;>/V#!X+!Y=AJ."R_"8; X/#P5/#X3!T
M*6&PU"FMH4:%&$*5."Z1A&*78]2,(0BH0C&$8JT8QBHQ2[**227DD?S?_M@:
MQ\76_:S_ &_O$.@W'BZTT#X8> /V&O#WAWXUP_M0?&/X=Z9^QU/\7;3X@:'X
M@^/%E\"_!\<W@GXH>%O -U<Z9\3OB?INOWVCP:_X>\-76F:[#?\ A^'49K?W
MCPU_P4>_:>UW4OV@I!X&^#_A.W\#^&?VM)/#^D_%_P <?"'P3#\--<_9W^(I
M\!^!]3^)=UX=_:.\5_%'4="\<P+!K'CN[\4_!/X(>&_!EUXD\*+I?BR7PG=_
M\)/?_K!\9_B[\$/@MITFH?$R]T"TD\>>(/AAX N]'33],U7Q%XF?XH_$[PC\
M#_"/V_0$!U76?#,/C#XDZ%I&L:C<6UYI.@Z;J5W/>&.V6:*2_P"!/'7PF\5#
M0/$-E9:)X3\6_%W0WN;7P_XGM/#GASXC^)M)\-FYT][>_P!&%W-K.M6^A6Z2
MH84EU2TTNRG0;K>&4I724?B]XI_X*@_M :39:%X/\-VO@O7_ !5IVJ_&U_'7
MQ$USPM\#?!GA'1KOX;>!O@IX]\$?#"?5->_;MT_X#^(/$GB[0/BQ?^+/%7B?
MX5?M%>.]3\.^"?"FH10_#*Q\36WB3_A%^Y\:_P#!3KXM:#\</A]X9T[0_!EQ
MH'B#XM_"OX!_$'P"UGX/.L?#3QQ\3/@/I7Q$O]3M_%;_ !T'Q ^(]AX0\:Z[
MHUM;^*?#W[/^D?"3Q=X0O1#HOCBYU%O^$EA_7N&#X'Q^%]8TB&'X6Q^#?AMK
M,ESKNF11^#D\,^!-?TAUUJ6?5K%%&D>%-8TN2==5DEOH=.U"Q>87[M"THF;8
MB_X5;K=[<>*(?^$#U74+BW\*077B&/\ X1N_O9K74)8;_P %03ZNOGW$MO>S
M:I;WOA:*2Y:*ZEU&"ZT99'O(Y)0#\C_@#^W5\?\ XF_\,T7'Q&^('[.?PKN/
MBM^SO^Q3^T;+X?\ $OA#Q+9/\89?VN?$5SH.K?"+X,7R_$JXU9-4^$<&F:=;
M7GBK_A&_%MQKWCCXF>#+;6_"G@[P;:F]UW+_ ."97[1WQRNHOV7_ (3_ !-\
M5Z9\1?#7QS^$G[<OQ&T+6]4MO$MY\2?#.J_LX?M@:)X'M;?Q-XXUSQQK]OXW
ML?%7A3XRZ9;6]G;^'?#B^"_^$)T_3-/O=;T^]>6#]>(=7^#MS;:;J=OJ?PWG
MM/A]JU[X7TB_AO?"DEOX*UNPTZ2RU+P_IUW'*8?#6JV>DV\EI?Z1:26%[;:=
M \%S;1VD11;$.M_"?0](TCQ/!JWP^TG0X--U*70M?BO_  OI^E1:1JVM:3;Z
MM)I6K)-!91Z=J7B"\T.'4'LKE;6]UBZTJ.Z,U]/9JX!^%7[0W_!67XQ_"CQ3
M\89? =E\/O'GA73/"G_!06Q\&1ZIX<T#PQ=>#/B!^QK\%/C3\3M 3Q3HUI\>
MO%/Q=U;3-=\1?!O6_!_B:X\;?"+X/:7KD-S8^(O -S_9%QHMQXH]O7]N[X_:
M7^T-<?LT>-_%GP&\!_8?B)X!O]8_:)\2^"M;TWX;:)X2\=? *]^-F@_!^X\-
M:G\7M($OQ'\2:OH7B?0O#?C"^\;Z39ZKX,\+^(]1@\'OXGLDQ]_?M-?&W]F'
M]E?P5JOQ2^.O_",Z+IWB;5M.T>Y2V\'0>*/%OC75-3CA\')##H&DZ7?:[XCB
MT_1]>>UU_4[B&72_#/A"?4KSQ#?Z9X;COI1<^)WQP_9N\#?&'X1_ 3QS+H-W
M\5_VA?$<.G>#O",/A)?$5W>77@OPIXY\>Z+KWC"XMM,NK'PMI%IIWPR\7+X*
MUOQ7=6*ZGKN@WNE^#_MFH:=J2V !XY_P2G\5>+?''_!.S]D3Q=X\\1:WXL\8
M^(/@QX=U/Q%XC\1ZKJNN:UK&J7%SJ)N;W4-5UV>ZUB]ED("K+J<\MZ(5BCN&
M\Q"!^@U>!_%7XW^!O@.GA'P[+X6\=^)M=\5Q^(+KPOX"^$7PXUWQSXCN=$\*
M)I][XO\ $ T3PU9BVT[0O#RZYI(O[R\N+1KW5M;T?0=%@UCQ+K>F:3>>;Z9^
MW?\ LU:[;6VJZ#XWN=:\-:EX$M/'>B>*K#P_K+:#K\>H^!M&^)FG>$M&FN;6
MVO[WX@:AX#\1^'_$5EX+_LZ+6+B/6+328XSXB%SHUN ?8E%10R&:&*4QR0F2
M-':&8()8F=0QBD$;R()(R2D@21U#JP5V #&6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R&_:)_8
M0^*?Q-^-GQ \8>'M'^"7B31_B1^T3^P=\>[3XE>/=1UJS^*7PCT;]D;XI_!+
MQ/XH^$'@?3[3P-K\5]X<\7Z9\,_$WBKPSJ4?C7PY;:7XR^)/CJTUCP_=V^IQ
MZK<^#_"S_@FC^T3\,K#]FRTTA_@E:>+_  #X+^ ?A;X@_$NYUZ'QM86:?!OX
MJ>-_%\G]C_"[XA? +Q1)>ZQI'AGQQKX^%OCCX6_$[]GOQ3IGC/7'U#QQ<:[9
M>&=*FU/]\:* /Q4\,?\ !/SXPZ#\%/ ?P_;P'^S+'KOP3UO]F">=]/U;Q+'#
M^VA8_L^>(?&.KZU>_M&:O-\-A#X6N/&EYXHA^)6DV#>&/BO>:/\ &NWU'7-?
M\3:]H%U:I$[P;_P3:^+F@W4=A9>-/ GP\\(?%?\ X7-XP^,NA>!)]8F7X6^/
M+;XA_%KX@_LBZ5\#8O\ A'/#-GJWAKX'W_QNU-M1O=8M?!8N=2^$WPYN]!\/
MV.G3QZ7X;_:FB@#\!_AQ_P $LOC!HO@_X9^&?%<W@*\7P9\:_P!AS5/%5CJG
MQ&@\6^&O&/PM_94U;Q_=^)I[3PUX:_9N^#6C6&L>++;QA%!8Z-XJLO''B'7-
M/$^B^./B5=Z98Z;;GZ*^'_[/WB;5;W]K*\T;X1?#;XK?#S2OB9=^"?V:/A-^
MT'X>\2_#KX>R^'O%?Q,\(?&[]H^XU.S\0_#;Q5+=>'K/XZ/K-_\ "O7=-^'M
M[HFM2?#+PBF@7@\/'2_%\?ZW48Q^/)_S_GCB@#\_O^"DWP;^.O[0W[,/C3X&
M_ ;PA\-]=\1?$N&QTC4]=^(_Q)U7X>:9X2T[2O%/ACQ:E_;_ -C?#;XAWWB&
M35)O#O\ 9MQIJ1:,MLTL%\]W=K%Y \__ &CO W[9OQ/\<_L6>/?!_P !_@6M
MQ\ _BW-\>_B'I6N_M,Z_I4EUKNH_!+]HGX'3?#GPWJ5E^SGJZZQ::7;?%_1?
M%]OXTU&WT5+I;36?#Z^&K686^JW7Z@T4 ?GQ^T;;_M^^,_# \'?";P=\&_#&
MFZW\1/B%I'BOQ=H/[0GB;PI\3K7X(6,6GQ_#R]^'^L:I^SYXJT/P;\5?'S7.
MJ0>-]2FT[7X?A'IVGK/\/]2\7>*-9TWQ'X.X'Q=^Q=K_ (@\.?!4_#_X;_"W
MX%WWPA^&/@2"Q\/>%/&>L:UJ \3^!M8\*:9X?^&VG_$Q_!6F:S;>%_#7PVTO
MQ9I&C?$\Z0/&1\;:OX"\82:;&?AK;6NJ_J+10!YO\']"\<^&/AAX$\/_ !+\
M2Q>+_'FD>&=+L/%7B.%'$>J:Q;P!+F<2RQ6\UZT8V6\FISVUK<:M) ^J7%I:
M3WDEO'Z1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-2016331_rdpiechart16.jpg
<TEXT>
begin 644 biib-2016331_rdpiechart16.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MP7\(+/7K.]B<7<>N:_J,9/V.ULP/)+7_ () ? N'X?V?A:Y_X5S>Z_X8\;>
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M"7[7G[+'P*/@_P 7?#_P=\8?B#XZ\(#Q!X#_ &@=3U:]\/?%N[\-?$_3M?\
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M^.7[0UC\!?"-U+I?B+Q'=2V&D:'J>OZ+?^+5_MK4[^VL[75Y=+M]1NEM;"4
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MXZL?C'\0]%\?KH4=_K'B'PG\.-,\)>"++44OK]+%?&OC_3-7BN$UR:W;R_\
M9)L_BQ\._CIIEEJ'PO\ $]YX,^+L'B;Q%H7BCQ/X<U;1M0\!?#CQ9KWQK^)=
MU/;Z?:64'A3X9I?_ !&TOPYJ7BGX4720>)T7X[?#+2;=W@^#VMOJ(!^NEQ*\
M$+RI;SW;H!BWMS")Y<L%PAN)K>'(!+'S)D&U3@EL*<J#7%DU&VTRXT[4=/N+
MRWO+BV-VMB\4J6#6@N5WV5_>&-U%["RB5$60%]CED*UN5R&KDIXL\).IY>#Q
M+;D$ @QO96%P<=PPDM8L'D;=ZD?," #KZ*** "BBB@ HHH)P"?3F@ HI,CCG
M[W3MGC/?^77\C2T %%("#T]Q^1P?R/!].AYHR,X[G_/X>V>O..E "T44@((R
M.A]P>^.H)% "T444 %%("",@C\P>^.Q(ZT$@=?I^?^>3T R3@ F@!:*** "B
MBB@ HHHH **** "BBB@ HHHH 0@'J/\ /^![CH>AXK%\1^&?#?C'P_K7A/Q=
MX?T3Q5X6\2:7?:)XA\->)-*L=<\/Z]HNIV[VFI:/K6C:G!=:=JFEZA:R26U[
MI]];3VEU;N\,\,D;%3MT4 -"(JA5554  !1M   4 8Q@!0% ' 4!>G%+@?3I
MT)'3ICT'MT/>EHH ;M7T'M[>@7^Z!@8 Q@\CFC:OH/3IU'/!]1DDX.>3GKS3
MJ* "DVCL,=.F0<#H,CG YP.G)XY-+10 4F!QP..GZ_XG\SZFL_4]7TO1;9KO
M5;^VL+=029+F58]Q&!MC0GS)7)(PD2NY)P%Y%>1ZO\<-!M7>+2-.OM6*Y GD
M*Z=:,<\%#*LMTRXYR;5 <\>H /;:Y#6P5\3>#9.JM<:];\=0\NBRSJ2#_#ML
MY <$D,R<8)*_/]]\;/%EP7%G;:1IR'[A6WFNYD />6XG$3$C@DVP]@"<C\Y?
MVZ/VM?V@?A)X4UGQ+X"\;VNBZGH/P^UOQ)HD\GA7PQJ@LM;BN;G2GO'AU72;
MN"Y4V-R84MKA);=3F4QB7#5VY;@:V:9C@,LP\J<,1F.-PF H3K.4:,:V,Q%/
M#TI590A4G&G&=2+J2A3G)03<82=HOCS#&TLMP&.S&O&I*AE^#Q6.K1I*,JLJ
M.$H5,14C2C.4(2J2A3DH*4X1<FE*<5>2_<FBOX?M(_X+3_\ !0W2[Z.ZN_BS
MX2\1P1R1L^F:]\)? 2V,R1R!VB=_#^F>']119E!BD>+4(Y!&<Q-%)^\K[#^%
MO_!PI\8])GB@^,OP%^'_ (UL=S"34/AUK^N^ M7C1W9@PTSQ"?&VDWCQ*VU4
M^WZ4LH1=\B,6>OW',?HV>)6"I.IAJ>1YO)*_LLNS1TZKVT7]J8;+*<GY*IKT
MN]%^+Y?](?P[QM2-/$5,YRI2:7M<PRSGIINVK_LS$9E44?-P275I7:_J^HK\
MI_V=?^"Q_P"QA\>[G3- U3Q=J7P3\;:G/!9VWAOXO6MMH6G7M[.TBI!IGCFP
MNM1\%7!D*HL,>H:QH]Y+)*D269D(6OU0M;NUO;:"\L[B"ZM;J&*YM;FVECGM
M[FWF19(9[>>)GBGAE1U>*:)WCD5E9'*D&OQS/>&L_P"&<5]3S_)\?E.(=W3A
MC<-4I0K1B[.>&K-.CB:5]/:X>I5IM[29^M9)Q%D7$>&6,R+-L#FF'T4Y8/$4
MZLJ,FKJ&(I)^UP]6VOLJ\*=1+5QL6*^1_P!OS3IM7_8;_;$TFWTVYUF75OV8
M/CMI8T:SAN;BZUA=1^&?B2SDTF""S#7<TFIQ3/9+%;*;B0S[(09"M?0.CWFJ
M>)YM1U6VU2?3M ^T&QT%;.WTZ2348K%Y8;[69I;ZTOF-O>WOF0:7'#Y4;6-F
ME^3+_:""'9U/4[/PIX>UC7==U*]GTW0M-U+6M3OGLFNKJ'3=-M)KZ\>*PT'3
MOM5VUO:V\KQ6UA87-_<L!#;PW%P\43>(>T?S;^/K+XP:+X]_8V\$^)?!_P 6
M/$6F_P#!-C]LW1OA+X5O=-\*:SJ=Y\7=/U#X!?M'>*/ GC/15@O+6V\>7UA^
MR_!\$_ \UU)?PV-Y\7OB/XV\)76M6&M:?-/%L^!OVU?VX/$_C#P?X(T7QSK&
MJ>#?B1XD_84N+'XIQ>$_"GC?7O"5I\;?BM\5?AQ^T%X&OFMOV9O@YX T#Q-X
M!T;1O!^K7WA9]-^*<OPF\8)):>*/B)XKTN\N?#Q_7#X=_MDR_&SX.>-OBO\
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MRC'XK+L=0DG2Q.$JRI5$KIN$N5\M2E.R52C44Z56-X5(2BVG_>Q^P[_P4*^
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M+YQQ7PE>WMSJ-Y=7]Y(9KN]GEN;B0DDO-,Q=B,]%7(1%Z)&J(.%% %6BBB@
MHHHH *_.[_@II%N_9I\4S[L>7H_BB()C[QGTNU?=G/&T6^,8.=^<C&#^B-?
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MIOA/XA:7J^@^&OBWX;7PW'I_@GXG0:=J5_X>T'Q!XPT0Z1?VOB!WM?GC2_\
M@DG\(K?X36WP9UOQ_P",/$?@MOB]\ OBCK5I?:?I5M/KUC\#/V/?AI^QNG@V
M[N;*:.>WT[QEX'^',.OZQJ]I+'J^GZ[K-XFF.+:VM7H ^A/@A^V_X"_: _:#
M\3_!GX=^'=>F\+Z+^SG\*?V@=.^(/B/0/&O@2Y\1Z;\5?B/\5O NC6>F^"/'
MO@KPQK%QX;N=.^&L/BGP[XZM+F\T;Q5I_B"./384CT][JYX#Q%_P4U^ .C_&
M'P#X"TZ[NM3^'OB?P-^TEXRUWXQ7.B^.]&\+VDG[/7BCX.^!I-/^&PO? WV+
MXZ0^,?&OQ8'@O2-2^%>L^($F\7Z1:>&M"M_$FJ^(].MU]&_9]_8]OO@Q\4;[
MXN>*/C/XL^+/BR;X!_#/]G"QDU_PQX/\,VUE\//A#XQ\=>*_!=Q)!X4L[..]
M\4W!\>:E#XLUB1(K36[V..^TS2?#ECY&BVOR]XK_ ."0WPU\=:%X'\!>,/BO
MXOU[X6?!CPE\2O _P'^'VH>#_A[>Z9\._#GCOX@_"+XJ:+:ZQ<:AHU['\2V\
M!>,?@QX0LM%@\::==:1K?@6VD\*^+M)UN_O-7\3:L ?:>C_MF_LZZQ!K[P^,
MM2TV_P#"OA#7?&OB3P[XA\!?$#PMXNT/3/"_B#3?"NOZ9JG@_P 1>%M,\36?
MB_3-9UWPO;R^"9M*7Q;+:>,O ^K6>CW.C^-?"U_JWBWQP_X*/_!CX;_"WXH>
M/? $5]\4-<^'(L)[/P_<:7XS\!^'_'^E1?&CP1\$?&.N?#?XB:[X*G\*_$30
M? GBWQOI^G^)-;^']QXKTFPU:72M+O+RT77M,OI:?A;_ ()Q?#?PS:_!B2QU
M[3_#.H?#'XRZ]\7/%%E\+/A7\,?A%X$^(UEXA@\*7M_\-=4\!>"]#MM.T_P.
MOC+X6_!3QPMQ<:AK_C*[U?X3^'K/5O%6I:7<7%K%XWI7_!'CX)>'?!'Q$^'G
MA77M+\):!XHT.U\*^%=9\-_!CX/Z1\2- \,K\:_ WQQNM.\7?%.R\.P>.?BC
M.NO> =#\/:==^(=6T^$^&[>WF\46/B_Q;8V?BF( ^N/$_P"WQ^RCX*G^(D/B
MSXER>'[+X7V'Q(U/Q1K^I>!?B';>#YX?@WKUEX7^+L/A+QE)X27PKX^U/X5Z
MYJ%MIGQ&TGP-J_B'5/!MRFH1ZY:VBZ/K+:?5UO\ X* _LL>'#>VVN>,_%>FZ
M[I>K_$'0K[P;<_!KXSI\0;+4?A;X.\,_$;QE'-\/A\/SXU2WL/AOXS\.?$73
MKU="-CX@\ ZFOB[P_<:EH=O>W=M\;?M3_P#!+C7/B5\#?CE\/_AU\4;_ %5]
M3\/_ +3UW^SE\/\ Q=9^&_#OACX5?$']K3Q)J/B3XI:U?>-M%\/W_B+Q%:6<
M_B?QQ9> +?6],O(/"FE>+M3LM7@\93VGAV_T'V^Y_P""<NB:_P#%6\^-_C7X
MP^+?%'Q,UF^^.$GB;7?^$7\*:)9ZQIWQ4^!WAK]GKPSI%MI&DP6]KIEK\._
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MCP/I_A[XN_&7X0W>D?$[P1XC\#ZW/K'P:^)GB?X::OJEG9^(M*TM[S3=0O\
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M[3_B9I)=T=PGPL^'^IA80N%<0>*O'D2>8[')2?3?",*( &4>)7)*K^TWP_\
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M+\PK9=B*V!Q-#'/'8/$8:<J52E'&1CBHJG.+3Y8JO*C*.L)QC*$DXMQ/T2\
M_$[P]X^MPEF_]GZW#%YEYH5U(IN4"\//8RX1=0LP>?-A42PC N8(3@MZ-7Y7
M6US<V5Q!>6<\UK=VTBS6]S;R/#/!,ARDL,L95XW4]&5@<9!R"0?K3X<?'N"\
M^SZ+X[DCM;H[8K;Q(J".UN&X5%UB&-0EG*<@'4(E6T<_-<Q6WS2M^+>+'T;<
MPR+ZSG_ -/$YMDT>>MB<@;GB,WRR'Q2E@9>]5S;!PU2IVEF5""ASK'I5L33_
M *%X \:<'FWL,IXLE1R_,WRTZ&:KEHY=CI:12Q2TAE^)GNYZ8&I+FY7A&Z5"
M?T[12*RNJNC*Z.JNCHP='1P&1T=25='4AE=2592"I((-+7\GM--IIIIV:>C3
M6Z:Z-'[ZFFKIW3U36S7<*^ROA!IS:?X'T^1\A]3GN]3*G/RI/+Y4&,@<-;V\
M+^AWYSS7R%INGW&JW]GIEHI>YO[F&TA !.'G<)O./X8P6E<G "(S'@&OO[3;
M&'3-/L=-M@1!86EO9PYZF.VB2%"W^T50%CSEB3FOUGPGRZ57,LQS24?W6%PL
M<)3D]G6Q52%27*^KITJ%IKHJT/Y@_7^OZ]!]ZF^TN4V>8'MYU*;0V\-#(NW:
M00V[.W:00<X/6OYA_P!ES_@G_P#M _$C]FW]CK5=7^$OASX0V=A\*?\ @G=I
MOQR\):SXCOM/\4_'X?"_]H#X2_%[XB^,OBYH&H>'-&UK3/%/@;X0^'?&_P -
M;3P[XN>_\4Z]/\2/&?@&[DM?!FEZ=<:__4%0!@8]..22?Q)Y/U/-?NX'\X?[
M2/[&7QN^'OPZ^-^N:9\/-/@NM*B_:VM=9^,WPAUO4KGXH?M#_#O]J/Q//X>^
M#'PP\7>#_"'@=O$/AKX9_LUZ+XI\)WWC*VN4\2>&/ W@'X Z+8_#K0-7\*>(
M-?T[P[D? C]D[QO\86\/^+/A;X!^&MMI/PXG_;LU46GBFWFL/V5-2^.7[0?P
MK_9\O_@QJ_P:\">&/#/A2[F^"?@GQIX*O1XNLK&U?7_"WQ(LO$OB?1=?U?Q3
M?6VKZ;_2F1D8/?\  _@1R#Z$<CM2*H48&?J26/YL2?UH _G6^'?_  34_:&3
MXK>#=<\3>&/".F_!.[^+7[(GCOQI\(=8\0_!R31X$^$G@+]MGX?_ !KED\&_
M!;X,?"7X9ZG9>.=/^+GP8LTTVXT/Q!K/C#PYI$D'C;Q!<MHL/A_2XO"'_!,C
MX^>&_A[X#T'5_"7A;6I8?V;O%GP_^+6E^'OBGH?AO5?'GB_P;^VU\+_C%^SW
M;:EK?BCX<?$?PIX^T_X:_ [PYXJ\+>$O"OQ4\&^)/A@^E7*_!KQ-8:?X UR\
MGL/Z+Z* /S@_94^!GQ&^&A^!UE\2?V?/@M]L\#VO[4UMX1^)?AJ_\':'XQ^!
M'P_^(WCOP-XE\*?#E?"_A'P;I?@S5_$?Q<M;6?4/B_>_""+X??##0-<^'GA^
M'0_"NIV>IVLNF\[\;_ W[0][^W[^SE\8/A_^SK8Z_P#"OX1^&?C;X4\8^.(O
MBG\._#6J>)[OX_:1\!-(B\3P>%;\Q:W>K\.;/X6:A8:Q'JDB:IJFGPZ1;^&_
MML 2VM_U!HH ^0M+\!_%3P7XY_;#^.]OX3T;X@_$/Q#9>'/#W[/?@N\\9V_A
MJTUOX?\ PQ^$^FZMX7\#ZIXNGT75X/  \8?'KQ7\6;S5]4?0]9CTRQU72-:O
M+/5DLK6TC^-?C]^Q-^U;\1OVE/@7^T!X6^+_ ,-&TS1OVK_@C\7/%/@KQ9\,
M=0U'7OA?\*OAK\$OBOX+O/A]X7\>6/Q8T:Q\9:(GB[XD>+M9BLE\#>'M6N_$
MWQ'U+Q;<ZM=Z?X5T_P .77[#T4 ?E9HW[)OQI^'?QQTCXD?!FW\'_#?PI?\
MCBV\)7WA>QU5=570O@KX*\5?"^VT./49]:M;^]U73?%OPX\-_%/2XO _AN]T
M>'P->:G^S]X?T>2T\-_".X>W_5,=/\_K[^M%% !1110 4444 %%%% !1110
M4444 %%%% %6^L[?4;.[L+M!):WMO-:W$9_BAGC:.0 \X.UCM;JIP1R!7PKX
MCT&[\-:S>Z/>!B]K*1#,00MU:OEK:Z0G@K-%@M@_)*LL9PR$5]Z5YA\3? __
M  E>F+>6$:?V[IJ,;7)"?;;8DO+8.Y& S$F6T9B%2X&QBL<TC  ^/J*<R/&S
M)(K(Z,R.CJ5='1BCHZG!5T8%64@%6!! (--H *\:^.'Q"_X0/P?.MC/Y?B+Q
M )M+T7:?WEJK(!J&K <$#3[>11;MT-_<6H (5\>PS30V\,MQ<2QP00123SSR
ML$BA@A1I9II6/"QQ1HTCMV16/:OR\^*WCR7XA>,;_64:0:3;?\2W0+=\KY.D
MV[N8IF3^&?4)6DO[@$DJTR19Q"H'\[_24\4_^(<<"5L+EN(]EQ3Q6L1E.2NG
M/EKX'#<D5FN<1LU*$L%AZT*&$J1:E3S'&8.M&-2G0K)>'G^8_4,$XTY6Q&)Y
MJ5*S]Z$;+VM56U7)%J,7TG*+5U%H\V_/\3D_B3R3ZD\D\GFBBBO\CS\S+VG/
MLND!Z2;H_P 6&5]?X@.<=^O(KHJY%&*.KCJC!AZ_*0WZXQCOGUKKLA@&'1@&
M'T8!A_.O]G?V9G&7]H>'_B!P)6J\U;AGBC!<0X2$Y>\L!Q3EWU.=*C%N_LL/
MCN&Z]>I9657,4W[U1W_#/%7 ^RS++<QBK1Q>$J8:;2WJ8.KSJ4GWE3Q<8KRI
M>04445_IF?E1Z]\.OB_KG@9HM/N1)K/AK=AM+EEQ/8!CEY=(N'W>01RQL9,V
M4S$X%M(QF'VWX;\4:'XNTU-5T"^CO;5L+,F/+NK.8C)MKZU8^;:SK_=<;)%_
M>022Q$.?S&KWK]G+P-X[\>_$G3M+\$WMQI$=MY%WXJUM466RTSPX+A4N3>VT
MH-OJ$UV0]MI6G2@M<7N9D:&&UNKF#^<O&+P*X9XMPN8<2Y95PO#/$=&E4Q6*
MQK@X93FKBN9_VK0HPE*GBJDO=CF.$ISQ-2=1K$X?'S=%4OVSPQ\3>(,HQV7\
M.5Z&)X@RS%UJ6$PF#@U/,<$YM1C]0JU91C/#TX7E/"8FI##TZ<.:E7P=.-64
MOU<^"/A5Y[VX\5W<1%O9B2RTK>"/,NY%*7ER@. 5MX6-JK#(,LTX!#0FOIJJ
M.FZ=9Z186FF:?"MO9V4"06\2\[40=68Y+N[$O([$M)(S.Q+,2;U?BO#.1T^'
MLGPV71<9UDG6Q=:*LJV+JI.K-72;A&T:5+F2E[*G#F]ZY_8C\M HHHKWP"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%OB/\ #%=>:36] CBAUC!:\M"5BAU3"\2*W"0Z@,!1(^V*Z&%G:.15F/R[
M/!-;326]Q%+!/"YCF@FC:*:*1>&22-PKHZGJK 'H1D$$_H77#^+O &A>+X_,
MNXVM-21=L.J6H5;D* ,17"G"7< P (YCOC&?(EA))(!^0O[2WQ!&C:'#X'TV
M?&I>(HA<:RT;8>U\/K(56V)'*R:Q<QF,@X)L;:XZK<+GX1ZU]>?M"?LV_'/P
MIXC\0^,=>T5O%^A7MU/>GQ+X0CN=2L;"PCVI:6^H:3L.L:+%86?D6^9+:XT]
M C.-1D)D<_(8P02"" 2I*D, PX*DC.&!X*G!!X(!K_'GZ0_$/%7$GB9G&,XG
MR?-<AI85O+>'LKS3#5<-.CD6#JU(X>M2YTZ5?Z]5G6S#$5\-4Q%!XC%U*5'$
M5*%*C;\OSROB:^859XBE5HJ/[NA3J1<6J,&U%KI+G;<W*+DN:32DXI!1117X
M:>.%=-9/YEK"2<E 8CGU0X'U^4C^=<S6UI3Y6:+T*2*/KE&_7:>O?I@BO[I_
M9Y\9_P"K7T@</D-:KR83CSAC/.'^24K4O[0P%.EQ-@:TKM)U?9Y'C,#0W?-F
M$H1^-I_GWB5@?K7#<\1%7GEV+P^)NE=^RJ2>$J1_PWQ%.I+RI7Z&M16EH^C:
MOX@U*VT;0=+U#6M7O7$=IIFE6=QJ%_<.V<"*TM8Y9F& 27*!%4%G95!(^[_@
MW^PIXK\036FM?%FX;PEH8,<W_",V$\-QXHU%.&\F]NX6EL?#\3J1YGER7^I[
M=\8BT^8+,O\ NAF^?93D5!U\SQE+#KEYJ='F4\37W25##Q;JU+O3F4?9P;O4
MG"-Y+\9X>X5S_BC$QPV2Y;7Q?OJ%7$\KIX+#;-RQ.+G:A2Y8OFY'-U9I6I4Z
MDVHOY4^$GP;\:_&?Q%_8/A*S58;;RY=:UZ^66/1="M7=5\V]N(T8S74@)-GI
M=MNO;PJS!8;9)KJ']$/VE=1E_8#_ & _VFOBQ\%K#1+WQ[\(/@=\0OB9I^J>
M+M'O-;L_$GC+POX:N]0L+WQ-I.C:AI.IZKIR7$*I%X>TK5;!Q9 :;IUS#/,]
MS+]R>$?!WACP'H5GX:\(Z-9:%HMBN(+*QBV*TA55ENKF5BT]Y>W!17NKZ[EG
MN[F0;YYI&YKD/CE\'/!'[0OP>^)GP-^)-MJ%YX!^+'@KQ#X!\7VVDZK=:'JD
MWA_Q-I\VFZDNG:Q8E;S2[X6\S-:WUL1-;3!)4RR@5_/'%_&^,XFG]6HQG@\I
MI3YJ>%YDZF(E'X:V+E'W925N:G1BW3HWT=2:]J_Z_P##SPRR[@JE]<KSAF.?
MUZ?)7QW):CA832Y\-E\)KGA!_#5Q$[5L0E=QHTY>PC\.Z3^UYXB^#/PAE^)W
MQD\7:G\7;3Q+\0Y?!7A=M7^ \/[!%QX?N-(\.W.L:G;ZSI7[6WQ:\+76N1:J
M+:1O#M_I&ZZU>[#Z?I6DWUI9:QK&E>6^*_\ @JSX>^('P^T[Q/\ LN^#-?\
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M;1]'GF\6WECX<TC3KV'Q;K\%]+J=Q^[E>5F^19)Q!A'@,^RC+,ZP3?,\)FV
MPN88;FM93]ABZ5:FII;345)=&C.K1HUX\E:E3JP_EJPC./K:2:OYV/S6\;?\
M$]?AL+O2T\*^,?&6A/K6JQ:=%;ZA_9/B&SLP+/4-2NIE\ZUT[49U2UT]TCCD
MU%F#L'>21<J.,F_X)IWXW&#XP6;?O%"";P/,O[HR@,6,7BEOWBQ%F 5 C2
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MM]1A^-OA_P ->(+E/#%GHOPX>Z^'7PP&L6]AJ_V/@=>XZ')R/H>HSWQU[T
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MGP@NI+S]=0H'0#N1[$]2/3.3G'7O1@<<=.G^?S_,^IH 6BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-2016331_reserves.jpg
<TEXT>
begin 644 biib-2016331_reserves.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &^ 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ 'PN\5V>B_#G4;GXH?'SX;_  -BU?XN_%"3X/\
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M<_,S?]],6(_ G%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]K3QE\,-/3X(Z+?_ +2$?P6\!?LTV,_B/7=.;]KCQGI\'B;PO8W]A9:W=PV
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MWO+^[\-R:SJ&IWUS_(WK/B[XA>)/V-=!^ -]X7^*NB^-;GX6_#%O%&ARZ?\
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M4 &3@#)V@[@N3M#?W@N<!N!\P&>!SP*5F9V+.S.S'+,S%F8],LS$DG  R2>
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MZ_IK[Q:*3(]1^8HR/4?F*+/L_P"O^'7WBNNZ_K_AU]XM%)D>H_,4M(84444
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M<.JFL(V=13<=5&RE*_TC_P -:?M$?]%1U[_P&T/_ .5%'_#6G[1'_14=>_\
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MB@ HHHH **** "HI_P#43_\ 7";_ -%/4M13_P"HG_ZX3?\ HIZ /Z??"?\
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M9X5U*SU'6-.TBU>Y6R3Q!=:9^N0Z#].<\=N><G&,G)YH _$'_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_$/_@I/_RDD_X(4_\ 9UO[4'_K
M'/Q!K]O(_P#5Q_[B_P#H(H _G,_:&_Y+O\8O^RC>*/\ TX/7CM>Q?M#?\EW^
M,7_91O%'_IP>O': "G*I=T0=7=$7K]YV"C. 6(R1D*&;T4G +:/KG'L=K?\
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M **** "BBB@ HHHH *BG_P!1/_UPF_\ 13U+44_^HG_ZX3?^BGH _I]\)_\
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M/)]/7IQZ=/7CGFOPW\.ZS^T(/VB_$7C+P+\,?VH?AQ\//C#\9_!GCGQ/X/\
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M(</F694Z.=YI"FL=BHQA]=Q$HPC3Q%50C34YR]G&*TY8<JLDFFDD@^!/@_\
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MP<#LKN/B'X6#NB&)'<7J!W2(LYB1WRR1;W\I2(][[=[?T:KT'T'\J_+?X8?
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M\SHO'S.BY8,H(!!! 8$$,K E64\%6 *G:PR#AE."<$'!'G@MU?;J?F]^R_\
MMH_$_P"/7CK]ICPE=_"[P')KWPC\1^'M,\*_!CP_\1+KPO\ M!:-+K?A;X87
M<7AOXK^$?BMX=\(Z=8PC7O&6OQ:I\5]"N6\$Z+>>&M7\.Z1IOC.#_A$O$?B_
MTGX+_'[XX?'S]F3]GWXS^#? WP<\)^)?BSH'B7Q+\1M2\>^-/%+?"3X/:1X5
MU+Q7IUW=AM-@TOQUXVM]2N_#T=K:7WF>%M.T+35UKQAXLN],L+"RT'43P#^Q
M/HGPX\??$[XI^'OC9\;I_B-XPDDM/AUXV\5:WX9\?Z_\#_#NH>%?@MX7U_1O
M"7_">^&?$>E>,[WQ!:_ GP-9WOB7XI:9XPUJ+PWI&DZ!%(U[I]]XCUWAK'_@
MGI8Z?\!_A_\ LXQ_M1?M"W7PO^'/B1M<TO0M2T+]G+4;'Q)HZS:EJEIX ^(^
MC7/P.;0/B+X"LO%NKWWC9/#WBK2[^#4?$(L(/$!UKP]I5AH<7T->>2U*EZ"H
MT(^TP37M*.-JN%..$K0Q<5&,^2K;$2P]2GS^S<ZL*L:KJT(J>(K3>RZJU_))
M;^NKO?=Z6.(L?V[/B#XDL?AEXO&C?#3X/^ ?$/P9^'?Q;\=:S\1/A[^T?\4=
M,T?3?&/Q%^)/@^^U^Q\??"G3]"\'>"/A4=$\ :;XJ\+?$3XKVFCQ:EHOQ \+
MZYK>G:-H]MJIB^W/V@/B#XH^%_@F3Q;X=NOA;H6DZ;J@'C+QQ\8=2\9CP?X$
M\.-')#;:M+X>^&^EW_B[QKJFJ:]/H_A^TTG2+[0+2R34;GQ!?ZM)::>FF:AQ
M_BW]FN\\?^'!X4\:_M!_'_6_#^N^#/\ A ?BIHMKK'PY\/:)\7?#C3ZP+I-;
MT;0_AM:V/P]U36=&UJY\(^)]:^"2_#34?%'@^&RT;5Y9;FQL]4M^OU?X0^);
MZ\U#5M%_:#^.W@S6QX]U?QIX2U#POJ_@)+#P%HVL^%]#\,3_  NT?PIK?P_U
MKPCXC^&M@-%?Q%X?L?'VB^*O%?ASQ7K&JZMHOB^SMY(=/BYZM3+)UJ$Z5.G2
MA&=5U:,G6G2Y'[-4HJK]75=M2]I+GJ+$)4U3E*G*7/A&76FSU[6OHM]4K;[6
MZZJZ:L_L\_%*_P#C=\#OA=\7=3\.VOA.^^(?A.V\2S:#8:S_ ,)#IEHEQ>W]
MI:W>D:RUII]U?:)KEG9V_B+0VU33=+UVUT?5[&P\1Z5IGB"TU2PM_9*\Y^$W
MPM\*_!?P!H?PX\&#5GT/1)_$.HF]U_4O[7U[6==\8>*=<\<>+_$>NZDMM907
M6L^)O%_B77O$&I-96&FZ9#=ZE+;:5I>F:9!:6%OZ-7F8ET98BO+#Q<<.ZU5T
M(N]XT74DZ47S2E*\8<J]Z4I::RD[MR%(WW7_ -Q__0#2TC?=?_<?_P! -82V
M?H_R''=>J_,_0S3?^0=8?]>5K_Z(CJ[5+3?^0=8?]>5K_P"B(ZNU_9E#^!1_
MZ]4__2(B*6I?\@Z__P"O*Z_]$25^>:_=3_<3_P! %?H9J7_(.O\ _KRNO_1$
ME?GFOW4_W$_] %?BWB[_ +QD/_7G,O\ TO!#Z/U7Y2%HHHK\=$%83>*/#*>*
M;7P,_B+0D\;7WAV\\7V7@YM7L%\4WGA/3]3M-%O_ !-:>'S<?VK<:!9:O?66
MEW6KQ6CV,%_=0VTDXE?:-P]#UZ'H<'\#V/O7XG?%+X8^)Y?^"H&C:QX/^$WC
M/Q!/XW\ ZX_BKQ/XO^%GA\0>!/#VJ>)?A'X#UGXZ? #]I_2-6MKOP/J'@'PQ
M!+J/ACP#XZC\1:C%XTMO$7P[TKP?HFC?$6#7K7T,NP=/&SQ$*M=4%1PE;$0D
MTFISI)-0;E**C%IMN;:BE&TG&]TTKW^76V[_ "_X!^R>G>*_"FLKKS:/XK\*
MZPOA6\N=.\4OI'B?0-53PMJ-E#)<WNG^*'T_4;E?#=_96T4MS>66N&PNK2WA
MFGN(HHH972SH>OZ#XHTFRU_POKVA>)]!U)))-.U[PSK6E^(M"U&.*5X)7T_6
MM$N[_2[Y(IXY()6M+N8131R0R%94=%_ W1?V;?B9XO\ #S:+9>%=1\&> /@W
M^Q;I'P3\5KX2_8^^(O@2]^-/C'X??'_X#?$KX;>'_BI\(?%^L:-XC^.OB"32
M/A;\09/CGX9^&>N>)_!4/A/XF^+]+\"?$GQOKWQ&;2(OMW]EB_\ 'W@_QG^T
M+XYU[X?:AI>C?M/_ !D\(S?!3P)X+^"WQ(^%_P +M-\5_#_]FJ.+Q]XNURQ\
M1Z!;>,_A!\,OB9XF\(V'AN'XJ_%?PEX-U+QQXQT@:E:^%8Y?$7A.VU7OQ>3T
M*%&O4HXV-:=+54G3=.37/0BHMR:2J3HU*V+Y;_NL/AIN=^=2@6_I-/MTW_X-
MD?HS#K.CW.JW^A6^KZ3<:[I5GINHZKH<&J:?/K>EZ?K+7:Z/J&IZ/%<OJ>FV
M&L-87ZZ1>WUK;VNJ&QOAI\MS]CN?*TJ_)W]CKP#^TAX1_;1^/7BOXV_!.T\,
M7OQ)_9:_9YO?B%\7=*^)VG^.?#OC3XO:7\6/VC-4U73O#LMEX"\-02Z?HVB>
M)-(\*Z#X,@U%KOX5?#?PM\/TU;^TY/%T-Q'^L5>9CL+#"8CV,*]/$Q]E0G[:
ME.G.$I5*,)S473J5%RQG*48<SC-P493A!RY4@HHHKC ZKP-_R.?A?_L.:?\
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MB^"4)5KAB#M?7U89!Z, 1T(!KF?^%E_#7_HI?PT_\./X&_\ F@K7_P"'+_\
MP2:_Z1R?L8_^(]_#O_Y34?\ #E__ ()-?](Y/V,?_$>_AW_\IJ_(L7X4T\5B
ML3B7GDX?6,16K\BR^,N3VU5U.7F^NKFY>9J]E>R=E=H>GG]__ ]?Z6N1_P +
M+^&O_12_AI_X<?P-_P#-!1_PLOX:_P#12_AI_P"''\#?_-!6O_PY?_X)-?\
M2.3]C'_Q'OX=_P#RFH_X<O\ _!)K_I')^QC_ .(]_#O_ .4U<_\ Q"*G_P!#
MZ?\ X;H^7_4;Z_AYAIY_?_P/7^EKD?\ "R_AK_T4OX:?^''\#?\ S04?\++^
M&O\ T4OX:?\ AQ_ W_S05K_\.7_^"37_ $CD_8Q_\1[^'?\ \IJ/^',7_!)Q
M&1U_X)Q_L8%DEA;!_9Y^'#J0LJ%@R2:(Z.I4'<KHR,N0RLI()_Q"*G_T/I_^
M&Z/E_P!1OK^'F&GG]_\ P/7^EKD?\++^&G_12_AI_P"''\#?_-!1_P ++^&O
M_12_AI_X<?P-_P#-!7SW^QE_P1F_X)RW'[+'P)E^,?\ P3C_ &7A\3S\.]'_
M .$W_P"$\_9V\%0^,3KY>Z:\/B--6T&+5!JGS()_[07[4%$:L0BHJ_3?_#E_
M_@DU_P!(Y/V,?_$>_AW_ /*:C_B$5/\ Z'T__#='R_ZC?7\/,-//[_\ @>O]
M+7(_X67\-?\ HI?PT_\ #C^!O_F@H_X67\-?^BE_#3_PX_@;_P":"M?_ (<O
M_P#!)K_I')^QC_XCW\.__E-1_P .7_\ @DU_TCD_8Q_\1[^'?_RFH_XA%3_Z
M'T__  W1\O\ J-]?P\PT\_O_ .!Z_P!+7(_X67\-?^BE_#3_ ,./X&_^:"D;
MXE_#3:__ !<OX:?<<?\ )1O W=2!_P S!6Q_PY?_ ."37_2.3]C'_P 1[^'?
M_P IJ/\ AR__ ,$FO^D<G[&/_B/?P[_^4U'_ !"&FU;^WI_^&V/E?_F-]?P!
M-)IVV\_3R]?Z6OV[I_QH^$"6%BK?%3X;@K9VH(_X3SPEP?(CR,_VQ@_49!Z@
MD8-6_P#A=7P?_P"BJ?#?_P +SPE_\N*^%_\ AR__ ,$FO^D<G[&/_B/?P[_^
M4U'_  Y?_P""37_2.3]C'_Q'OX=__*:OV.$>2$(7OR1C&^U^5)7MTO81]NZA
M\:?A UA?*OQ4^&Y)LKH ?\)YX3Y/D28'_(8XSZG@=20,FO@I?B7\--J?\7+^
M&GW$'_)1O W90#_S,%;'_#E__@DU_P!(Y/V,?_$>_AW_ /*:C_AR_P#\$FO^
MD<G[&/\ XCW\._\ Y35\9Q;P='BJI@:DLPE@OJ4,1!*.&6(]HL1*@VVW7H\O
M+[%V^*_-TMJ[]/3\/^'9D?\ "R_AK_T4OX:?^''\#?\ S04?\++^&O\ T4OX
M:?\ AQ_ W_S05K_\.7_^"37_ $CD_8Q_\1[^'?\ \IJ/^'+_ /P2:_Z1R?L8
M_P#B/?P[_P#E-7Q__$(J?_0^G_X;H^7_ %&^OX>8:>?W_P# ]?Z6N1_PLOX:
M_P#12_AI_P"''\#?_-!1_P +*^&G3_A9?PTP6#$?\+'\#X+!2H8C_A(<%@I9
M0V-P5BH."0=?_AR__P $FO\ I')^QC_XCW\._P#Y34?\.7_^"37_ $CD_8Q_
M\1[^'?\ \IJ/^(14_P#H?3_\-T?+_J-]?P\PT\_O_P"!Z_TM<?\ X65\-,<_
M$OX:8 "C/Q'\#8"KG"C/B#A1DX X&3@<T[_A9GPVR3_PLSX:Y8Y8_P#"R/ ^
M6/JQ_P"$ARQSSDYY /45\\_MG?\ !&;_ ()RV_[+/QRD^#G_  3C_9>/Q/'@
M'4O^$*_X0/\ 9V\%3>,1K@N;)K8^'4TG09=4_M/8LHB^P*+DQF55)C:16^G/
M^',7_!)R1I'?_@G'^Q@&>69L#]GGX<1J TKE0J1Z&D:(%(V+&B(JX"*J@ '_
M !"*GUSZ?3_F6Q\O^HWUM\@^_P"_TOT_K3>QD?\ "R_AKT_X67\-,>G_  L?
MP-CW./\ A(,9.!D]\#/04?\ "R_AK_T4OX:?^''\#?\ S05K_P##E_\ X)-?
M](Y/V,?_ !'OX=__ "FH_P"'+_\ P2:_Z1R?L8_^(]_#O_Y34?\ $(J?_0^G
M_P"&Z/E_U&^OX>8:>?W_ / ]?Z6N1_PLOX:_]%+^&G_AQ_ W_P T%'_"R_AK
M_P!%+^&G_AQ_ W_S05K_ /#E_P#X)-?](Y/V,?\ Q'OX=_\ RFH_X<O_ /!)
MK_I')^QC_P"(]_#O_P"4U'_$(J?_ $/I_P#ANCY?]1OK^'F&GG]__ ]?Z6M_
MP7\3_AC#XN\-2R_$WX:+''K5@[L/B+X(<A5G4D[4U]F. .B@L3P 3Q7VS_PN
MKX/_ /15/AO_ .%YX2_^7%?"_P#PY?\ ^"37_2.3]C'_ ,1[^'?_ ,IJ/^'+
M_P#P2:_Z1R?L8_\ B/?P[_\ E-7W/"?"\>%\+BL-'&O&_6<1&NYN@L/R-4H4
MW'E5:MS7Y+WO'M;J(_1O0/$OAWQ78MJ?AC7M&\1:<MQ+:-?Z%JNGZQ9+=0!&
MFMFN]-N;JW$\2RQM+"9!+&)$+JH=<[=>*? 7]F_X"?LM^")_AK^SE\'?AQ\$
M/ %SKVH>*+CP;\+O"6D>#/#<WB/5K>PM-3UN32-%MK6S;4[ZUTO3K>ZO#'YT
MT-C:QNQ6",+[77U@!1110 4444 %%%% !1110 4444 %%%% !112,<#/?@#/
M3+$ 9QGC)&3CB@!:*_+WPS^VQ\3]6NOAA\8+[0_AW_PS7\9/VK/%'[*WA70K
M"R\7CXQ>'KBQ^(?C[X->#/BKKOB"[U8>%-7L/&/Q0^'EQ;:C\-[/P5HUWX,\
M&^)M*\1R_$+Q#J>D:MX>E]I_9._:,^*WQM^(G[7'@?XK?#SPM\-+[X _&/P+
MX%\,Z!H/B.?Q;JQ\+^-_V>?A'\:+&;QMK\:P:#=>+H[CXBW5MJ5KX2MI/#>E
M106^E6&L^*&LY?$FI@'VS17YT_MD?M(_M2?LQ?LU_M=_'30_A1\,?&-Q\()_
M%OB_X3_VIXFU+1/#R_!?P?\ !7PUXRU/Q9\2X;6^U'Q#K7BAOB5;^/O".D^%
M?"%MX?&JV:>$Y-0U#PWIS:OXJ;F?VK?VYO$7PA^*_BKX5^!+OX?:)=?"CX">
M%_VA?B7X@^(O@'XW?$'0O^$<\;>+O&OAKPYIFIR_!#3-6U/X/^!;&S^%_CK7
M/B+^T#XOTGQ9X5^'EF/#JIX&\5&[UM]% /T\HJI87D&HV-G?VL]K=6U[:V]W
M;W-E<)>6=Q!<PI/#-:7<7[JZMI8Y%DM[F/\ =W$+)-'\CK5N@ HHHH ****
M"BBB@ HHHH **X/XI?$+1/A)\-/B%\4_$R7DGASX;>!_%WC_ %^/3H!<Z@^B
M>#/#VI>)=62QMR\8GO'T_2[A;6$NHEG,:%@&)'PK\-_VJ/VA$\2?"7P]\3_
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M[&#3]9M]&GL8)[S5M)U+6ISJB_8U% 'S=^U7^S5HG[6GP>\3_ [Q=\1/B?X
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M)T>"ZL[RTGFMKJWF1XIX)9(I%9'(/P-\-OV(M5^&GQ"\1W6E?%[QQ>> M/\
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MHHT 5(XXU"1HBCA41%554<  "I* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3(]_P C_A2YS_\
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M&TWPI8:WJ]OIJK$+RXDU.^O]8O=4U.ZFO7^@: "BBB@ HHHH **** "BBB@
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M\U_PSJ>IZ-/9V48T+3+/4]37P]HVBOJ-Z\WU+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$@
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M '^0%XT_X+N_\%D_!GC+Q7X/?_@H_P#%?Q,WA3Q'KOAR3Q)X.\4>#/$'A'Q
M^@ZG=Z8^M^%=?LO"KV6M>'=8-H=0T+5K-GM=0TRYM+J%FCE!K_0B_P"";/\
MP51_8J^#_P"Q=\"_"_[87_!7;]F7XU?M.:AX2M_&'QI\7^,OVC?AGJ%[I_C?
MQF?^$AOO VG2:;<V-BFB_#RVO;/P99FW@47=QHU[J<A\Z_<+#^T1_P $"?@I
M\;O^"Q?[,_\ P47&B^#-/^%_P^\$WNM_&;X4)I5E;67CKXY?"\Z78?L_^)AH
MD6E/IEWIOV'4Y+_QH));:%[CX4>#K-['4(_$VKS6W[P_\*=^$_?X9_#YCU+-
MX)\+%F)ZLQ_LCDD\D]R2: /@S_A]+_P27YQ_P49_8W. 20/CYX")PH). -5)
M. "< $U^D'AGQ+H'C+PYH'B[PIK&G>(O"_BG1=*\1^'-?T>[BO\ 2=<T'7+"
MWU31]8TN^@9X+S3M3TZ[MKZRNH6:*XM9XIHV*.I/)'X.?"8@@_#+X>D$$$'P
M1X5P0>""/[(Y!'!'>O0K:VM[.W@M+2"&VM;6&*WMK:WBC@@MX((UBAA@AB5(
MHH8HT6.**-%CC151%50  #\4_CS^W#^T1X._;.^.?P6^&FI^&M>;X2>"OV3=
M?^'OP&A^!7CSQAKOQINOC9KOC^#XCIK/QF\.:[%H?PEM/#.@>$/[1TOQ)XBT
MQ?#WABWM=3\2^*8-7T&RNX8N_P#"_P#P65_9A\:>%_%/B[PCI_B;QCI>EQ_"
M_5_"=GX(USX;>--?\:>%/BW\>?A_^SUX2U>;0O#7C?4K[X;ZU?>,?B9X/UBW
M\"_%A/!7C"[\(:U;:M#IJ7UCXDTGP]^CWAOX+^ /"?Q3^)_QET73+NW\>_&#
M1OAQH/CK4I=5U"YM-2TSX4VGBJR\%PVVE3SOI^FM86_C/7TNI;*")]2-S$U\
M9C:VY3P2V_8)_9[MO"6H?#]K/XBWO@*76/AEJGA[P/J?Q>^)6I^$/ %K\(?B
MEX4^,O@+P[\.?#E_XDN=)\&>&=#\?>#/#]]#H^D6D:'1-/M/!J31^#;+3] L
M@#S'4?\ @I#X%\*_#KXG_&;X@?"/XJ>#/@U\+_\ A,_#^H_$^[N/AOJ?A;5_
MBG\.?B3IOP6\9?"VPN-.\>/+I>K1_&+4+OX=>&/%7BJ/P]X"\5ZMX:\3ZM:^
M);'PO8Z;K>L\AHW_  51^&GBZ'P;IOP\^%WCCXH>-O&&L_';PU;>&_AUXR^#
M'BG08M>_9_\ A[\._BIXO@L_BG8_$8_##7]+U#P1\2] N]#US1/%%W9?V\M[
MX1UM=&\1V5[8VOTCJ'[#G[/&K:G\2KS4_#WBB^TOXHOXOOM;\(2_$CX@1^"=
M#\1_$'Q1I/CCQQXU\!^%;;Q'!I7P_P#'?B7QSH.C^-[GQEX2BTO7]-\8VD_B
M?P]>Z+K6KZ[>ZKI:/^QS\'=-U[X?^+M2E^(OC'QC\-XOBO'H'BWQ]\4_'?C;
MQ!*WQI\.>&_"?CU]3O?$.M7J74=]X?\ "6@Z?I=C#!::5X>2R>;1-/LKF\OI
MKD \._8T_;IU?]KOXQ?M#:!HOPUDT3X(^ /"O[,?CGX-_%&;5M,;4?B+X7_:
M,^!_AOXS:9-KGA=-5NM4\/7\6F^)+62S@>RB@BLXI;:_G.I@(W@/[2O_  5D
M7X??L]?%/XK?![X)^+/$FI2_#'XK>/?V:/$/C#5? >G^ _C;IOP@^(?A3X8_
M$+Q3965GX[3Q9I&C^$;[QII'CK3M \667A'6OB)X'@N;C0+C3KZ.]MK#[U^!
M?['GP1_9OUC3M6^$&D^(O"T=E\&OA9\#[K1?^$Q\0ZIX=UOPI\%/#>D^"_AA
MJVO:)JEY=V6I>.?"O@S1K3PG;^-V2+7M0T ?8-8N-06&S>U\[UG_ ()S?LLZ
M_I'Q \.:KX5\67?ACQ_H'C?PJ/"TOQ+\?/X8\!^&_B;XTT3XB_$C0_A1X?DU
M^32?AGIGCGQKX<T37?$%MX3M+!9#IEGI%A_9_AZVAT= "?XS_M73_LI_!WX-
MZM\5O"_B?Q]\3/'MO)X?N=)T=_AK\/[:3Q7X5^%WB;XG^.9M>\2>+/'NG?"?
MP@UKH?@KQ$NGZ9%X^U5-;UM+?2O#,^K6(O-7L/&_!O\ P4^\'^+-*F-O\'OB
M)>^)8]6_9\\ 6.E:)=^'8M,\5_&C]ICX-?"?X[?#?X8>$-0\<WW@/6&F@^'/
MQ/F\1^+_ !)XQ\->#=,\)Z;X+\1G4X1JL^B:-J/K'[:?[)/B+]I^7X/7>C>+
M-"L;#X5>)/$_B6Z\">*3\1=*\/\ BW6/$&CVNA:/KMQXN^$GCKP#X_T74O!%
MJ^O3Z3IMOJ=_X;UR;7I3KFEB^TK0-6TJUX._83^&UK\-?$'ACXEZYXK^(_Q&
M\?\ B7X4_$SXD?&9?$7B+PKXYUCXT?!SP'X&^'?@CXJ>%=3TC6GU+P'XBT3P
MU\.O"FG02:-JDDFJP6-])XLF\1W7B/Q3/K0!YA#_ ,%.OAI-XN^'W@9_AGX^
MT?Q+XK\4>(/ GB6Q\7^*?@KX'M_"7Q \'_%[4?@GXS^'VCZUXO\ BCHWAOXL
M^.?"'BK3U\0Z]X7^$VM>*]5B^&^K>&?&5C;WY\6^&-&U;V;X"?MH^#OC_P#%
M7XE_"S0?!WB+PYJ7PXG\8PWK^)O$OPP@\2K_ ,(/XXD\ ZB?$_PFL/'5[\9?
MARNOZC$?$7@2Y\=^ -&TSQ=X'N-/\1VVI6DFHV.EW%#6?^"??[.6N^&['P;?
MV?Q,;P?+!JMOXY\*I\:OBL/#_P 81K_C+6/B)XBO/C+I,OBR6S^(^M>(_&^O
M:QX@\0>)-<B;Q)K!U"XT6_U>;PP8]"C]#\'_ +)OPE\%_%(_&"S;Q[KWC&PL
MO'NF^#_^$X^)OCWQYHGPXT[XIZOI&O?$73OAYH?BS7M5L?"FG^+=5T#0YKRR
MLE:WTVQTFQT+PXFB>'X$TJ@#YG\:?\%./AKX#OOBG<:[\*_BG'X(^%'Q2^-W
MP+UGXA1/X!.@W_QB^"OP2U;]H&X\&:;I<WC*'Q9)#XR^'N@:POACQ*_A\:"G
MBJWMO#.LW6G75]#.MP_\%*/ 4%K;ZY?_  E^*6G^#]#\,_!OQY\8/%=U=?#=
M;3X'> OVB/$VH^'_ (+^)?'6E_\ "<C6]1;Q'IVGCQOXFT3P78>)=7^'W@JZ
MM[[Q/;PZTQ\/A/#_ /P3/^$$_B']HK7/BGKWBOXCVGQZ^,WQT^+$7AB'Q-XU
M\)^$?![?'7X-Z'\"]<-MX4T[Q==>'=0\>:1\.X/%GAW1_B7%I>EZS8Z;XTU5
M;*RM-1BBU*O;]<_8B_9\\0:]X0UV_P##GB&-?"OAGX6>#[[0-/\ '7C'2_"'
MQ!\/?!#5V\0?"#3OBMX2T[6;;P_\2H_A[KTMQJF@/XKL+^1GN[O3]5;4]$N'
MTJ@#X5\<_P#!5R;PSX]^#GB]/A!XVL/V:/B+\%/C9\3=&\1:E:^"[GQ7\4[+
M0OVA?V-/@-\*O&/@2/3OB!<-X6\,W]Y^T;K/BC6-#\=Z9I?B/4/"3>'=6MK>
MRU2"_P##P^CH?^"B/A37?B'X[^%7P^^"_P 7OB1X]^&OQ ^,GACQ?X<\+'X>
MIJ%IX.^!=U\+M,\:_$?3+?7O&^BRZ]87VM_%KP[H?@SP=I2W'CGQ;J=AX@BL
M=&ACTP2W'0W/_!-S]E2^;4X]0\*>+M1TVY\%?$KX<:#H5_\ $_XA76@_#WP-
M\5O%7@+Q[XI\,_##29O$+6OP[TZW\>?#/P5XQ\+-X5&G7G@[7/#^DMX9NM,T
M_2='T_3K%O\ \$ZOV9[2.Z>RTSXC:=JNL>)?B!XE\6^)-+^,?Q.TGQ3X\/Q;
MM_ T?Q7T#QQXBTKQ-9:KXF\*_$:[^''@_5_%/AZ_N6LIM9THZCIG]ES7EZ)P
M"M^R5^UKX\^._@W]J#Q?\2?A(?AO!\!/VD_VB?@SH5O8>(]#U]O&/ACX(^(M
M1T>+77:RU>]73=<NDT]H=3M+QK*Q-[(DNF[K -*OSUX<_P""R/[.>M:E\*;#
M4] \1>$#\4_!/P#^)MM:>*_&'P@TOQ7I'P]_:=EMK;X+>((OA^WQ#/CCQE>:
M]ON]<\1^&? .A>)?$G@3P?:1^(O%>G:?-J%CHTOZ!>!_V=/AI\.K[XU3^$[7
M7M/TWX]>)M6\:^//#,OB?6K[PNGB_P 36EW;>,O$7A?1;VZG@\(ZAXVENSJ?
MBQ=!:TLM6UJ)-8:SAU"2YGN/-/#O[#?P$\'_ /"JX_!UEX^\'V?PH^&WPF^$
M=AIOA/XJ_$3PUIGC/P!\"[7[-\)=!^*-CH?B&P@^(Z>"5>Y%A>>)ENKZ^M=0
MU/2-<N=6\/ZC>:/, >'>/O\ @J-\#_AOX/\ "WB/Q9H7B+P[JWB>]B\(OX=\
M6Z[\/_!,/ACXJS?$7XB_#1OAMXS\9^+_ !9HW@7PUJ.FZO\ !?XU:MK.O7WB
M :!9^'_A?KMS:7.I:GJOA?2-:Y.\_P""N'P131&\5Z-\.OBCXF\':'\#;+]H
MGXA^*]$D^'<^A^ ?A=;?&OXA? ?QGK,]_)XYCL_&+^#O&/PV\0:@%^'UUXHM
M/&GA.-/$?@.]\06LMHMY]4:M^Q)^S[J<OQ+O[?PYK^@>(?BA\7M)^/.J>+/#
M'C?Q=X?\5>&OBQHGAJ/PKI_B[X>ZYIVK177@*5M-EUQ]4TCPY]D\/^(+WQG\
M0;KQ#I.JGQ[XL35L3Q/^P+^SAXST7Q[H?BG0_&?B&'XF_L^I^S+XXU'7/B=X
M_P!;\0>(/A4/&/B[Q]-97WB36=?U#79/$%UXJ\<^)=2N?%)U ZVZWL5C'<Q:
M?8V-K;@'BOCG_@JK\ /AII$OB+QSH'CK0?#MIK'[<^BWNK31^%V@@OOV%/C+
MH_P-\90@2^(K6,M\2O&VOZ-;_#9[BXL[7[+J$-SXSN_"L$=U-;XES_P5C^#"
M_#^P\:Z=X0U;7&/Q-\1_"K7KC2_B?\ F^&/AWQ-X;\ Z!\33;77[1%Y\4[/X
M!W%SXI\*^)+"T\":='\0(K[Q-XRM?$/@UXM,U+PGXGFTKWO6/^">G[+7B'Q;
MXF\7ZYX)US5;GQ2_QIEN-&O/'_CF3POHEQ^T/=^'-:^,U[X-\/+KR6'@G4O'
M7C#PIH7Q"O\ 5O"HTG5-/^(FGP^-=$O-+UY5NUZ:_P#V-_AQJ/A/3?#-SXZ_
M:&:\L-9UW6IO&:?M&_&-?'.L/XGTK2- U_2]=\0?\):1JWAR_P!#T+2=/B\-
MW-B=%T>6R36M LM)\22W6MW !].>'M:A\1Z#HGB"VM[BTM]<TC3-8@M;M[*2
MZMX=4L8+Z*"YDTV\U'3GN(8[A8YGL;^]LVE5VM;RZMS'/)L5R/@#P)X2^%O@
M7P9\-/ .B6OAKP-\/?"GA[P1X-\.V+7$EGH/A7PKI-IH?A_1[62[FN;N2WTW
M2K&ULXI+JYN+F1(1)<3S3,\C==0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-2016331_restructuring.jpg
<TEXT>
begin 644 biib-2016331_restructuring.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M'^RM4_Z&.^_\ -%_^5]']E:I_P!#'??^ &B__*^MZB@#!_LK5/\ H8[[_P
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MUO44 8/VOQ#_ - 6Q_\ !XW_ ,IZ/M?B'_H"V/\ X/&_^4];U% &#]K\0_\
M0%L?_!XW_P IZOV,VHR^;]OLH+/;L\KR;XWOF9W;]V;.T\O;A<?ZS=N/W=O-
M^B@ HHHH **** "BBB@ HHHH **** /Q _X*3_\ *23_ ((4_P#9UO[4'_K'
M/Q!K]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^
MXO\ Z"* /@'Q!_R']=_[#.J?^EUQ616OX@_Y#^N_]AG5/_2ZXK(K^-\7_O>*
M_P"PBM_Z<D 4445S@%%%% !1110 4444 %>M_!7_ )'9/^P1J?\ Z'9UY)7K
M?P5_Y'9/^P1J?_H=G7T/"?\ R4V1?]C/"?\ IV(UM+T_5'U[1117]7B"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MPE_X*Z/\2_ 7[3G_  2C_:6\(?LZ_M&_M%>"/V;?VA_CSXN^*F@?LR_"C5/B
M_P"/M%T/QC^SAXF^'WA^]7PQIMYIV;>\\2Z_9V[7%WJ%G!';PWLJR2SPQ6MQ
MV"_\%HK555?^'5W_  6E.U0,_P##O[7QG QG_D?Z_:K%)@>_YG_&@#^;W5/^
M"F^JWNIZE>Q?\$O?^"RXBO-0O;J(/_P3_P!>#B.XN99HPP_X6*<-L<;ADX.1
MDU1_X>7:Q_TB^_X+*_\ B &O?_/%K^E# ]_S/^-&![_F?\:_/:GAEPS4J3J2
M_M'FJ3E.5L7%+FE+F=E[!V5V[:NVF]M0_FO_ .'EVL?](OO^"RO_ (@!KW_S
MQ:/^'EVL?](OO^"RO_B &O?_ #Q:_I0P/?\ ,_XT8'O^9_QJ/^(7\+_]3+_P
MLA_\H]?Z6H?S7_\ #R[6/^D7W_!97_Q #7O_ )XM<_XI_P""K5AX'T'4/%/C
M+_@F]_P5]\+>&M)2"35->U_]@_5],TC3TN;J"QMFO+ZY^(Z0P+/>W5M:1%V&
M^>>*,9+BOZ<,#W_,_P"-?.O[5_P<U[X^_ 'XA?"7PSJNDZ+K?B^ST.VL=3UX
M7SZ5:OI?BSP]X@F:[73X;F\*R6NCSP1>3"Y\^6+>!'O93_B%_#'_ %,?_"N'
M_P H]?Z6H?AS_P /+M8_Z1??\%E>X_Y, U[MP>1\1<'ZC(]*/^'EVL?](OO^
M"RO_ (@!KW_SQ:_I.1-H()/+NW!/\;LP[]@<'WIV![_F?\:/^(7\+_\ 4R_\
M+(?_ "CU_I:A_-?_ ,/+M8_Z1??\%E?_ ! #7O\ YXM'_#R[6/\ I%]_P65_
M\0 U[_YXM?TH8'O^9_QHP/?\S_C1_P 0OX7_ .IE_P"%D/\ Y1Z_TM0_FO\
M^'EVL?\ 2+[_ (+*_P#B &O?_/%KM_A__P %5+WPGXA&KWW_  2Y_P""S<T"
MV%W;!(/^"?\ KQ<R7#VQ7/\ Q<,D*%B<D@-SM& "6']#.![_ )G_ !HP/?\
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MTO\ XK^U_P#^;^OVHP/?\S_C1@>_YG_&@#\5_P#A]':_](KO^"TO_BO[7_\
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MTG]O+PG\#/A[\,/#7[1?Q&\/?$O4/V?/&WA#X;-X!^(W@7X&>'[B[^%WQ"^
MQT#Q!KOQ6^,6H>,/#NI7VMVMI\0O%6G?$3P_?_"+P9X<B /Z!**1>54_[([Y
M[>N!GZX&?04M !1110 4444 %%%% !1110 A('7^1X'/)QT'!Y.!2Y&<=_\
M/7T]O7MT-?A?^V/X[OK3XB_MS3_$#XK>,?AM\3OA/\#OAWX@_P""?GAKPY\4
M/%7@:Z\3>,M5^'?C>_M_$'@+P#H>J:;I?QL\>>+/V@[:'X6^)?"6JZ'\1EE\
M.:/X3\(W?AO3M'\;WD7B;TC2OC+9Z%_P5<^%7A/QW^TQ92ZUX[_8E^,5KKW[
M/]W\7_!D'@GX=_%>V^+G['T/A[PCX9^&^F7>EW-WXYU%/$/CFZL/$7BZV\0?
M$+Q'I.HW&EZ+?6_A?28=*A /V'SSCVST./SZ?AG/>@L ,\XZ<*Q/Y $_CC%?
M-7Q9^'.DVGB;Q#\<=1^.?BWX.Q67P?N_AE?:Q_PE&@V/@;PGI5_XYTCQ3=>/
M5T?QXNH?#NS\;VRVCZ!IOBOQ!H>H'3]/U!K?R[F()93?B?\  KQQX3^/?_!.
MO]C[1O$'[5_PRNY](^/7Q?TWQ]XN^.'[07Q'U>+Q"UAJG[3EIX(T?X@>//AM
M\1O"OBCQ'XE2T_X1_P 5Z/X<\:_$[P)IWBVUT%-2LM3N[S2-'TB[ /Z1@<C/
M//J"#^1P1^(HKY6_8H\7P>-OV9OAGK%IH&F^'K"RB\6>$=,BT+Q#XJ\6>&-?
MTKP!X[\4^!=+\>>"_$OCAI?%VN^ _B3I_ARV^(/@35/$%S?:G>>$?$VC2SZG
MJRE-4O/JF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \AL/@3\+=,\8?$'QM9>&$AU/XK6]I'\1]*.I:O/X*\9W]E9Z;I<7B3Q!
M\/;B^F\"ZCXSDT71M&T"\\:S>'CXJU'P_HVD:'J&K7.F:996T/<^'/!GA'P>
MMXGA3POX<\,IJ#P27Z^']"TK1%O9+:-H;9[M=+L[07+V\3-%"TXD:*-F2,JI
M(/2T4 <?XC^'O@/Q?=17OBOP5X2\37D%HUC#=>(/#6AZW<PV3RM,]G%/JEA=
MRQVKS,TK6Z.L+2LTA0N23MQZ%HL-];:G%I.F1:C9Z:='M+^.PM$O;723)%,V
MEVUVL(N+?36F@@E:PAD2T:2&-S"612-6B@ HHHH **** "BBB@ HHHH ****
M /,/BC\'/A]\8].T/3_'FC75[+X6\0V/BSPEKFC:]X@\(^+?"'B;3XKFU@UW
MPCXR\):GHGBKPQJ4NGWNH:-J%QHFKV1U?0-3U7P_JHO=&U.^L9]J;X;?#VXU
MX>*;CP+X.G\2B^M=4'B&;PMH,NN#4K%$BLM0&KR:>VI?;K2.-([:[^U?:+=$
M18I$55 [6B@#.U;2-*U[3KO1]<TW3]8TF_B,%]IFJV5KJ.GWD!96,-W97L4]
MK<Q%E5C'-$Z%E4[<@$<Y8?#GX?Z7INJ:-IO@?PAI^D:VT#ZSI=CX8T*ST[5G
MM=GV9]3L;;3XK34&MQ&@@:\AF,.Q?**;1CM** &JJHJHH"JH"JH  4#@  8
M '    &    *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-2016331_sga.jpg
<TEXT>
begin 644 biib-2016331_sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M "BBB@ KXF_;G_:VN?V0/ 'PN\5V>B_#K4;GXH?'SX;_  -AU?XN?%"3X/\
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MIMK'X=_;(B_9FMO&L&E:O##<7D%SX;MOV:=%3PY=2P3B27Q-JDVH0S"QL8W
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M:6\LEM:6;RP6T$,CVEAY_P!BM6DBC1VM[3[3<?98&8Q6_GS>2D?FR;@#\-_
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MG6.G"_O)]1O18VEO:"\O[DJ;F^NA;QQBYO+@JIGNYO,N)BJ^;*^!@ T****
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M#Z#_ +4U;_H7+O\ \&.D?_)M']J:M_T+EW_X,=(_^3:^??\ A?.N?] +2/\
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MY=_^#'2/_DVC^U-6_P"A<N__  8Z1_\ )M?/O_"^=<_Z 6D?^!%[_P#$T?\
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M'($E*"01N48+(8V(5PC$/L) ;&TD YH >70'!=0>F"PSGTQG-.K\@/B9\=_
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M+EI6IQ<JM:K3IX=56Y<CLO/9/=7UMLK:O6Z\O1V_I7_X77X('5]6'_<,D_\
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M:\H0D[;7E%-V\KLDI:E_R#K_ /Z\KK_T1)7YYK]U/]Q/_0!7Z&:E_P @Z_\
M^O*Z_P#1$E?GFOW4_P!Q/_0!7XIXN_[QD/\ UYS+_P!+P0^C]5^4A:***_'1
M'E'QULCJ?P>^(NG#7O&/A9;_ ,.26<OB7P!X:U_QEXNT*WN-0T]+O5-*\)^$
M[JQ\6>(K:VM#.?$6D^%+ZP\477A-M?7P[?V.L"RO(/P1_99T'X9^.?V1_@?H
M_P 38?A9\)/A'X*^,OC:_L?B5XV^$GQ;^-_[,OQ%U?Q9X \<:7_:?ASP#\6[
M_3O#/PL\3>!KZZ;196UG4-6^%/B#Q<;@^#M9U[XJW>MV]C_2,K,C*Z,R.C*Z
M.C%'1T8,CHZD,CHP#(ZD,K ,I! --LE&FQ10Z<!IT,$;0P0Z<%T^&"%Y7G>&
M"&R$$4,+3223-%$B1M,[RLID=F/KX#-G@<+6PZIU)NK7A7C.%:%/V;C1JT9V
MA/#5X5)2A4M'VRJTH:RC1C5Y:L7=6V_K33?3KKOT/Y[OBIK?C;6M"T?6?BA\
M-/A?X/\ #>A?L9^$M0_94^$NI_##XZ:9HWQ"^*WAGXJ_&/3?$?@']GSPIX \
M3^$O&'P#^-/Q5\*^'OV??$G@/6_[0\0?%[X5>#?&7AK3?#FB76AZ3\1]0F^D
M_!XO)?CQX3NKK2=0TO\ ;1N?V]/'>K?%.&ZA\5W>O67[#E_I?CBXLM.UK7HH
MV\*ZE\#M,^#TGPRT/P8UK=R>$W^.^G>9X<MHOB,=?8_L*EQ<1^;Y=S<1^?GS
M_+GF3S\[L^=L<>=G?)GS-V?,DS]]LM\Z;RA!Y\WV=6WK;^=)]G5\D[U@W>4'
MR2=X0-DDYR3734S[VE/V:P:IQ4:\8QIXAJFE6A&'LW#V-YT)M>UQ5.<Y3Q5?
MEJ>UHQ@J;+JVWS^[^O1_,_$C_@HU\3O'7Q>^"'A[Q=\*OA;\6/BG^SO##^S%
M\7_ /Q&^%E]X&L-'^('Q(U/]J?X86]@/$6@>-/B#\/OB5I^A^ /"6F7X\/:9
M<>";C2]?\??$+3?$'B*?2M ^'9OX_P!MYIWNII[J2SN=.DNII;J33KPVK7FG
M27,C3OI]XUC<WMBUW8/(UI=-8WM[8FXAD-G>7=J8KF5&EE:1IFEE:9BQ:9I'
M:9BP*L6E+&1BZDJQ9B64E6R"13*\S$8R-?#8;#0P\*,,+4Q,H2C.<YSCB(X=
M6JMVC*HG0<YU(PIQFZEH4J5.$()!1117$!U7@;_D<_"__8<T_P#]'K7W=7PC
MX&_Y'/PO_P!AS3__ $>M?=U?NWA+_P BS-?^QA#_ -1:(!1117ZT 4444 %%
M%% !2'H<<G!P.N>/0<FEJM>W,=E9W5Y,MR\5K;3W,JV5G=ZA>-'!$\KK:V-C
M#<WM[<LJ$06EG;SW5S*4@MX99I$C8 _$7QKH+:I^W/\ $G4_%.@?%7P9JM[\
M9?@8NBWWPO\ ^">>G?$'PA\5/"?PXM_ 6N^ _$WC[]H3Q%\)O%.OZIJ/@GQK
M<ZS!?>,=.\1:)X8^%<-EH-WH$UOJGAO_ (21?W"'3OU/7ZG_ "#W'/>OP>^)
M'@72_$O[6E[JUCX%U:YG\?\ QR^ _P 5;#]HW7_V%_VV=1_:*^$.FZ+8?#"[
M7X1> /BG9?LYWGPQT;P+JMIH$VBZAK>J_%?P3X9^%^E^/_B5H7Q-^'WB75K+
MQ:^J?O".!^?;&.3P.!P.@]1@T ?A[_P4M,P_X*0?\$*C D4DO_#5W[3NU)I6
MAC(/['GC\/F1(9V4B/<R 1,&<*I*JQ=?VECF\1^6G_$MT3[B_P#,;O\ T'_4
MOU^+W_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#010!\'^,S*?%O
MB4SI'',=:U RI%(TT22?:'W+'*\4#R(#PKM#$S#DQKTKFJZGQQ_R.7BG_L.Z
ME_Z4O7+5_'^;?\C7,_\ L88W_P!2:H!0"000<$$$$=00<@_@1FBBO/ \ ^%?
M[+/[/OP2\5_$7QK\+/A7X5\&^)/BEJ$%]XLOM,L8_*6"#1_#VCG0?#=E,KV?
MA#PG<KX8TG5+WPIX<AT_0KO7HGU::S,B6,-A?U;]FSX':UI&JZ)>?#VP@LM9
M^)OBKXS7LVAZ[XQ\):RGQ1\<P2VGC+QIIWB?P?XET#Q1HFI^)["XN=,UNVT3
M6M.TB^TF[N]*ETTZ=<S6K^X45T/%XN53VKQ6(=6T(^U=>K[2U.*A37/S<WN0
M7+'72.BT \_TCX5?#?P_)\.G\/\ @GP]H*?"/PSKW@WX8VNB61TK3O WA7Q/
MI^A:3KV@^'M+L9(=-M-.U'3?#.@V<L;VLTL<6FQM;RPRSWDESQGB#]FKX'>*
M'UV?6_ 45U?^(OB'JGQ7O]:MO%/CW1O$EI\0]<\,:-X+USQ-X:\4Z#XLTKQ-
MX*EUKPGX?TCP_J^D>"M7\/>'-4TVT,=_HMQ+<WDUQ[G14QQ.(A+GCB*\9I-*
M<:U2,TI3E4DE)24DI5)SJ25]9SE-WE*38<WX.\&^%/A[X7T/P3X&\.Z1X2\(
M^&K$:=H/AS0K1;+2M*LO.FN7AM8 7=GGN[BYO;VZN)9[W4=0NKO4=1NKO4+N
MZNINDHHK*4I3E*<Y2G.3<I2DW*4I2=Y2E)MN4FVVVVVVVV[@%(WW6_W'S]-I
MSZ<XZ>]+2-]U_P#<?_T U,MGZ/\ (<=UZK\S[ST^;Q#]@L=FG:,4^QVNTMK5
M\K$>0F"RC0&"D]2H9@.FYL9-OSO$?_0-T3_P=W__ ,S]7M-_Y!UA_P!>5K_Z
M(CJ[7]F4/X-'_KU3_P#2$(YG4)O$/V"^WZ=HH7['=;BNM7S,!Y$F2%.@*&(Z
M[2RYZ;ESD?!@^ZO^XF/IM&/_ -7./4U^AFI?\@Z__P"O*Z_]$25^>:_=3_<3
M_P! %?BWB[_O&0_]><R_]+P0^C]5^HM%%%?CH@HHHH **** "BBB@ HHHH Z
M;P691XN\-&!(Y)AK-@8DED:&)W\]=JR2I%.\:$_>=892HY"-TK[7\[Q'_P!
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M;[K_ .X__H!I2V?H_P AQW7JOS/T,TW_ )!UA_UY6O\ Z(CJ[5+3?^0=8?\
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M3_R(Z1ONM_N/GZ;3GUYQT]ZD,<@!)CD '))C< #U)*@#\:B<A4D)( $;DDG
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M97?M/CGCD_L=?$$ ?4D@#U)Q7[<1S1>7'^]C^XO\:_W1[T ?"_CC_D<O%/\
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M/.Z[J2J8^*JNHZE>/)6K0I.H\/2KUXR<:V(I485ZJJ5/:5)>UJ<[Z*9YD?\
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MT$^,M<T[1[C4IY],BUB>SL;:6<S:A<:;ILC7VJBPCN8M-L(+C4+V2"PADN5
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MRK%4\9@,5%SH8BES*,U&<J<XRA.,*E.I3J1E3J4ZD(5*<XRA.,9)H6BC.?\
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M^*=(^)>J:QH7P^U;0O\ 3BFHZ5XSUW0-7T/PUJ5N[V6KZU9/I-I/)J,D%M,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-2016331_tecfidera.jpg
<TEXT>
begin 644 biib-2016331_tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MPZU+%XFT5+WRK]K[_@GMX>_:L\2>+/$S?%/Q1\.+CXC?L]ZM^S9\18-)\/\
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M3I\^O1W1EO$EU=._X)OQW-OJ][XR^.WBSQ#XM\1?M5_LX?M6:WXCTOP1X/\
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MDB-=H%N&660&0B1P0#\(_P!O']H*]U;XK>.M9L?B)X:O?@GX!_9%\,_&_P"
MD^@?M1>-/@Y:_&OXC6'Q ^-&D?&+0/@9XJ^#L\\/CO\ :#\/P>#OA'X9\$0Z
MN/'^@>!]0\:65C+\.?$S?$O6+>U_2+P+\7M5T#Q9^U?=ZU#XLL_!W@3P3\,?
MC-;6GB#2]2\2Z_X2U+Q=\*==USQMX*7POX<FU#7)[_2/^$&TOQ->>$M#ADNY
M]=\8ZC:^'XI6U&UB7ZZM/!OA+3]/T;2;#PQX>LM+\.W?V_0-.L]$TNUL-#OM
MUT_VW1K.WM([;2KS=>WC?:M/BM[C==7#>9NFD++H/A'P]X:O?%&I:-IXM-0\
M::\?$WB>]:>YN;K5]:&D:3X?@N[B:YFF=5L]"T+1M'L+6 Q6ECI^FVMO:P1*
MK;@#^>CP?_P52_:1\4^-?"_P[T>\^$>KK\1_%W[#-_X5^(]QX<\)7EA:>%/V
MJOC#X\^%'CC1)_"'PM_: ^*-AIVJ^$;?0-!\0^%-#\1?$*'QOIM[<7>E>.K>
M>RU'2]2B\[_:F_;\_:&\>_LK_MM>#=4^*OPQ^"6O_!GX*_M.^$-#\26&@^(?
M#'CC]J#QW\,OVB/VF_V<-5U;X&W>G?%2WU;X<:UX'TSX)^#O$?B33/#)^(.L
M:'XZ^*FCBZETOP;8Z8_B#^F&W\+>&K18DM?#^AVR0737T"0:1IT*PWKWSZH]
MW$L=LHCNGU*234&N$"S-?2/=ES<,TA6;PQX<N/+\_0=%F\F;5KB+SM*T^017
M&NI<1:U/&'MF$<VKQW=U'JDJ8DU%+B=+UIUED# 'P1_P4#^(W[/GP^T3X;2?
M&_XC^+(=7\07WBO2_A)^SYX1^.J_ BY^/?CI--TJ\2YU#Q-9^+/A[?V^C_#'
M3X)M9O\ Q/K?CW0OAMX A\0-XK\6V^I^(;7P$MK^:?COQO\ $GPEX \=6WQ9
M_:7U+Q/^T-\(/V#_ -FO7_V)?%_@#XS:]!HO[0W[2MY;?%:S\7Z]X*T/P[<:
M9HG[0FK>./B]I?PQ^$_BW3];\.^,9M2\!7V@RZMX>\-1?%#6GUG^ACQ+X)\'
M>,X[6'Q=X4\->*(;+S39Q>(] TC78[4SM TQMH]5L[Q8/-:VMVE\D)YC00E]
MQBCVV[7POX;L8-$MK+0-%L[?PT&7P[!:Z3I]O!H*O:RV3C188;9(])#V<TUH
M_P#9ZVVZVEDMSF)V0@'XX:+\9M,T7_@IM^T?\/+[]K*'7]2UO]A[P_J.D_#[
M4OBEX7O]'^&7Q.@^,GQOM[OPKX#^%_A0VUPGB/PCX9TG3)?$%S_PC>N_%/Q#
M;65M=>(KN\ABT72[#9_X)N7OAKP5X[O?A=X4\0_"?XQ+XF_9]^'WQ*\3?%WX
M*_%SXW?%;2M UK3-7A\,Q>#?B'??%SQSX\ME\2>,9=:UOQAX3\0:4GP^UOQ+
M8^'?&<7B;X;:*-#TF\O?U>B^&_P]@UX^*8? W@Z'Q*;^?5#XAB\+Z#'KAU.Z
M1X[G4?[733UU+[=<1NZ3WGVK[3*CLLDK*Q!Z6PTC2M*%ZNF:;8:<NI7]UJFH
M"PL[:S%]J=Z4-YJ%X+:*(75]=%$-S>3^9<SE%\V5]HP ?#OP9\):G\6=.\+_
M ![\5^.O'_A3Q1X&^,?[75U/H'_"57">$7A;QCX^^!^BZ-XK\.KJ">'=3TKX
M?>$/!>@WVBV&HP26ECXBL[SQ!,EOJVH:C=/^;?PI^)WA7QY\%O\ @I;\,'_;
M.\,?$F\T3]N?P8UK\0OBK^T/<S6P^%.H^"/V'=0\3KJ7B3X)7MIJ/PR^$?B/
M7]:\:^#T7X=:?X'\ >#)O$=[H*ZGX4MDU;6;7][M!\&>&?#(\1IH>DP6$'BS
MQ!JGBC7K1'FELKS7=;AMHM9OULIY9;6T;5WM5O=3ALX8+:^U2XU#5;F&34=3
MU"YN:.A?#7X=^&);F?PWX$\&Z!->:?)I-W-HGA;0-(ENM+EE$TNFW$FG:=;/
M/I\LRK+)92L]M)( [Q%AF@#\H?V<O'\OA=/ASX3^'L?AW7=(\&_MIW7P1N_'
M?PB\>_$+Q?\ "'XU^$_B+^SS>_$KQ/KN@3_$OQY\1-6$WP]UF#1[/Q)I5EXZ
M\;67AWQ1\-M8ATC6K3^T_$WAW2_V34Y )&"0"1Z9'2N.D^'W@Z34O!VJ_P!@
MV,5S\/UU8>#8;97M--\/2:WIAT74+G3=(M'@TJ"\;1I+O2;:[%F;BQT[4]8L
M[*2W@U?4DN>RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *"<<_R!/Z#FBOGS]JCPY#XM^ /Q)\.W,?Q#EMM4T>RM[E/A=X?A\7^+_LP
MUW2)KAX/!DT\'_";Z%'#$\GC/P-;_:;_ ,:^"5\1^%=-T_4]1U>UTZZ /7+3
MQMX-U#PW9^,K#Q7X:OO"&HPVMQI_BJSUW2KGPW?6][<1VEE/9Z[%=OI5U#=W
M<L=K:RP7<B7%PZP0L\IV5MWNH6.FPK<ZA>6MC;O<6EJLUY<0VD37-_<PV5E;
MB2XDB0SWEY<06EK"&\VXN9HK>%'FD1&_E*_9)\(WEO\ LN?LL>/?%7P,^'[?
M"+X;^*_%MIIGA3Q!^S3^T'/\#_CP_P 6_A!X!T^^^+6J?!CPIX$^+'B+X<?$
M_P"$NJ:'K?PY\&^)M4\!3?"WXQS:]X_M/#-WX5\1^--'UJ/HOC'\(_V[-,_8
M@_9.^'_CW]GCQ[\9]+^#]]^Q7XK\,P:7XO\ !VC^*M*^()_;>^'OB"WM_B-\
M/-?UO7/%&GZI\&/@5IWA+X=>';^/4_$>@^ KCQ'\2O&7C753;^#=*U_20#^G
M2'QWX*N/$DO@Z#Q?X7F\6P^9YWAB+Q#H\GB*+R;<7<OF:&EZVJ)Y5J1<R;[1
M=D!$S8B(:MNZU;2[&[T_3[W4;&TOM6DGATJSN;RW@N]3FM8&NKF'3[:65)KZ
M6WMD>XGBM8YGA@5II%6,;J_&;X;^&9/AY^UU9Z]X$\-ZMXC\=^*?VA/C5J7Q
MM\/>*OV,],\&7GPW^$OC2R^)GB^?XAZ;^T_;^$IM9\;W=KXDMO"_A#PCJME\
M5/%.C_$7P9K-AX.TKX9^';W2KV]\+>!?MY>&]7^-MWX_^(?P5\.:Q\1_%_[6
MW[(7PWT?]F.Z^(?[./[0%A\4?@#\2-%U'XCZQ\/O%WP0UF]^'>G:+\+?%E_X
MI\8>'/&'Q5TGXJ>*?@9XH^#]QX-\/?$CQA>^*O#UI:>%]! /Z)J*IZ>EW'8V
MD=_+%/?);0)>3PQ&&&>[6)%N9H8228HIIQ)+%&22D;JIZ5<H **** "BBB@
MHHHH **** "BH/M-OYYM?.B^T"(3F#S$\X0ES&)3%N\P1&13&)2OEF0&,-O!
M42A@03AN.>4<'OT!4$].@!/YB@!U%(&!!/.!GJK \>@(R?; Y[9H)P,\^O )
M/Y 9_#&: %HI 01D9[CD$'CV(!^AZ'J.*6@ HHHH **** "BBB@ HHHH ***
M* "BBHIY?(AEF\N67RHY)/*A3S)I-B,^R*/(WR/MVH@(+.0H/- $M%?,M_\
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M^)A^HT3.?4]3W-'^J7%?_1,\0_\ AES+_P"9O-?>'^M'#/\ T461?^'?+_\
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M$?\ ;'\>S:-I?Q9^)NE>'OVA? >JVWCGPI^SJVNV7P:^)%_K'[*GB7XAI/\
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MPX][KT*W_AY_$6H^*9(;ZS:YLGU-M5MX;@/;300_3W_#@3_@CC_TCZ_9]_\
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M6<#10( ?6=%?FOXY_:V_:0^$\7[%6C?$K]GSPSI/B+]H;XY>$?A!\7-:L_B
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MAO3P?$?B75/ \_@WP&-&\5>(5^'WMG@[_@I)\"/B!_8^B^"])\=>*_B;K?Q
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MP?XB\%>$?#GC:U\2ZMXLN=4\1Z;_ &]XJ\1>'_!UWK>LZ;X&T#PWX<U"71
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-2016331_tysabri.jpg
<TEXT>
begin 644 biib-2016331_tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #L 3T# 2(  A$! Q$!_\0
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MC72O#.BZ4IU;PR\\OAV_F73;*T6YN-"FN)I]'>Y$O]FW#_:+,0S*K@ _+?\
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M*NO$&M:UXIUS7O$^OSWFHWEW:Z?%I&C:5]1U^ O_  \*_:5_Z"W@O_PC(/\
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M][&W;QU-<[\.O^2?^!_^Q/\ #'_ICL*[*O\ .G'Z8W%_]A-?_P!.2/[XP?\
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MWWAA;/3/C)\5=-M%E\+6DLJVMAX_\16EN)96N 99!#"@>0@&1@7(!)%>3_\
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M3EG_ $ 83_P1#_+R7W!_:V9_]!^*_P#!T_\ ,^H/^&P/C9_S_P#A7_PD[/\
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MQ4_\**__ ,L\OS[L/]9,V_Z"(?\ @BC_ /('Z0?\-Q^$O^B>^*O_  <Z%_\
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MM%EEV>7&UU<V]NKLIGGAB#R* ?F7X\@_9<\#_M/:C:ZG^W]XN^$'Q0\9^/\
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MZK\P/\Y']HW_ ).'^/\ _P!ES^,7_JR?$]>-5[+^T;_R</\ '_\ [+G\8O\
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M]?L^_P#@E\0G^?B6C_AP)_P1Q_Z1]?L^_P#@E\0__-+7]<X3Z54\+A<-AO\
M46-18?#T:'/_ *S./.J-.%/FY?\ 5^7+S<K?+S2M>W,]U_*N*^C'#$XG$8A\
M;2A[>O5K<G^K:ER>TJ<_+S?V]'FY;M<W+&^]ELOXJLC^\G_?V+_XNC(_O)_W
M]B_^+K^U7_AP)_P1Q_Z1]?L^_P#@E\0__-+1_P .!/\ @CC_ -(^OV??_!+X
MA_\ FEKH_P")L:G_ $04?_$H?E_U3OK_ %MS_P#$KD/^BXET_P"::]+_ /-0
M>OW_ '?Q59']Y/\ O[%_\72%E R6C ]3+$!_Z'7]JW_#@3_@CC_TCZ_9]_\
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M#/#_ .WA\;/'W[(/[,OQQT/P+X"\(?$?X[_%/X@> ?$6BIX<^-WQW\*^#HO
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MJ0/K0 44F1ZC\Q2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^^()2/NFOT#PO^H?Z[Y/_:?U/ZERYC[7Z_[#ZK?^R\9[+VOUG]S?VO)R<_\
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MTJ>=/#-WI5O8V'B/6[O6/&&JZ:?*\6>(?$=S;V%W9@'V31110 4444 %%%%
M!1110 4444 %%%% "8'H/R%&!Z#\J6B@++M_7])!1110 4444 %%%% !1110
M 4444 %%%% !00#U /UHHH 3 ]!^0I:** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biogenlogostandard.jpg
<TEXT>
begin 644 biogenlogostandard.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
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M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
MCR; 4;#U?\RZH:R3;_:U'ZC+7XVOXZ783G>K":0:/&^FO*+_*+.C4YN%$&RC
M1(L;  "+_X  CM2_\+G)?ZZZ+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U
M*-RBR)N@$+"BN(M(  "+ZX  A+30GWCS==?*67B#9J[$;WA;5Q&^UGA]1K.Y
MDWC:-0>U"'E8(/:R=WFN!^NRV7M%  ")^8  A&+/GX!N=9O)?G]G9G##C'ZM
M5LZ]UGY$1G&X='XI--FSS'Y0(/:P_GZ?"&>PZG_G  "*%H  A$K.A8?%=6_(
M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
MA$;-?(\6=5_';(T99B#!<HMG5G:[FXH:1B2V*(E(-+6Q9HC^(2RN28GD"5VM
MFX95  "*18  A#G,F):%=5C&>)0'9AW <)'P5FJZEY!)1B&U%8\D-,2P58[?
M(5JM((]["<RL0H:@  "*6(  A!W+U)XA=5#%I)L:9BB_CIB05H.YKY:91CBT
M+Y5+-..O795*(9*L&)1 "C2K&X;F  "*:(  @_[++*7/=4K$[Z(Y9C>^S)\[
M5J&XZ9S]1ERS;INY-0ZNFINM(<VK,I;;"I&J'X<E  "*=8  @]S*FJVF=47$
M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
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M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
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M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
MAH>ZWJ)?> FUVI]D:/6P[YRN63FL/IIK2,*G[)C;-SFD+)BJ([JAF):C"YRA
ME(?9  "$FH  ADVZ8JJ5=]6U6J<>:,:P:Z/V60^KLZ%E2)JG7I_E-Q2CII\*
M(ZJ@_)@="\"@M(?R  "$>X  A@VZ$;,^=\"T^*\Y:+>O\ZN#6/6K(ZBH2(BF
MO:<Y-Q.B_:0/(\*@8)@M"_&@'8@3  "$88  >V[+,7+];9G%MG,W7UC ?W.:
M4'.[@G0G0)ZVWW3++T6S(75D&P:Q^'5K V^P37>)  "#)(  >VC*0'J(;:O$
MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
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MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
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MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
MF$JA98A*B0V>8X=$>1B;AH93:$Z8V86$5H"6<X3C0Y.49(1J+MZ2_X0K%0>4
M/H2   "#*(  EWZ@?)#=B$.=?(]">$>:H8V]9W27]XQ85=&5@8L:0OR3>XHU
M+FR2#(G1%,J3&XE   "";(  EM>?L)FKAY><N9=Z=Y>9WY579LF7+Y-352^4
MMY&-0GN2FY! +@R1)Y .%)*2%(U&  "!SH  ED:?'**/AQB<*)_/=Q691)T-
M9CF6BIIT5)V4%9A!0?^1_);)+;20;9:%%&&1.(W(  "!2X  E<Z>L:N7AIV;
MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
ME76>8K3PACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0
M#(V'  " BX  C)RO-&X ?E>K>V\7;UVH W O7WFDP'%+3HRANW)H/$&?-W-W
M)\V=]W0D#2^@N'/%  ""?X  C"RN.79!?@:J>G:.;P"F[7;R7QJCE7=L3BN@
M@W?[.^B=]'B,)X2<F7CD#3J>XGC1  "!Q8  B[JM#7Y=?7.I6'W_;GREPGV[
M7HNB:7VB3:>?5GVH.WF<QWW&)S.;5WW>#3^=-GX[  "!(8  BS"KZH9G?,^H
M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
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M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
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M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
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M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
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M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
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M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
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M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
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M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
MD%>'.X^^@E2&2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#
M9X@Z  "  (  CZB&8IBU@9J%>)<7<H6$B94Y8F>#J9-&46V"\I&*/U6"99!"
M*V^!^Y =$>6"'HP9  "  (  CR"%O*&^@0F$V9^6<>F#X9T;8<R"])J+4-6"
M-YA:/KF!LI;T*O"!.I9&$;*!$8OW  "  (  CKZ%1:KW@)>$9:A7<6.#8J5%
M83^"8J(A4%B!EY^8/E:!"IYE*IN CILU$7& 18O+  "  (  AWR8G6,5>FF6
MF&59;$24XV=X7.&39&ER3$F2#VM-.C:1(&SU)=F1.&X!"SR3E6UT  "  'U&
MAM66_6N*><^5'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1
M&')%  "  (  AB"52'/;>.Z3B'2E:M*1V75D6WN0478>2PR.]7;4.2Z-^G=T
M)0Z-U'>["QR.R'=]  "  (  A4B3L'P6=_Z1_'Q,:<R077QS6J:.VGR72DN-
MC'S .)&,E'SE))R,6'SF"P&,O'T,  "  (  A&^27819=RJ0L80':/B/&(.A
M6<:-FH,Q2:B,08+). 6+48*')#B*_H)G"NV*\8'N  "  (  @[J11XS(=G*/
MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
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MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
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M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
M8&BR]7S25.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".
MP8    "  (  8"ZQVH/Q5,>N@8.72*.K)(,J.YNG\8+!+6^E2(*#'26D$(*@
M"B>CS((Y  "-XX    "  (  7_VP_(L45+6MC8I]2)BJ'XF\.XNFX8D(+5VD
M,8BV'2NBWHD@"F6B2H:(  "-,X    "  (  7]FP5Y)&5+*LRY%^2)BI2)!V
M.X6E^8^)+4NC08]E'1BA[(Z\"GRA'X<7  ",G(    "  (  7\&OW9F@5+NL
M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
MG<1JEJ+3CHIKXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO
M-9%Z  "  (  G51I\:R7C@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#
M,U9O_YMX&L1N1Y(9  "  (  F%!_EUY:BDE_<&%&>QA_>&/X:I9_GF9V6-A_
MUVC51<: +FL-,.6 OFS>%K6"/6TT  "  '9<EU-]&V>8B49].6FD>@%]9&N'
M:9%]G&U-5^U]XV[^1/M^07"/,#E^O7')%C9_LW&[  "  'IGECEZUW"^B %[
M('(!>.5[8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "  'WS
ME05XQ'GGAKQY*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69[
M'7NF  "  (  D]-W!X,.A:YW?X+S=H1WZH*P9DUX4H)251]XQX'[0I9Y2(&T
M+E=YDH%V%.EY38%3  "  (  DM1UI(Q+A*EV)HN'=81VEXJ195AW!HF#5#IW
M?HB#0>!W]H>N+<9X,(<M%(%WQH:F  "  (  D@=T@I6)@]MU#)0C=+=U?9)\
M9)%U[I#!4WUV;(\I04%VXHWA+5IV_(U3%#EV?HL6  "  (  D6ISH)[,@S=T
M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
M9"NBZ&IU60R@N&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*
M>W>B  "  (  8YVA!W&K6&N>XG)Z3&B<R7,\/W6:T7/U,1&92'2-()"8WG3#
M#(Z:&715  ")%'OE  "  (  8PZ?;GCP5^&=4WE82]Z;.WFM/N.9/WGL,+27
MJ7HG($V7+7HQ#(Z8 7HJ  "'T7^<  "  (  8I">+(!65W&<%H!A2W69^(!(
M/GR7\X :,%663G_Z("65HG_X#)66'H 1  "&M(    "  (  8B:=+8>_5QF;
M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
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M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
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MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
MDX]B8I(2A65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK
M(XG'  "  (  DMYA+IN)A+)C.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R
M+I-J+I$E%E9J%8WE  "  (  DF9@3:3SA"YB7:)G=/MD*9^$9-EEUIR<4]AG
M>IH70<%HV9A3+B)I&)=@%>5I3([.  "  (  CGQXYUBQ@2=Y4EP)<K=YX5\H
M8OYZA&(34@%[,634/YU[[V=>*SQ\Q6E;$-Y^4&E@  "  '8)C5)UX6&Z@!!V
MF61 <9QW4F:;8?UX#VC341]XSVKK/MUYE6S3*I]Z1VY $(A[A6WV  "  'H?
MC!US&VJU?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY
M$'++  "  'VUBM5PDW.R?6MQJ'3 ;RERH76M7^ASC7:'3T]T>G=+/6=U3W?[
M*8YUO7AI$ -V['?P  "  (  B9-N:WRN?%!OF7T6;@MPJ7U77KAQI7UZ3EUR
MGGV:/(IS?7VZ*-USQGW##Z%U)7V>  "  (  B(ELI(6V>T=MXX5Z;0YN_X4,
M7<=P"82"37]Q!X/_.^-QVX.9*%MQ_X-E#UISH8+Z  "  (  A[)K+(ZZ>G5L
M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
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M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
M>KYR>)Q\;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW
M"H6&  "  (  =4Z*MU?::8")^UKP7+*)?%W>3J2))V";/S2(_F,;+?.)2F4I
M&7^*^67S ?6*%&<8  "  'Q?=%B(&U_G:+.'F6)36^B'+F2>3?B&V6;%/JF&
MJVBY+8Z&XFI+&4^(,&J[ BR';&OZ  "  '^#<VJ%D6?G9ZR%/FFS6PN$Z6MF
M32.$H6SY/?B$>&YD+0>$H6]]&0"%F6^@ DZ%$W$V  "  (  <G"#/V_?9J&#
M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
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M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
MDX%-N)@:A7M1;99$=HA4Q91)9I%7VY)259U:MY"30XQ<^H\M,"Q=>(Y\&+E?
M.8SM  "  (  DO1,=Z&7A.U0-Y\$=?=3DYQ$9@=6JYF95259B)=)0RQ;QI6-
M+\E<$Y3[&%E>9I!V  "  (  D5AIK%-B@YYK3%<O=/-L\%K,91MND%XW5!!P
M(V%X0:QQF&2 +75RI6<)$]%SQF?'  "  ''DC\IEPUR^@E-GP%^W<[9IH6*)
M9 -K;V4W4QEM)V? 0-ANKFH:+,=ODFP"$V%PYVQ2  "  ':5CDMB*F8@@-UD
M<FA)<H]FC&I78NAH@6Q#4BEJ5FX70!9KZV_%+#ELI7$5$Q)N77$/  "  'JS
MC+=>Z&]N?U-A:'#7</YCJW(E8:%EQG-84/YGPW1X/QMI8W6 *W%IZW9%$I)L
M1W8,  "  'Y'BT5<#'BX??)>M7EI;ZUA('G\8&!C67IU4!!E;'KF/D=G%WM1
M*M!G:'N=$C1J>GMO  "  (  BA%9H(((?-)<:H(';J)>\H'?7V5A1H&@3R=C
M9X%D/9UE"X$[*DUE)($L$>9H]X$[  "  (  B1E7F8M/>^=:?8J>;<5=&(F\
M7I9??XC(3F1AKH?M//IC2X="*>EC)X;_$;-GL(9#  "  (  B%Q5]I2">S%8
M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
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M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
M<PYK&'R>9V]LCWT36MIMSWU:33)NXGU^/FIOSGV<+@!P4GV]&N%OB'W"!)AX
M/'Z"  "  (  <CII,X3Y9J%JOH3D6A9L"H213'AM)80B/;IN$(/$+6YN=8.7
M&IAMB(/>!)IX.(*#  "  (  <9)GIXU&9@!I0XRQ67AJEHO-2^1KL(K./2AL
MDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "  (  <15F<96-981H&I2.6/=I<),B
M2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(!&QXAX+]  "  (  ;,6"V5)[88*"
MS57G54B"]%DL1\N#.5P].-:#H5\!)]F$>&$L$O2&NV&5  "#.F6N  "  'P#
M:Y9_A%I.8)!_P5TA5&: !U_01Q" 56)3.$. N620)W2!:V9$$M>"^V9?  "!
M"6IB  "  '\V:H1\4V(C7V]\RV1>4W9],F9\1BY]D&AN-XM]^&HG)NI^BFMG
M$I1_B6L_  "  &]Z  "  (  :6UY9FGX7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][
M:&_.)DQ[VW"A$CE\CW!(  "  '3^  "  (  :&-VU7'3751WD'+U45UX)7/U
M1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "  'GB  "  (  9W-TH'G%7'!U
M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
MGOM3U4W5C\A7"%(=@ 1:(E90;UQ=+%IC7:5@&5Y12K]BM6(1-G%D8V6!'E]C
MEF?T 7M]@&L9G-%.A5@(CA12+EMO?H15LEZ^;@A9$6'R7&]<0V4&2:M?!V?V
M-8!@F&J?':U@,FQV 8M]9&_/FMI)K&(^C#M-P&2Y?.]1G&<B;(I506E[6R!8
MJ&N^2(U;BFWH-)I<\V_:'0Y=2G$D 9I]2W3BF.A%/&QDBFM)LVWY>S)-U&^(
M:Q]1N7$-6=I55G*%1WY83G/P,\A9A74T'']:VG8& :9]-GF+EPI!-G9XB,M&
M"G<X>;Y*>7?U:;U.CWBJ6-A27'E>1IQ5:'H0,Q=69GJS' I8TWLJ ;%])'V(
ME6<]J8!^AVM"U(!L>)M'BX!<:,-+W(!+5^]/QH ^1?=2WH!#,I%3H(!8&ZM7
M*8"H ;I]%(#EE HZEHIQADI #XF(=[%%!HBG: %)B8?45SM-DX<515Q0K89[
M,BY1-88A&V=5RH:2 <)]"($PDO4X!I0_A64]P))V=OE"[9#$9VY'F(\U5KE+
MNXW61-Q.U(RV,<-/&(P;&S%4KXO+ <A\_8$TDC,V#YVTA+X[\IL'=G%!0IB&
M9P1&"99+5FQ*/Y1C1*5-69+C,8E-7I)0&O=3SX_P <U\]8$XDX-:ODWNA4-=
M85(@=EM?_58Y9GUBBEHO58%D^5W[0SUG%V&/+T]H0&2Q%JII=694  "  &W2
MD7E5F5>9@]58NUK^=2U;MEY*97]>C6%V5*-A,61X0H!C:F=*+KED76FW%DYF
M8&K:  "  '*PCYI0Y&%)@@)4;6/7<YE7N6909 ):SVBO4U9=I6KR06-?\6T0
M+=%@G6[:%;%CX&^*  "  '=BC<I,DVKK@$=0<VRG<?54 6Y68K174F_R4BE:
M67%X0&I<KW+G+1-="G08%3AAN'1S  "  'MVC!Q(KG2&?L5,VW5[<))0K79C
M86!4+'<\43177'@-/Y19NWC4+'%9NGE[%-5?YWFL  "  '[SBK%%2'X;?81)
MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
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M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
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MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
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M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
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M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
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M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
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M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
M2B?_A5(S_X99/O^%8$C_@6A2_WQO6OQW>6+W<X-H]&^,;O%LDW+O:IIU[6>@
M>.QEI7KK9*I\ZF*O?>EAM7[H8+M_Z%_#@.=?RX'F7M6!X&#;@==BWH'48]^!
MU&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]V) ;_=S40_WE"'/^"22?_
MAU$R_XA8/?^'7TC_@V91_WYN6OMY=V+W=8)I]'&*;O%MDG/N:YEV[&B?>>MF
MI'OJ9*I]Z6.O?^ABM8#G8;R!YV#$@N9?SH+C7]>#W&';@])CW8//9-V#SV3=
M@\]DW8//9-V#SV3=@\]DW8//9-V#SV3=@_]W) ;_>#40_WQ!'/^%2"?_BD\R
M_XQ6/?^+74?_AV11_X)L6OM\=&+W>']I\W2(;_!PD'3M;)=XZVJ>>^EGI'[H
M9JJ YV2P@N9BMH/E8;Z$Y6#'A>5@TX7=8MF%TV3<A<QEVX;)9=N&R67;ALEE
MVX;)9=N&R67;ALEEVX;)9=N&R67;AO]X) ;_>#40_WY &_^(1R;_C4XQ_X]5
M//^.6T;_BV)0_X9I6?R <6+W>WMI\W:%<.]RCG7L;I5YZFN<?>AIHX#G9JF"
MY66PA.1CMX7D8L"'XV'+A]]BU8?59-J'S679B,9GV8G$9]B)Q&?8B<1GV(G$
M9]B)Q&?8B<1GV(G$9]B)Q&?8B?]Y(P;_>300_X _&_^*1B;_D$TP_Y)3._^1
M6D7_CV!/_XIG6?R$;F'W?GAI\GF"<.]TBW;K<)-[Z6V;?^=JHH+E9ZF$Y&6P
MAN-DN8CB8L.)XF+0BMADV(K.9MB*QV?7B\!HUHR^:=:,OFG6C+YIUHR^:=:,
MOFG6C+YIUHR^:=:,OFG6C/]Y(P;_>C00_X,^&_^-127_DTPO_Y51.O^45T3_
MDEU._XYE6/R(:V'W@G1I\GQ_<.YWB';K<Y%\Z&^9@.9KH83D:*F'XF:QB>%D
MNXO@8\>,W&/4C,]FUHS':-6-P&G4CKIJU(ZX:]2.N&O4CKAKU(ZX:]2.N&O4
MCKAKU(ZX:]2.N&O4CO]Z(P;_>S00_X4]&O^/1"3_EDHN_Y=../^75$+_E5I,
M_Y)A5OR.:5_VAW!H\H%Z<.U[A7?J=HY\YG&7@>-MGX;@:JB)W6>PC-IFNXW6
M9<>.T6;4C\=HTX^_:M.0N6O2D;-LTI&R;=*1LFW2D;)MTI&R;=*1LFW2D;)M
MTI&R;=*1LFW2D?][(P;_?#01_X@\&O^20R3_F$@M_YI,-_^:4D'_F5A*_)=?
M5/:39EWPC6YFZX=W;^: @7;A>XM]W'63@]=QG(?2;J2+SVNLCLQIM9'):,"2
MQVC/D[]KT9.X;-"3LFW0E*UOT).K;]&3JV_1DZMOT9.K;]&3JV_1DZMOT9.K
M;]&3JV_1D_]\(P;_?301_XH[&?^402/_FD8L_YQ+-?^=4#__G59(^)M=4?&8
M8UOKDVMDY(UU;=Z&?G78@(=\T7J/@\QVEXG'<I^-Q&^GD<!ML).^;+N5NVO(
MEK9MSY:P;\Z6JW#/EJ9QSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY6E<L^5
MI7+/E?]\(P;_?301_XPZ&?^70"+_G$4K_Y])-/^@3CS[H51%]*!:3NR=85CE
MF6EAWI-S:M6,>W3.A8-]R'^+A,)ZDXJ^=IN/NG.CD[9QJY:S;[:8L6_"F*UP
MS9BH<LV8I'/-F*!TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.
ME_]](P;_?S,1_XXY&/^9/R'_GD,I_Z%',O^C3#KXI5)#\*182^BC7U3AGVA=
MUYAP:,Z1>'3&BH!]P(2(A;I_CXNU>Y>0L7>?E*UUIY>J<[&9IW.]FZ5SRYN@
M=<N:G7;,FIIWS9F9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F/]^
M(@;_@#(0_Y X&/^;/R#_H$(H_Z1&,/ZF2SCTJ%! [*E71^2I75#<I69:T)UN
M:,>5=7._CGU]N8F$A;.#C(RM?Y.1J7R;E:1YI)FA=ZV;GG>YG)QWR)R9>,J<
MEWG+FY5ZS)J4>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)F4>LR9E'K,F?]^(@;_
M@C(0_Y(W%_^</1__H4 G_Z9$+ONI237QK$\\Z:Y50^&O74O5J&19RZ%K9\*9
M<W.YDWI]LHV!A:R(B8RFA)"1H8"8EIU]H)J9?*J<EGNVG91[Q)Z2?,J=D7W*
MG(]]RYN/?<R:CWW,FH]]S)J/?<R:CWW,FH]]S)J/?<R:CWW,FO]_(@;_A#$0
M_Y,V%_^>/![_HS\E_ZA"+/BM1S+OL$TYYK14/]VS6TG0K&)9QJ1J9KR=<7*T
MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
MRYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+F_]_(@;_A3 /_Y4V
M%O^?.QW_I3TD_ZM!*O6P12_LM4PTX[I4.=BW64C+KV%8P:AH9K>A;W*OFW5\
MIY5\A*"1@XN:C8N1E(J3EH^'FYJ+A:6=B(2PGX:$OI^%A<F>A83)G86$RIR%
MA,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;A83+F_^ (@;_AR\/_Y<U%O^@
M.AS_ISPB_JT_)_.S1"SINDLPX;]2-=.Z6$?'LU]7O*QF9;*E;7&IGW-[H9IZ
MA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR B,N;
M@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;@(C+F_^!(@;_B2X/_YDU%?^B.!O_
MJ3H@^[ ])/"X0BCFOTHJW<-/-,Z]5D;"MEY6M[!E9*VI:W"DI'%ZG)]X@Y2;
M?HJ.EX:0B)6.E8*2EIE^D*"<>H^KGGB/N)]WD,F>>8[*G7J,RYM[C,N;>XS+
MFWN,RYM[C,N;>XS+FWN,RYM[C,N;>XS+F_^!(@;_BRT._YLT%/^D-QG_K#@>
M^+0Z(>V]0"/DQDDCU\=,,\G!546]NEQ5LK1C8ZBN:6^?J6]YEJ5V@HZA?(F'
MG8./@9N+E'R8E)AWEYV;<Y:HG7&6M9YPEL:=<I3*G'22RYMUD<N:=9'+FG61
MRYIUD<N:=9'+FG61RYIUD<N:=9'+FO^"(@;_C2P-_YTT$_^F-!C_KS4;]+@W
M'.G#/AS@S44?T<M+,L3%5$.XOUM3K;EA8:*T:&V9KVYWD*MT@(BG>H>!I(&-
M>Z*)DG6@D99PGIN9;9VFFVJ=LYQIGL.<:YS+FVZ8S)IOE\R9;Y?,F6^7S)EO
ME\R9;Y?,F6^7S)EOE\R9;Y?,F?^#(0;_D"L-_Z S$?^I,A7]LS$7\+XT%^7+
M.Q7:U#\=R\]),+[)4D*RQ%E1I[]@7YRZ9FN2MFQUB;)R?H&O>(5ZK'^+=*J'
MD&^HCY-JIYF69Z:DF&2FL9ECI\&99*7-F&>@S9AHG\V7:)_-EVB?S9=HG\V7
M:)_-EVB?S9=HG\V7:)_-E_^$(0;_DRD+_Z(P#_^M+A+XN"P2Z\8O$.#5. O2
MVCT<Q=1(+KC/4$"LREA/H,5>797!9&B+O6IR@[IP>GNW=H%TM7V';K.%BVBR
MCH]DL9B28;"CE%ZPL)5=L;^57;'0E&"JT)1AJ-"48:C0E&&HT)1AJ-"48:C0
ME&&HT)1AJ-"48:C0E/^&(0;_ER@*_Z8L#?^Q* [RP"8,X] H!]3?,@O)WSX9
MO=M'++'63SVDT59,F<U<68[)8F6$QFAN>\1O=G3!=7QMP'R":+Z$AF.]C8E?
MO)>,6[RBCEF\KX]8O;Z.5[[4CEFVTX]:M-.06K33D%JTTY!:M-.06K33D%JT
MTY!:M-.06K33D/^((0;_G"<(_ZHG"ORX(0GIRAL%U=X@!,GE, ^^XST=M.%&
M+*C>3CJ<VE5(D=9;58;386!\T&=I=,YN<&W-=79GRWQ[8LN$?E[*C8):RI>$
M5\JCAE7*KX94R[Z&4\S5AE3$V8A5P=F)5<'9B57!V8E5P=F)5<'9B57!V8E5
MP=F)5<'9B?^-'07_HB4&_[ ?!?+"% /9VPX!R>8@![WH+Q2RYSHBI^5#,9OC
M2CZ0X5!*AM]75'S>7EUTW65D;-ML:F;;=&]AVGQS7-F$=EG9CGE5V9A[4]JC
M?%':L'U0V[Y]4-S3?%#4X'Y1T.!_4=#@?U'0X']1T.!_4=#@?U'0X']1T.!_
M4=#@?_^5&@/_J1\#^[H2 M3-"P#)Y@\"O.T@"[#M+AFE[#DGFNM"-8_J24&%
MZ5!+>^A74W+H75IJYV-@9.=J95_G<FE;YWIL5^>";E/GBW%0YY5R3NB?=$SH
MJG5+Z+5V2N?#=DKHW79+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@
M=?^=%@'_L1(!T\,) ,?1"@"[\A$$K_,A#Z/S+AV9\SDJCO-"-H3S2D%[\U))
M<O-74&GS7%9C\V-:7?-I7EGS<&%5\W=C4O-_9D_RAV=-\(]I2^^8:TKOH&Q)
M[JEM2.ZS;4?MP&Y&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';O^G
M#P#3N@< Q<<' +K6"0"M^A,&HOHB$I?Z+Q^-^SHK@_Q#-7K]3#YQ_5%%:/U6
M2V'^6T]<_F)35_YH5E3];UA1^W5:3OI\7$SY@UU*^(I?2/>18$?VF6%&]J!B
M1?6G8T3TL61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9-:R! #$
MO@8 M\P& *S<"0&@_Q8(E?\E%(O_,A^"_SPI>?]%,F__2CEG_T\_7_]50UK_
M6T=5_V%*4O]G3$__;$Y-_W)/2_]X44G_?E)'_X131?^+5$/_D55"_IA60?V>
M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
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M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
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M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
M7O,< 5GT)@)4]# $3_4X!DOU0 A']D<*1/9.#$'W50X_]UP///=C$3KX:A,W
M^',4-?A]%C/YB!<Q^908+_JA&2[ZKQHM^[X:+/O/&RO[YQLK^^L;*_OK&RO[
MZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X  %[R" !9_A$ 4_\:
M 4[_(P))_RL#1?\S!$'_.@4^_T$&._]'!SC_3@@U_U0),_]:"3'_80HO_VD+
M+/]R#"K_?0TH_X@.)O^5#R7_H1 D_ZX1(_^Z$B+_RA(B_] 2(O_0$B+_T!(B
M_] 2(O_0$IRR  ".O   @<<  '/1  !GW0  6>,  %/]!@!-_PX 2/\6 $/_
M'@$__R8".O\M C?_,P,S_SD#,/\_!"[_1 0K_TH%*?]0!2?_5@8D_UT&(O]E
M!R#_;@<=_WD(&_^%"!K_D@D9_YX)&/^H"1?_LPD7_[<)%_^W"1?_MPD7_[<)
M%_^W"9"Z  ""Q0  =-   &?<  !8XP  3?   $?_ @!"_PP //\1 #C_& $T
M_Q\!,/\E 2S_*P(I_S ")?\U B/_.@(@_S\#'O]$ QS_20,9_T\#%_]6!!7_
M7@02_V@$$?]R!0__?@4._XH%#O^4!0W_G@4-_Z(%#?^B!0W_H@4-_Z(%#?^B
M!?\Y+P+_/# #_T$Q _]$- 3_1#H&_T1%"/]%40S_0UT1_T%I%O\^=AG_/($<
M_SJ,'O\YEB#_.)XA_S>E(_\WJR/_-K(D_S:Y)?\VP"7_-<HF_S77)O\UY2;_
M->\F_S7X)O\V_R;^-O\F_#;_)OPV_R?Z-O\H^C;_*/HV_RCZ-O\H^C;_*/\Y
M+P+_/B\#_T0O _]&,@3_2#@&_TA#"/](3PW_1UL2_T1G%O]"<QK_/W\=_SV*
M'_\\DR'_.YLC_SJB)/\YJ27_.; F_SBV)O\XOB?_.,<G_SC3*/\XXRC_..TH
M_CCW*/LX_B?Y.?\G^#C_*?@X_RKV./\J]CC_*O8X_RKV./\J]CC_*O\Z+P+_
M02P#_T8L _]*+P3_3#<%_TU!"/],3 W_2U@2_TAD%_]&<!O_0WP>_T&'(/\_
MD"/_/I@D_SV@)?\]IB;_/*TG_SRT*/\[NRG_.\0I_SO/*?X[X"K[.^LJ^#OU
M*?8\_BGT//\J\SO_*_([_RSO._\M[SO_+>\[_RWO._\M[SO_+?\\+0+_1"D"
M_THI _].+ 3_430%_U(^"/]22@W_4%42_TUA%_]*;1O_2'@?_T6#(O]#C23_
M0I4F_T&=)_] HRC_0*HI_C^Q*OT_N"O\/\$K^C_+*_<_W"SU/^DL\3_T*^\_
M_2SM/_\M[#[_+^L^_S#G/_\PYS__,.<__S#G/_\PYS__,/] *@+_2"8"_TXF
M _]2*0/_5C(%_U<\!_]71PS_55$2_U)=%_]0:1S_370@_TI_(_U(B2;[1Y$H
M^D:9*?A%H"KW1*<K]42M+/1#M2WS0[TM\D/(+O!#UR[L0^<NZ43S+>9#_##D
M0O\QXT+_,N%"_S/<0_\TW$/_--Q#_S3<0_\TW$/_-/]#)P+_2R,"_U(B O]8
M)P/_7"\$_UTY!_]>0PS_6TX1_UA8%_Y59!SZ4F\@]U!Z)/1-A"?R3(TI\$J5
M*^])G"WM2:,N[$BJ+^I'L2_I1[HPYT?%,.9'TC#B2.4PWT?R,MM'^S381O\U
MU4;_-M)&_S?-2/\WS4C_-\U(_S?-2/\WS4C_-_]&) +_3R "_U8? O]=) /_
M82P$_V,U!O]D0 O_8DH0^EY4%O5;7QSQ6&L@[E5U)>M3?RCH48@KYD^1+>1.
MF"_B3: PX4RG,=],KC+=2[<SVTO"--E*SS752^0UT$OP-LU*^SC*2O\ZR$K_
M.L9+_SO!3/\[P4S_.\%,_SO!3/\[P4S_._]*(0+_4QT"_UL< O]B(@+_9RD#
M_VDR!?]J/ GY:$8/\F50%>UA6QKH7F8@Y%MQ)>%8>RG>5H0LVU2,+]A2E#+4
M49LTTE"C-=!/JC?.3K(XS$Z\.<I.R3K(3MTZQ$_M.\%.^3V^3O\]O$[_/KI/
M_SZV4/\^ME#_/K90_SZV4/\^ME#_/O]-'@+_5AH!_U\: ?]G( +_;"8"_V\N
M!/EP. ?R;T(,ZVQ+$N5I5QG?96(?VF%L)=1==BK06WXOS5F',LI7CS7(5I8W
MQE2=.<13I3O!4ZT\OU*W/KU2PS^\4M,_N5+H/[52]D&S4O]!L5/_0:]3_T&L
M5/]!K%3_0:Q4_T&L5/]!K%3_0?]0' '_6A<!_V08 ?]L'0'_<2,"_74J _-V
M,P7K=CT*XW-'#]QO4Q?4:UX?SF9G)LIC<2O&8'DPPEZ!-+]<B3>]6I$ZNEF8
M/+A8H#ZV5ZA M%:R0K)6O4.P5<Q#K5;C1*M6\T2H5_Y$IU?_1*58_T2B6/]$
MHEC_1*)8_T2B6/]$HEC_1/]3&0'_710!_V@6 ?]P&@'_=B !]WHF NU\+@/D
M?#@'W'I$#=)U3Q;+<%H>QFQC)L%H;"R]9G4QN6-]-;9AA#FS7XP\L%V4/ZY<
MFT&K6Z1#J5JM1:=:N$:E6<='HUK>1Z%:[T>?6_Q'G5O_1YM<_T::7/]&FES_
M1II<_T::7/]&FES_1O]5%P'_8!(!_VL4 ?]T%P#_>AP!\G\B >>!*0+>@C,$
MTW] #,MZ3!7$=E8>OG%@);EN:"RT:W$RL6AY-JUF@#JJ9(@]IV*/0*5@ET.B
M7Z!%GUZI1YU>M$F;7<)*F5W62I=>[$J67_I)E5__29-@_TB28/]'DF#_1Y)@
M_T>28/]'DF#_1_]8%0'_8Q$!_VX2 /]W%0#[?A@ [8,= .*'(P'6ARX#S(,]
M"\5_212]>U,=MW9=);)S92RM;VTRJ6UU-Z9J?#NB:(0^GV:,09QEE$298YQ'
MEV*F291BL$N28;Y,D&'03(]BZ$R.8_A+C6/_2HQD_TF+9/])BV3_28MD_TF+
M9/])BV3_2?]:$P'_9A  _W$1 /]Z$@#W@A0 Z(<7 -V+' #0BRP#QX@["K^$
M1Q.X?U$<L7M:)*QW8BNG=&HQHW%R-I]O>3N;;8 _F&N(0I5ID$62:)E(CV:B
M2HQFK4R*9;I-B&7,3H=FYDZ&9_9,AF?_2X5H_TN$:/]*A&C_2H1H_TJ$:/]*
MA&C_2O]<$@'_: \ _W00 /]]$ #SA1  Y(L1 -:/%P#+CBH"PHPX";J(1!*S
MA$\;K']8(Z=\8"NA>&@QG75O-IES=CN5<7T_DF^%0HYMC46+;)9(B&N@2X5J
MJDV#:;=.@6G(3X!JXT^ :_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+?VO_
M2_]>$ '_:PX _W8. /N #0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&NB$T:
MJ(16(J* 7BJ<?64PEWIL-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']NJ$Y]
M;K5/>VW&4'INX%!Y;_).>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__2_]@
M#P#_;0T _WD, .Z#"P#;BPD U)$* ,R5$P#"E24"N9,T![&/01"JC$L9HXA4
M(9V$7"F7@6,ODGYJ-8Y\<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERIDYV<K-0
M=7+#4'-RW5!T<_!/='/]371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B#@#_
M;PP _'L* -Z&!@#5C@@ SY0) ,>8$0"^F",!M98R!JV3/P^FD$D8GXQ2()B)
M6BB3AF$NCH-H-(F!;SF%?W8]@7U^07U[AD5Z>8])=GB93'-WI$YQ=[%0;W;!
M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
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M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
M_SX0 /]!% #_0QH _T(C /5!+@#M/CH!YSU& >$\4P+=.EX#V3EH!-0X<0;1
M.'H'SS>!",TWB G+-H\*RC:6"L@VG0O&-:0,Q36L#,,UM0W!-< -P#;/#KTV
MY@ZY-O00MS;_$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L _T,-
M /]'$ #_2!0 ]4<< .M&)@#C1#( W$1! =1#30+/05@$RT!B!L@_:PC%/G0)
MPSU["\$]@PR_/(H-O3R0#KL\EP^Z.Y\0N#NG$+8[L!&U.[L2LSO)$K$[X!.N
M//$4JSS]%:D\_Q:H//\6J#S_%J<\_Q:G//\6ISS_%O\]#0#_0@@ _T@* /]+
M# #Z3 \ [$P4 .%*'0#62BP SDL[ <E*2 +$2%,$P$==![Q&9@FZ1&X+MT-V
M#;5#?0ZS0H00L4&+$;!!DA*N0)H3K$"B%*I JQ6I0+86IT#$%Z9 V1>C0>T8
MH$'[&)]!_QF>0?\9G4'_&9U"_QB=0O\8G4+_&/] "0#_1@4 _TP% /%/!P#F
M4 D XT\- -5/%0#,42< Q5$V ;]00P*Z3TX%MDU8"+-,80JP2FD-K4EP#ZM(
M>!&I1W\2IT>&%*5&C16C1I46H46>&)]%IQF>1;(:G$6_&II%T1N81>D;ED;X
M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
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M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
M_Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5)P#_$2X _Q Z /\.
M1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5 ?\*FP'_": !_PFE
M /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8 \PG_ /(*_P#Q"O\!
M\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_%RP _Q4W /\31 #_
M$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.
MJ '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_
M >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!
M_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T
M$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5
M_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_)B4 _R0P /\A.P#_'T@ _QU4
M ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9D0'N&9<![!F= >L9HP'I&:H!
MZ!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32
M'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$ _RPK /\I-P#])T, ]R5/ ?,C
M6@'O(F0!["%N >DA=P'G(7\!Y2&& >0AC0'B()0!X2": =\@H '>(*<!W"&O
M =HAN +8(<,"U2'3 M$BYP+-(O0#RB/_!,@C_P7'(_\&QB/_!L8C_P;&(_\&
MQB/_!O\L$@#_+@\ _S 0 /\S% #_,QL _S(E /HP, #R+CP ["Q) .<J50'C
M*E\!X"EI =TI<@':*'H!URB" M4HB0+3*) "T2B6 \\HG /.**,#S"BK \HH
MLP/)*+X$QRC,!,4IX@3!*O$&OBK^![PJ_PBZ*O\(NBK_"+DJ_PFY*O\)N2K_
M"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4 X#)" -LR3P#5,5H!
MT#%D LTP;0++,'4#R3!\ \<O@P3%+XH$Q"^1!<(OEP7!+YX&OR^F!KTOKP:\
M+[D'NB_'![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S
M# #_-@8 _SP) /\^# #]/1  [SP5 .0Y'P#;.2T TCH\ ,TZ20'(.50!Q#E>
M L$X9P._-V\$O3=V!;LV?0:Y-H0'MS:+![8UD@BT-9H)LS6A";$UJ@JO-;0+
MKC7!"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_
M.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_
M802T/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\
M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
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M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
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M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
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M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
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M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
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M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
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M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
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M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
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M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
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M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
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M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
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M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
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M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
M #[[ 0 Z_PP -O\3 #+_&P O_R, *_\J 2C_,0$D_S<!(?\_ A__1@(<_TX"
M&?]8 Q;_8P,3_W #$O^!!!'_DP00_Z<$#_^]!0[_X 4.__8%#O__!0[__P4.
M__\%#O__!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_
M   N_P< *O\. ";_$P C_QH '_\@ !O_)@ 8_RL!%?\R 1+_. $0_T !#O](
M 0S_4@$)_UT"!O]K @3_?0("_Y " ?^C @#_M@( _\T# /_L P#_[ , _^P#
M /_L P#_[ .(N0  >,0  &G0  !;W0  2^,  #[I   R[@  *_\  ";_   A
M_P  '?\( !K_#0 6_Q$ $_\6 !#_&@ ._Q\ "_\D  G_*@ &_S   O\W 0#_
M0 $ _TH! /]6 0#_9 $ _W4! /^( 0#_F@$ _ZH! /^[ 0#_NP$ _[L! /^[
M 0#_NP'_+RL!_RLR O\O,0+_,#0"_R\Y _\K00/_)TP$_R-8!?\A9@;_('0'
M_QZ""?\>C@O_'I@,_QZA#?\>J0[_'K /_QVX#_\=P1#_'<L0_QW;$?\=Z!'_
M'?(1_QW\$?\>_Q'_'O\0_Q[_$/\?_Q'_'_\2_R'_$_\B_Q/_(O\3_R+_$_\B
M_Q/_+RL!_RXP O\R+P+_,S$"_S(V _\O/@/_*TD%_RE6!O\G8P?_)7$(_R1^
M"_\CB@S_(Y4._R*>#_\BIA#_(JT1_R*U$?\BO1+_(L<2_R+4$_\BY1/_(O 3
M_R+Z$_\B_Q/_(_\2_R/_$O\C_Q3_)/\5_B;_%OPG_Q;\)_\6_"?_%OPG_Q;_
M,"H!_S$M O\U*P+_-RT"_S8R _\T.@/_,D4%_R]2!O\M8 ?_+&T*_RIZ#/\I
MA@[_*)$0_RB:$?\HHA+_)ZH3_R>Q%/\GN13_)\,5_R?/%?\GX17_)^T5_R?X
M%?\H_Q7_*/\5_RC_%O\G_Q?\*?\8]BO_&?0L_QGT+/\9]"S_&?0L_QG_,2D!
M_S0I ?\Y* +_.RH"_SPN O\Z-@/_.4(%_S=/!O\U7 C_,VD+_S%V#O\P@A#_
M+XT2_RZ6%/\NGA7_+:86_RVM%O\MM1?_+;X8_RW*&/\MW!C_+>H8_RWU&/TN
M_QCZ+O\8^2W_&ODM_QSS+_\<[3'_'>HR_QWJ,O\=ZC+_'>HR_QW_,RD!_S@F
M ?\]) '_0"4"_T$I O]",P/_03X%_S]*!O\]5PG_.V0,_SEP#_\W?1+_-H@4
M_S61%O\UFA?_-*(9_S2I&?\SL1K_,[H;_S/%&_TSTQOZ,^8;]S3S&_,U_AOQ
M-/\=\#/_'^XS_R#G-O\AX3?_(=XX_R'>./\AWCC_(=XX_R'_-2<!_STB ?]"
M( '_1B !_T@E O]*+P/_23H$_T=&!O]%4@G_0U\-_T%K$?\_=Q3_/8(7_CR,
M&?P\E1K[.YT<^3NE'?@ZK1[V.K8>]3K '_,ZSA_P.N,?ZSOQ'^@Z_2'F.O\C
MY#K_)>$Z_R78//\FT#W_)LT^_R;-/O\FS3[_)LT^_R;_.20!_T$> ?]'&P'_
M2QL!_T\B ?]1*P+_438$_T]!!O],30G_2UH._$EF$OA'<A;U17T9\T.'&_%"
MD1WO0ID?[4&A(.Q!J2'J0+(BZ$"\(N= RB/D0=\CX$'O)-Q _"?80/\IU#__
M*L] _RK'0O\JPD/_*L!#_RK 0_\JP$/_*L!#_RK_/" !_T4: ?]+%P'_41<!
M_U8? ?]8)P+_6#$#_U<\!?Q52 GV4E0.\E!A$^Y.;1?J3'@;YTJ"'N5)C"#B
M2)4BX$>=)-Y'I27<1JXFVD6Y)]A%QBC41=PIST;N*LM%^RW(1?\NQ47_+\!&
M_R^Z2/\OM4G_+K1)_RZT2?\NM$G_+K1)_R[_0!T!_TD6 ?]0$P'_5A0 _UP;
M ?]?(P'_8"P"^E\W!/-=0@CM6D\-YUA<$^)6:!C>4W(<VE%](-9/AB323H\G
MT$V8*<U,H"O+2ZDMR4JS+L=*OR_%2M PPDOH,+U+^#*Z2O\SN$O_,[-,_S.N
M3?\SJD[_,JE._S*I3O\RJ4[_,JE._S+_0QH!_TP3 /]4$ #_7!( _V$7 /]E
M'@'[9B<!\F8Q ^IE/0;C8TH+W&!7$M5=8AG06FT?S%=W(\A5@"?%5(DKPE*2
M+L!1FC"^4*,RNT^M-+E/N36W3\@VM$_B-K%/]#>N4/\XK%#_.*=1_S>C4O\V
MH%/_-9]3_S6?4_\UGU/_-9]3_S7_1A<!_U 1 /]8#0#_8!  _V83 /]J&0#T
M;"$!ZFTK N%L-P39:D4*T&=2$LIC7AK%8&@@P5YR)KU<>RJZ6H0NMUB,,;17
ME32Q59XVKU2H.*U4LSJJ4\([J%/:.Z54\#RB5?\\H57_.YU6_SJ:5_\YEU?_
M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
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M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
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M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
M %O, @!0T@< 1]H, $;<& !%W"< 1-TU 4'=0 (_WDL#/=Y5!#K?7P8XWVD'
M-=]V"3/@A LQX)0,+^&F#2[AO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:_Q8H
MVO\6*-K_%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3
M  !$VP0 /^D- #WI%P [ZB, .>HN #;K. $TZT(!,>Q+ B_M50,M[5\#*NYK
M!"CN> 4F[X@&)>^:!R/PK@<B\<@'(O#M!R'L_P<AZ_\((.O_"A_J_PL?ZO\+
M'^K_"Q_J_PNHGP  FZ8  (VO  !_N   <<$  &3*  !8T   3-8  $'=   X
MY   -?8, #/W%  P]QX +O@G "OY,  H^3@!)OI  2/[20$A^U(!'OQ= AS]
M:0(:_7D#&/Z+ Q?_G@,5_[,$%/_3!!3^] 03_/\#$_K_ Q/Y_P,3^?\#$_G_
M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
M '"N  !JL X :+$= &6Q+ %AL3@#7;!#!EFP3 I5KU0.4J]=$4ZN915+KF\8
M2*UY&T6MAAY"K)4@/ZRE(CZMN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND_R8[
MI/\F.Z3_)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT
M  !>N08 6[H4 %F[) !6NS$!4[L] U"[1P5-NU '2KI9"D>Z8@U$NFP00;IW
M$SZYA!4\N9,7.;FC&#BYMQDWNM89-[CT&C6V_QPTM/\>,[/_'S.R_R SLO\@
M,[+_(#.R_R#!@P  M)$  *:8  ";G@  CZ4  (*K  !VL0  :[8  %^\  !4
MP0, 3,4- $O%&0!)QB@ 2,8U $7'0 %#QTH#0,=3!#['708[QV<(.<=S"C?'
M@ PTQY -,L>A#C'(M0\PR-,/,,;T$"[$_Q,MPO\5+,'_%BO _Q<KP/\7*\#_
M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
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M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
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M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
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M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
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M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
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M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
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M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
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M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
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M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
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M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
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M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
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M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
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M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
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M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
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M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
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M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
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M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
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M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
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M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
M9#(T &,R/0!A,T0 8#-+ %\T4@!=-%H 7#1B %HT:P!9-74 5S6" %4UD %4
M-9\!4C6P 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\
M  "2/   A3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q
M %TX.@!;.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!
M3#JN 4LZPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  ".
M/P  @3X  '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]
M-P!6/3X 5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L
M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
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M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
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MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
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ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
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MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
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MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
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M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
M &[_"@%C_Q "6O\5 U+_'01+_R0&1O\L"$'_,PD\_SH*.?] "S7_10PR_TH-
M,/]0#2[_5 XL_UD.*O]>#RC_9 \F_VH/)?]Q$"/_>! B_X 1(/^($1__D1$?
M_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1_UPB _]7+07_6#,'_U\V"?]C
M/0W_9482_V90%_]E7AS_9&XB_V%\)_]?BBO_7I8N_URA,?];JC/_6K(U_UFZ
M-O]8PS?_6,TY_U?8.?]6X#K_5>8[_U3L//]3\3S\4O4]^%+Y/?51_3WS4?\]
M\U'_/?-1_SWS4?\]\U'_/?-1_SWS4?\]_UPB _]7+ 7_6C('_V$U"?]E/ W_
M9T42_VA/%_]H7!W_9FTB_V-[*/]AB"S_7Y0O_UZ?,O]=J37_6[$W_UJY./]:
MP3K_6<L[_UC5//]7WSW_5N8^_U7K/OU4\#_Y4_4_]E+Y0/-2_4#P4O\^\%+_
M/O!2_S[P4O\^\%+_/O!2_S[P4O\^_UTA _]8+ 7_7# '_V0S"?]H.@W_:T,2
M_VQ.%_]L6AW_:FHD_V=X*?]DA2[_8I$R_V&<-O]?ICC_7JXZ_UVV//]<OC[_
M6\@__UK20?]9W4+_5^5#_5;J1/E5\$3U5/5%\53Z1>Y4_D3L5/]"[%3_0NQ4
M_T+L5/]"[%3_0NQ4_T+L5/]"_UXA _]9+ 7_7RX&_V8R"?]L. S_;T$1_V],
M%_]Q5Q[_;F<E_VMU*_]H@C#_98XU_V29.?]BHSS_8*L^_U^S0?]>NT+_7<1$
M_US.1O]:W$?^6>1(^E?J2?56\$KP5?9*[57Z2NE6_D?G5O]%YU;_1>=6_T7G
M5O]%YU;_1>=6_T7G5O]%_UXA _]9*P7_8BT&_VHP"/]O-@S_<D 1_W1*&/]U
M51[_<F0F_V]R+?]L?S/_:8LX_V:6//]EH$#_8ZA#_V&P1O]@N$C_7L%*_UW+
M2_]<VDWZ6N-.]5GJ3_!7\5#K5O91YU?[3N18_TOA6?])X5G_2>%9_TGA6?])
MX5G_2>%9_TGA6?])_U\@ _]:*P7_92L&_VTN"/]S-0S_=SX1_WA(%_]Y4A__
M=V G_W1N+O]P>S7_;8<[_VJ20?]GFT7_9:1)_F.L3/UAM$[[8+Q1^E[&4_E=
MU%7U6^-6[UKJ6.E8\EGE6?=6X%K[4]M;_T_76_]-UUO_3==;_TW76_]-UUO_
M3==;_TW76_]-_V @ _]=*07_:"D&_W$K!_]X,PO_?#P0_WU&%_]^4!__?5TH
M_WEJ,/]U=CC_<8(__&V-1?IJETOX9Y]/]F6G4_1BKU;S8+A9\5_!7/!=S5[M
M7.!@Z%KL8>%:\F#:6_9;TUSZ5\]=_5/,7O]1S%[_4<Q>_U',7O]1S%[_4<Q>
M_U',7O]1_V$? _]@)P3_:R8%_W4I!_]\,0K_@3H0_X-$%_^$31__@UDH_W]F
M,OQZ<COX=7Y#]7&(2_)MDE'O:9I6[6:B6^ICJE_H8+)CYEZ\9N1<R&GA6]IK
MW5KJ:]-<\&;-7O5AR%_Y7,1@_%C!8?Y5P6'^5<%A_E7!8?Y5P6'^5<%A_E7!
M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
M;CWP>GE'['6#4.EPC%CE:Y5>X6:=9-YCI&G;8*UMUU^W;]1>PW#17M)QS5WG
M<<=?[FO"8?)FOF+V8;IC^5RW8_Q8MV/\6+=C_%BW8_Q8MV/\6+=C_%BW8_Q8
M_V,? _]F(P3_<B($_WTG!O^%+@G_BC<._XU %?^/21[ZCU,H](Q?-.Z&:C_I
M?W1+XWA^5=YRAE[8;8]ETVJ8:L]GH&W,9:APR6.Q<\9BO'3$8<EUP6'@=KQC
MZG&W9.]JM&7S9;!F]F"N9_E<KF?Y7*YG^5RN9_E<KF?Y7*YG^5RN9_E<_V,>
M _]H(03_=2 $_X$E!?^)+0C_CS4,_Y(^%/R41QWUED\H[I%;-.>+9D'@A&].
MV7UY6-%W@F#,<XIGQV^3;,1LFW# ::-SO6>L=KIFMGBX9<)YMF75>;)FYG;_
MXGT024-#7U!23T9)3$4 #A*N:.QOJFGP::AI]&.F:O=?IFKW7Z9J]U^F:O=?
MIFKW7Z9J]U^F:O=?_V0> _]K( /_>!X$_X0D!?^-+ ?_DS0+_Y<\$OB911OP
MFTTGZ)=9-.&08D+7B6Q.SH-U6,A]?F'#>(9HOG2.;;EPEG*V;IYULFRG>*]J
ML7NM:;U\JFG-?:AJXWJE;.ERHFSM;*!M\F:>;O5BGF[U8IYN]6*>;O5BGF[U
M8IYN]6*>;O5B_V4= O]M'@/_>QT#_X<C!/^0*@;_ES(*_9P[$/2?0QGLH4LE
MXYQ6,]J68$'/CFE.QXAR6,"">F&Z?8)HM7F*;K%UDG.L<IIWJ7"C>J9NK'VC
M;;A^H6W'?Y]NX'Z<<.=UFG#K;YEQ\&B7<?-DEW'S9)=Q\V27<?-DEW'S9)=Q
M\V27<?-D_V4= O]O'0/_?AP#_XHB!/^3*07_FS$)^: Y#_"C01CGIDDCWJ%4
M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
MQ]8. +W5)02RTC81I\Y"()S*3"^2QU0\B,-<1W_!8E!WOFE7<+QP7FJ[=V-E
MN7]H8+B(;%RWDF]8MIYQ5;:K<U.WNW-2M])S5+?K;U:R[VI7K_%G5Z_Q9U>O
M\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@ O-T.
M +3=(P.JVC,-G]9 ')332BJ*T%(W@,U:07C+84IPR6A1:LAO5V3&=EQ?Q7]@
M6L6(9%;$DF=3Q)YI4,2L:D_$O&M.Q=-J3\7M:%# \V11O?5A4;WU85&]]6%1
MO?5A4;WU85&]]6%1O?5A_X8* /":! #4J@0 R+8& +[!!0"WSPD L.,1 *CC
M)02?XC4-E> ^&8O>2"6!W% P>-I8.G#87T)IUF=)8]5N3U[4=E-9TW]75=.)
M6E+3DUU/TZ!?3=.M8$O4OF!*U=A@2]3M7DS1]UQ,S/E:3,SY6DS,^5I,S/E:
M3,SY6DS,^5I,S/E:_X\# -JB  #*KP, O;D$ +3&!0"KU D I.H4 9SI* :3
MZ30.B>@]&'_G1")WYDXJ;^97,FGE7SACY6<]7^1O0EKD=T56Y(!)4^2*2U#D
ME$Y-Y)]02^6L44GENU)(YL]22.;H4DCD^%%(X?Q/2.'\3TCA_$](X?Q/2.'\
M3TCA_$](X?Q/X9D  ,VI  "^LP( L[X# *C+!0"?V@D F/(8 I#R*@>&\C,.
M?/$[%G3Q0QUL\4LC9O%4*6'Q72U=\68Q6?%N-5;Q=C=3\7\Z4/*(/$WRDCY+
M\IU 2?.I04?SMD)&],=#1?3?0T3T\$-$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R
M^D)$\OI"T:(  ,"N  "RN $ I\0" )S2! "2[0P C/L< X+[* =Y^S$,</PY
M$FG\01=B_$D<7/Q0(%?\62-4_6(F4?UJ*$_]<RI,_GLL2OZ#+DC^C2]&_Y@Q
M1/^B,D/_KC-!_[LT0/_+-#__XS0__^\U/__O-3__[S4__^\U/__O-3__[S4_
M_^\UQ*H  +.S  "GOP  FLL  (_: @"&_P\!?O\< W7_)09L_RT*9/\V#EW_
M/A)8_T454O]-&$__51I,_UP<2?]D'D?_:Q]$_W,@0O]\(D'_A2,__X\D/?^:
M)3O_I"8Z_Z\F.?^Z)SC_RB<X_]PH./_<*#C_W"@X_]PH./_<*#C_W"@X_]PH
MM:\  *>Z  ":Q@  C=0  ('F 0!Z_Q !</\8 F?_(05?_RD'6/\Q"E+_.0U-
M_T$/2?]($47_3Q-"_U440/]<%3W_8A8[_VD7.?]P&#?_>1DU_X(9,_^,&C+_
MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
M +JK  "MM   H<   );, 0"+V04 A/@1 7SX'P)T^"D&;/@R"F3X.P]>^4,3
M6/E+%U/Y4QI0^5L=3?ID'TKZ;"%(^G0C1OI^)43[B"9!^Y,H0/N>*3[\JRH]
M_+DK._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@  *ZP
M  "AO   E<@  (G4  !^Z 4 =_\2 6__' )G_R8%8/\O"%G_-PM4_S\.3_]'
M$4O_3A-'_U851/]=%D+_9!A _VP9/?]U&CO_?ALY_XD<-_^4'3;_H!XU_ZP?
M,_^Y'S/_R!\R_^(@,O_G(#+_YR R_^<@,O_G(#+_YR R_^<@L*T  **W  "5
MQ   A]   'O=  !R_0D :O\1 6'_&0):_R(#5/\J!4[_,@=)_SH)1?]!"T'_
M2 P^_TX.._]5#SC_6Q V_V(1-/]I$3+_<A(O_WL3+?^&%"O_DA4J_YX5*?^I
M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
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MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
M *"T  "6O@  B\<$ ('0" !XV0X ==D@ 6_8+P1IV#P)8]9&$%[64!59U5@:
M5=1@'U'4:").U'$F2]-[*4C3A2M%TY(N0M2?+T'4KS _U<(Q/]7A,#_3\C _
MTOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$  ):[
M  "+Q   @,T# '78" !OY!$ :N0@ 63D+0->Y#@'6>1!"U7D2P]1Y%023>1=
M%DKD91A'Y&X;1>1W'4+D@A] Y(XA/N6;(SSEJB0[YKPD.N;3)#GE[B0YX_HC
M.>+_)#GB_R0YXO\D.>+_)#GB_R0YXO\DOYX  *^F  "CK@  E[@  (K"  !^
MS   <]8" &GE"0!D[Q0 7_ @ 5GP*P-4\#4%3_ ^!TOQ1@I'\4X,1/%7#D+Q
M7Q _\F<2/?)P%#KR>Q4X\X<6-O.4&#7THADS]+$9,O7%&C'UXAHQ]/$9,?'^
M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
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M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
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M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
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M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
M ):8 0"0F1, BIDD 868,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%DC6TE
M8(QU*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(_RE5
MB/\H58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH  (Z>
M  "'GQ  @Y\@ 'Z?+P)XG3L'<YQ%#&Z;31%IF54699A<&F&78QY>EFHA6Y5R
M)5>4?"A4DX8K49*2+DZ2H#!,DJ\Q2Y+",4J1X#%,D?4M39'_*DZ0_RA.D/\F
M3I#_)DZ0_R9.D/\FWG   ,E]  "\B0  LI(  *>7  "=FP  DY\  (:D  !^
MI@P >J8; '6F*@%PIC<$;*5!"6>C2@UCHE(27Z%9%ENA81E8H&@=5)]P(%&>
M>B-.G80F2YV1*4B<GBI&G*XL19S!+$6<WRM%F_0I1IK_)T>:_R5'FO\D1YK_
M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
M--\; #+@)P QX3( ,.$] "[B1P MXE !*^): 2KC90(HXW$")N1_ R7DCP,C
MY:$$(N6T!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X  )BE
M  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1  *^X8
M "GN(@ G[RL )>\T "/P/  A\$4 '_%. !WR6 $;\F0!&?-Q 1CS@0$7])("
M%?2E A3UN@(3]=8"$_3O A+R_ (2\/\"$O#_ A+P_P(2\/\"FJ0  (VM  !_
MM@  <;\  &/'  !6S@  2=,  #W:   SWP  *N,  ";T!0 D^PT (?P3 ![]
M&P <_2( &?XI !?^,0 5_SD $_]! !'_2@ 0_U4 #O]A  S_;P$,_X !"O^3
M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
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M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
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M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
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M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
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M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
M (2'  !]APD >(@6 '2()@!PB#(";(<]!&B&1@9EA4X)8855#%Z$7 ];@V,2
M68)K%5:!=!=3@'X:4(")'$Y_EAY,?Z4@2G^V(4E_S"%)?NL?2G[\'$M^_QI+
M?O\93'[_&$Q^_QA,?O\8U6<  ,-S  "V?   K(0  **)  "8BP  C8T  'R-
M  !UC@0 ;X\2 &V0(0!ID"X!98\Y F*.0@1>CDL'6XU2"EB,60Q6BV$/4XMH
M$E"*<11-B7L72HF'&4B(E1M&B*,=1(BT'4.(RAU#A^H<1(;[&D2&_QA%AO\7
M187_%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !L
MEP  9I<. &.8&P!AF"D 7I@U 5J7/@-7ET<%599/!U*65@E/E5X,3)1F#DJ4
M;Q!'DWD31).%%4*2DQ= DJ(8/I*S&3V2R1D]D>D8/9#Z%SZ/_Q8^C_\5/H__
M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
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M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
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M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
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MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
M@%,8 'Q3)0!Y5#$ =50\ '-31 %P4TP";5)3 FM260-I4F $9U%H!F51< =C
M47D(85&$"F!0D0Q>4)X-7%"M#EM1P Y:4=X/6E'U#%I2_PI;4O\)6U'_"%M1
M_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H >E<5
M '97(@!S6"X <%<Y &U700%J5TD":%90 F965P-D5EX$8E5E!6!5;0=>57<(
M7%6""EI5C@Q959P-5U6K#E95O@]55=L/557S#555_PM65?\)5E7_"595_PA6
M5?\(VTT  ,57  "X7@  K6(  *-E  ":90  D&,  (-<  ![6P8 =5L2 '%;
M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
MC#T= (@^*@"$/S4 @3\_ 'X_2 !\/T\!>C]6 7@_70%V/F0"=#YK G(^<P-P
M/GP#;SZ'!&T^DP5K/J &:CZN!FD_P =G/]X'9S_U!F9 _P5F0/\$9D#_!&8_
M_P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T A$(9
M (!#)@!]1#( >D0\ '=$1 !U1$P!<D13 7!#60%O0V ";4-G FM#;P-I0WD$
M:$.#!69#CP9D0YT'8T.K!V%#O0A@1-D(8$3S!V!$_P9?1/\%7T3_!&!$_P1@
M1/\$X$$  ,I*  "[4   L%,  *=5  ">4P  E4\  (M)  "#1PL ?4<5 'E'
M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
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M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
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M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
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MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
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M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
M                                                    !A\Z\^MJ
M>UNNNQVS-Z8VY.9/;MP\WM50[O;4JJ^&KQ+'ZR+1L=SY=6U]7$Y5IM5@8K9T
MD6+J3OGO-)3?6L*P^L1*A6OI[_>J61>>E7BR6U4$S=$;4JG">5JZQZ\C='\R
MME%=6Z:P0KQ[)'IYO2QJ^GTKY@85&6[A]%?<7U>R=-FTJ>CW?NZ$F!^/MVB:
M<OO+I[O _'4J>CL]'#W^(!+*B@X+PX>79V$)+3::\/+M]L IRLHN"\/B)9-!
MV\/8\O+0 I*NI.WAQ3U>_P"X2:H@TUX %&5]-V\/+3WO>)%41=O#R]!^.35-
M/<]D%$U\&G-P]/H\D)#41Z:Z>7O^6IP HVNB[?DU]STKJ2.H9V^C[GM^8 I"
MLC[>'EZ/E)+,WM^3VE +2Y[C27R@66G9K<:%'R4RM1.:>/MEI57SK(B<S/0]
M$[$52W6;8XV]T"RP,1;A1(^2F5$^=.S@LM,OIYT1%9Z'IIP15*3RZP)>J#O(
M6:U]&CI*?3@LS%T62F5?/SHFK?0Y/,BJ4!N'C#\@LSYZ%FMWMS7ST:-3YU5'
MIK-0JOG65J:Q^B1$3@CG'7/NNU-':HNBIIV*G:B\."H=?^Z5%5%1&JG!>'%%
M\Z*G L<L6BZ*B(J+HJ*G%-.WAIVH=/I+PK55JN5'-545J\%14X*BMX(U44=U
MZG>7M'[W?K][[H[I/5_Q4.'[\^;GX_\ 4CN_^%Y>T?BQZ^A?93\T_.Z_X/N?
M<.1MY_K]/;T^X?/=^A3Y6+U(OL</D/E8?5[B_*1<=Y_K_?T_,^ ^%C]2+[';
M\2GPL>GI3C[1\+%[/L*A,X;QV?..-8_1JB^A?+4XG1>K7V.TX71>KVT[/<)U
M3WCL^=Z//\OG/QBO@D;+&JL>Q55',56\%3E<U5:J*K7M545/.BJA$VVX5]EN
M-'=K74RT=PM]1'54E3$O+)#-$Y%:J:ZM<U>*.:Y%:YJJU45%5"A=R-ML*W<P
M/+]L=Q\<M^6X'GF/W/%\LQRY-D6CN]DN],^DK:61\$D-532K')S13PR1U%/*
MULL3V2,:]*BHKTZ-['LDY7-5%147L5/B73W"KX)FU$+)V-<UCU<W1SFN5KV:
M<S'.;HBN;JB]C55%1=$U0R=[9;@4.XF,T]X@1E/<8%;27JWM5=:*X,8BO5B.
M57+253?T2%RJOS%Y57F:Y$\T[Q+^@7-?#WZD;]M;=&W*\;8Y(ZLRG9'/:UL4
MB9=@4M6L<-'<:JD@IJ1,QQ*61M!>(&Q4Z]^UE5'"REJZ5S[KVNXQ7.E;/&J(
M]-&S1Z\6/T_^BY.*>HY2X9CS)B      ?;&ZKV>QZ_S#Z:W7V .W@A'Q1ZZ<
M/9]?W$.=$UX(<S6Z=O:OO'.B(B$TABUT\NW[GN'.UO8B>VOQD0QONK[Q^DYI
MX>SAY>CU$2QGF3L3M\O213&>;W5!/*:#LX?+Y<"*8WL7W$(MC.Q?-YD/IK=>
MWL3WRH*:G7@1C&>[YU]!&QQ_=7XD.8J*EI]=.!&QL[.'L)\9'1L]KXD!4M)3
M:\O#7T_'Z".CC]6OQK\B$?%'V>KWO9]:G,UO*GK\Y4]'2]G#S_ 1\;/N^M?0
MA,(H_+T>OV5/H[_=$G65G_2+F[:JA=6Y'M?D%5 W.MOWU*I3UD7S8OO_ (\D
MSOJ]LRJ@@3]#E^;'5QM2"?YO=R17&P;,[AA]=S1J^IM=0]J5]O5VC7IP3OZ;
MF7EBJHV]B\$>GS7<-%;ED\*[Q3MXO#6W:CN-KDNF<=/^97"DCW>V9EKU;1W.
MF3NZ=<QPQ*J1**P[B6>F:G<SIR07&%B4M6O)W,U-&4TKH%U[6N^DWS>RG]<;
M>.UVZ&#[RX/8=Q=N[[2Y#BN0TJ5%%6TZ\LT$K?FU5NN5*[]'M]UM\^L513RH
MV2*1JHJ=BKW!M=TH;S0P7&W3MJ*6H;S,>W@K53@^.1B_.CEC=P<U>**>E=T]
M]0FT?5-M%A^^.QV86_-MN\VM[:VU76B=W=31U,?Z'<;%?;=(J5=DR.R5:.IZ
MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
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M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
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M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
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M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
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MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
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MBIZF*#N:3\V.
M
M
M
M
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MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
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M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
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M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
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M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
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M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
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M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
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M']S+-OP[=^U^S &YZ9 0
M
M
M
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M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
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MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
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MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
M                              '3WKJZ8Z/JQZ<LSVSBCIVYE1QMRW;2
MX3NAB2ASRPT]4ZTP/J9U2*EHK_35$]KJI7:I%35KY$3F8W2S^^FV4.[&W-YQ
MEK8TO,+4N^-5$BL:D%^H(Y5I(W2/5&Q0W".22EE<O!D<[G=K4(6LITJ8'Q_G
MT^=&OH>WL37S([L7V0:,5RI+C8[G<++>**KMEVM%?5VNZ6VO@DIJVWW&WU$E
M)6T-932M;+3U5)4Q.CD8Y$<Q[51414,&U3%44-34459#-2U='42TM52U$;HY
MJ>HIY'13P31O1'1RQ2L5KFKHJ*FBE)*BHJHJ*BHJHJ+VHJ<%1?6@*^VVVIW4
MWAO'WAVKV]S+<&[-5G?TF)8]=+XM&R1>5L]QFH:>>GME*BK\Z:H='$U.*N1"
M?8WBF59A6?4,6QZ[Y#5)ISPVBWU5<L+7<$?4/@C?'31)YWR*UJ>=3[CBDE72
M-CWKZ&M5=/9T[ 9:-C?!)ZCLZ6CN>\V2XMLI8WR1NGM+)H,[SA\/S)'(VW6&
MMBQ>B2>)RM1\EV?+$_Z=.NFB]LL'Z)MQKZL-3F5QM6%4+G-62D1[+]?%9\UR
MHE/03-M</.U=$5U6Y['=L?IF,-IG?HLKFQ)Z/IO]QJ\J>Z#,QL1X5/1_LA]2
MN51@K]VLKI>[D_9)NO+3Y+ R=NCU?18DVFI,.IF,F1'1.DH9ZF+1-)E755[E
MX)TK;081W-3)8ERRZQ<KOOCE;H[DQ)$T55AM*1PV>-&O35BN@?*S1/GKVDUA
MMU+#HO)WCD_/2?.X^IO!OO R-4U-345-3T='3P4E)2014U+2TT4<%-34T$;8
MH*>G@B:R*&"&)B-8QJ(UK41$30[%Q11PQQPPQLBAB8R***)C8XXXXVHUD<;&
MHC6,8U$1$1$1$0CD33@G!$X(B>8&B+XT_A_R](V_LVZ>W]H=!L'OO=[I>\>9
M1TSF6_!,]F=)<LHP"18VK3T=!.Z1]QLS/T-JT+Y::-BI0R/77<Z\NFU^RNY#
M\PQJB6/;C<2MJ[A;&P1*E-CN1O5U5=\;=RIW4%-(YSJJ@;\U/JZOB8BI3N<O
M4C='#EQR\+<*.+2SW>226'E;HRDK%57U%&NGS6L757Q)P^9JU/H*H,+!T-+7
M  'RYK7)HY$4_454[#]153L/M'JGK]Y?=)=/;HY$56I[7EY:G(DGIX+Z4.1L
MFGI3V.PYFR^OVE[?=)#4V?M^9Z?,<K9/6B_#\IS))KZ%]CXSF273SJGL\4]@
MD%19^WYOI/M)/93V#D27UJGL\?E.5)?S44E$UFXK\WT^;C]T^TD_KO=^Z<B2
M?\%?87[JGVDOK7VTU^526R6;^L][RU/KO->SE\O;/WO/5[_W#Z[[UI[B_F$(
MZS?UGM:>_HI^\Z^KW_E'>>KW_N'[WOK;Y>V<?WFX_0_ZWA\A6VW^W.X6Z^2T
M>';9X5D^>Y37?.IK#B5DN-]N2PH]C)*J6FMT$[Z:AIU>BS5$O)!"SYSWM:BJ
M5'BV*95G%XI\?P['+UE%[J>,-LL5NJKG6+&CFM?.^&DBE=#30\R+)*_ECC;Q
M<Y$XD#<;Q;K12OK;I74=NHX]$?55M1'30-5W!K5EE>UG.]>"-UU5>PYX+!+,
M](X87R2+V,8U55?7HU%5$37BO8AG9Z7_  (]P<E=;\FZJLSBV\LLC(:AVW&!
M5=NOF<SHY&N=2WK*'PU^*8ZYB\%2C;>'/35.:)W%,F>R_AF95>5I;SO;D$>)
M6US62NQ'&*BEN>2RHJ:NAN-Z<RIL5I5OG[A+@KDU36->)UTS+J0M5O22DP^B
M6\5*</OG<8YJ6UL7YBZPTNL-PJ^US5YOJR-5$5%>A65MP'FY9+C(D+."]Q#R
MNE7U.D5'1QK['/[1L*;"]+VPO3%CW['=E-N+#AS9X(X;K?(H7W'+,@[M6OY\
M@RNY/J[]=F]\BR,ADG6F@<Y4ACC;HTRK;8;+;8;-VK[T[<XC;+ V6)D==<V1
MNJ[[=N14=S76^5CI[G6M[Q.=L;I.YB55[MC$X)U.R[.\FS"I^L9!=ZFN1CE=
M3TG,D-!2ZII_<U#"C*:%W)P5_+WCT3YSG*5_06N@MD?=T5-'"BHB.>B<TLG_
M -DE=K([CQT5=$\Q?=SO,G;YU\O.70+?S3=O$F!"N=YD[/.OEY@2J:;MX^7E
M[H(9[_<^$XW.UX)[:DIGGTUX^7R@A7O\Z^TAQDGFF[>/EY>X"&>_SKV^9/+S
M E4TW;Q!#/?IZU7WCC<[7@GMJ2B>?77CY?*"&<[S)V^=?+SG&2F:;MX^7E[H
M(5SO,G9YU\O,"4S3=O'R^7X 0SWZ^I$]\XW.UX)[:DHGG[>/EY>X"&>_SKV>
M9/+SG&2F:;MX@AGO\Z^T@)3//V\?+XU4%)Y+BN/Y53I3WRW0UBM:J03\8JNF
MU\]/51*V:-->/+KRN7M12#JZ:GJF\DT;7Z=CNQ[?/\UZ:*GP%K\^V\PK<:@2
M@R^Q4=T;$UR4M8J.@N5"KM5YJ*XP+'5T_P Y=5:CN1Z\'-5. .NV1;'W&WOD
MJ,:JVW2F35R4-6Z.GN+$UUY63:,I*K1$[56)WF1%*=J++*SC3O[UJ?G'JC9$
MT1.Q>#'>\=$LZZ1;W99)J[ KHR_T#>9[;1='PT=[B:B:I'#5(V*VW!41%U5W
MU9W8B-<H+82VRNMM0ZEN%)4450Q51T-3$^&31%5.9&O1.9BZ+HY-47S*2Y8W
MQ?,D8YCNU6N147T>?S<#K[58]>,?KGVZ]VRMM5=$YS7TU;324\BHURL5\?>-
M1L\#G-7E>Q58Y.**J FE,SL\O3]TY&)PU]/Q$^H(?H\/1['M+Y@5#2Q]GL^7
MEZR(8G#7TE;V^'LX>CM3XT!4E)'V>7W.SB1#$X:^GXBN[=#KR\.'#SII[X*F
MI(^SR]SV-?<(EB:)[/'Y"OK;!V<$\WF3Y>(*HI(^SA]S\S7W"):G!$\_QJ7"
MMD'T?-V>CC[B [B=/NWZJJYQ=(-(X^]IL?BD;PDDXQ5=S1%[6Q:.AB\RN5ZZ
M(K6J5!;:;_\ 2'IP35L2>\K_ &NQ#8,\(_I*?/._JASNV*VDI%KK/M'05L.K
M:JL_1*"_9PULFFL5#I+;J%R\R.F=4R:-=% ]1VQ)R9^0              ><
M']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP          #TN_L2_
MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
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MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
M      $[Q['[ED]VIK/:H5EJ:AVKGKJD-- U4[ZJJ7Z+W<$+5U5>U5T:B*Y4
M1>2.-TKT8Q-57W$3SJOH1"Z>S.SN;[[[A6/;? +:ZOO=XF1]14R(YENL=HAD
MB;<<@O52UKDI+3;(Y4=([17O>K8HVOEDC8X=\,3Q:W8A9J>T6YNJ,_1:NJ<U
M$FKJQ[6I-4S::Z*[E1&MU5&,1&^;4G\,386(QOLJOG<OG53;4Z>=@\+Z<-L[
M/MSAD/>MI_[OR&_3PQQW+*<DJ(HF7&^7%6:\KI>Y;'!%S.;34T<<2*Y&<RBI
M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
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M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
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M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
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MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
M                                            I#)L5AO3%JJ;D@N3
M&Z(]>$=2UJ?-CGT['(G!K^U$X+JFF@ZK=0W359]VZ6;(K!]6LVX-+3M;%6N3
MNZ#(8:=BMAH+SR-565#&(C(:M$<]C41CT=&C>[%E:FFJ*.>2FJHGPSQ.5KXW
MIHJ*GG1>*.:OF5-45.*< 8BLAQV]XI>*_'\CME5:+Q;9W4];05;$9+%(U>#F
MN:KHIX)&_.CEC<Z.5BHYCG-5%4< )*#\541 ?+G(U 0[W^=>WS)Y>8$NFF[>
M/EY>X"&>_3UJOO'$YVO!.SX24SSZ:\?+Y 0SG>9.WSKY><^"433=O$$*YWF3
ML\Z^7F!*IINWCY>7N@AGO]SX3C<[7@GMJ2F>?37CY?*"%>_SK[2'&2>:;MX^
M7E[@(9[_ #KV^9/+S E4TW;Q!#/?IZU7WCC<[7@GMJ2B>?77CY?*"&<[S)V^
M=?+SG&2F:;MX^7E[H(5SO,G9YU\O,"4S3=O'R^7X 0SWZ^I$]\XW.UX)[:DH
MGG[>/EY>X"&>_P Z]GF3R\YQDIFF[>((9[_.OM("4SS]O'R^-5!#/?YU[?,G
MEYCX<[3@GMKY><E$TW;Q\O+W00SWZ>M5]XXB4S3=O'R^7X <():]ZO75>SS(
M #X        !4.-8O>,LN4=LL],LLJZ.GG?S,I:*%7:+45<R-=W43?4BN<O!
MJ*O Y(HGS.Y&)JOG5>"-3TJOH+Q['[$;D=0N;4F"[;65UQKY.[GNMUJEEI[!
MC-K=*D4MXR&Y,AG2AH(E7@C623SN3NX8Y)%1BCNSA&"VG"+=]6HT^L5]0UCK
MC<Y6-2>JD:GT&(FO<4D;E7DC15TUU57.556>P4[(&Z-XN7Z3E[57U>AJ>@VD
M>ECI0V^Z6<,6R8TQ;SEMYBII<SSFN@BCNE^K86:I2TK&HY;7CU%,YZTM&US^
M1'*^1\LKG2.%;'.=I                     ><']MY_&GZ'_R?]POXQ8#$
MWXB?^&FW7X+W3]5F@&D&8ZP          #TN_L2_X@O5=^5_4?Q,;7&7?P\?
MW,LV_#MW[7[, ;GID!                           /$%\5G=NEWV\2[K
MRW6MM7]>LF6]6&^4N,UO>1R_6L1M.X-\L.(5'/#)- O>XQ:J1VC'O8FNC7.:
MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
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MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
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MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
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M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
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MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
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M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
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MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
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MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
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MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
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M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
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M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
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MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
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M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
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MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
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MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
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M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
M   ]POPP>H]_5QX>71MU%5=:ZX7W<SI]VZN.9U;GK(LFXMFL5/C&Y3$E<JOE
M;!G]DN4:.=HYR-151%54-B[9S+%SG:S <K?(LM3>,7M4MP>JZJMUIZ9E'=TU
M7BY&W.FF37M70 [VER@    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?J
MLT T@S'6           79V$V:R_J*WPV>V"V_@;4YQO7N=@VU6)QR,D? F09
M[DUMQ>USU?=(Y[*&FJ[FV2=_9'"QSE5$15)YC-@K\KR.PXQ:V\]QR&\6VRT*
M*BJWZU<ZR&CA<_EXI&Q\R*Y?,U%4 ]S?IRV(P3I?V$V<Z==LJ+ZC@.R>V^(;
M:8M&^.&.IJ+7B-DH[/'<[DL#&1SWB\R4KJNMFTYIZN>21RJYZJNQYB>-6W#<
M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
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M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
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MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
MR8 ?Z_?QDO\ >$]0'Z<6/]81_*;W\_?2RC^^*?\ Y, /]?OXR7^\)Z@/TXL?
MZPC^4WOY^^EE']\4_P#R8 ?Z_?QDO]X3U ?IQ8_UA'\IO?S]]+*/[XI_^3 #
M_7[^,E_O">H#].+'^L(_E-[^?OI91_?%/_R8 ?Z_?QDO]X3U ?IQ8_UA'\IO
M?S]]+*/[XI_^3 #_ %^_C)?[PGJ _3BQ_K"/Y3>_G[Z64?WQ3_\ )@!_K]_&
M2_WA/4!^G%C_ %A'\IO?S]]+*/[XI_\ DP _U^_C)?[PGJ _3BQ_K"/Y3>_G
M[Z64?WQ3_P#)@!_K]_&2_P!X3U ?IQ8_UA'\IO?S]]+*/[XI_P#DP _U^_C)
M?[PGJ _3BQ_K"/Y3>_G[Z64?WQ3_ /)@!_K]_&2_WA/4!^G%C_6$?RF]_/WT
MLH_OBG_Y, =<.J#Q.NOOK3P&T;6]5'5-NAO?M[8,PM^?V?%,VK[=56JWYE:[
M+D&.V_(:>.CMM'*EPI+)E5QIF.5RM[NKD33545*3S'>'<[<&V06;-,SO.16N
MFKXKG3T5QEB?!%<(:>JI(JIJ,AC7O64];*Q..FCU .B!;4           W]O
ML.VZ+DJ/$.V5K*MRLDAZ>-T<=H45>2-T+]V,3S.K5'2JG-,D]A8G*Q%T8O,Y
M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
M               ,+GVB+!V[A>"SU_V%T$E2E!M)9,X2.*AEN#FNVRW,P3<E
MDZP0RQ/CCI7XFDKYU564K&+,YKFQJU>OO53;DNG3YN?3*Q7]U8Z>XZ)&Z546
MSWBVW9'\K5:J(Q:+F5W8Q$YEU1- #QJC 2           5'AV3W#"LNQ7,K2
M^2.Z8EDECR>VOAJ)J25EPL-SI;K1OBJZ9S*BED;44C5;)&J/8O%JHJ(1=!62
MVZOHKA JI-0U=-60JU[F*DM-,R>-4>Q4>Q>=B<4XIY@#WQ[9<J&\VVWWBV5#
M:NVW6AI+E;ZIC9&,J:&NIXZJDJ&LE8R5K9H)6N1'-1R(O%$4V:89HZB&*>%R
M/AGC9-$]$5$?'(U'L<B.1%1'-<B\4U (XY     #SM?M<'@UW/#<UN/BH].V
M+S5>#9S56JU]7N+6.W(C,*S=[:&Q8UOA%3T3$C9CN>*V"W9!(K&+3WY(*R1\
M[[K4.I\5?7)L%-07"7>C%:-S[=<GPPYW14T7"WW%4CIJ3(T9&FB4EST;%5+H
MG)4\LBJY9W*P#11,;8          !56#YSF>V688SN%MUE>18+G>&7JWY'B.
M98E>*_'\FQJ_VJH95VV\V.]VN>EN-KN5#4QM?%-#(Q[')JBD;;;E<+/7T=UM
M-;5VVY6^HBJZ&OH9Y:6LHZF%R/BJ*:HA<R6&:-Z:HYJHJ* ;\?A4_;$[(VSX
MWLQXI^-7*FNU$VCM-OZMMKL=6Y45TIT1(OKV\VU5C@;<:"NIV,YIKMBL%8E6
MY[6_>:!625$N3397KTIT@I,?WHHYF3QI'!%G%FI>^CF;]'O+_9:=J2Q2,1-7
M3T39.=51/J[=%<X#=IZ>.J_IFZM,0BSSIFWYVIWSQ5T-/+4W+;3-K#E,EH?5
M1MECHLCMEMK)KMB]V8UZ))17&"EJX7?-DC:Y%0R'XKFV(9Q0-N>(9+9,DHE:
MQSYK1<::M6!7HBI'5PQ2.GHYT1>,<K62-7@J(H!V"*H       ,3'7%XX7AF
M>'Y0WFFWRZF,/OFY%ICJF,V-V=JJ3=;>2KN5,QLC;-78MC%9-08-653%7N9L
MHKK#02*U4^L(O!;(;C=1>T&U\=0S(\OH*F[0(]$QRPO9>[_),Q$7ZO)14<CH
MK=(]/HNK)*:-=/I 'G5^,?\ :0>J;Q0H[OLS@%#6=-/1XZL5';4X_?):W-MU
M(*=S4I*S>O,Z-E%'=[>LC%J(L=H(H+-32/:E2MRGIZ>L;BHW\ZL\SWD2?'[9
M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
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M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
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MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
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MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
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ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
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M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
M                        ",M]ON%WN%#:;30UESNESK*:WVVVV^FFK;A<
M+A6S,IJ.AH:.F9+45=95U$K8XHHVN?(]R-:BJJ(<D44L\L<$$<DTTTC(H88F
M.DEEED<C(XXXV(KWR/>J(B(BJJKH@!M8^%[]D\ZU^L.IQ_<OJ^9>.BKI]J9*
M2O?;,KLS9NHW.;4Y8YGTV-[97%8DVYCK(FO@6X94E-5TCW,GBM%PA71>ZNS?
M1)N'GCZ6[YVE1M[B[U9*L-;3H[*[E NCE926>73[U)(B*WO:WD>Q51S8)6@'
MHT=#7A[=)7AS;14VS72=M/9]O;!+]5J<KR695O.X>X][IHGL_9%N)F]<U]ZR
M:Z*Z:188WO90V]DKH:&GI:=&PMRN[<;6X/M18F6#"+)!:Z9W(^MK'?W1=;M4
M,:J?6[K<9$6HK)M7+RHJI'$BJV-C&:-0#NF7"           / ZW'M]':=P\
M\M=NIXZ2WVW,\HM]!21(J14M'1WRNIZ6GB1554CA@C:UNJKP0UE[O%'!=;G#
M$Q(XH;A6Q1,;]%D<=3(QC$]36HB %&$O           -N[9/['5UQ[Y;,[1[
MUX]U.]*-HL&\&V.!;I6.U7FHW>2\6RS[@8K:<LMMONJ4.VE71)<J*BN[(Y^Y
MEDB[UKN1[FZ*O>G'N@K<;([!8\AI<QPF"FOUGMEYIX*AU][^&"Z44%=#%-W=
MI?'WT<<Z([E<J:HNBJ@!<[^A,=??\Z[H_P#[YWH_T6DX_P!7CN;_ ([8)_QL
M@_68 ?T)CK[_ )UW1_\ WSO1_HM'^KQW-_QVP3_C9!^LP _H3'7W_.NZ/_[Y
MWH_T6C_5X[F_X[8)_P ;(/UF ']"8Z^_YUW1_P#WSO1_HM'^KQW-_P =L$_X
MV0?K, /Z$QU]_P Z[H__ +YWH_T6C_5X[F_X[8)_QL@_68 ?T)CK[_G7='_]
M\[T?Z+1_J\=S?\=L$_XV0?K, /Z$QU]_SKNC_P#OG>C_ $6C_5X[F_X[8)_Q
ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
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MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
M                                     'G!_;>?QI^A_P#)_P!POXQ8
M#$WXB?\ AIMU^"]T_59H!I!F.L           ]+O[$O^(+U7?E?U'\3&UQEW
M\/']S+-OP[=^U^S &YZ9 0                            #Q8?')V%H^
MFGQ;^O;:BV4T=#:(M_+]N+8[?"U64]LL&^%MM&]]AM=(Q8XU91VRS[B04\+=
M%TBC:G,[Z2Z^74;C,>([Y;F62%B10-R:INM-$U-&0TN1PP9%30L31-(X8+JU
MK?4B<5[0#%*64           -US[$KO;/CG63U?=/<M7W-LW:Z<\>W2BIY'L
M;'5W_9'<2W8[100-<O.ZL^\V]MQEY6=L,#W.^@FF0OP\,B=29]G>+.DY8;YB
ME+>6L541'U6.W6*EC:W7BLGU?(I7:)VM:J^8 ])PRV@    &F%]MH_$%Z4?R
MOZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_$%ZKOROZC^
M)C:XR[^'C^YEFWX=N_:_9@#<],@(    !XYOVDK"GX'XVO7C:%I^XCNF<;=9
MK"K9)YHYV;@;'[8YO)41S5#6N=SU-_D1[6ZQPRH^)JZ,0P*=6MN6V=0^Y<')
MRI-<K5<6\7.1R73';/<5>CG(BKJ^J75$X-=JB=@!@Y.N0          !Z0?V
M(C+XZWI/ZVL!1].LV-=0^"Y>^-L%4VJ9'G&VS++$^:J>OU&:GD=MZ](HXT[V
M-S9%D^:^+3+-X=E<DF$;B6S5FM)E5MKE1&O1Z)<;0E.BN>OZ&YBK:UT1/G(J
M+KP5 #=U,B0                      !B4\>'*J;#O!W\0Z[U7U?NJSILS
M/%6_6:A*:/ZSG3Z#"*/ED5K^:H^N9#'W,>GZ-+RLU3FU2QW4K6LH-AMU)W\N
MDF)5]$G.[D3GN2Q6Z/1=%U=SU2<J?GG:)YP#Q<C7X           (JAHJNY5
MM);K?335E?7U5/145)3QNEJ*JKJI604U-!$Q%=)-/-(UK6IQ5RHA]QQR321Q
M1,=)+*]L<<;$5SGR/<C6,:B<5<YRZ(GI /?,Q#'V8GB>+XK'4-JV8UCMDQ]E
M4RG2C94LLUMIK<VH;2-EG2E;,E-S)&CWHQ%Y>9=-39JH*5*&AHZ)'(]*.DIZ
M5'HSNT>E/"R)'(SF=R([DUTU73T@%1$6     8YO$O\ %$Z6O"NV)EWGZCLE
MFDN]]=<;7M-M%C*P5FX^[^5T--'42V;%K9+(R&AM-L;41/NMYK70VRUQ2QI)
M(ZIJ*2FJ;4;O;R89LOC3L@RRK<L]2LL-DL5'RR7:^UL;$<ZGHH7*C8X(4<U9
MJB16PPM<FJJ]S&/ \H3Q2_&5ZQ?%?W'=?=\,J=B6S>/W:IK=KNG'":VKI=L<
M"IW(^"DKZ^%4@J<^SKZF]S:B_75LE3S33,HXZ&C>VCCPF;S[^Y[O;=EJ<CK5
MH;!2SODLV)VZ21EGMC>+62RM^:^YW+D5>:IG17ZN<D:1QJD: 8FRR(    !7
M>V.UVY&].>XQM;M%@F6;E[CYI=(++B>#X/8;EDN49#=*A5[NCM5FM-/55U7(
MC6J]ZM9RQQM<]ZM8U529V>S7;(;G1V:Q6VNN]VN$S:>AMUNII:NLJIG]D<-/
M U\CUTXKHFB(BJO! #9XQ3['=XL>2[+VC<JMN?35ANX%S:M9/L)ENY]\9G]H
MMTD,+J:&XY%C>$Y+MDW(I)GO[RC9>WT\,36JZJ6570,[AT709O=68_!=Y)L1
MM]TF3O'8S77FH2Z01*UJL;+5TENJ[.E4KE76-*A6M;VOYM6H!C(WY\ _Q@NG
M-]>_/N@K?*^VVWMFGEO>SEHM>_UG6WPJ]5NDE3LE=<^DH*%(&+,]:ME/)3Q<
M9V1*CD2S^3=,N_&)K*MSVSR.IAB1SG5-@@AR>G[INOZ,K\=FN:Q1\J<R\Z,5
MK?I(G$ Q4Y;A>8X#>I\<SO$\FPK(:9O/4V'+;#=,<O5.WO)8>:>UWBEHZZ)O
M?0/9JZ-$YF.3M12RM=;Z^V5#J2Y4-9;ZIB:OIJZFFI*AJ<SFZNAJ&1R-3F:J
M<4[44 ID@P          "*HJ&MN5736^W4E57U]9-'3TE%14\M55U51*Y&10
M4U- R2:>:1RZ-:UJN5>Q#[CCDFD9%%&^661R,CCC:Y\CW.71&L8U%<YRKV(G
M$ RG=-?@?>*_U855M;M)T.;Y4]DN;H7P9INEC:;(X*ZAE:V62Z4N6[P5&$V>
M\T,$"J]?O=)632:<D4<DJMC=>C$>G3>W-GP_>/;G(VT\RM5MPO-)^QVVK&J(
MJS,KK\^W4]1&UO']"61R]C45VB &RYT=_8G=T+[):<CZ[NJW&\ M3I(9[CM=
MTUVF;,\MJ**1K7/HZG=3/K99\7Q>\0<6O^KX[D=+S?1E<G%>W>!>'G>:E8*O
M<K-:2UPJK72V;$8'7"N=&NBK&^]7.&"CHYV]B\E)5LU[%4 W ^A/P:_#I\.B
MFH*WIKZ=,5H=Q:.%T=1O=GS5W%WIK998)*6KFI\\R9E55XI#7TTBLGH[!%:+
M=*G%:?555>]VVVP6U.U#(I,1Q2BCNL;51V17-/OKD,CG-5CW,N56CWT396+H
MZ.E2")?Z@ R@EY               #PDNL'&/V$]6W5'AGU>CI/V)=1>]N,?
M5;=_]SZ;[P[EY-:OJ]#^AQ?W'#]4Y8OFM^8B<$[#6RSNC^]V<9E;^6-GU'*\
MBH^2+^Q,^K7>LAY8^#?T-O)HG!. !UT*4           /<>\-&]T^2^''X?^
M1TD4T%+D'1+TJ7NF@J.3ZQ#3W78G Z^&*?NW/C[Z..=$=RN5O,BZ*J&QKM%4
MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
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MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
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M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
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M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
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M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
M       'R]C)&.CD:U['M<Q['M1S'L<BM<US7(J.:Y%T5%X*A^*B*BHJ(J*F
MBHO%%1>U%3SHH!YK/VD[[.Y>.F[)<PZ]NA/;JX77INR*HNF5;_[.8A13W&JZ
M?[_4S55SO>?XCC]!2.GI]BZ]%=45L$7>1XG/WCD;%9UC;;\1_5OTK5&)5E?N
M9MM:I9\2JWS5N3V&AC=*_&*I[GS5%SH:6)BN;C<O%TC6ZI1.U^C!HD0&E>8^
M                                             "?8ME.2X/DN/YGA
MF07K$\OQ.]6S(\7RC'+G6V7(,<R"RUL-QL]\L=XMTU/<+7=K7<*>.>GJ()&2
MPRL:]CD<B*1-%6UENK*6X6^JJ*&OH:B&KHZRDFDIZJDJJ>1LL%13SQ.9+#/#
M*Q'-<U4<UR(J* >KU]G9\=6S>*-M#4;';[UUEQ[K?V4QVDFRRCIWQ4-%OKM_
M0MH;7%O'C%N<K4I+]35\\=/E-L@1T%)63P5E-W=-7-I*+-GTJ]2-/O+8G8YD
MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
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MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
M      -B7P&O :W/\5[<^+<O<N+(-M^A[;?((J?<;<:GB=07K=&]4#H:FHVF
MVFJ*F%\-1>*B%[$O%X1DM+8:65%5)*N2GIY.U733TTWC>R\-N]W;56G;FTU3
M6W:[-:L51>:B)6O=8[&Y[5:ZH<U4[^?1S*9CO.]6,4#UF=L=LMOME]O<,VGV
MHP^PX!MMMYCMLQ/"<+QB@BMEAQO';-3,I+=:[;1PHC8X8(8TU<Y722/5SWN<
M]SG+F\L]GM>/VJWV2R4%-:[1:J2&AMUOHXFPTU)2T[$9%#%&W@C6M3MXJJ\5
M5555 *Z)D         :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$
M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
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MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
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M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
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MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
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M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
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M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
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M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
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M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
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M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
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M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
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MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
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M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
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MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
M      N_LEU!;Z]->:TFX_3WO%N9LGGE%R-ARS:[-<AP>^/IV2)(ZAK*[';A
M02W"USJG+-25"RTT[%<R2-S'.:L^QW*,DQ&X,NV+7Z\8]<H]$;76:XU5NJ5:
MBZ]W))2RQ.EA=V.8[5CD545%10#8^Z7?M>WBM[&14-FW@J]F^K3&J?N()9=U
ML#AQ#/8K?3M:QE/;LSVCJ,'H9:QS6HCZN[VF\SR<7/5SUYCMCAO77O9C;8Z>
M_26#.*1G*U77NVMH;FV)J:(V*X6-]NC=(J)Q?/!4.7M75>(!GBV-^VY=+%_C
MHH.H_HNWWVNJW\L-97;.YM@>]=L9+KW:5JP9>FQMPIZ-ZZ221L2JEA:JM;W[
MFHK^RV.>(CA=4D;<LV^R6S/71LDMAN-LR&%':Z=YRUW[')6QKVJB<[FIP3F5
M.(&5';#[53X*&XT=*VZ]3.5;47*KA[UMIW/V,WCHY(7MBGFEIZJ\X9AN:XG3
M30QP=K[BD<CGM9&Y[W<I>BS=:?3U=D8DV7UMDF>W5(+SC=^C5JHCG.8^HM]!
M<:%CFHWSRZ*JHB*JKH =Y<+\;+PC<]:QUC\1GI$H4?WO+^S3>K#MMW)W,<<C
M^=NX=QQ9T>K941G,B=XY%:W5S7(EQ[?U#[&7/1:;=?!8]>;_ .Z&0T%I^BB*
MNJ766B5.#N&O:O!.** =B<=\0+H,R]]OBQ/K;Z1<HDNT*U%JCQWJ2V:O;[G3
MMIWU;I[>RVYG4NK(6TL3I5='S-2-JNUT15*KI=T-M*Y8DHMP\&K%G;SPI2Y;
M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
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MR)NLU+(Y7L5%5JR1\LC@,4Y90
M          VK?!0^S'[_ /7]78CU"=6M#E'3MT9224=ZMM-6TLEEWEW_ +:K
MTF@IMOK+<Z5\V'X'<H6H^3*+E!I54\D:VJFK&ROJZ3NIT]='V3[GR4.4YQ'6
M8K@"JRHA9(Q:>_Y/#KS-9:Z>9BNH+;,U-5K)6_/:J=PR1'*]@'IU["; [-]+
MVTF$[$[ [>8WM;M/MY9X+)BF&XM1-H[?0TT2<T]95S.=)6WB^76I<^IN%QK)
M9Z^XUDLE14S2SR/D=F&QG&+!AMCMV-XQ:J2S62U0-IZ*@HHTCBC8WZ4CW+K)
M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
M%-JMR<Y=$F)8-D]]BF71E;16BL6V)ZY;K+'';8&KKVOE:@!L8])?V-/Q#=W9
MK3=^J7<O9WI(Q2I;%)<[-'<4WSW:HD=J]8(\:P6XT&VKW<J<KGKF"K&YR+W;
M]%0[7X/T";IWUT$^9W>PX/1/Y5FITE_9)?(T7BK4H[;+':%73@J_7^"KV* ;
M771#]EE\*KI FL^49EMQ>NKS<^VN@JOV5=2=5;\EPVEKV) Z7[S[-VBAM6V[
M[:L\"/ACO='?JN%7.1*IR*=U]NNC'97!'4];<+349U>85:_Z[EKXJN@9*G*K
MOJ]@@CAM*P\S=6I4QU+V_P!6H!L86FTVJPVRWV2QVRWV6S6FCI[=:K1::*FM
MULMEOI(FP4E#;Z"CCAI:*CI86(R.*-C6,:B(B(B':Z"""FABIZ:&*GIX(V10
MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
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M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755273664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Apr. 15, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,051,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755714272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">329.5<span></span>
</td>
<td class="nump">330.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">87.9<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,726.8<span></span>
</td>
<td class="nump">2,555.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">313.0<span></span>
</td>
<td class="nump">312.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">437.3<span></span>
</td>
<td class="nump">460.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">497.3<span></span>
</td>
<td class="nump">560.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">88.8<span></span>
</td>
<td class="nump">95.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,348.4<span></span>
</td>
<td class="nump">1,437.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,378.4<span></span>
</td>
<td class="nump">1,117.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(52.8)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,325.6<span></span>
</td>
<td class="nump">1,102.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">356.4<span></span>
</td>
<td class="nump">281.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">969.2<span></span>
</td>
<td class="nump">820.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 4.43<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921537776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(47.6)<span></span>
</td>
<td class="nump">87.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="num">(100.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">935.6<span></span>
</td>
<td class="nump">811.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 933.9<span></span>
</td>
<td class="nump">$ 809.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756364544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,130.7<span></span>
</td>
<td class="nump">$ 1,308.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,454.7<span></span>
</td>
<td class="nump">2,120.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,395.1<span></span>
</td>
<td class="nump">1,227.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs, net</a></td>
<td class="nump">315.1<span></span>
</td>
<td class="nump">314.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">964.6<span></span>
</td>
<td class="nump">893.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">941.1<span></span>
</td>
<td class="nump">836.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,201.3<span></span>
</td>
<td class="nump">6,700.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">3,189.8<span></span>
</td>
<td class="nump">2,760.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,258.9<span></span>
</td>
<td class="nump">2,187.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,012.2<span></span>
</td>
<td class="nump">4,085.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,917.9<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,094.6<span></span>
</td>
<td class="nump">1,107.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,674.7<span></span>
</td>
<td class="nump">19,504.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">496.5<span></span>
</td>
<td class="nump">208.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">271.3<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,003.9<span></span>
</td>
<td class="nump">2,096.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,776.6<span></span>
</td>
<td class="nump">2,577.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">6,535.6<span></span>
</td>
<td class="nump">6,521.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long-term deferred tax liability</a></td>
<td class="nump">117.8<span></span>
</td>
<td class="nump">124.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">916.6<span></span>
</td>
<td class="nump">905.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 10,346.6<span></span>
</td>
<td class="nump">$ 10,129.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(259.3)<span></span>
</td>
<td class="num">(224.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,179.3<span></span>
</td>
<td class="nump">12,208.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,611.7)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">10,326.8<span></span>
</td>
<td class="nump">9,372.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">10,328.1<span></span>
</td>
<td class="nump">9,374.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 20,674.7<span></span>
</td>
<td class="nump">$ 19,504.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921420320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6753540320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 969.2<span></span>
</td>
<td class="nump">$ 820.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">149.7<span></span>
</td>
<td class="nump">147.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(20.2)<span></span>
</td>
<td class="num">(32.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(160.0)<span></span>
</td>
<td class="num">(128.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(88.6)<span></span>
</td>
<td class="num">(21.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(180.8)<span></span>
</td>
<td class="num">(205.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Current taxes payable</a></td>
<td class="nump">225.1<span></span>
</td>
<td class="nump">154.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="num">(69.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">963.4<span></span>
</td>
<td class="nump">733.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,181.1<span></span>
</td>
<td class="nump">373.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,914.4)<span></span>
</td>
<td class="num">(323.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of business, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(198.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(126.9)<span></span>
</td>
<td class="num">(97.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(43.0)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(1,203.2)<span></span>
</td>
<td class="num">(502.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of stock for share-based compensation arrangements</a></td>
<td class="num">(14.5)<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess tax benefit from stock options</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(192.4)<span></span>
</td>
<td class="nump">311.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,308.0<span></span>
</td>
<td class="nump">1,204.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 1,130.7<span></span>
</td>
<td class="nump">$ 1,478.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746327840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, the FASB issued the following new standards, which we adopted on January 1, 2016:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have an impact on our financial position or results of operations. For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is expected to have a material impact on our financial position. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. We are currently evaluating the potential impact that this standard may have on our financial position, results of operations and statement of cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6739681056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 21, 2015, we announced a corporate restructuring, which included the termination of certain pipeline programs and an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in workforce. We anticipate making cash payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this program, which includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to previously accrued 2015 incentive compensation, resulting in net expected restructuring charges totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$105 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These amounts have been substantially incurred and will be substantially paid by the end of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to our workforce reduction and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to the pipeline program terminations.&#160;We previously recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of restructuring charges in our consolidated statements of income during the fourth quarter of 2015. Our restructuring reserve is included in accrued expenses and other in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the charges and spending related to our restructuring efforts during the first quarter of 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746316672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for discounts and allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">616.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(262.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(48.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(229.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(283.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">612.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6917990832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">607.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">964.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory included in investments and other assets in our condensed consolidated balance sheets primarily consisted of work in process.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the FLIXABI program, which have been capitalized in advance of regulatory approval. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our inventory included </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with our ZINBRYTA program, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the FLIXABI program and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the BENEPALI program, which had been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746400464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(510.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,578.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">427.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,331.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(561.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,769.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,662.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,650.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,012.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$88.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$95.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. In-process research and development amounts are adjusted for foreign exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$418.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc (Elan). The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,689.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in acquired and in-licensed rights and patents during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Samsung Bioepis, which became payable upon the approval of BENEPALI in the E.U. in January 2016. For additional information on our relationship with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was completed in the third quarter of 2015. Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">265.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">321.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">293.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">277.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">271.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">259.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,688.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">257.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,917.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918074800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,568.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,536.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">554.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">603.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">563.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,543.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,058.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">992.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,880.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,053.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,521.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,506.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">461.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$303.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$301.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6900793648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">488.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. Our overnight reverse repurchase agreements are collateralized with agency-guaranteed mortgage-backed securities and represent approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of total assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,225.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,222.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">507.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,023.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">163.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,181.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">373.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746374272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and, beginning in the fourth quarter 2015, in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,251.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,375.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$721.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. A net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts was recognized as a component of other income (expense), net, for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to a net loss of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918058896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,394.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,330.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">). We are building a biologics manufacturing facility on this land in the Commune of Luterbach over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$158.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918093152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$953.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$970.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918058896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(26.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(70.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746334912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746322032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Grants Under Share-based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">73,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">351,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015, our stockholders approved the Biogen Inc. 2015 ESPP (2015 ESPP). The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP (1995 ESPP), which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,200,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares were issued under our 2015 ESPP, compared to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares issued under our 1995 ESPP in the prior year comparative period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6910392496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our effective tax rate increased due to a state tax benefit in 2015, described below. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S.&#160;federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S.&#160;federal tax examination for years before 2013 or state, local, or non-U.S.&#160;income tax examinations for years before 2004. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2015, we received a final assessment from the Danish Tax Authority (SKAT) for 2009 regarding withholding taxes and the treatment of certain intercompany transactions involving our Danish affiliate and another of our affiliates.&#160;In April 2016, we received final assessments for 2011 and 2013 regarding withholding taxes for similar intercompany transactions. The total amount assessed for 2009, 2011 and 2013 is estimated to be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$67.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including interest.&#160;We are disputing the assessments for these periods, and believe that the positions we have taken are valid.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended March&#160;31, 2015, the net effect of adjustments to our uncertain tax positions was a net benefit of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily related to the state impact of a federal uncertain tax item.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the tax authorities. In addition, the Internal Revenue Service (IRS) and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hiller&#248;d, Denmark. We initiated a mutual agreement procedure between the IRS and SKAT for the years 2001 through 2009, to reach agreement on the issue. In addition, we applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years. Over the past year, we have reached agreement with the tax authorities in the U.S. and Denmark regarding the tax treatment of these items for the years up to and including 2009. We have recorded the results of these agreements, which were not significant to our results.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746374272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets includes prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$613.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">582.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">635.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,003.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL, our Italian subsidiary,&#160;received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In January 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only "the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months" of TYSABRI sales, which ended in mid-February 2009. That appeal is still pending. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. As a result, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. AIFA and Biogen Italia SRL are still discussing a possible resolution for the period from February 2009 through January 2013. We have approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recorded as accrued expenses and deferred revenue both included in our long-term liabilities in our condensed consolidated balance sheets for this matter as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information relating to our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921123616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007, we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. Our anti-amyloid beta antibody, aducanumab, for the treatment of Alzheimer&#8217;s disease resulted from this collaboration. Based upon our current development plans for aducanumab, we may pay Neurimmune up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$275.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. We may also pay royalties in the low-to-mid-teens on sales of any resulting commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration agreement. Accordingly, we consolidate the results of Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are required to reimburse Neurimmune for amounts that are incurred by Neurimmune for research and development expenses in support of the collaboration. Amounts reimbursed are reflected in research and development expense in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were immaterial. Future milestone payments and royalties, if any, will be reflected in our condensed consolidated statements of income as a charge to noncontrolling interest, net of tax, when such milestones are achieved.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also consolidate the financial results of our other variable interest entities where we are the primary beneficiary. We may pay these variable interest entities up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments. We have provided no financing to these entities other than amounts provided for in the contract.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$38.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income, as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746362768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Swedish Orphan Biovitrum AB</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2007, we acquired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the stock of Syntonix. Syntonix had previously entered into a collaboration agreement with Swedish Orphan Biovitrum AB (publ) (Sobi) to jointly develop and commercialize Factor VIII and Factor IX hemophilia products, including ELOCTATE and ALPROLIX. We have commercial rights for North America (the Biogen North America Territory) and for rest of the world markets outside of the Sobi Territory, as defined below, (the Biogen Direct Territory).&#160;Subject to the exercise of an option right that Sobi controls, Sobi will have commercial rights in, essentially, Europe, North Africa, Russia and certain countries in the Middle East (the Sobi Territory). The collaboration agreement was amended and restated in April 2014. For additional information on our collaboration agreement with Sobi, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTA, the trade name for ELOCATE in the E.U., was approved by the EC in November 2015 and Sobi had its first commercial sale in January 2016. In March 2016, the EC approved the transfer of the marketing authorization for ELOCTA to Sobi, making Sobi the marketing authorization holder of ELOCTA in the E.U. As the marketing authorization holder, Sobi assumes full legal responsibility for ELOCTA, from a regulatory perspective, during its entire life cycle in the E.U. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$165.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ELOCTA, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, are reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ELOCTA in the Sobi Territory, which is the Opt-In Consideration for ELOCTA. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, we and Sobi received a positive recommendation from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of ALPROLIX. The CHMP's recommendation was referred to the EC, which grants marketing authorizations for medicines in the E.U. If approved by the EC, upon the first commercial sale of ALPROLIX by Sobi in the Sobi Territory, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in expenditures for ALPROLIX, net of an escrow payment and other royalty adjustments as described in footnote (3) to the table below, will become reimbursable by Sobi under our collaboration agreement due to Sobi's election to assume final development and commercialization of ALPROLIX in the Sobi Territory, which is the Opt-In Consideration for ALPROLIX. This reimbursement will be recognized in proportion to collaboration revenues, over a ten year period, consistent with the initial patent term of the product. If EC approval for ALPROLIX is not granted within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months of the filing date, Sobi shall have the right under the collaboration agreement to require that the escrow payment be refunded and revoke its option right for such product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table below over a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ten</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year period, consistent with the initial patent term of the products. Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net revenue represents Biogen&#8217;s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If the reimbursement of the Opt-in Consideration has not been achieved within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years of the first commercial sale of such product, we maintain the right to require Sobi to pay any remaining balances due to us within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> days of the six year anniversary date of the first commercial sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Should Sobi terminate the collaboration agreement with respect to ALPROLIX, we will obtain full worldwide development and commercialization rights and we will be obligated to pay royalties to Sobi subject to separate terms, as defined in the collaboration agreement.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012, we entered into a joint venture agreement with Samsung BioLogics Co. Ltd. (Samsung Biologics), establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;Samsung Biologics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;Under the joint venture agreement, we have no obligation to provide any additional funding and our ownership interest may be diluted due to financings in which we do not participate. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest is approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the agreement plus a rate that will represent their return on capital.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our level of influence over Samsung Bioepis, we account for this investment under the equity method of accounting and we recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a loss on our investment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013, pursuant to our rights under the joint venture agreement with Samsung Biologics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of one anti-TNF biosimilar, Japan.&#160;Under the terms of this agreement, we have made total upfront and milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which have been recorded as a research and development expense in our condensed consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make an additional milestone payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we made the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment, which has been capitalized in intangible assets, net in our condensed consolidated balance sheet as BENEPALI received regulatory approval in the E.U. in January 2016. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016. We reflect revenues on sales of BENEPALI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. Our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the Samsung Bioepis commercial agreement will be recognized in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in relation to these services as other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921123328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv), the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Forward Pharma German Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On November 18, 2014, Forward Pharma A/S (Forward Pharma) filed suit against us in the Regional Court of Dusseldorf, Germany alleging that TECFIDERA infringes German Utility Model DE&#160;20 2005 022 112&#160;U1 (the utility model), which was issued in April 2014 and expired in October 2015. Forward Pharma subsequently&#160;extended its allegations&#160;to assert that TECFIDERA infringes Forward Pharma's European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025 (the '355 patent). Forward Pharma seeks declarations of infringement and damages for our sales of TECFIDERA in Germany. Under German law, disgorgement of profits on infringing sales is a measure of damages. With respect to the '355 patent, the hearing has been stayed pending the outcome of opposition proceedings that we and others have filed in the European Patent Office, and with respect to the utility model the hearing has been stayed pending the outcome of those proceedings and proceedings in the German Patent Office.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ALPROLIX Patent Licensing Matter </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are in discussions with Pfizer regarding its proposal that we take a license to its U.S. Patent No. 8,603,777&#160;(Expression of Factor VII and IX Activities in Mammalian Cells) and pay&#160;royalties on sales of ALPROLIX. </font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. On January&#160;12, 2012, we filed an appeal in the Regional Administrative Tribunal of Lazio (Il Tribunale Amministrativo Regionale per il Lazio) in Rome, Italy seeking a ruling that the reimbursement limit in the Price Resolution should apply as written to only &#8220;the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months&#8221; of TYSABRI sales, which ended in mid-February 2009. The appeal is still pending. In June 2014, AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. AIFA and Biogen Italia SRL are discussing a possible resolution for the period from February 2009 through January 2013.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, four qui tam actions filed against us by relators suing on behalf of the United States and certain states were unsealed by the U.S. District Court for the District of Massachusetts. All but one of the actions has been voluntarily dismissed. The pending action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. The United States has not made an intervention decision in the action, which we have moved to dismiss. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015 in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff seeks a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest, and attorneys' fees. We have filed a motion to dismiss, which is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015, the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. A hearing has been scheduled for late 2016.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Petitions and Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. A hearing has been scheduled for late 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG filed petitions in the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating multiple sclerosis and Crohn&#8217;s disease using specific formulations of natalizumab (TYSABRI). The USPTO has not yet decided whether to institute review.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 10, 2016, the European Patent Office revoked our European patent number 2 137 537 (the '537 patent), which includes claims covering the treatment of multiple sclerosis with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. The decision was issued verbally and will be followed by a written decision, from which intend to appeal. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2015, Swiss Pharma International AG brought an action in the Patents Court of the United Kingdom to revoke the UK counterpart of our European Patent Number 1 485 127&#160;(&#8220;Administration of agents to treat inflammation&#8221;) (the '127 patent), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat multiple sclerosis. The patent expires in February 2023.&#160;Subsequently, the same entity brought actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of the '127 patent. A hearing has been scheduled in the UK action for late 2016 and in the Dutch action for early 2017. No hearing has yet been scheduled in the German action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF), and Novartis Pharmaceuticals Corp. (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. No trial date has been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016 we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918311808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006, we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013, we paid this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment as TECFIDERA was approved in the U.S. for MS by the U.S. Food and Drug Administration (FDA). We are also required to make additional contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior twelve month period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2016, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level related to the Fumapharm Products in the fourth quarter of 2015 and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of Fumapharm Products during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments shall be due. These payments will be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm. Any portion of the payment which is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 1, 2015, we purchased land in Solothurn, Switzerland where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6908936144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B and FUMADERM for the treatment of severe plaque psoriasis. We also have a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group, which entitles us to certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our innovative drug development efforts, we aim to leverage our manufacturing capabilities and scientific expertise through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics) that develops, manufactures and markets biosimilars as well as through other strategic contract manufacturing partners. Under our commercial agreement with Samsung Bioepis, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL in the European Union (E.U.).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2015, the FASB issued the following new standards, which we adopted on January 1, 2016:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-05, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have an impact on our financial position or results of operations. For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2015</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. The adoption of this standard is expected to have a material impact on our financial position. We are currently evaluating the potential impact that this standard may have on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. The new standard simplifies the embedded derivative analysis for debt instruments containing contingent call or put options by removing the requirement to assess whether a contingent event is related to interest rates or credit risks. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have an impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. The new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The new standard will be effective for us on January 1, 2017. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. We are currently evaluating the potential impact that this standard may have on our financial position, results of operations and statement of cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6746386432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and spending related to our restructuring efforts</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Workforce</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reduction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pipeline</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">33.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring reserve as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6644342320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the changes in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">548.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">662.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">480.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">616.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(74.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(262.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(48.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(229.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(283.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">612.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in condensed consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">144.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">732.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6908911024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">607.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">577.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">143.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">964.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">893.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,001.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909029120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(510.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(506.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,578.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">427.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,552.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">452.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">718.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">730.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,331.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(561.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,769.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,303.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(502.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,800.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,662.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,650.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,012.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,646.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,561.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,085.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this analysis, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">265.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">321.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">293.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">277.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">271.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">259.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,688.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,663.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">257.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,917.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755412544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,855.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,279.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">509.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,568.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,536.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">554.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,510.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,875.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">494.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,895.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,857.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">603.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">563.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">602.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">565.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,543.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,497.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,058.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">992.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">992.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,880.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,733.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,764.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,733.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,757.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,053.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,521.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,645.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,506.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">506.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">461.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6917869616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheet:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">488.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">673.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">820.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">909.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">629.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,225.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,222.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,823.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,456.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">507.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">508.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">394.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,116.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,120.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,723.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,724.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,152.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,155.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">491.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">493.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,454.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,120.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,122.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,026.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,023.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,575.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,583.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">162.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">163.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">185.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,644.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,641.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,880.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,181.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">373.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755929952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,251.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,375.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,103.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918253872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock', window );">Reconciliation of equity attributable to noncontrolling interests</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918032000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(195.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(224.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(26.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(47.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(99.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(59.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(30.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(200.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(70.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6900208576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">822.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">218.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6893915776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock', window );">Summary of equity grants to employees, officers and directors under our current stock plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our equity grants to employees, officers and directors under our current stock plans:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance shares</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">73,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">549,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">351,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of restricted stock unit grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfRestrictedStockUnitGrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6903691664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918074800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">518.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">504.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">270.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">582.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">635.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,003.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,096.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6895787728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock', window );">Cash reimbursement as an adjustment to the Base Rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to recognize the effect of the cash reimbursement as an adjustment to the Base Rate in the table below over a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ten</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> year period, consistent with the initial patent term of the products. Under the collaboration agreement, cash payments are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rates post Sobi Opt-In</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Royalty and Net Revenue Share Rates:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Method</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate prior to 1st</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">commercial sale in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the&#160;Sobi&#160;Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Base Rate following</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1st&#160;commercial&#160;sale&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">the Sobi Territory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rate during the</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reimbursement</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period:</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sobi rate to Biogen on net sales in the Sobi Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">N/A</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base&#160;Rate<br clear="none"/>plus 5%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen North America Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net sales in the Biogen Direct Territory</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Royalty</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17%</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 5%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biogen rate to Sobi on net revenue</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">from the Biogen Distributor Territory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Net<br clear="none"/>Revenue<br clear="none"/>Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Base Rate<br clear="none"/>less 15%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mechanism for reimbursement, under the amended agreement amounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6902470368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756350944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of December 31, 2015</a></td>
<td class="nump">37.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(29.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of March 31, 2016</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">$ 37.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of December 31, 2015</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(25.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of March 31, 2016</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">33.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Expense</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of December 31, 2015</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="num">(4.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve as of March 31, 2016</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756452576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestructuringandRelatedCostExpectedCashPayments', window );">Expected cash payments</a></td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring charges</a></td>
<td class="nump">105.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">$ 93.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated', window );">Restructuring and related cost, expected percentage of positions eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="nump">$ 15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Pipeline programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Adjustments to previous estimates, net</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringandRelatedCostExpectedCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringandRelatedCostExpectedCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and related cost, expected percentage of positions eliminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Restructuringandrelatedcostexpectedpercentageofpositionseliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755397312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2015</a></td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">616.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(262.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(283.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2016</a></td>
<td class="nump">732.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2015</a></td>
<td class="nump">56.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">127.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(74.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(48.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2016</a></td>
<td class="nump">59.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2015</a></td>
<td class="nump">548.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">480.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(187.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(229.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2016</a></td>
<td class="nump">612.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2015</a></td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(5.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2016</a></td>
<td class="nump">$ 60.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755490256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 732.3<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">144.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 575.4<span></span>
</td>
<td class="nump">$ 518.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6917899888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 249.5<span></span>
</td>
<td class="nump">$ 213.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">607.9<span></span>
</td>
<td class="nump">577.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">144.1<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">1,001.5<span></span>
</td>
<td class="nump">933.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">964.6<span></span>
</td>
<td class="nump">893.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 36.9<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755268304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="nump">$ 33.8<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Preapprovalinventory', window );">Pre-approval inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Preapprovalinventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-approval inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Preapprovalinventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6757369520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,662.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,646.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,650.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,561.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,012.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,085.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">88.8<span></span>
</td>
<td class="nump">$ 95.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2016 (remaining nine months)</a></td>
<td class="nump">265.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2017</a></td>
<td class="nump">321.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">293.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">277.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">271.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">259.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Finitelivedintangibleassetsfutureamortization', window );">Total</a></td>
<td class="nump">1,688.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(510.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(506.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,578.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,552.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 427.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 418.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,331.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,303.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(561.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(502.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,769.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 718.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,689.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Finitelivedintangibleassetsfutureamortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>FiniteLivedIntangibleAssetsFutureAmortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Finitelivedintangibleassetsfutureamortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909184560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 356.4<span></span>
</td>
<td class="nump">$ 281.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">257.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">2,917.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6757370000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 5,644.5<span></span>
</td>
<td class="nump">$ 4,880.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">820.6<span></span>
</td>
<td class="nump">909.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,568.9<span></span>
</td>
<td class="nump">5,895.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">508.3<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">$ 461.8<span></span>
</td>
<td class="nump">$ 215.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">554.9<span></span>
</td>
<td class="nump">520.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,855.1<span></span>
</td>
<td class="nump">1,510.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">3,279.9<span></span>
</td>
<td class="nump">2,875.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">509.5<span></span>
</td>
<td class="nump">494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">820.6<span></span>
</td>
<td class="nump">909.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,536.1<span></span>
</td>
<td class="nump">5,857.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">46.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,855.1<span></span>
</td>
<td class="nump">1,510.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">3,279.9<span></span>
</td>
<td class="nump">2,875.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">509.5<span></span>
</td>
<td class="nump">494.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">508.3<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">508.3<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755836896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 6,521.1<span></span>
</td>
<td class="nump">$ 6,506.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">7,053.4<span></span>
</td>
<td class="nump">6,645.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">603.7<span></span>
</td>
<td class="nump">602.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">563.6<span></span>
</td>
<td class="nump">565.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,543.4<span></span>
</td>
<td class="nump">1,497.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,500.7<span></span>
</td>
<td class="nump">1,485.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,058.7<span></span>
</td>
<td class="nump">1,014.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">992.5<span></span>
</td>
<td class="nump">992.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,880.8<span></span>
</td>
<td class="nump">1,764.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,733.7<span></span>
</td>
<td class="nump">1,733.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,957.1<span></span>
</td>
<td class="nump">1,757.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,721.2<span></span>
</td>
<td class="nump">$ 1,721.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921779392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 238.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">506.0<span></span>
</td>
<td class="nump">215.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 508.3<span></span>
</td>
<td class="nump">$ 461.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6757433024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Changes in valuation techniques</a></td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 303.2<span></span>
</td>
<td class="nump">$ 301.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755266864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 820.6<span></span>
</td>
<td class="nump">$ 909.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">90.2<span></span>
</td>
<td class="nump">134.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">488.7<span></span>
</td>
<td class="nump">673.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 234.3<span></span>
</td>
<td class="nump">$ 79.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909687344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 5,644.5<span></span>
</td>
<td class="nump">$ 4,880.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">5,641.0<span></span>
</td>
<td class="nump">4,891.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">629.4<span></span>
</td>
<td class="nump">394.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">629.5<span></span>
</td>
<td class="nump">394.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,225.7<span></span>
</td>
<td class="nump">1,116.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,222.4<span></span>
</td>
<td class="nump">1,120.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,823.2<span></span>
</td>
<td class="nump">1,723.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,823.0<span></span>
</td>
<td class="nump">1,724.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,456.7<span></span>
</td>
<td class="nump">1,152.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,456.0<span></span>
</td>
<td class="nump">1,155.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">507.4<span></span>
</td>
<td class="nump">491.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">508.0<span></span>
</td>
<td class="nump">493.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921214544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">$ 2,454.7<span></span>
</td>
<td class="nump">$ 2,120.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">2,454.6<span></span>
</td>
<td class="nump">2,122.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">3,026.9<span></span>
</td>
<td class="nump">2,575.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">3,023.1<span></span>
</td>
<td class="nump">2,583.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">162.9<span></span>
</td>
<td class="nump">184.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">163.3<span></span>
</td>
<td class="nump">185.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">5,644.5<span></span>
</td>
<td class="nump">4,880.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 5,641.0<span></span>
</td>
<td class="nump">$ 4,891.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921135760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,181.1<span></span>
</td>
<td class="nump">$ 373.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755739472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets', window );">Overnight reverse repurchase agreements, percent of total assets</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">15 months<span></span>
</td>
<td class="text">16 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Overnightreverserepurchaseagreementspercentoftotalassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Overnight reverse repurchase agreements, percent of total assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Overnightreverserepurchaseagreementspercentoftotalassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918295296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 102.0<span></span>
</td>
<td class="nump">$ 96.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909511168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1', window );">Expected settlement time for contracts, in months</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 680.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 721.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,375.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,251.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss francs | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian Dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 58.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of time remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909240048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,330.1<span></span>
</td>
<td class="nump">$ 1,394.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">$ 158.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Solothurn, Switzerland land purchase</a></td>
<td class="nump">SFr 64.4<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6897178704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract', window );"><strong>Reconciliation of equity attributable to non-controlling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, beginning of period</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Fair value of net assets and liabilities acquired and assigned to NCI</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Translation adjustment and other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, end of period</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6918183440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Equity increase during the period</a></td>
<td class="nump">$ 953.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6756281056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">$ (224.0)<span></span>
</td>
<td class="num">$ (59.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(26.6)<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(34.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(259.3)<span></span>
</td>
<td class="num">(70.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">71.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(38.9)<span></span>
</td>
<td class="nump">122.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="num">(8.7)<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(47.6)<span></span>
</td>
<td class="nump">87.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(37.4)<span></span>
</td>
<td class="nump">159.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(37.8)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(37.6)<span></span>
</td>
<td class="num">(30.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(195.6)<span></span>
</td>
<td class="num">(99.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="num">(100.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="num">(100.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">$ (186.0)<span></span>
</td>
<td class="num">$ (200.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755498544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">$ (52.8)<span></span>
</td>
<td class="num">$ (15.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">356.4<span></span>
</td>
<td class="nump">281.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,309.4<span></span>
</td>
<td class="nump">2,172.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">970.9<span></span>
</td>
<td class="nump">822.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6909405376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc</a></td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="nump">$ 822.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">235.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">219.3<span></span>
</td>
<td class="nump">235.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6744662640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="nump">$ 91.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">87.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(26.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(21.4)<span></span>
</td>
<td class="num">(35.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(34.7)<span></span>
</td>
<td class="num">(55.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (36.0)<span></span>
</td>
<td class="num">$ (60.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921315680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 54.3<span></span>
</td>
<td class="nump">$ 91.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">87.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">30.1<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755384592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfStockOptionGrantsAbstract', window );"><strong>Schedule of stock option grants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Stock units</a></td>
<td class="nump">549,000<span></span>
</td>
<td class="nump">351,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfStockOptionGrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of stock option grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfStockOptionGrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921269408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Employeestockpurchaseplanmaximumshares', window );">Employee stock purchase plan maximum shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember', window );">1995 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Employeestockpurchaseplanmaximumshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Employeestockpurchaseplanmaximumshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A1995ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A1995ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6904893648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="num">(8.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6745259664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2011</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net benefit for a previously unrecognized position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member', window );">Tax Year 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member', window );">Tax Year 2008</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member', window );">Tax Year 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices', window );">Proposed deduction disallowance by tax authorities</a></td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proposed disallowance by tax authorities for payment for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProposedDisallowanceByTaxAuthoritiesForPaymentForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6758014864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 732.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">505.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">180.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">161.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">582.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,003.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,096.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(63.3)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on sales of investments, net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(52.8)<span></span>
</td>
<td class="num">$ (15.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 575.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755400960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 613.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 550.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="nump">$ 2,172.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement limit stated in the resolution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Amount reserved for this matter | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755392416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 38.8<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement', window );">Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement</a></td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement', window );">Research and development cost in support of collaboration agreement</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_OtherVariableInterestEntitiesMember', window );">Other Variable Interest Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Additional investments committed to if certain development milestones are achieved</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected total payments including upfront and milestone payments as well as the greater of an annual maintenance fee or usage-based royalty payments under the terms of collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RemainingPotentialDevelopmentMilestonePaymentsAndRoyaltiesOnCommercialSalesUnderTermsOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cost in support of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_OtherVariableInterestEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_OtherVariableInterestEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6755429264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 437.3<span></span>
</td>
<td class="nump">$ 460.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember', window );">Sobi rate to Biogen on net sales in the Sobi Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement under the amended agreement method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate after first commercial sale</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base&#160;Rate
plus 5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to Sobi on net sales in the Biogen North America Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement under the amended agreement method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember', window );">Biogen rate to Sobi on net sales in the Biogen North America Territory | Sobi Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate after first commercial sale</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to Sobi on net sales in the Biogen Direct Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement under the amended agreement method</a></td>
<td class="text">Royalty<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember', window );">Biogen rate to Sobi on net sales in the Biogen Direct Territory | Sobi Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate after first commercial sale</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen Distributor Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementUnderAmendedAgreementMethod', window );">Reimbursement under the amended agreement method</a></td>
<td class="text">Net
Revenue
Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RateDuringReimbursementPeriod', window );">Rate during the reimbursement period</a></td>
<td class="text">Base Rate
less 15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember', window );">Biogen rate to Sobi on net revenue from the Biogen Distributor Territory | Sobi Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatePriorToFirstCommercialSale', window );">Rate prior to first commercial sale</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BaseRateAfterFirstCommercialSale', window );">Base rate after first commercial sale</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember', window );">Biogen Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of stock acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodForGrantingOfApprovalByApprovingAuthority', window );">Period for granting of approval by approving authority</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reimbursementrecognitionperiod', window );">Reimbursement recognition period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementCostAchievingPeriod', window );">Reimbursement cost achieving period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimePeriodForPayingRemainingBalanceDue', window );">Time period for paying remaining balance due</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember', window );">Swedish Orphan Biovitrum | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BaseRateAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rate after first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BaseRateAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodForGrantingOfApprovalByApprovingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for granting of approval by approving authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodForGrantingOfApprovalByApprovingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RateDuringReimbursementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate during the reimbursement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RateDuringReimbursementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatePriorToFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate prior to first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatePriorToFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementCostAchievingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement cost achieving period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementCostAchievingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementUnderAmendedAgreementMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement, under the amended agreement, method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementUnderAmendedAgreementMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reimbursementrecognitionperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement recognition period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reimbursementrecognitionperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimePeriodForPayingRemainingBalanceDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time period for paying remaining balance due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimePeriodForPayingRemainingBalanceDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_SobiRateToBiogenOnNetSalesInSobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenNorthAmericaTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_SobiTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetSalesInBiogenDirectTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyAndNetRevenueShareRatesByTerritoryAxis=biib_BiogenRateToSobiOnNetRevenueFromBiogenDistributorTerritoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecHemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SwedishOrphanBiovitrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6745572272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437.3<span></span>
</td>
<td class="nump">460.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="nump">52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Variable interest entity, qualitative or quantitative information, ownership percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity minimum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Recognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share with Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6897701792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2014</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReimbursementLimitStatedInResolution', window );">Reimbursement limit stated in the resolution</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReimbursementLimitStatedInResolution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement limit stated in the resolution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReimbursementLimitStatedInResolution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921327776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences (Details) - Fumapharm AG - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember', window );">Seven billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">7,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EightbillionMember', window );">Eight billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash portion of consideration</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember', window );">One billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember', window );">Three billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SevenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SevenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EightbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EightbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_OneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_OneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_ThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6921134320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies Commitments and Contingencies (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_CH', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 180.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M P04    " !:AY5(2'4%[L4    K @  "P   %]R96QS+RYR96QSK9++;L)
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M_1JBP\N)*UM;WQY3/Z*S5U5^ 5!+ P04    " !:AY5(F5R<(Q &  "<)P
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M]S_#7DR:%V$_)AQ_TXU_=MA:3]BJ5^K,G_O>?=4\W+<C[_?D/_P/4$L#!!0
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M1YO7F[8ZOYW4WHZ+-_\#4$L#!!0    ( %J'E4@E?!_MM $  $0$   8
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M9=:BP%H,J1_.6EO\4] *JD65LGQ[DT&K!= B78RT2%%DAC0'L@;';&D9M5I
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M<+SU9S,-U&0X["_?8_FCY5]02P,$%     @ 6H>52/)+5@^? 0  L0,  !D
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M^9>-_6\0'7@IR<V>DL[_G\60T+AP_.[/9AJIR7#87S_(\DO+?U!+ P04
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M[\/93B,U&1[[ZP=9?FGY%U!+ P04    " !:AY5(%LWA#* !  "Q P  &0
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M?]G8_QK1@9>2W.PH:?W_F0T)M0O''_YLQI$:#8?=]8/,O[3X!U!+ P04
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MA+,=1VHT/':W#S+_TN(?4$L#!!0    ( %J'E4A/$NKBU0$  $4%   9
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MNZ/A)K5*67"II'>NX-Z]!.N"0VO]]-[-]=P<\\*JX=KJZWM3_0502P,$%
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M]F*3IA?=:T:/2@IB <?NVQ?0L:[E1N#P_9R#'/)1JG?= ACT*7BGCU%K3'_
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M>FOG:FJ.:6%D?VWUY;TIO@!02P,$%     @ 6H>52,>H0"BC 0  L0,  !D
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M5 _2[31*"VK=4K?8]!IH'4B"8Y*F.1:4R:0L0NQ%EX4:+&<27C0R@Q!4_[T
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MHO- 0F5]=^_Z>KRUX\!B=WV#\X\@_P]02P,$%     @ 6H>52'8R\-VA 0
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MI*R[/N&0&Z4LN"CIC<O2N4<Z+S@TUD]OW5S'>QL75O675SC_%92?4$L#!!0
M   ( %J'E4@IU)6VT@(  &P+   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;)5638^;,!#]*XA[ 9O/K C2)E75'BJM]M">O8F3H 6<8F>S_?>UC4,
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M,GE>L-0*-&&@"0&M5S\AH"FS/B>,-"&D=0 ([<W6US]AI DA;5L73"LE_T$
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M13;7K6%,8J7H>VK8K7I?EPW!C=1AJF(^/3G31K+A]H NKWCY!U!+ P04
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M6.T!Y*1/>\L-4$PF)D 'BQ0#*F4\S19^\E*;B#&?,TP[,#V6;J!EFHVKZ@G
M.%.ANF)8\AC0//\*DO[DE/0O( !KE2F4;2RA3(%LA^:$191IN@PS+'T,:)]W
M9V*^KC&K5,+&>0$XQ8+W)H8ED"$-#,T*2Q?+Z(GA6'$X4!PO,=Q7$L%-YETP
M ,>M4:'$<*PXG('$!"XZ'C R$YP,QRK!*5Z&(Y7(/"\#8#*3H7L#QY7-066;
M@)OAN!;Y!#_#<2URBJ,90->JF(Y3$H.X1'!%<XJ;X20[@U!!/\-Q-7.*HQE
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MMYS.7YKR^/G2UN7-L=7_4$L#!!0    ( %J'E4CRI$B@'0,  #D.   9
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M%ZF'L1KS_J+J)Y*UCWMWO/SS/U!+ P04    " !:AY5(K<9L!VH$  "A&
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M@YPS<_?-0M#Q_I*MSVGQ'U!+ P04    " !:AY5()Z17"\X!  #6!   &0
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MYC2[,U<+H<%8"9^,E]8\,NN 0:UM]Y/IR^G>30,M^N4569^RXA]02P,$%
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MCLX3(-(14088QI@!_A(B!,?\\?AV3SCFC[,;/'&BR71Y8 I0Q1%QD3E&F2,
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MH@4K1H3Y]ZJ+D(S>*+Y'T8=MV\ZT@YW)@I'F)D0C(9H(4?PE(1X)\9T0?DF
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MI>UT;^9R;*9QH45W>QKF]RG[#U!+ P04    " !:AY5(;QP"F?P#  #-$P
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MX[OJ0\G2""8A(1(:63(9!T8%X-(Z*IB#A#AH! EQ$ 0;R0*;(8XYR $'R3+
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MB(R#:.H@"BP5>DQJ,-V \;"520_2&V=$Y0MBQ2"3&&""+"8])IO$6&'/ NU
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M+8T6A(M*TE;Z]R4I6=[8-CY8Y/ M,Q0YR@<N/F0+H+Q/2IC<^*U2_1HA6;9
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M6 JFW*]7'I46_$SQ/4X^^V?=N&?7O\F"@083PH$0CH31!R9$ R&Z$.(O"?%
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MNTS-6O9CHM]HT9ZGWCAZBW]02P,$%     @ 6H>52/*L@4T4 P  " P  !D
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M!ZF'J1KS[J[H)I(UEZMON'_SOU!+ P04    " !:AY5(*7P)?1,"  !D!@
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MA9,RVUCO13<$NX/BS6VF#W\LV7]02P,$%     @ 6H>52$UL^C*E P  /Q,
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M3NC#':5)=H@>@F#QL*&D#R]A#A1T/FZ_A+W-/T<./ ZW7WU^;_4_4$L#!!0
M   ( %J'E4@L9K19=X(  &8, @ 4    >&PO<VAA<F5D4W1R:6YG<RYX;6SL
MO<ER(VF2)GCN>0J3%$\)4 1$8%^\JTH$3J='LM(7)DF/R*R1.1@!(VD9  P)
M YS!/.5#]*5%NB]]Z5>8\\R;Y).,?JKZ;[:  -VC.TMJ#NXD ;-_T5]_W9=_
MRO-M],MRL<K_^3</V^WZ]???Y[.'9!GGK6R=K.B;NVRSC+?TY^;^^WR]2>)Y
M_I DV^7B^VZ[/?Q^&:>KWT2[5?J777*6[5;;?_[-<#+ZS;_\4Y[^RS]M_^5M
M-MLMD]4VBE?SZ'RU3;=/T<5*QDRS570:Y0_Q)LG_Z?OMO_S3]WA'WNM%'[+5
M]B&G=^;)O/CMAWC3BGJ=9M1M=X;%+Z=K^K(SJ/[RN?7\G]/;?+N)9]O_J_BF
M/GR5W*=X@H;X&"^3XE-O+C[]</XQNOAXUJH9X(QFW\0+FG6>_!+]/GDJ/G>V
MVVRPPG=I/J/G_I3$&T A>AMO2].=GG:ZI[U.S53OTD6RB<[HO?ML4YKG?;RY
M3Z+I;);04_3,7)ZOA=C-T[HT?Z=]^H?:%RZ339K-:]=N#O'_^$__:>])^7!X
M1Q^6<*7XI,Y;^>P?2K":TJMS>7T1WQ>_O8L7>6GEYB2SY9)0YGJ;S7YN1M>,
MQ]&GW3;?$G*EJ])89QD=^2HG0--O>;9(YPSUZRW]P +R*+LCM)AERR1J?%[%
MNWE*WY_0'?E\_39JO#K1NQ*EJ^A#NE@0ON;-Z)7_Y[Z+,BA^>95\25:[)']=
M_.)RD\UWLVTS6B7;NI>BNTVVI%NT34_/WG;;T?:!D&B=[+;I+%IOLOM-O"RM
MYA,>*GYXDVWIS#8Z;!EFN=S5Y)<U8%=>+#]!@,OC14+@2'Z9+7: ?A0OL\TV
M_:O<:WH@GOUEEVX(X.F*#N@^O5TD49SGR;8TZ562$[+-'GCB.:ULD:UQ0,7G
MKA."^NJ^&=TGJP1W&L_'\V6Z8A*Q3;^44&?Z-8O:;NA4=AML;O: VUMZJ/$#
MD>.3:)'EA$RKZ"Y.-]&7>+%+",#+),YW&\8TS#PC^DHCX2_Z-4_G( *TJNKS
MF17/H?B8XBUC!7$.&:L: VBO@N,ZUDDEHNF MPD1Y\2\LHU_,2N0U1#TZ";2
M#9 MW]&O7PA02<)CX@-ZI69H;[#2#7_1N!_I&UEH_3=1 R.>1/%VNTEO=]L8
M)[[-HE6VPHEL,D8IH$-"5WV;'S9?:;@W:49'"VI2XD/>6W1.0E-*M^I-G--%
MIENPHM7D[L%C)GJ;+G8@<%\WRD])>O] PYS&7PBKB&,I$=SE?&LBHOBSW2(&
M+E?0A@,H+I%Q$FL>Z#FZK_OI[UY::T>M';1>N)![,0M>DC,J[>GSBF2P1?I7
MVL<]7?9<$"HAE*(+GR<SH@_;E. 3?XG3!<.7+A!3QWVHM'?469P_1'>+[#%Z
M2.;WR5Z<W#L0[AH(WRW1R[N4AKA=I/>55$>$H-E3!%$K7PB]C.=_WN7;*DHL
M1"JKA:+>NGT+/ZMZ[0@\K7S_&U[VJO$/Q/<W\2)>S1(244APSU^"VV^36;T<
M8016X5OE2PCL ;%F- +%)HZ$RU<AK/R<"(P<'I<8Z&P&+2,GAC9+:*1;Q>O2
MBG?)(2)*#>LA861;(3+K-0WV6\,O]SY# A;1PNU3,UHO8E5& !B6,FJ65! /
M*I_Z(<OFCW2$51N2BY/S7')1]JV_^CMSTHLTODT7?#[EX]9GUA!T1,A995LB
M2.OXB<_6+> N71%>LJRVH6M^+S2YM*#X%_=V+3K4?[_9)4YL<;/O/S=OAR7^
M^56[>9^M[D_INB])L+Q+-A#]((>8^6I0;F'?VK,PV<&>!Z"PI!X:6!%P5GX8
M1H'7^3J>)?_\&Z([>;+YDOSF7Z*2G* $<9[,F"H*=W[(%B1.YM^I?%9&?[/U
M7'2G=6S$U%?M5KO=<9)"U1; YRK?:P_J7YS.B>(1/A*$UG$Z/V7)89T2Q"I0
M9K>$1)',*SD*2'I9.-\2L_-DG=+9;%CZ?C(KC[<L4E<?H<=E GC^_6__M0:B
M'VL82O7XU6.4T,>3L+^>T30N8URLAX2H;[P XWD5?5]C_ DDJ7=RK:#79WGZ
MC)&F'K,.1*2729!@;.](/GH1;STSTE4>:$^@(S-2(:NI[-2*0CD$"F*&A $I
MT:.5D^XA:-!?LY>,_S8AC">HB]P%M=937$OGA5,\O8T!)MP5 ECE<V_-X3AM
MKH)(/8!VLI'#6RFS(UZ(AZ#, \N@*4L(AW.%0QB X7#;?8Q)184C-U.EJWGG
M1U++%U+4Y]'M4^4Q/H=:HL0^<_0DG,R29*ZOL%F%U[J,MT:W()Q?'B*L7>XV
M!('\B#>FL(?(->>7;G<YT=7<2<8,#6,UV3O?>I^057'/*ZTAA$3"">@RO=LM
MXS6A^C*:_B!+D(4^<VA&4:T"_G,'YLD4AQY8FN<[)L*PB8&ZB?Y7<T7WRBKG
MO\P(]"R?&(U-<(*'S=:5)IX]*%NUFQKK!-AE(NK]@=K#^=U=,F,427Z1:Q?!
MJFVO8';$6+4J2Y, <9^NP.)937M@&TJ:E3!QSP@):,V^=Z]W2[HK3WCH.KU?
MI7?$,0DOE:YAZDMB1!4RV[]4/+*'67KSY-X\L1MD73//X2N,WN@%CCY](1$R
M31Z-=),258GN%]DM<?;;-..+1=+FCN4#QM%X12@#(SX$L54T3_-91H.PQ56M
MLOS[,E[M[F)C&16;[2*5)U7IPTKH!J\)YYEEXDK@ +:$9ULC::R2W2:;)V+,
MA?$64P(/Z=#@$MMFB^R>=$<B$'.E4,P9=]LL72YW*WX^VT!2:T6?=ANE>+3Z
MM1C4P0=@G4ZBF_.S=Q=OSZ^FS6CZXZ>/YW]L1I?OSW^XNGC[IV9T\Z?KZ9NK
M"Q[\W?3#Y9^NIKQ@$DJWZ1KD<[9(-B0,D;CQX?JD&9V__W1V,[TYYZ=HI01,
M8BIQ-.4AIN\OKSZ]O_AC\=LW,L'G#U-:R(=JD.0$YDT" OH7$K+7M+LTIGE;
MT4^D^2SR+'J("4PQ@62QB&\SI9GQ_281^>TQW3Y$/Q! 22"=/31%I&W8#VCM
M<?1(TNWBZ31[A/R\3):WQ#?U?EQE,_K_ATVV6S?IN71&5PF^EP7;_W"B,Z+P
M)'E;/L%[NK,BXP:VPUR608+F&A2"WKJZN/G\Q^G'&C3(5J>_R^;W/Z>K[_)H
M\;1</V3+N$F$9).MZ/CED]D3S B+9/=SLB1@-L[>OS_QQ0B+(\WHA^F__>G'
M*9W]G% ;Z% Y+0T@BX<,#XOFQIO;#;PF[9- P,Z&T+!!.-XB $>Q:CK8:+:#
MM7V5?5%\WNSN?8=&E-S16D"4'ND4TR5>621J9\T8@_VK10I3J!SD,UPG7'\6
MI4A )**])3CM[A^BZWB9[^@MNN_).J4Y,."?,])-(IA7=H17?"[><^]QOW(2
MM5O1^^V<,,7[CN]>?D+#D^ZD>\C]RV_%%%RZ'#0E3Y<IP9$^)Q1(%K!JV-4)
M--E-D^BE9BI9V#(I!ML57^C/I AL> ]$FY;)AO&K@.FE+1-893T"+JSAS?G'
M\\OI^PL<:D3R$(T^2]9;;[T1*S&)<,KSCV^NSM^#$P)CSG<0:NC%SRN<<..\
M];EUTHI@K6>9YQ*:^FHKU_!"W@&55$,,[2T67M_DKT#JF<YBIIW17!AY1>F9
M^4J/NU:Y4W\,18L!7J>4-$6,$GF'+Q51=[CY(%^+!$ B.)$0"':0,L!.<"]B
M<5JM_8W0^X![Y?QXA]5=PEYAIRQM8V>;.<M!?#(^4Z/Y9Z"CN?';+9[P/1V"
M"&J #,'7ZGG0ZEK7+;K'TTL"]LT#!!,7,J 0T%?I'/ZR(Z1)-C3J)H$5#,SK
M'3T>P5M.DEBV6Y X!)=<+!Z,;/7GW6K&@_%B!<F>@SPPJG2(8FKSEX3!IJL5
MP3JZ*BWG]Y86/<&]GB#8(GI+!\)4V!A\HX;\L&^="'^KD!0B>'?F23[;I+<.
MFG__VW^+Q&Q&!"90I)UV[ZG4?__;?S<K#^?E/>_6_&H3M]GB3M-"WT):3@K[
M.DU6M4A]JR8+#FJ)Z+/8X)X2:@:NR@/KW6:=0;UXI+F)'-!G<U6J 0Z]/E6G
M18+CCH;/Z%TZHN#60*Y99#D3L$VB[F"2EBW.R4;H:^+_?,N=?]6QD@<B1-%2
M8F;D&#^P"]M$R41-/AI,;H"6+IX,4\+FE.<ZO=+,:.:XV]%J&4_H [ZK)* I
M'=W=YK1T$,+P,K*D($/"<DVXY\^0)_="C(2WT^G]^Q+R'"KC[GZ2:WLPZ20R
MOV"5I8:V@483MAGR%\A) '@Z3^D0$T,)]%$C$7VA[UC9-L9 $9WP_.,#A#JP
M_$TB>@@=& BP:'FTC,U3"Q<IW$3Y?5H+< '#$/_/<M&3%ZPTDMI%U[#]6X-7
ML%!E2V+AS!5AL-K,?6O5D:XR0R!J )X'!CJ=@C"4 $R#JNXU X>Y3XHKQ)8
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MEK1DP>N&MY@( W:2X'%4EEFJ41B7\<^$$&:"9O3GW?Q>J2W3^3S?+<6P)6B
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M\6H/H+@1P2'-;-P-"M#,34J*2\PSJ::==M>+HF ==C+T/BFJL,Z\^:MD:(A
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M(*,&?OZ5IM!'4>5]$;WCCH<9Q!LL]D3D(%N7R>Q)RF(MT_GIN^1VHTWJ2%R
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M(,)ATPP?1+W;H!S%;D%Z+]3HKR[B4;8'< G(ES$[17AE^]Z5<'NN)BTC>$"
MN/3\NXKU4HJ2MK\C[%\D]R+UBY5*:NBX93;5'8$P"62-(-29=" C_31-RV>
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M#2:%L*;!<Q?IEC60+;/%V=83TB[51F^MI9X(_GN"[!S6@,RD7_&7O_=E4!,
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M]*]P37F>AL"VC72;^(DNR._HGF\?9M Y+L/H?%TI/T;WP(ONWS0U6 <Q@ZP
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MA5H/Q>\YO&LC140]*?(X&LSLV*BB[ >P\S6=!U_CSE&J?NVY/[EEJCC-A )
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M1;:Z%[7==X;"6-#1)[Q,EF-6#Z7O!4N#]/(RX)>%QZ^$/S2@9PX E^@%F^Q
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M[5^Q6_QR=5KL/(*E3S7AE5FLXH6=V-V.85T5[\\AL/L,E*._$DNFGN?C)39
MPHBKIYESR"J=A #+:4IXJD5F>4=%<XG#25,M)$VR#:2\)_5E? 7'Y.3W-;10
MBF"*%N]:<G:F>$/]-$NP^^U4((PP.YP%XJV\K&Q$A'N"!*>0U)PL1T<D^'+-
M&#;!UUP^(\W7=%2UCLABLYX]B7+<!G 6DWF!;"9]/NE(LW8E1)H0#E3\*W.O
MGLDHR4'HJ!PAD^Y^X@6A]HD?G^\8BRJO4:J\K$$\6BT9J!90QFB_XJ S<0<9
MYYQ%X&6YJPE/-6-<\P,,&3?Y>A0R)IS3 Y'Q0R@"U5SG.O8SB-SQ>G[7=%-!
M1RM[3O_+V>L7HW=O!G(EL67X<CG=Q?24GV/]?GE^]MO@Q1GY6DW.[EP^6JY@
M"'2I3O$1HL=B/ET^82R;XF9?Q/O!]0HG%#)Z?E4>B,T$2WAX58F<Y)9:CC%E
M/C8;@<G#H5J72,^64Y\DN^_D)\G12^J3?>JVF?HD08BA-#%V7$?L'J=3TXCQ
MC@'8T6EN13<'5/UD67C?U3=R5\XV,YF+=EM^4!W?*?6&GPI(;Y]?>J7ZQE^Y
M^OI"*1QL+^4>N6>]P_2:Y/8*=P_>7KP>_D8_Z]8"D$/<$[M\Q/<XLVQ^("SD
MCWX C4A#^HB#$-YB4G=J5M^LIA\VMRB3D:<%/B+WX5C;$/FH&51B@:Q$N5Y2
MQKNKP8O1F=/+ON?P$UNN@1GZHWLVMI['?)'$.2^R0 G(/6U&E&\.'+#). ]/
M7IZ=#D<#-<(O-[/Q0FTL9\7@CT3KD(A[N?J#VG"Y31[!'QJ@%;,Q3 P4K9K9
M"=H)V19! 51#QIJ2(RR/6.PU[1S%.Q$M+P4W57_(ATAQ6ZQ<8DW"."F!$"/]
MVQ7'!O2W*RH]=K]>?@.UK6.0.CWX'O*%:;NEY[R"K=><]+:V7FO[%YL'V6OU
M=A^@BIQ7_##5)[WGAZEZ.R\[SDB\]XO>0O%M7_)VJLY^P=NIMOW+;=(U,O2T
M6DZSJ+H6P/TZ-7HA6W  ,92IP;K@2TH-;&B!7*)$%>0, A)#D-O(2Y! P +6
M[Y5(@,#^J]\KH?X [I?]]OO);]_E*<:]@TWZX^E+0>+LJ' XZAW1OCCT'=LG
MF;$7NSVJO3>.5:X!4P?]TCP&D5YS9&DRN_@O/DC%QTLV)\/D1RVLG%B2'T'^
MR(\"3#!W0]-(&70)XQ\,-U@G\!%S4AJ#C^Q\"(>/]%U$\>4-=L:,[FW'3BU:
MSX2-7R6L*&2;S*+0&N_2\8KDZPG83_0M-7#3TA_PN&-TWQ^AIJ7='"D]GYEV
MCQ(B[6@0I_0EPOMZ_:/*5QX&;1"0L#" 598T@??58=EHR0^'_#3NL49&6(?%
ME;4L*B[H'&TL?0#HD_'>)^#*.I$>)ST>[V^#,.XG"V,S,:S^1(@+$Z_>LM-5
M0[NM[D"LUOT C=1RL>E8'Y3J#)[/#-/=.Z!K=W?O*?UQ8((-'1HPY,'Y+U0?
MV#''&\*%(^$"/X1I YLS2T'<F=(;)SXE)D7;C>JT5:E>.EAPA_LP5ZV(V#;O
MI2^)5+KF(UY8FY_ THN1"0'3I)D91D[I[*&E#F'17KSE3 ="NZ<@ 9[P[OL]
MX0)X189^\++?OW\PG=\'X<QJA$Y0$#R[L3E-6PV1Z2!5P:33+&$\YNM&$!;Y
MEC^JF>(CZ#Z.%JA=O<ATPT&)OBO=,*\^3P\X%=EX#.4I(MW8%G\7SWHV1K%/
M^?V(!$'D%^9UQD*"OC5V* :;RF\""3"QPKKEL@0Q:B.ZL6JBKZ=-96?^9KI8
M?1DO6@R,]>W_3N-Y;-L3YCCMYQ5XT7TP,4O>% OQ+],E9$'W@MQJ5(A8AA%"
MA\AIM0"/^*YC&3'#<\<U_MZCX6+F5)\3X*I@$',XT[)"/-XQGG-)'6'0IQE]
M0IYIY/XVDZS/0MUNT8ZG>JIYJMLM72GF:BQA\H/3V\KHH/$!\:N5@G3U<NDK
M1IWT@_+#DY]>%COJ>8;QZ]TE^$S'VQ>U>GH^=3?3Q7(Z*05OD#OM>&YXFNA(
MSXCMN:J:",7\5DV F^5=!UBYZW],E[<8MH;^'&;?0&33< +S8R32 8*[201!
M"=_'S1!9!#_9)GP/A!_9_#:0_-C>1BW2M3>3'Q6AGR^M.XP7W<57^*#4P%SY
M&J3!N6*?7 VA!1T/Q$L>B0B*#(.Q)1 98\6\'WOLEG$$SH.-<24P V,D,4TX
MH 6>!;?2NTV\\SF'=:P7X-VJA\1;292N\V<EZN4'/#6L8^QB)9^"$YSZ&W+L
MJG")V+,\[>[_\95D&/$)S:UJN06[);8A]BE)S+BTHN\M2TK/>-@6M!?&K3>-
M,MO(Q,[0TICIU;!#TM6DBEP667)E'%']H3;D,M+5*+R,:' -.#%ZYM:"*D9-
M?SD -?YI9+(0C:*1XL(?Z,7NX+%GV>>T'C+HQ.<H#'D>6AX%S<*-Z+XDE7 4
M:V\&XF@5,(ZHN:!&_,JME3\^::)CQ13;Z-MM%]*G07H9L*Z;4@V&#?-D0X ;
M8$=DRU6''9$Y(N=SBXX0GB((4X5'MUYY7[SA2.75XVGR?&T_;^[45K3+A]&Z
M_NJYX^++W70)B ^=?7=G>'5Q^2-&>"K5;P/S6S1>/88;FVGKM-#(WO'Q83&\
MNKP4IM5RM0+[G(9G<?<A7H>[$-*G)#I!"&.J7P4H$SW7\AA-I#O<_3MX9$81
MY1+3B3S_;*_'/ _()^;G= 04;3SCE1,!0]'G>_1Y 1I%.M/;>\;UL;=WQ/Q\
M&=*EZ&GD$7=$N<_]R#294JF(T!UQ#E# K**_LG*8O0_OQ<]X)VMG=2(Q?54#
M*E>[23SR%?(N332$'ZRG*V<I=AXP,$U_FM_JU"JJY"K1BIK1/=J1-=1PRJ -
MP@&K]-B1)VZ_J:]]667;L3 $YO,IWH%#1+_;)?&:8&*;K]!*9B.[;\J5PT(!
MMA]:/=ZL/\V%%&=>\<2'T[](XC8S(64M;!IX9#'TCRPN..M0*V 6F4[:\;+$
M)4)$9I'61ZA9O-:3'HBO7Y%+ .7(9DSP7(W<)EX6]+$:N\WEQ:M#W!H/K1B0
M&]NKR!E@JD@FWDWGLO_^\]\9.T4?+R*9RGT=YD"X)\"4#'\9%3NJ'7'#O'C7
MI3DPJ]+GI$Z9E\OI8ES>\&K!F1)/$NH;TK$ ]++66YL;"Y12@C6'S2B=_/H'
MPMF^291G/O4;<^)7KL )9XVGFJK;5(BK,V]5]=OQLC2Q!D:XAVH,U@'E*76V
M$LJ*CZ5GOU%%7Y=S+RY9)\HNIR8#(6PL;J9PL%T:L_HU:/C!?O&S;8/S=)Z:
M_M!52:DIL]GFCF$O6<! 91;PD=4S2%"T!B>]"NX&N!\WB>&V,J"H620L8NE4
M!U9Z;F7!<;0Y CH;J;H(QEK C)U1I/[JY7=/),UXX!LVAI4?Z&2Y-AXT976X
MS Z6(>!-/I7J*M%JM@DNW/7O QM+MB3_/+ZS$PC5-\)&#)9+F+,K,4#/6>D6
M;3(>3W2[H@YBK<AY\7FGDL&Q^C>8+YR$%#/$"?(+,RD6>7,:FFL\1I>4'$C4
MVCY+L:IQ!$/6(W^T -7_YU_PY ^+V\VJH$$'V\$$LMW&:C& X*&J51-WPUL-
MF(])@\^._3UAAULNKK';@%?/ZH1SA4F!*C*[EA^,5OW#E9 DQ)>&7I8X9#6M
M>618Q.$A^ZNIZ*?I;+[X!,?QS(;;X]-I,X\]V":SU)>IVEQ\*BZ6"XBF465_
M+L&/@RD3CAU!0T'[ESE0=<0EM4?3_X_L/+-3:YC-S+Y1P_S9>:+7Y1D?83D:
M3H_KDM[3LJP&\$Y=5+U0*[^F(5I5P2+);JB;NXDQ2AT[];:'YQ<G;P9OAAF/
M#,XO1Q?G9X3ALMV%U;@(&/:LKTL*G,&.TD%_AQ]>"$OMR^GU7M$_1EV]+VC]
MOCZ_+]P3E/.GT:^@\_\>S3DH]Z7A8--:*[B3\I%CV#G78AV:-ZDID4AGJ53=
M->@%'^#(2.GR);,WOQK/5ALE9^J=K]3V ?RL!F[Q?O\*08JDL1A6 [,)?",X
MU=AB5+M,:SIJNV#-=OK5FZBSZZHF)).,)U-5T(1!S;WEE>YOG>+O< ZZUE*E
MOAKU3[B@_UW>H9E>!X;.G5&ZPF/6JWG&6FAI'\T,M]4NUB?%\=\P7$CWLYA)
MR":NP<?<CPWE\U[?!\><:=(YUZOY%$QN^D0&SUH\(9HN2NHBIB;3CR9C@&1$
M#W;II "P.E>[Z++A+.$$]P^5ZEP]6=M^^G2<%K";+F%F^KW8)\U"*&Q@ ZL,
M7V1AL! ?:JK09R&B!<UH0_ 1Z"3;X>3@UL9J!T7F!)ALE!#C %!C'KH2X DX
M:E^W4 $1%HP6$HH80AZ=<;7W@RVON;78+'!N^Z*:^TUZ_J*ZGPP;9E*0FB[*
M!08W1J_ZIY?Q,\O*X9&*L76@MR<B7J4-$EW%,4Z\=EIG[(GOK&D3(HPG:'ZJ
MRGJR6JW_\#]02P$"% ,4    " !:AY5(Y_6>P$,"   I+P  $P
M    @ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0    ( %J'E4A(
M=07NQ0   "L"   +              "  70"  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( %J'E4C (=1E@0(  .TO   :              "  6(#  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %J'E4AVJ_+JR0,
M *02   0              "  1L&  !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 6H>52/S7JY0_ 0  :0,  !$              ( !$@H  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 6H>52)E<G",0!@  G"<  !,
M         ( !@ L  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !:
MAY5(]4$"\:8"  !_$   #0              @ '!$0  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( %J'E4@E"2T#F04  -P8   /              "  9(4
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !:AY5(QWJL8T,"  ".!P
M&               @ %8&@  >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 6H>52"^'F9#7 P  9!$  !@              ( !T1P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %J'E4B&>I]WCP(
M .<(   8              "  =X@  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !:AY5(7^Q_@7<$   Z%@  &               @ &C
M(P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 6H>52"5\
M'^VT 0  1 0  !@              ( !4"@  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( %J'E4A3F)8C.@0  'H3   8
M  "  3HJ  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !:
MAY5("QC@F*$!  "Q P  &               @ &J+@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 6H>52'?79?NA 0  L0,  !@
M         ( !@3   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( %J'E4CMR&&PHP$  +$#   8              "  5@R  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !:AY5(;- ;;J !  "O P
M&0              @ $Q-   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( %J'E4CR2U8/GP$  +$#   9              "  0@V  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 6H>52%Y ;PV@
M 0  L0,  !D              ( !WC<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !:AY5(RVA_L* !  "Q P  &0
M@ &U.0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %J'
ME4C\D #6H $  +$#   9              "  8P[  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 6H>52&H "KFB 0  L0,  !D
M         ( !8ST  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !:AY5(!VR9>: !  "Q P  &0              @ $\/P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %J'E4B(KGNHGP$  +$#
M   9              "  1-!  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 6H>52,1&4,J@ 0  L0,  !D              ( !Z4(
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !:AY5(JQ2>
ME*$!  "Q P  &0              @ ' 1   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( %J'E4AJ+Y1'GP$  +$#   9
M  "  9A&  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M6H>52!#0&Z:> 0  L0,  !D              ( !;D@  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !:AY5(14MV/*$!  "Q P  &0
M            @ %#2@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( %J'E4AF([M4G0$  +$#   9              "  1M,  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 6H>52!;-X0R@ 0
ML0,  !D              ( ![TT  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !:AY5(YJOD.Z(!  "Q P  &0              @ '&
M3P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %J'E4A/
M$NKBU0$  $4%   9              "  9]1  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 6H>52);B)GBB 0  L0,  !D
M     ( !JU,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %J'E4@Q/FBLR $  . $   9              "
M 2A=  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 6H>5
M2'4T3V&[ 0  >P0  !D              ( !)U\  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !:AY5(QZA **,!  "Q P  &0
M        @ $980  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( %J'E4BGE50>K $  !8$   9              "  ?-B  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 6H>52'X[E_VB 0  L0,
M !D              ( !UF0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !:AY5(IOLO.;L!  ![!   &0              @ &O9@
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %J'E4CPY]EB
MH $  +$#   9              "  :%H  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 6H>52';1):JP 0  % 0  !D
M ( !>&H  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !:
MAY5(=C+PW:$!  "Q P  &0              @ %?;   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %J'E4C[>#+OL@$  !8$   9
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M970T-2YX;6Q02P$"% ,4    " !:AY5(37:J@QT"  !P!@  &0
M    @ &+>P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M %J'E4@&UG!$[@$  .L%   9              "  =]]  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 6H>52-ZJ/8)+!0  _1P  !D
M             ( !!(   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !:AY5(M*-@SD\"  ![!P  &0              @ &&A0  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %J'E4BC(1!FIP4
M $4F   9              "  0R(  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 6H>52/*D2* = P  .0X  !D              ( !
MZHT  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !:AY5(
MQZ]DZ#P"  #O!@  &0              @ $^D0  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( %J'E4BQ,NX;<0(  )0)   9
M      "  ;&3  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 6H>52"V.(&E$ @  " @  !D              ( !698  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !:AY5(K<9L!VH$  "A&
M&0              @ '4F   >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( %J'E4@!Z9H=2P(  )P'   9              "  76=  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 6H>52 AW@YKT
M 0  6@4  !D              ( !]Y\  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !:AY5()Z17"\X!  #6!   &0
M@ $BH@  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %J'
ME4@)-!Q=IP$  /$#   9              "  2>D  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 6H>52) $!GV_!   Z1D  !D
M         ( !!:8  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " !:AY5(E2<T?R<"  !#!@  &0              @ '[J@  >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( %J'E4@!+<?^)P(  &,&
M   9              "  5FM  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ 6H>52#7"ZU7< 0  JP0  !D              ( !MZ\
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !:AY5(;QP"
MF?P#  #-$P  &0              @ '*L0  >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( %J'E4CA'"TEXP(  &<+   9
M  "  ?VU  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
M6H>52$1O)GR. @  H0D  !D              ( !%[D  'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " !:AY5(J0 8K[,"  !""@  &0
M            @ '<NP  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( %J'E4C<1[Q"O (  ,$*   9              "  <:^  !X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ 6H>52$BB5P%% @
MQP<  !D              ( !N<$  'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " !:AY5('J7;DPX"  !,!@  &0              @ $U
MQ   >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( %J'E4B@
MU^I_5@(  )4(   9              "  7K&  !X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ 6H>52$#Z4)<T @  A@<  !D
M     ( !!\D  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M" !:AY5(\JR!310#   (#   &0              @ %RRP  >&PO=V]R:W-H
M965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( %J'E4B_A9IP30(  (L'   9
M              "  ;W.  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L!
M A0#%     @ 6H>52"E\"7T3 @  9 8  !D              ( !0=$  'AL
M+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " !:AY5(36SZ,J4#
M   _$P  &0              @ &+TP  >&PO=V]R:W-H965T<R]S:&5E=#<V
M+GAM;%!+ 0(4 Q0    ( %J'E4A=(W-? @,  %X,   9              "
M 6?7  !X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 6H>5
M2++\^JZL 0  ] ,  !D              ( !H-H  'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " !:AY5(V JO]:("  #B"@  &0
M        @ &#W   >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( %J'E4AC7VW_E $  'L#   9              "  5S?  !X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ 6H>52"QFM%EW@@  9@P"
M !0              ( !)^$  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@
0  !9 %D 81@  -!C 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>253</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Reserves for Discounts and Allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</Role>
      <ShortName>Reserves for Discounts and Allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Restructuring Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringTables</Role>
      <ShortName>Restructuring Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Reserves for Discounts and Allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</Role>
      <ShortName>Reserves for Discounts and Allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetails</Role>
      <ShortName>Restructuring Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuringTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails</Role>
      <ShortName>Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Inventory Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryInventoryDetailsTextual</Role>
      <ShortName>Inventory Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2423403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Commitments and Contingences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencesDetails</Role>
      <ShortName>Commitments and Contingences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20160331.xml</File>
    <File>biib-20160331.xsd</File>
    <File>biib-20160331_cal.xml</File>
    <File>biib-20160331_def.xml</File>
    <File>biib-20160331_lab.xml</File>
    <File>biib-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0000875045-16-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-16-000050-xbrl.zip
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MVQT^+/Y&:Y#_-'AZS'Z"F][#75G>;I;/K7]H_H$\NUU*B?@)KA8W]MO-Q23
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M7[MWX?LC3-'9[9E9#M9,:ZY5:*UBG*U*HI9B/1W(8K /Q[HOJQ282\6\O%+
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M @\OG4@TYZ6D)<X>."7]Q8>R%RPP%1D*,#G'"+.42BXD<45,3KAP^-TOTY$
M9H-V"B.+%-:$_ ED&Q-_0G#=Y(U6]M#(_T@NW>@?29CZ%9A<9#9ZQ1FV1"GJ
MC<6%MT"PB'X6IA? ,3XQZJI[/?S:;[?:C?QI$Z,X+\4<)C%&S:1C3FD2J$7%
M0B/$2&%1QA+_6/+]HC',#!!<SI0U[6:#YMB];'1;7;"7XW]LYSPZ Z&Q,30H
MQ"FA0!RHF\!@M)01CRL9$$WI7"G%NM&\8-@KUS0AIF>:,*QPP. VDH $#)MC
MS\&[)Y5"&O :,=]YW&,U.EH>&&3-^VZOT[M[<KV'QT:W#4'*?6-@\LQG,&D/
M[6[6NNG9['=P9[K]7J?= G>FM>PXLNWF*BC,0!_0"!;56:J%%Z;0IVY13E>3
MYR0?C))CX;6*28P-RKG -4?!1Q:0U&765V):#8R4.B9>:1'EOIVW/C?RP=-5
M]__K@<W[._P.=L[TP>\I78@Y%(YS7M>R'&*4.DH(1$G ,E($H9 J630H/AL.
MC HA":B=9UG$'0"Y(##GBMP(B\%33;4&UTD2KLDDD)02_(5*R27A^T-R]I:1
M\WT]YWS/ON^4@Y$(H1N)C"/C+'B<CCK,BN(V^%$O]*95X4YO 4()W,=>DO]!
MWNMT(%IM3\2^W6V"M]K/8)RC/WLI5;%)8F&.(6S4%#-E%40L&#$5(BLR] P+
M1A:OW4R(V6)@^R%F36H^6N*#UU+(H ,/T5@G2NWL:<6:O82.3]^RO)M6&7/P
MPO,^/%'$Y(V"D_J/XWGMW0YZ@T9G'&6LM<^SJ1!P\S U@>#((G?,2_!/"I_/
M@N.ZD-<0*BHF=AWC 8A\9E1GB21"@E9W7 "AW%#I0=<71%)+[1(BV;Z(_-QX
M&MU4Y( ?'SOMK&7N&FFSRKJD[$M6DJA3S')F*%,F1$*PE$5R7I+H6$49"S+G
M<.YKX*^&Q"M6Q1L.S$2IQRY L"05YT6>P!(7*NM)6,VO>UP\M"\KE8_"@*[5
MSBN!'0755)9+@E>A*EZP9/1-@KOKTA*6E!NB"'.&R.BC=[' EX+O40E%3QC=
MLC!_:^WH*0@Q!X48I U2"T.Y+D'0LAJ:*DKVAD,Y[%="X?4T8T!!!,NEAKA?
M(\J%(L5^(62#JSA\A&CY9F!]D58,%M2<0B8(@DE:/ V>%:L43&N^H(;AS0&[
MJT;T)@*@-JT,1LM ,5!>Y%VX5KZ"+=^?H[0 VM&.96".O^9IF;A[]^D67IGW
MOC4Z]FG\-_C1#"'Z3-7W:S'<]72JV6)$(B"HMS)8S DR'NE4\0%&.F(G)4Z;
M U2Q.6#+X4_)[C2ZXQPW/.NSVPQ,12LEKK)N?\0"Y?Z,)#"=7MIINC#:*0DO
M'[!/Y5__UL[RM+[Q-"U6J]Q^U7T<#L;%8/A9X=K,*W\=;W9-@,8\^^]AUFT^
M+7[?S)TP\2E="P"LX4@-CCO$_T$G+Q-B,2K2ROPX<(Z@4I?%FKN@>-I30(XU
M!194@HY4,Z.HP9$R1XLJ%6TCJFPS9/,U8Y<W$_1HPF (H&XQ]D90Q[U!94#
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MUR+X> [6;M!LZV 1<!JH9BY8$:S%7D1OP,$RG 2)I:T621[/<NX R'[<+$)
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M)"JG07NTH %UI2[NA*?CP.=#$$9\.GV7B0"0>2UPD8@1@9)*Z?-)8+?3JGP
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M87D0S%;H6&+]-X^]MAQX*5I7W6]9?Y $*NU^>G9,_,-#EC?;C<[GQF.6K[,
M1@KO(/:13'AE%7*2 L5:&6X\J:[*$[PHEW%4@N?WZ:Y+SW,%&E=0B8BVVO 8
M=:+7,NJTDM7]_%(ORGD<E=Y?>]WLZ==&_D<VB,-N:QW%.'H<.24<- _5SA*E
M/5!LP.XPZ7RE4%-(^KP,YN@D?\D>AV#30?+-79Z-#<FZ54G!(**A!D-08R1&
M"M10(IMA2V5@"])"E0S[X<A>E0>*H\9R&#.*P"507A.A8.#**XA !*I$($L,
MW\$&OG\=9 6AT=*T$45'RY36+B2*F501*U<YAK)R8NO1Z=U*!1&7.O\'1UT
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MJEBT;J 0!5;TO!"LTLUFR4!V&NLJ(,%YX=@[C],>:PCO'1,%D%1[4VE3($&
MGK/<UF,MS,\7"++&D=9T$_+JE,;\>Z8;>Z^S;KN7?^P-LGYJ8/.YU^X.;O[L
M35[KA]G-G_#G4P33^)1N6+?+6D$D)*ESRD;M9 A$N$(2<3J:=L$N:P@I.5D&
MRBJ*CX53;YB/</JO+.^-0'L&U@2R3="RB$F+D%5*"B&UQ+&L6K28H,5HL=D
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MS[1SF:8B7K:".5L)G<7@[0RK9=$_YU11!C&_LCG'7OB0_ Q868-%%E\_$;[
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MSD74!LL07GH:*V!159K,KF'63]P[G(<D1H8X<U8SPWW3VQ72&H_4PMP#>!Z
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M-P9Z^J;/5T4Q_F4PO99[>(T6[L!'GXI.47X+TK.L.D4I)(@GV.089SGFK#:
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M\2[-QAIIX6.)+R;)Z4A.QT&O;)((WA=!IM !\J])!),()A%\1 13MC )8!+
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MW(^#]>_'>QS@A\"9LAG\U[=Q3')F@0V7"_;D1!/Y6?$4/!K&[,Q<6.0'X8D
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MJ"J^UG\;]@J:RW)N0H,]P8T3&4[N>)8;8V @/#"[G#AY>+X(& >W$K[ SK/
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M7>NEQ*E3>MY[['^Y%_/@&?1NJP]H"2Q@@:P&(N]$M5;KFWQU&H 88E\8(3C
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M3M>Q9+D6>-PH!N\?PW<M?SK"2@HRW%^>[Z_=:&FR*^^9R<)NZHA3RD "$_.
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MD6$8<\^:%^I;F;7>0[5AZYM<W\"^"L_Q _;1CT388$];>2A4I,!JFP\/@7C
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M"ME/0]!RI5*$\6VYOH$!"V+PG)!!<KF^2D;@9<1&">5JZ)+.=S84L/PIDP4
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MO-92;_C9X2/'I6:IY5 ^I+6)XXCC2D(XXCCB..*X\A.. L#S21E^E0/)#2X
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MFV::35#Q!8/)&,UV(9-IL$"$,V%%SB.L46.O-$SIS*4I[NN2,%6>>2#&+KP
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M(3+5E ?P2& :%]8<48'Y<<"N_OWIX[O_@]]]&YB@P9[@-1/VQ)&[+#00$%&
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MFJ%%/G1].Q0\P@\+%WP#87&2$-F?(JVJ"UU#2MU+W2;CCL)?WA^L3M,H)_:
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M3R,=^/-O$ ');8I.& 0O7.:4.;[=+1Q_ONSZEZU=6V7.0YKW#J0.";"\"A_
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MQY>!WYBT=52,\GJ#5JM$P)#*<%UU',_**,&L5/9%C7/5BWP.6ZY6:2(2PQ7
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MMRK9(4TTX58%.*?HL>"50,NZ*H;F2AW+_0U0W3)]I#SCC5]B[9)'6Q8Q?%6
M !!;91WG*"*JM$'B*^5V&.NG@9!#4LB%!0A0BI' O#E)<E@.LL-Q!:(#\!S*
M@L03PBR_U%<IV_M8;NTM\ ,6=9+ IA,PT2^;%]<C&LS+<;AM)YB/A1N"A^U
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M#WP5XU=T:]$6KB-_B=EJ 1\#U6"NV1@8'7M7PK !Y;%%@>#12%V ]$0<^+:
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M(RX2+!\(>C8/:Q8?\QY0?N2HF]FAA5"&8I+2:4&-">%,X)3CP9#=\E$8PU.
MM6*,2;LXX)^^ Z]]@*<P8Y>H*O.[*\2VD)WY%785V4#GF>\(]\)#&)Y'>@UA
M%GC5G"1DA(CGH0/[R(,0DWL?A>OBGWIVDA;""!A.*$"%OP-QYY<\YD'D(9BR
M>SC)0!78'(U$0-PQQ:<S2X9ME?.1VX5S..U^Z7[M7%TB23(!"B$,)<919K[
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MH!0>4HO#,!Z-)9T3 ""Q\WY?HYGTG6([L9%LQ(!L1KDN)>8Z2?"HA$*3\#4
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M#B 34Q0DK"KM3KF'E1I'>H_"NT3#21/ $@L5"#=9&6DTA+F+$5;JIW,@=M]
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M8$YB/C$@!NAEJG\?E#>02%2U(;T[ST:8K8#:,+>%7G\ZT])\\M/YC2KS7_
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M_GD]I\G][H$\UOI"?]/'H6.#IK:&DA/3V;0OA?/7DG$!>[E]@EQ(@K/6]EJ
M&I.8=PF%B[.WP#XJL9X8.)ZGRB[+P,PV67LA$J^.H;NUTX5VH'I%@ZDB]G-K
M7?HJSVF&^+(MW1GZ*[+KE!'66T"\72&L%SEYU[US^XA8--YQY3D=E%=1 [=/
M,;O3*W1&:=O?1J%?GJPL2GH=1H$PY8%_?XDE8AIWYS6,@UJEM3&M+:7%XAJ%
M;DGU?8YWQV@B:V+6?>!)R87U];68W3=F>QY[&>FZJ$I@YJ)6GX3H@LLCW%*7
MMU1-4IBE3#T!Z6LD[NLE1;5R4KC W1==V0A+(RP7%O:HU==&1_O"+T;Z+<K
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M*_72$J;3JIDNH>^64H%TX/[5YH:;E9IIA])MQ4!7( 2Z([1"E&IM-"?MH@K
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M_UO.%^MWK(X!UB%=5#@1+"S'B!F6=^U\G4SE7$J<"VZPXH[TNW)>!GS#@^0
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MF3F96;U[SPV74J9M[99%-R5EI?OI?T 2Y9,D4A0)T:[N0Y7328"(+SX"$8%
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M>86-(YJDH<V!V?TEC=IJ=Q]).L!EQ9E^U?]LE/:)6;%#[3N?SS!%SAOO%&/
M82PE@;#ZHA1S.-MI6?6E]KT&W0&EGZ:MHC^0W@P'DNO^B1C#5GURE3]:,]_G
MB]]F93Z:3OZ5/RH1\$L8=UPV?WUBQ!^VCQIUE7E$N"6 2,2T%<9SIG4%A@6.
M)B+*+A_E)4M.U&>1%*ODQ*E&ZP-N-I]/KF<K*ZS\O\L@U]7]9'9=G67^:WYY
MG1]+IG;=9P)!Z,+"S9U'3#(J.6!;[4#7ROA KY%@2?!+2SH;E9-?ZGP6?EC$
MG?*YNOSOY?KC.89>#3K*,.).*X$-<$)CX*4#U2*@  :J#9'PJR-2]TBEI<R7
M,HQX7?JE'54.=) )*:$0WG!J@K026$"WWXJELA5%R*NC2'<(I:7&H7A!F#\_
M7'T9?3\]-%3UE#EFH( 2&"RX\<&-!-)LOQ+C$P53&I(E65BE7Q03$.K0J'5^
M593YIWP\'<WGJUV;50FJ!N0ZH=< $<'0"RN(0((3C2W"%43(*SDH"R@9T=(A
MFH!TSX<:;;P&2)IE&2LE?<S+27'9@(5=OB;#SE.N$"(0 PPUH!1L0>1,PD'9
M4\EH>4:(SSPYGC@+;H7FF$B/('&**ZZ51Q+(2FA'D!B4$3:(Z:XE= ]\^8^?
MG^XR#G'C\1G9T^P\/O^:'^SA#\N >1,)&FQ*=OB63#E/ /0.$6V45!8Y*% @
M ^:*&@/JOIYA[5=BQ2GW&@!)A*9**:#<1AABM4%I3.R#^Y5GT=WAK<SC4/MC
M;64B9+VADB@>EE,"'2<&5]@ 8UH9+6FW,AMK]ZBMS.-P>37;6 $<(QWV#@MF
ME-9225F)%?[O7^E69F-M-=K/:@?2F^' Z]K*3*OZ/]16)D22:>HD0908[N(%
M)EMHM6:MXBR)MS(;Z_/4K<SCL/KW5N8*-.HQY<Q1K(06DCAG,*A XX"V,F<3
M;V5V0[ D^)TA;-?4Y*\Q84_I-A/6>&:]I5(2AI@2D*#*B7"0@#0D.X>%FQ"V
M 7.KUDHZK>/,,Q(L$&4!LP(!S8U%9.ND2C;<[, T].B(DR>!_6]V[@5L:,;^
M6R3EJR%CK=5W6L<9  IZS!3%4"&N@(2J,I8H (0/RJ%(18J.N-@*X@1<?%_,
M8MV743S&N1ZI^WX7[QHY0+.];3++$0T6MG> 6$(TA9S 2CS/6*)P94L&G2,4
MWA64"9BRK5:Z&>$F)>\ 3_:TR()9C+EQAG)#'%286*DKT2B6K79,>_,KA\"2
M;H!,P)'/HVD^_Y1_RV?+/!8*C5N]A_8^=CR><0TI\('W0%D"*=)25^X418ZV
M6H5ZR],8 CLZ0#%%*D8US6TX?"B@\.+9# ,-N*6:006$!@0(LYT-'8"M2-%;
MDL402'$JA"E,CWSQ\E#Y+G/C\7.9(81YRB'GP$H'1.#V%A#(<"N/B;YE)IP"
MWRM)N=E54Z>[N@3'WHN<\LV=7%6<)C?IZ5#+<C2[7M]"$X8=S.#QGK]>9?>/
MQJO1-TE.ZO(U&5 ,8:FAU6&R5  1R@R6D$D!E+2H[H!%3T;6^":_7$[S>)_E
MR;+69CAU_K(,2^28Q(98%WQAB87#?@.J9$8GBGD=S)(Z#XF>VW7GAGZHJ59?
MPNC"XOD@:,W^U,[G,X&81MPC8+D0U&L!&*BP$(@GBG8=M_%T1D84W6.:8IO]
M!32CW6C4[Z@?UU,FG;= &8&\(8 H*]D#%)Y#.]A]IQ,U^WPC/0EL?V@F#6V/
M:-@$.H(X+XLEQM]DGW_/+R?SFP_EW<UHIB?%MTF\ VROVFO;9!Y:#ADG5&F.
MF6.&4U@-F4#6ZAAO?R<S^])'T0]<":8&O9P'8R]ZJ_]<3N9K31RV2/:TR#1%
MTFGJ%:/A8R$JIJU5HAG/$T7&7ZM-T@VJ9R),_+',ZQ,.:MMFEFLGD>9.>X^$
ME2A\%96XVCH]6,OC9/TUX$,74+UYA@S-HA@>,4ZW(O0JWG=QF8__FM\6=S>3
MZ61TV(;8WR+#<9N86(V@=\01I)5!U7"A]V90%D2'Z!=]P)/@\_Y8%I?+\>)#
M^3DOOTW&=0FVNQ[/A(9,"TD=44C#8$-+8K9"65!7Z;6C?=+7:BMT &DZGD14
M-N.<UT[_>]MD @0S7- @D8IU)!Q"!%?B6</E8 V#TY2U6_.=X?/F:#"TU7\@
MVC]]R7?O/I@OZHL[O,P_?2H#G'@,*2)*,0481T)O_6=$\;"6]@[0+;J"HHV&
MU+N/GSZ\N_C[80T]?2J37B*K/-$&&>4D)2*6&MM04?-A57SL6$,G0=%&0Y^*
M^]%T<1_-A'RQ27I:7;+S:;3(Y_K^2UZ6DWB_\!Z3ZOA.,AF+DQ!B$%-48T]P
M<#<JH8!'B7*/7INAU3O0O;)G[_+:IILL?#V$*TAC&2]AK2"$NTHPIS09G.'5
MI_):\>,D(-\04X9BF[U6@G2P^U-\G<27?RG6 8</LS"R50KNQ2S^W79$-1M"
MQW638>@ (!93 P)J%@EDM[8/A(X-P@SL5V5%,OC:Q_/68XHC>#RB]=^]+\K%
MC;K-R\EXU) E)W6:84T,$UH8YK"U!$I,R':C3+-$1ZL'PYF48/;#(#LI\_&B
M,^[L["Y#SC +D--*A3$:&_=4JW0UH54KUG1^_F)(K.D"QL[XLH$A5JJH1C=?
ME).ORS"T4XAS1+^9)PA1:[47RCCFN>&Z\B2#YXY;W;'1^6&-,S.H/SQ3'/.J
M"F#\DA?7Y>CN)LR7TZ9U[IZWR0*:''&O)6<$6(HH =5NCZ((MDI_.?Y$QVOS
MK[O&-05MUNG!CP=:&\;>VR83X>OS$D !A,?6.:NUK,0+WL4KJ)777F//.= Q
M2&^."T-QFX=(@6Y<XB/<WN?+&Z$F&-4" D]!/!Y!N*YVYU4PH895=J(#G)_[
ML:?A<9YDI(]AK0PPC*[#$OBW8EV]8)&7^7PQW^1R7!Z7H=2@PTQ9+#6P4L(P
M3J:I$;"ROI0CR38NFQ%E$$>(D@"=I&+./ ^ON0G8V6 X3XN[5<'1]=%F]WT\
M75X&0:KQ7\P^EL4XB&V*^:'R R?TFB$(3/C>$65*,R.,5WS[D5+7KC!S;YM^
M@^!B.K3;K&'KFRQ\4?X2A(Y?Q8<K=7=7%M]&4WV__BF.;KFX*<)D?;]O?3NR
MFPPS9RE V (B</3Q@G>Y!3/\.(A@RR!HE #>5OM$^>3VZ[*<KR0M\W%QO=;'
MW6JD>[>%#K;*!#.0.1@,B3!B+*2A1 ?_T,)H5)!V!T)ZJW9Q?E9TBN;))/AM
M%O!6MZL3]>JZS//U=72!DLWH<*!])I0-]B"&GO(P(0(J\(.-J85O%9OMK?C%
MP(C1':ZM*!(<OH^!CN67PD_*^<(4M[?!$IN,IC&6O)<8!UMES#@"$:, NN W
M>AZWMZIA8ZU;!5K9&Z9#EVBVBMB/YJO(LKH*%O<1-*AKEV&!(2:2"1LF.JR0
MH6 +AT6NU;DQ_G:)T#&>;><#NRR#M?)DDOIXV&PXU"BSSGB@,1>>*,>(8]#:
M!R,9M5H<Q-LE09=@GFPT1"]'C6\F>;1?:TA0TRZ#G'I'*.3!WH7>!1-'AL4,
M<<F0)<"U"H;*-\R#;O%L0X4OD]M\Z]I\'-VO.!GA"S_HT70T&P>F[ET=FK7.
M-#720ZF4Y%P90*+_$\2@W"M+J6]W.1EXN[SH!=8'=G1<4*V+4F'K*S36)O'#
M32KGK!GVL,^Z9VSO&E0$:]Y))A!P%ABEE<&64<F9WE2%ID8H7O>-G F$YC6\
M#G60>1CF.<X$=-!X+SA!$E3"8\D2[<,<K,O5ARKW5MWJ$*S10"MI=7$.U6DE
M,.424A+L9>D9 ;A"(J#4RNQ,5D>K&QTW.5MZ'$RO[E ATN'SDA@P;H4" 'I#
M1"6><<8--AOC-&4U/EW8#I\W1X.A)6(,1/L=A);<>_=1O;NH2>U\\E1&7>@F
MV,#&$ VQ@EXAOYW@8&UYTZ&<+6V,;M$5%"D2I&K6J)>_S?/WH]J[VD[I-F,Q
M(\5"9!2-%_=(R^$6:!A\GC2;WD-:ZA/"F8!S^T;;\";;?0TS;*Q%#FD%D97
M<23M5E!KY' +3Z11[\ZK;SL&\PVS9V@VQ6LD30=)H*/;^7)VK2?%?'([F8[*
M1WNL!S-":]IEP0H+]I>D2$ACC->4:UT-73DYK#NENE)#T1]";93[:+W4]U]N
M)N7EQU&YN+^8_9\B /6W\/MEF:OYQ_QA;/OTW:*K#', K"3&6>&L9EJ0ZN)
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ML,KK5;92)7+ HM4=))UG\/3'B-0 I@LDO)C0/ESME^C0.M*JO\Q9I0E!V"(
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M:9F1(%7PTQB05F KN<9^N[Y"XQ/=(]Z*'*>'(KL%)S$/&BH]4P 91B0WUE+
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MYRPAP#NN*O@!Y*U.8_86ZWS%A.],!:_O"_B<+Q;3VMO@^WMI!K7SRN&P-G)
MG6.>@*U#X&@[)Z>W_(]7S/'VF)]EN^#PA<1O?-, 4BVIT0Q8!YE5\<36YNQ6
M+.S'_[UI<#ATB60P6T @-%'".*@ MIL*_ 0H+X=P)VZOK.AIT^ X6(>Z:7#J
MT27--2862:,II H)CJM+J@BCB"?:D3K+ED!C M0?=SH.Q5=VV,5+;2A0TGCO
MM'&< ,LJX8PQ:+"Q_E,4U?342SMPWA@#AA:Y'X+B.\U!'=(9&2T((QQ!8!&4
M"GHJH:X$EPRDNKSAQ*S4QNKK\HS,<="]PC,RFF-!$<',<@&=AP@35 GH6A9%
M3W]^ZE1N] 37FSDCHRD77@:3W]AXTIS'TF7;N9BH8<4!^V-)[\B]B3,RT!K(
MXZ5V1!.J.-48^DIDY3EI0Y;T!ZI.)4O?N+W:,S),<"8@D-0@)X1S5#/^(*9N
ME2^0_@C5R?3H#;$$GLJJJ.'%[=UH4D98S,VHO#Y<7GQG@[A9C8URPB$@& &&
M!SBUH\82AZ@#P[H3*F7$K!.\SI5?%$8;,)E?S.+?K*,W^?AF-OGG\NA=^X-]
M98(!+8VTED%&(4<!YLHXYR3 .RC;-25]^H8R>3#D8K;(RWR^^#1:Y)\7X1^7
MFSES=-W\",^A3K)@GQ')F0Q?%N#A(S,$5O,YAX#4[7@,?Z>[+9=ZPW"8N6WO
MB]EX5?;T4,7BD_K-).868 VL-+$X"\)(X HF;D@K VA0&\YMJ982UK1[RJOM
MB_G3$6SWDC?#..&5 :S9>#*:/GRG2=^UV3$_QU;Y[GMZFFR+U[3, #88& $$
M"68^"1Y\L+C6= )4.U'WE?:]!;Y[^,TWN ^TSRB 0&#&I)72&1(_7UJ)S@Q,
M%"\^N'W=F?;V;E5W!]!0-Z(?KK'Y$L99LQ']\N$L;KG&,AZ"$V1\^&^\[6B#
M0@QW#7HCNA/U[KT7J"5&"4RBIV,TP8*[+LK)OU:K:NUYD/K&F4?$*0(]U01I
M1+TUUF\_/ _]8+>>3U'>01YT"-,?@!]#VY@>%BV2TR&8XK=A>@WVWL=1F&<;
MW &_X_E,Z;B/2IW"##,+D(>(5V(YHE.=(VSF\72IIA>WN)^.3@*E?\KO-@<P
MU'69KSV86LWO;Y09'B3$  -%O6:*.R1=)6 \S3&H.%V/ZN\,H@0<^+68Y?>_
MCLI_Y N_G%W6ZW]W@XQX3(APP&"+E:"8 [HUQ(UO=V2JM[A:C[KO!)Y$<=?G
M][O71%A?7 ?/H<8"0(T\UL83)H03E5# LE89JKT%N'K4>0?@I%CBG[I :F%&
M97D_F5VO[R^KO[^M60>99!([1"1C6@##O7%,5X);@UH51^O-".@KOM +5F<G
M26MR9(IKA 0T!FFGN1><DBV.$J2*(1Q!BBZ5=Q0WCH2JO_CV_@#P6>X]>@CI
M[+^ANTD\^*A^,DHQ#B::<,9(%I,".=O,XE!+ANK,FO-!T3Q"7--'9C4#REGJ
MC%56>0:IV]QZ#A53= B5T7K2Z=Z8<;>0#35N_.OHOXLR&DOS#U?1Q GK9)RV
MX@G/2MR:8'+#'C)!M9$0 &F!1@0A;Q6N\-+6)<H/:AEA[HP,SSV)7L!+X5+6
M#[SVP$OC/C(.O%".:(J8\1YQY?C#UPS < /1G>OW>/Z<!.$?CDE#"UF_'@*=
MGM%LBO*N*(/3_M377M]<O#B<O]RD;<8Q@EX9B82C"(I8TGHK @1L6%YK#YHI
M^@6L0YV_+V:GJ/UY\RSX5]"PL#Y[KZ&B7&)C*D&L8GI04>OS:/Y$S-HH_Y?B
M6U[.HIE[Y-=>VS!3*MA?1G"H+$,J^-1.RVKP6,A6NU2]A:I[5GC7:'6EZJ8?
M>9.VF>(.QH@N$QY!0Y1F6%4B"(9:E>GH+4Y]!H6?"%@;G?]:E(OKT74>I/NP
MN,G+U4$(/1K_([\\\GL_OJ?,"*^900AIS@T@5FF%*O$<H:WXT-O)I)[YT#M\
MO;&CZ131JK.,>,DEI\%4YLR[N%OK:"6D4JR5,]#;#4]#X,B)"";P)I]#4KOI
MN;M!YK!!!$K!1(!0!A>*/O#?8]8JS8&_/FITBE**PXQ[XW0-]C[K&V=,H&@%
MAU63*8FI1 3XK:&D1*N31;UYD&DBYIVC=E::M*)'L)^I)8;)6+M*<F9<<)@J
M 8%O=W%Q;[3H4F&-N7 D1.>=*L;CY>UR&@_$_5(6\_EOLS(?32?_"G\,^.K\
MJBCS+Z/O[6:29GUGA'IG;5"#U2A\F(Q+LX4KV.NMS-?> A9G850_2 Z4>+&>
M<%_$>])WIH,M!\-"@%#X4 WU%!*]_4ZY:D6\W@(G R/>*4B>EWBWP?J/$IAB
MWM)">MQ#ACA! !/,K5+26<$TQ%O1@X$QJ&#,>4AT E[G2 ?:=^%BGV=0\1G>
M>;A2="]OKA_-4&Z[?->N0O6#CZ&!P<@([)3'"B-'(?7K4N&&<E1[.TS?F5:U
M!6T[K#F].9U(@],-(*?4> J"-ZVJ&X0,-=P/(>^J&X6VKR+=!JA_9ULA3@U1
M1E))F1:*: &WBE':O/*[)H_D1,NDJ^,P?'.I,I8#SXQ6CA$?/G..K)/;;SM
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MP34CV#"/O:"5[%IAFH8.1[G!'2BRZ Z2!+[(=GBU'L>S)S,#A630<@P]9((
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MSYNCP= B# /1_NEAA?]W\5Y_^J\OZG!,X>E3F:-2"(&Y 8@Q#SU0,DYP0@"
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MJJ5.G]?&Z :2%#52=HRTOCC*WD:9$Y1B:PU@EF( *?1*5 )BK_!@O:[35=:
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M0\5],:ASJ!)P(\:!@B,VCL.[B*2^+O/Y_)>RF!\BQ8%6F5*,6X2$%=0%AT
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MER+KJ296\&"(0\TK@1@WPSK8U*MK<3(XJ;6]D;RIOC>/9UPA#*#5AAH!8I%
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M]]<O6\P)J_5BZGM2U3@_MZ ^4327,>4VF;<OE^DG9=GTZ<P7X"(G!LBQB>V
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M0P$2SZBPB5 L0VN->%:9;\C"]WA7^Y+M]_U(Y7Q]O 7(A7;L(P?!R L(2N+
M#TEGD 'A[JP*%@PN<(V@K '5G&]"GB#H3+_3P.HRNID.1U[?>JR'&^[%D^*N
M;(=CY>ZU[4,/=D *HM"/XI0X, Q\[,;V:#SRL- :B1Z3II="]@\/6=TN7S8'
MP&SB:^A]CSUDP;4/381S+G%,S[7@2L81MV\JVWPK%5S4G5N0T,O],C1/MU,O
MEQ=,<":R-[^DY#X=:IA1?0,,T\@&&!$$?1B1) "HL^B $&#>)4<5$V9WW[>H
MGI7W,VZU/T'1A;WUJL0NHX=I\>2-W?-ZV!'?E#':QONZ'EZ5/71E$CO(@[$3
M>P3XR/;MJ%\0I.8)"3RQ&0UM9B>8SAC?*Z4E1C&@E=U(H<JRZ(Z)">F5WQHQ
M@KRR>IBS+VOQ,LBUT4%3$):A>_K=.KEU02MO$MO4ABV/I*K9M0>''7+=B]M)
M'-HH38(4)RA!)'2"?IN<XZ 0!:GDAC1%JQ-N/4.O]X0>GP&\\(*\:?9%I7)*
MXN6U4HUSTWO%SE/(MRM,4QB6II;:_#J]TTLK<[QZ^7/VWU7]A?Y*<WU[ZLAG
M^^9+$./(L>THL6/7=UV2(&^P'B>IT*8M738-:V4+TVIQLJY[]KRT^#-9VHCG
M$\HY.!>326UT&U%)3O[.:*3N""Q#(;5[59EMM]K5L7\/!=@$HM2/ S?$A+@
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MD#^QI//&/M=+^<3(/M>WB3FSJ561R67L8%5UHM+:NO2?#?U0E/G[7?[0K(+
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M8*<.U +NM)_2VVJ>[J"0L8\6T=,>%<Z:^X_94[O;<!6%7@I!$- 2(0;8MY,
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M(ZD3U)SI4ZID+J,?*7M1Z6UBHE.>7_-R?W0Q5!0C+W;"$*<>"3T( @?XO9D
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M<U-JG0PF@<ONP.>O=I4,&=;DMVHHZS<&SVKQ"5:P:ISR5:N3T2FFU/),&JE
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M8-K^##_GY_!U$#M_;]'IS.O9?7T<&3CHUSVP?$?[.?VJ*3;](\O=<9C$]U(
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MK#,:I$ARD9&?*LX%QN<NGEQ=E&1B 6,]:>B5AI:@/,%_X@:-#^,SC[9+D!M
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MKG+)-V<QKE)JV4G86!M%V 6I%WK#-"K!]%N"%UCI,6H^X5\0"<&+KC11S3>
MG(%CL=0[ CPY^+?2"S2;N0^+B[@SXS;-S"]C.*;;J9?79IG@3*\&_I+OKF^_
M9-]6,/  #C$.0A(G<9K&  Z[6@F(8M$GWO0:GV 0=+.3N.1/,\4Z-= (MZ:T
M\,JB<%D!2P$O41<',I7U43@J?R:=%'=.2B\E.9QVP01GCP75$_9=]%#MR]T*
MVQ&!:0@</\;82U :0S"@13$!JS*_8[Y_F7K]1!PJEV1$G62\\DI@X]R(Z_3
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M= F/M65T6;;U;O)Q8R=-0 )3VW9AD#IN"J/!M@^]L-_DDY87<K9>J^);? :
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M(Q)%F$1RT_XQ=@QKVBDT?FG14PM.3L=&$2DF8%-Q**=<Y_1UN&ZL&MFT@C5
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M$:>5]D#UC6,F(SE^&%M("+7/FEJ_K#[,)Y[50]N);XL?PM2#I#B"3?!4+'\
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M>=IH1O>W<[T8XN.";FBA;U[]T.-"J?%QDM23^!^?5W&($ACZ+%E! 0@!2A)
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M4>+)'8A2,F$X?>I066Q6G5D5PR5[\DF-.#$QFH S.17JZ>*(+ YI)OFYS,R
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M?:W16@SNM,HGP>. $IJ(QC*4T8AGI?EG66$%[T-9E$_U/E%^I?1)[6M%(($
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M]/FJ*W;]V">T@T+"0.H@L!$ AC5SZ-55.#%L)@9BFCD[_7("JLZ\$<U486]
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M'9Z5971 <(T%9QFR:\Z]<J*'W(P$_V>^?\B+CT7V7UFZ2])\QQM]92O/CPB
MCN< )XJ)'[D(DPY40FW)LZV&P1B7Y^C 5W>LLLBL9X:,/:W6-JN8#F35/G_D
M>RVM.X;6^L;AFM%BU3CI5>8) F12IV^L#[S+S>WW;,N2YS_92/O OL?]J)LH
M3GQ-[#C2-4CYR&C^7,(^UEE%F=?"L5'1;_?@9!M^N?<JPC'T/!!BZMD.\!WJ
MP*@#YF/;GT#XY0#-)_YIA]-:,Z 3R+YDI Q*O[D032__O2\6=X9?&)!?GT\M
M9R!X$0+=@X%:?'_B 4'181V#PABNM1=D[O;9CN&Z?=B5A_N')/]60ZR. Y>#
M<.)!FH2N2P+'\YRP/:G%\+D)E3PH.QVN28:)E,,\CA3[!JUUQTNU_#M,;>)^
MQB"0=LX=2\UEG4F#:'8@X<#90%):K3,6]V;Y4XDW0Z"C0*0MS#_7>*+1;]62
MDF;FIQI=7HZ U$_<P(T0B4-@1[Z34)+T]3#DF5H+T()M*:/,RYQVVO%%,IK3
MC#'FPCC+.//SS%F$ F)PU%$+_/\>(X^B[YI'GS$1$#KD)07PPJ#H!9@0&+()
M5\"/F0'?Q?V@&-JV(S;@3 )EPO'E=#A17^:8)D##8\CB(J,X9/"F/M;9PO^K
ME>@:?SU*U&-')3W-G"9B$J?#EA0YM2-BMP]Y51\-L7;\^&O%MR36K=6/;Q/?
M^;'AH:Q.LH'O#_GZP>)7U?#+HM?\_=N7UB/W^/5;:O'QH_[4K^F67\5F50]9
MMK<V7>N_XZ>Q42V[+W=U_E!D>;WO-JVLAVR[^6U?_O;84/IL%>QYV^_2#3^O
M=L0U]EK'D?&\D"M,^I@LX.S:9*Z6,[R&Q@?^E_F(#0"BR(]) #SL(  (=3M8
M<83-#_YR<&9* %26NJ8+D;'AWUQL)DT!5*H!TT7/>"I@+HH:TX%7@W^ZK]^U
MFZ89V]W)U>852P$V67T+:[I>[[*VE_N+AC E']1_VS^DQ6_,T%.YX[M+\\<G
M)L>/QZN@'K+-/1O<;ZR<?7[Q_'\RCJN/C=ZL0^V)_&DS#T5WQV<?8W@>7_Q>
MQ;8'/10C'Y+8)4F$;+^O=80 8)E#/R/,&#[D<\M_Q4I?%S9/U6QY"V-*-4=A
MKI=>0!1W1+@:*,F-ZOO%W_>CT1=O>%T&7X5>C CR'8^9],(X"('7[Z=V*(W&
MO'6CC2_A7=2Y.#0^&FKK/Y,&8O023YVA?[D:@B6LW[Q%J(1<:HO-,D54GWMO
M2*MF'D4%]WCG.[_Y$Q>;LPM ;SG$%00V0*[OAU$8QM1#OFLSV;=CUP;0I[8O
MTAY/KT4I:95OAM>!K,_H\8MU^0SG_(9=ZZ\:Z_538"89%U/2Z<F6DT\]/!O1
M3"'J!H12+_7+4$?-/I4F'U8Y'7Q7?,N:@LLM^SW\@PDNP$F8@("@P'-HPOX7
M^;0S9-/(EA$]A8\WK'!'1!:'9/W%04E*F0II8KIEF"\YD9*DRH@:O29D0'I&
ML+<,G1GC0*GM21JC(+2K@3:]'K/'K]ENE3A>C#T[@<1SB .3B$9)9Y@D=J*N
M*$KF)E:8EQBMOZ+R,<V+49*CQK**!!DG6%62JK>)G$"0+M$C+%"CN%VB8(US
M:%# -' E*FBT?'S,=NL\W7Y*G[)=:PL3@CP?QMCU73\"3F([06<K]@B2V["M
M9L/XNO@1EO7$<<EIE")Q8K)DGC$Y)3JAJ@9D_=5 FEB.+M(RH$#C:%R&Z(ST
MH=3Y8,E)R^?LJ;W5!M_OLJP>QUJ#-& 67> "#!/BXR!VPK@S&) HE-.7$8:,
MB\Q']EM%?O^PMW;9-YY>\1T"+5HK[>'*:<\89L4$:")*Y53H",HZHII)BJX3
M-*!'&EA=ABCI<*34_L3)R=.?99$]_YGN_L[VR:'8=,:\Q/4\% /J1BY&T T
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MAG<%+8NJW.;\6HH-:6ZJ^,(OJJCZ_=2)$R&?.'$8>IX#8!RX '3HL \3B4N
M)D1E?"G[Y#A)W8O<>FI\JKN3,*=X%EE[=3PNPH^*G#CV\F80P01S\N@.:^B2
MPRJ9B+;Q_'AGM6Y8K1]=)EI9G2?L"^O4%ZMUQFJ\$3F6,F]0):X56FAPU6X7
M.GEIQ[ZN8^_=T<?KA:%XKL@MX!:>.;PNYWU?Y&8F_.!!_=;@[;;\SLU6]?;9
M!E^+9&7[?'N<#SP$01PY/G:QV]EVW%!J;ZH>BX;G+,WM()T*3)MD"Q$TD''K
M)7@9Z;=FGTJ3CZ1JU39.=T5>W%>?LMV7AW27\9LKU@Q'E&\/3!7J0M>Q4(%M
M$!/B4X0QC8!CAP2U5PCY"6:#B]S&45,HC"?>-;RZ?KMI %I9ZX#%^VE6W 75
M8JWF@,@6;.>+A'K1ML-L,=!6C?K&.H:H1;Z@HJT4QT*%6S-16X8*&_?R:@'7
M)*LR/>H+1O_SI24]X-M)[(8V!H'ONQ1[ :"U2>P&!":2731&F3*NN3TZ^>[S
MZOR)J>=DQ,E)9 ]K&7L&AE@:$#DMY"Y#R?2X<J'9O"9^1#6);\5C4\<]T\:L
M6#^_*^[*W6.3RGXM#_OW^3Z_;YK=IWL^#>IGD\2)8CL,G82$#!<D4=!NW4()
MBFE,!=\W8_;-O8L<LG6"^<8Z06VE'+9UQ&VUP&=K+J/*\,![;#QHRWC'S;M9
M3OPRC-&&/&NO ./W73A1F$00V(D=102VZTO,6$@C1Z:6HVC"</'F[ VONWZJ
M7#:H2J"*=!KA;I0PBM V@>)UQ CKF3232U0K>2<&M4B1D[>4IE[!WCVOWMVN
M;.PZ?)+%/@R[MA^X-DRZ#_:)([214.+C#"O(NWVZ%9S=R' P+ R&W)><J=SB
M]_^E\KY7V?KW^_+;O[1>-*][^Y?S-_WHZ86W6H&&>=]@%<"E<LA'Y@#OCTU'
M/8\2+_$CX@0!#6Q(;-(9A#80/10_PL*T0]G[N;KK7F=(9DR3IW6AXYJ"(V^-
M;:K<"&V>^ISECU\/; CA&PS>YX_Y_LN>K]*^*SZS!W![J#=-) [V(A Y08AL
M+V9#:1" ?ES%+A49_O19,[ZA\P2CM>4@K:I&R7=)[!_J[1,M5HDM+WJ(%MBA
M-#G'<N+UDMX:G]4 Y#N-/L]'K<0^H<DI5ML!)/,DC]WB(T+)M<T[6NE<P+8<
MO?Z4IAX\R4W^FTW./S[=)EU'\9,2T.6:<."[F+>@P[$;^<"F0=-_*DP\ ATJ
MV?Q)NWWC*TG=B?V3?74]]D;SFH.6V3[-MY+G!/1'0RPAGC<,<D/-$>L)[Z?E
M\$4L5TDS.I!7FXO.,M)M@_Z='V PS*10<OZ.C?C%??YUF^'Z[H;X!]]0R28&
M?Y3EYGN^W9[M#/!CWPY!@ "A*(HC3  .FE6X),84"W9F-V)Z@F7[#G![T85$
M JF=9X$T?4Z"99?W>V8;J%:/U>K RFQZFH!_B5Q^SCBHI?6OGG0KZ^-QWX(>
MF\Y+LG(MLS=%[@*2?&.NE1,\G&J;>,L[-A;F^^Q]_HU/.5Y"2PY[-ASBQW*W
MS_]9/]#QCZ>LJ+(SB+%C>Q[AUX4[3H2H;;M^#]&-(D^E)\,DP R7G>)JGS_6
M<X2[&K"5GB"V6.9AI>O_=<AW]>1=::B;)YQBTXK%1E)NJ#S=+-PX\EOMB?5J
M#+VQ&F^L4W>LUI_%;"'6$0Z!?<631GT9,YEY7+^R WD&_N4/D/1#7F\Q]&(O
M"+ ;4A1X@,#8]9/.(DHB7_60B+PEX[.;D\.<[$.V?#SXGNXV]8GLA\Q:/[ ?
MKL]S]AF@ZK$0!9KE)-XTO^J*K3*9,7R"XQ55 FHZAN!EB>,H3ZZ>MAC+CG#%
MO);/?ANDYT$2QC0*6"H>NHF3V)[OL/3<97\A/I8\0R'YX<8%"G_Y$M]^D2QB
M2Q(D6*$VQXQD^;F9G,^UM?HE#T-%8S7"EB$5JN#/R[UC.) 3!'K8[;)BW]OR
MB9MX,220;^>P0XI)V-MR(RQ[1XJ2#>/RT )JYZO_JJ(3TKS)R(5)PE14X\;J
M&)M7/LYX>5-%5'E<DI@H^W!14\8Q(G-E[^L[V,]OX(1!Z$9.E "$D4V"T/=H
MV-F.'#>4O[EWO$WSTB-]8[FQFV??9&O@_=++]C+>-\T^7;B.5C=CXZ_^:?5@
M!9W89G9#C'WL^"%QD4=ZN[$OV>%BO#WC[^&?Z>[O;%]/K*L>G:Z+?H19%4P*
M)J53,D$8OM"G!;B4*WQ:.$.)@S:NER%J&OT1OIY'C2GU_KX?LGUODCC Q2B*
MDMA'$4$)3=S.)()0,J<89<I\D>-U>]\;J\@D;Z081Z>@@$W%HZ1VO>[U>V,Q
M9'/)U@!+0XJE@]R%B)465]YL_JO,C] VN>B0<<_28I_3R %\UVWZE!WV^?II
M5][OTL=J19 =!38&D$+?]ST/0-_NK'H8>A([XS18,RY4#&-SRS1'^1N':9W@
MM#J@$N*EC>AA_9J#83D)$Z1V8E8E-KQ-S*[JT96^%[P V?7V&'Z;2=T0KUL4
M?=IEO^W3']:Z_(W]X&-9[[!@7]WE; "ZSPKV.?5V&_[Y_)=?_!R;(_(EU7J#
M/O_T^G[V^N*.=[?_^/_PA[$;[-Z.PK4]=1KCMX!M=#J]*<T\Y8I]U-B8MZ+$
M)C1P40(P)A[!#O9A8X)92P*DV#=-Y*.-CS%O]TDSV]V+D3"0HREQM8R<3 WZ
MM6Y=\OZ+/NGU\:871>Z5:_N) V,<.Y$7PA!%/@@[0SX))2>#"@:,/_7-F:[U
MB^4LN>F?"FUBDS[#?,GE20U19ZM9TTK%:SX&!&,$><N0C3$.E-H>I!$KXJL
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M6BN+QE:MYUZJEEJB%J9T&6(SQH$WEZ0EN1 5FS_SHMS56WN:[3HKWO@X\$(
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M9<UNOHIN^9;JNSS;D.?Z%%FZWA_2[9]-FO4<I?OL3(GMR/4@M&-($;))@!R
M@PX2!4DHIX=&H4R9KJZ/B$^2U'^UTM?ONZJ&F@V;F+@N)EYRJGL"VSKBMKX^
M6R?(K0ZZQ;'/KL5CJ!X0Z4DBN SUGL;5<H8W1/8B@'2;_S/;_)'F!3\M];$X
M 7F>: =A@'$ "(81  GR?>!V"!+J2!9H=5HVKN:?=N4ZRS95<[+E\2P)5E5M
MK>2+B?1<K,MI<H?2XC"M7][7!S]+WJ#XJ-5S:[ $DP.2:R(>RU!8(YZ]NFW
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MW^PY6:0,DS2B'@UMWPE(3!EIKT,+&8L2WP==WJW>C&%A;9&)O<W; 1NJ.G#
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M=6TK#0(<.@'&CI,.[3.,(>*@KU7#RM&]YM+=^;U"=^46U0]%):[]J67?Z#/
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MMT7)O[O<YEF5L[S][R)(,?,3*[0HM6-/G*+V+)IXMN-XH8L33].9$,76C>^
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M7'_\\/>^!I%&#B,IIK$CWD+W<$CI(*HTP-*2!_Q<TS74#@U@:$.)D9 \@YP
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MM?$W Z'79TMIHH<!\W>VVQ:;^Q>SB'8)8L&2.+6H&X0I)HF/$]]FK&_02QQ
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MVG$<H6_1*(X8\VW?LP/'MUBO=@&FB=2%@>9:-ZQ-'39QZ?;W'AVJ!W@PB3+
MO9QZ799VF+ )K*@!BP[17J$#5PR(T<W[KC B?&!&SVBB.>_,0RX-VE=.U<_5
M[FSB,\G;8M.T&9?-Z>]F=6E3%9SRYML?B^RV6!?UL[AM:K?=\I\O(C=@EBNN
M+HE=.W4=UPG='E,08P(KRYG%8KPHM\>*EH=@47F[+NZ;+X$J;-@Y<HH\'Z_
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M^5?_\6_]=_C_$_6/__BW_P=02P,$%     @ 6H>52+4@N)03D   F2$' !4
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MMS&5NWE!)J'F"@(?3 &M*5+*&;8!CA#9-KYN@ YE:D:?1#^]KKZFF 0>%M'
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MGHG@^VHAJ2,*:1@,04E,)90%+5-$#C .:T"+5@>*2,>NB,IFG//:E6IGFTR
M8$4*&B12,<V;0XC@4CQK^/E<03Y.N=N9<C2>;98E]_ZC^:*^N/U+T?.G,L")
MQY BHA13@'$D=.4P((K/9_GI0#-%5S"VT:YZ?_'IX_MW_[E?N\^?RJ27R"I/
MM$%&.4F)B#F6-S36_'S2\W>LW:-@;*/=3\7#:+)XB M:OM@$_J[J)G\:+?*Y
M?O@2P!X'W3SL,!D.[R23,=L<(08Q137V! =3O!0*>-1[_.V/9$CTKIY>.;?3
MBFC331:^.<(5I#&+K+!6$,)=*5@\4W[S*TZ?RF[%IU; M]KG+;Z.X\N_%&NO
M[.,TC&QUE^'=-/ZN&E'-UN]AW608.@"(Q=2 @)I% MEJ\870O?WBH/VJNT@&
M??O-EO68X@B>CFC]NP_%;'&K[O+9^'+4D&%'=9IA30P36ACFL+4$2DQ(M26N
MV=O/+Y*.;RD5T0_[['B67RXZX]W6[C+D#+, .:U4&*.Q\>1E(Z@26K5DW( V
M?8;$N"Y4T!G7-C#$-%'EZ.:+V?CK,@SM&-(=T&_F"4+46NV%,HYY;K@N7:C@
M[N*6%0@'Y"F<F'W]Z2+%W>(R7.MO>7$S&]W?AGEZTC0'Z\LV64"3(^ZUY(P
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M<1G61%F*;1%.%8.;CCZM]?YR/[P'>%-,.M]&XTFTGGVQ2N;T.;]<SL)\FY?
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M*Z4>0L6=G63!,")">86Y 8)K086H !#A[V=T9'Q*#G:E@%,P<+4[$ 2X6D:
M\MI*A<TZR 0F,OANUCMG)#74 %]BZSV1+2MT')ZH^*SGOBZ@3\BY8"T\M6U7
MH]^"4P/R->PI(X!S+FE,A>$)T)H[)$HH8DV,OC=XSGO^ZT<+@]K%Z63W)M,H
MEE_B'FJDG8HSOZD  )"TI.$ 4](D)&%O\)^.?YLKGMWL(N[I+*P0W&+-B8*8
M"$,M<[@"A&I\3M5+4NXB=@=YXEW$=_/Y,B9K^'B]"NZ>_S:]BC/Y98 MFA73
MJ^TQW]'<G5=)4587B3_>QU\TW6OL_+T9,M"$N40! S #GE$H=04S$"V9/<C
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M]A!FY]KB,TW:9U@PPR$UL9:\ M8B D@IMK.TI5M]<*#D_6H:""R8+=X>S_I
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M*I@Z9(KWH:P3<_LB_F"55'$=:UD$^/+%>+9:/3>'AJNC[<[F]B/>F&&)G4,
M*T0A5(Y:RBJE(M-VFZ;MO8,?]CM(I\(3?QUA*<O'-U.S#-287CY\F069 JAK
MV5?_-EF3J:N/H_T+,T*Y!Y)2*;1&5D "8&7#:D!2I;?XT=>(9!H<B&][I..:
M:6 9Q1X9YJC27A-F164)0MDR]_?A]RAZ/TT<,FE;:B/%[OSK 3=@WIY6&6 !
M-P@4E5@$\!31IC+/K.(M4^<-,"?&J0G7G1).R[,CJV,>V7.F#--">.V%] X:
M2+0L/TFFE&UYT:SYR=$/9/.F5=5I6=UQ#=B.WY11XY6%A K%-<$<!<=9EU!:
M05L&?0RPT.: .9] <:<]@!W F>MZ"-6@FF6OWM8BLV&^(40B8P%PV&',R2K-
M'C2(.%E[%;X?\3[EW_+ILM$UKY>/9E(KK"%CQF'/L. 4<K(1B!J*6CJT@]S7
M/UJG1:=8)EB9X@G!?#/,OQ7%U7Q_ML5MCV<X&"<ZN,N.0XZ$-LHBO!&*>4I3
M$:3_H_;VZGQ9VN1X&/=RX^MX_'6E<8 W^HX_J<8?)1M-%V-C$8C+WN@^7R[&
ME_>SXF8VNML68W%(\PP1+H/CRF+>9"<L5<C!C2 <<=&R./<@3TF.9D2/P*;:
MF'I*YOVSQ[;',R4$@EQ1+ZD0&EFJUW=)HE"6RI:SQR!O]'0V?W0 9 )VE.(V
M,#8R:90V3GL:R\UCY8FEIJ(VL;W7G$GF9W3&@9;0)?%VYXMYS$ZTKE[3Q.C<
MU22#(IA<D$'L@')*8T,=+84+LK7,<#;(M:1KX[,C3!,1YN/URA#Z7#Q"M(,G
M3Y[,O E^+O646 < 8U:&#Z@411+7^S7\A/0X7IU;^-$>RR3KQSP/KXG1YC9,
M=I-BE>IL([_[OMD4*9/PO9NN;K'.YU&NO4M.ZUXS"P@3'',K/'?(.:*]*"&"
M0I[3;-0YW=+AGL)MSE>[;7_+I\%*G\12J%=WX^DX0A3#DNJK[S7K()/,,(VD
M"5^B!-XA!*TJ!3<.G%,%R,X)UPO$";CUM*INW!M=C*8WXZ^3^HR)^QMF85+'
M!'E$$6 (8DRXK;Q'+_4Y!:9TSJ5.H4VS="YFR\N8S'MZ8VY'LYL:-^SUXUF\
MPN^,!\1I:AV.\<&Z%$H#=SZ9-?M8ZHZ%,P%'_&@\6UW6^S4?S9?KH,%_CA>W
MOTV+K_-\MJJV]VYZOUQ5WUL5\EA7 /\4 \JC9'HT'\_+XE8/?QN-I_&P;'U:
M%5=P-YI-PV/[B)=L#!GE5!&I33!EJ5 40FQ09=T:UW*#89 9.COG\U"U=(*]
MC /V,#*EK> 6*<$=%#[\FV$EW,);TC+":8#9.'MQ38^ ,L7.=UE$J-'5U"U/
M1YN! D&DHIA1CI 'DE0B&=WRE.3PTHN]LZ/K?:WCP4R1D*J8%L_'6>\3[FR3
M8<4T)5ARCZ1E2CJE7"D>U;IE-:9!FNY=LZ4K4!-PYDGP>H#%%-,PYF48]H;P
MQ72N\^MBEC^I[?CK>%K$>CUEV$^8,Y_W$E,T+!Y^S1>W,:U13%E\5Y,3*.$H
M,@]E4"/4C"$B)?&$&E^J@%G3\LKH (/.NV;U<)64[#L)0FV^Y,U-IUI.OVJ1
M*>)$\-0I@2Y\\HX[0:HI0"#5<DODX!CTMSBO=@-I\EGUV/EPUT>"%&4&*2RE
M8X!S#)17CP:(Z3WS?MK:LCW.9=T G(!7%[,B\+W&\']\*#,((L^X\A0X!X/E
M067EPE@D6S)D@)'47?.C-88IS/RG27&.#-T_N*_, "T<#U:K)AA"A+WD9<2/
MD RTO+,GA[=#V[E3T#/4J9G7E%695M1K H47!@$E):8,5+8<!VWC)<#YST+'
MX)B #N4.ZD4^6^65;Q!SM:M)9L/4ZKE"5%&J UX*V7(35AC9-M$K'&143=<T
MZ0C4$S F[M%?'D"7U?.99$Y( 34RQ@D>I>*B6I&Y:<N5(5+E>-76<*4-HB<@
MBAU/EHN]-6QWM,B(=A)+%(3 B",GB:C">(369Y4^J7>RM,,T 5W^F8]O;L/(
M5(!Y=)-_6-Y]S6=E$9^/R\5\,9JN(KWJ5ZA#N\HHDXBI,%4;0 *\U- J!%YP
MW#:*' Z285VO7#V#/2#FU:UT!_63 6Z$1P!A8+1#RA+*8+4Q 7#+4]Y!KH#]
M4:0E%]MHX'1$W$S9KZ0XG(J[>LH0%  SI*!@2""IJ2;5:L  3)5;MO\=@5-3
ML2,-]'KO_C%-XKMI#$A[MM.=\G+]UH&HZ55,V/BLL(\=SR\G10PQ:F ='-%K
MYHR#W##-D#/ <8)(S TIG9)>6BSK]D$& ].7H$ =1O-[MSA5W68($,@%H3$G
ML[ ^X.4KH"ASY[2Z)>%3<3+=I)]J;+X8C2=_SCCK:Y[&4BL45-P[(JW30$KM
MM%1&&H%K]^I[#@%^FE)7CR:Q[NKGVSQ?O(_C"'S0#X\/Q&B#*-*7,%+]L)'=
MYO/QS73U[)>XD=XDYK?SEV;4$N,PI(+2X$ISXFQ8?S<@(V5270?LW_Q)PL1=
M4<"GUEL""][F7Q>/R*KOXWU'+*\?SA"&!"((H-6 <$&U#>O!1B J8:IELW\B
M#H$4K];4(]61G%\?1G>Y+>Y&XVECECTVR;@0 C )J39 QZ3]P)8X68YXRWLZ
M ^3:,8K=RY'68+9)PO,YV$[%[$.QR.=?_B@NBG%X_WB:7^2S6-K<+O,O?X0_
M'];__#6/[N865K3M*J-22"<9Y-Y[%<;&A;:E@![XECL$@V=+&Q472:%.<9EE
MDPR[9CU[^ECF.?5(4(4M#%Z-#4:#1J40F+>]IC# ':4!KF1'**(QF^;!C;LI
MOOURN7G7FDWEO[UD4OGS3$TFF]%%(W/7VK7O\9C-RE.!(=/>,DHY-E:4 DE)
MVA[6#(]9[=18= YAWYQPOWW:QX'PZ\Q)X<,W$"9$P8$$PGN@JP$KW_(BRZ"V
MD[I1V$OM'PY>W]HV?_?[M!U^G2D%.,3"QIOQ@A+$F3!AP!IR)I7V+</K![1V
M]*/KPZ'K7=?*[M6ULIGVC")"+)82,PZI8QR4TFJ#6]J5@\I4TI.V#P8OV:6)
M*KB@-'UJ#,<]K3(NB0+ $ >L<\A+KP4N1:2 MMP1.?RZZX]H1W:GE]-1KW9_
M9&^[+$AH!+)4$6\-(4("ZDHQG0;G8VQVHNMF_&D%;8KD7#$QZLZ=DRU/90S$
MLS,)" GS+@;0&V@V(CAG_?D4B^Y(D]O26;>",F6FALU%Q5IB;&^0@7C[0TD!
ME164DWC@RJ-%IC$-?\J6VZP#,F;[Y4@GJ*:@2TRMO#-I0#UY&C3/B*,,>BN)
M9''O46K-RW7<(:Q:3C<#M(5ZHE+W&"<Y\MER9%NF0JILOD_YNBSA_'9\7WOL
MV*;#3#C#-'>4!Q=3>6,0]=%1L8 !3!%H2;[#,VW_B(9X$I4EX/*6@=;:YSO;
M9(0A*:TG2@G,O!2:\QB08&5PI3ENF^1T@-97W^HO^D&\S2FG&<UOKR?%'_/9
M.DW]_H/,[4]G-E@ EA!@J""*.\VL<&O!&> &G$]AF0XT570-YU%:KY;F?)/!
MK:'^=[3+L$(6&*X@AXH#1+%1T7,-'X;WQ+KS.87LBPG= 'LB,^G3>/Y["V.H
M;)8%?((UR+$B !@&G:6<E;8@]+3E C/ 3+9OQ.1IJ9BD['N*2H/8K-W-,@$T
M]$ : 21CA!!#>!EOZ20"J<X\3V/>'*[JG?PY&MH$_-E4G7??+V]'8:XMAUR[
M;;"W74P^8@'E-KC*3B,(C5?5GAIT*%6$7]I+&,>H^V7D<H?H)CD!62>=^31:
MY)__&-W7LF=[@PPH&3XSPA1GBC@-#8057%CXEKD9!F@T]4*:3D!-P)9MRWN-
ML;2K2<80 IAS#9A&Q/I@91)<8:502T/IX'R(/Z2AU)%23L2X6A-I=Z.,A^5?
M X>#<XJQ=3CXIF6<K%/XC (!CU=Q \ZT C75P<HZ;&:Q+IO2[#!E2Y/,81J^
M+*&E!+&4!D8(EB<'SC)TWHPY5,';3D^.!S458Y[D &W&EU<-,N^<M$) 0+01
M4!E. =\(YA%DYY,4H2^V' MI JZHR\O9,BAB4V-DW"  9%>3S'ND.0:>ALF8
M*DVY1V6(MM>:M<S4.L#CV1[XTA&H"0_ZUX&8BT.84]<T$Y!2IZ@TU#$'%3,8
M^E)8QT#+.I$#/&/M:\;I#MQTIZ%//($:_VM[@XQ"J*S44J,PLS+OH"T14X )
MGZQ>T(_H?76BDI-PK>G!^ZLF&09*"<:<BULBDBA43<D*6L3/YRKHL<JMY4HK
M0),<9ZR'F%^I^6;4CUOSM<M<@]891HQX"AB3GDJ!C,:.ER(+U[8B\B"WIH]7
M^ZNCC:[Q34"IL#)?5>.NI="6IS,EJ--<*0L U<&O](J04B1D2,OSL &Z8YT3
MYG@T$Q#D4SQBJ3& JF<R*I63@<>0@? /P0PU6#N#G*=A[6X;C7AX58P?T>9I
MJX54)*J=79X\E4&*M6$0:(D(E!0ZJ/5&!.MMVUH8 S1F6FAMF]Y;P99 \[^.
MI^.[Y5VM[I\]EP5W$(?_$\\4\X H"N+5:(.!":*%B?&\M'^H[HKNH$O!@-'W
M9@QX^EQF,/<.4,DE)Q9*#<*:&,0@DG$(A#R?",%.&' $=$FCL.;5LOE^/,W?
M+?*[9D& 6]IEA&E%G=<$"^\MU5H 65I*@-&6Q28'6"UI@*9&EYI)2L#5"5DU
MY _YXJ TH3M;9X#AL&IK3#VAU%JDI<.ER%AQFVC!2AO2=93N=S*J*Y"3\JH:
M[\?K%Y(T(M;NYAG60'NJN5'8>.&0A@A60CM]CK=I.F# 3G9UAO3IZ54>I3RT
MIUC518:XUAY0ICGA/)B*W(ARWP$9=48W,DY(L[9HM[FZL_5N6LPUOAQ-]JQY
MC=MF4#.(U_?6M YNAL!EC%,0 <E4T:AO;\7K"^*D$]*G/.Y\!I/RU]%B&<N0
MPT:3T.MFF8Z5C>(U-F*DQX(B)'GT>;3RG#!^#B<./6A\Y\1S-,*-:53F'ANO
MHHDBB?#F[Y$^^ E]UC]],L@/1517D/NN6$ZW34,U+3+F$'<*.XF4X,HS*Q4H
M<9+ OOW5JC_*= MMFZ7IM^DL'TW&_YU?E7>E\_G'Z>921YE<\\F<&U9FG5^'
M7W\9?=^U9!W39R:@< PCI#FPRNM5,%PI<L"B99F!0>6ZZX]/J>%/MV/Y:BK]
M>+U;HGWK7ZO^,F>5)@1A&]1,HZF(; 6+XZ:EXW=PT-G;9&5*Z$^=;.93?CD9
MS>?CZW%^Y0.VZO)R>;><Q$/EC^;=N^FBV"34N;[.8R&1_**8159\:+@YT>TK
M,T0PEI8JR1T#SA-#$"O!M4\+6K[5V]LIS;V3ZF8 Q"]NIG'5>3==R_1NFK^0
M2DVOUH:-^WXY65ZM(:E$G^;SH)1Y3*1PW-?0Z3@R!XVA-%89M!H&?7A,*AN,
M8M#R:./@>WMO>^H?LLJ2?#E/ZV4\N_T:\[==;4I=C&[VU?9JWDE&*9'&,P$,
M8SY(;PVMU"2A:AE].J!HYQ2,[0GM!'0K/ZP]5O\3Q(+/N3=:<M^I<,=OR@BV
MVJM86)@R8;#@#M,22NS:)HL].&3M;4^VIU7*([]3U<)<'9__60IS7:$>(>2]
M, )P9KV*]5')NFXIU0C@NAW<?F#Z?'F;7RTG^<?KY_M;\X_73\H[/XI]4<S'
MJPQ=*\TVJ</;T1LR[F,U:>@ \Y9(;0..OH3/2M_2V!O4!GA2EKU,9GT2-258
M<1\%VVOIOIM6^7H_7OOQ=#2]'(\FP92X+F9W,83H,*YW]*Z, D^CDXFPQ]!;
M)A2KU D8;GDY;N#'AZ=@_6D4=GK^[Q!M\W57Y[@=L/_0-V482<4A83$RUR!H
M+7=Z V4T=5JFNQC4><. N=^SNOJU18O+=;'4Z96;+L:+AW?3U9<:^SK,&-T5
M-K+G!;5A(PW:9@8" B4'BG(>7%AAO%F#*3C!"M;EOFMR('V5C^,L0N)?HHCD
MR>01?I2M!_<IOQG',:UKB6Z1:=>CF;!&62Z]@!I9([4!C)4B.,7;%X/NP^GK
M5"=%I\@<'&G03+$FCY'/DW>!_=__GWQ;<-S.9S,C$"5>8RBI8Y J >RC -*T
M#$9!;U&UQT'3N6XW&8Y\6"9&D_\W'\W<],J&:7R'>G<]GEGB;:"I=,YI'/ZG
MM9:E&!+!EO?*\-O2<$?H]/0!^_$DGYDPG)MBMO_S??9D1K1D%&F/#4%:44&=
MJ!@*%6MY:8R\+=4>#TSG6BUEC5=1=JCSZ2,9)U813ADD!D-,L2 >/ X7M3Q)
MH&]+CT<@TIL"@U\X+J[V3[Q;G\V(!% :J1#7-A@%0 8A-@)09-I>CV%O4Z7'
M0-.;;A_7 A]^LNW\9<_3&9"QW@!WWB+N4/@_QZ(4 E+:TF[B;U._QX'3LX;7
MY&NNXR?/9Q@PBX+E)ZS6X0]KN%>E(#SXR*U/RMZNEMO#T[F>51C5U6IDD]'-
M#MT^>R933C@ *"',6  X=H"5UA[%SK=,C"C?ECZ/@:0O#[:XNRNFGQ?%Y>^?
M;P,T\R<'%?O=V3T-,R(D%QI;IZ0SC'$3_+=2-.M%VW,F\+;4W3E0O>[WN=$L
M1JW.PS2S&N<I#IQ?CJ'!:?*N)IFQ#D(EB,;"2:<1H.4AFO,X('V2H^*7HVUR
M)+"S36:],<P1Y"PR3"$A%3.EB$;IEO?B!GF<>[R:BWY03?I-VGPQ&D].$@O2
MY:?)@(JUR!34QL9X=X8%0(IKS*6QN#;A2M]G?"K,VU?CR3(>YGS.+V,0_SB?
M/XW,#'/Z_7*MTH_7KY@4#_,;'?%U\:*,244)UX 0H$58H&)%W V8UJLS*D]_
M/)UV'MZ=0!$)3JV/E$H_;.^@)D%?CV_-A#: >"-5P-E*A)CUK(08$ICJ F__
M7#\5-5^F9!^,+D_VN<3#QMH\R75-,QNL$L4M!LX1P0BC3*M2V/"?5&78^B?N
M(!C3B,6MM=/F'O+*_?MXOPKVBW[FW?VD>,CSU8\OEK/+V]$\OYB,IOMKW1[6
M2\8E!)0C*I AP"+M@*^^>FY4RYOK@W0/NE-QD0KO-C3Z,K[+_Y'/%_G5I_#/
MV?@R_&TUFM^FXSU%;AJWS6QPFK#  $B(,.28(HNJ3TS)EA<4!ADJV0]E>D"Y
M#5%^'<U^SQ=-J;']Z2SXTH@2J8"-M2VE#[.M+H<I:-MT8(.,'>R'#)W@.GQ'
MX7V#_)I=O2+S.H"G#.060$ICZ)>J%"&-;VE)#2@=RWFY &T5UV;2TZ/Y^#*L
MTS8.-[\Z8,?JD.:9$XQ1+)'"V,5L(@P140J"!$U5^^1TTV*?RB]Z5TB"^?1#
MOEA?]([W'AILE&Y]/L,>6V>E55;*8"UH!T6%F:;B''C6CYI?EK[H -W4I&E*
MEDP"1ZB@+)J-L8Z'!-7>9S!+S#F0I",][F/%@3 F8,,_\_'-;;RQ') =W>0?
MEM%R_'C]Z@2YP>QR:%>90U!JY#W%RD&,--.L@A09V_)$85!.8)*)IV?@!\3"
M%9(=4'#53V9,,!2T-R+ P 1VWKL*!L?U^9QH]4>0EDQL@W^*_#*O]X,;I!G8
MV2CCCAN$H88!,A\$53ZFH%P+:)AK&2(\J DN.<4Z@SL!G\+"/UM=RAQ--M%9
M*SC48C$;?PW>3+R,7ZS/(T;S_.IB]+"*#YO-8OV4NIPQQW>>$15\(H$Q,5P[
MR6&LD%'YZA"ERL.?Y-)N![0I3JR 4RW$&[OE];=\]5_+=<WU0Y?D^AXS[5$P
ME9U ,8$JPT(XXS;0N!B#D6K_K0CJ?6O,3(/YZ>S"7:(<;AGNZBDC #H L0IN
MF3&280-%>0;LA/:I\B?W3[]3VX8=:2!I>.3I,F5U&1T)-9<( B<QT!H#C+C@
MJ_A3S;R$L"ZJM^_HR%<A&\^]Z!8YK0[J,5,!&JV9$4H9"R+IA2_A40"?TX[7
M\139&?'8)^;]?O/_6CXI0Y3T&U^]N<F7_>S!3!(4:S13[N/:K1&S=GW'0W-,
MC3_-1835H?1M,0GDGZ_'^Z%8Y(^9<1I]P4W[R+S3C J(D'""2:,%)Z"$0%#7
MTF@<YC?;4ODOO]2>L$WP;9[RDD+;3]1P([@C2$OHC("$J(U-HX$UY-!,03O.
MIV,BZ.GE>#(NCTO7@WCFEWXHIJMRFL5DLDI3NL[+NV^_JZNN,\(QY% 0X(0!
MP;T!Q. -"%! T_**YIOX2)NJOS@IY D<NU_'TV*VN@*Y'NJ>3^CEHYF!+F;N
M!UIQ  R%0EM8"D,@2Y5<]'YU3?KS8C1;]'=TE%3YKVMP'P-\\OB'EZ!<O@:E
M<6Q$@[XRR0RU'""-' 4B0@I<"8<EK'UBK>',8R?G8-]:24'2K>-<;1Z/YGF,
M;=++^3B67C#%W=?Q]%GBPVU$;=-?9JC46$L$A&$J_,=1!Y#2-&*$G6A)UL/W
ML_HM97!2JB;02YMHQ>?C&F_&-=Z,*]C5JS^+Q>WNN.T#NLBD@IYKB8T#'DI*
M,"^/-#34TK1TP9J7^))KHDWSFYB(_\OY\:UGC0S<^*/.0B-8^&28(!81J(4O
MA?&B;6;Y@RMMW9?YKLZ+6QW!GL[YW]3Z>$M[ (Z!>".#6Z$X8QQJPC"6D$E!
MN<#F1$D)7FT#K;- E<N7W<PH!^W2;>\B"X99X*74QFBA @NUMZ $()8F/%__
MO['J:S?I.H%VL,'&@F,"E?(Q094FP$M(7"F&=2I5'?8$J2:ZX<<QZ"68JT]X
M7-IRC@9>"62H$LQZ@C3'C*[WNBU&7A^<T?VX?=HM7D5]19]N7Q FED@AZ*D3
M"DEN 7\$Q$G5\K[N6YBS&U.AQ9YMY\#W^C%7921^#6O-<O8\0#'E5UT-Y/&8
MJDF@[KYF6;Q!3Z1&RF,HK96J2F@*A/2Z+E0WG:!-#DSWMLLX<4A9H@*%8* 7
M [;,O R$96US40_R6^Y&Y45_Z*;_8$]X:MK'=VL]5  C[62PEA#A"A&M'708
M"@"0/*;V2@>"JOD\7]4&>C\>?0W+08SNW"CCZN/T4XSXG,78NNE56 UFY;_&
M&)EY77:WSMZ16:LIP%IQ@F6\,\L,826$DK=-F3O :S#=$&G7;)!8#PF<MTHT
M_5#]]>_C?!9>??OP/O^63VI2M#7K(!-"<(DU5-Z+ #56U+@*>ITLTBXA =-Q
M91=;N]1(2BH^7<I>2U";0.V@?C)K(("<:\"E<#%XPU-4PL T2.7U)"1F1[38
MQ;H>4$])OG?3^^5BOL(#[LQTU*!5IC2#D%NDC6"0$B/4(Y *\',*@>I)][L8
M=C38)^(3:L4G5"7ZDI91CK F824(XC%8+0<$J7.X27]Z/K4#^T1\PJWXA,M/
M!@@%#:"4:H TI4ZXZI-Q5K4L.S;(C&RGXU,[L-/:_4] \;/\7\M\>OG0W.C?
MU3I#B'$N@%%:,.8)(8:#4F2#1<O;=0,\X!F4Q=^1.DYD[E=#;F7DOVB=04>8
MT,AK%DM]*H$YJSYD9\Q9FO;'Z[^!77\<T*=R):L/L/FRN:=Y1CDDA&(1IG(9
M[[ QI:LIW=JSNCO8*0>:^(W'89UV^5S-^F8RFM<5,]C9)H-6&>6X]%XA+J"(
MA3)+\9!L6P%V0(&[@UPJCU)"2HZMP=H"SPJ/WZ;%UWD^^Q9A65F>SP^FG\K9
M?%7M^)698#Y,"<Q(BHC$FALIRMD!"L?/)PU7!_S:?_AP*ITD(+PI9O?%;+3(
M;?YU\9@JI7:YWMLN QH!8C'T!GO''1.<V$I,:U-=)4NZ3I^,*D5_FDE P-\^
M?YFM,'L("\_?BJ"R:31':@FXMUT&E8K7J)&TU!GD@[R\7*H@0VUS/ ][XVXH
M!.Q2,PD(N));CRY_SZ\.F/_VM,HHTI!IC!PQE 7KG#/"2Q$1;QN(/>Q=OJ&0
MKSN]I+<V6YGF[QL4;^CT/1EV@B! /1)(2 2T9!"6,"J*6F[Q-+^)]B-Z3B=0
MW #YOY+GD,BV-OUF3 !."#0*">,1PRA82"5,!.)S*KMU(GX=R?)CU)7*H'@\
MZGH,BFO W-JV&4/0("JU,L YSC7'N +9^MHK%.?,SI:\V&9!=*B"%$[\:'X;
MT(E_Q!L1WT:39X>MCR+L<^B;]I'!8*=+A1R2PBCA%#2T="&9L>B<@FPZY,)+
M+[TGN%/,;]]&XTDT:WPQ^QS&_6AG[YO8=C8*QI&E5C"+#::>Q!+P$E0":I\J
MR"9!;=7>V-09N@GH\V[Z+5_G13YPAMK?,.,40RB%8BZ(*YWD0=924"Y]2[=D
M@ <Z_=&H4X13^ _%+!_?3$U8_N.IZ"IE0Y!_!=!AW#JPITQ02HG#0F/LL8"
M>&@J*%3;$CL'^\!O>PWL%_0V.7UB,>"-O,7,;C012^3ET_E*6<U8U;JOS"HI
MG-7 "RZ8@$XI78DH9=N2SP>G87F;O$H%^RE]R#:^8X88<M1B;9CE5/@PBQM6
MV0 "M3R.8S\&J[J&-P%[GKC)[;8AFG40# (#D(60 QH&8BP!U88/PU:I\SUE
M2[07T8L>3F>8S4MY'CJQSO9VEP6OQRM!+.".*J9CGHD2\_C)GU.L8-<T:6:G
M=0E_ DYNR1(9)0G?:D X_&T^#@K>Y /8R+6'DBUZRP0(ZXX*_C>DF%-",1*J
MA$2ZMM&K ]SHZ)F/_6-_\C6Z]=J< 8&\Q@@@36Q8=3111I2".F1YJFV0W@LL
M]4RR3F$^63J2%TE(WVX^$D.8DP[!8*YKH  $2J[3OT@,@:[-3]J/H#'"[MTT
MC' 9,:_++++EZ8PS3 2F7L'P"@L9-8R58D&I4YTUGSA'2&/EOJQ9>C2B"2;Z
MYX.LN:_P^N&,>$2(A3%F)'@-R@(,:260HRWO] V0(D=I<R\S6N"8G!@?1G=Y
M[5V!74TR1@!SU!G I8IQ1E!(40JG/&WIB0^>)(<I=B]'6H/99I\YUH*:7XP>
MUAD+?1C U?ARM#/HM+9-9@WCR@,;S%HJ).7 6E4.V=<G/WY+SN[Q:BOZ0;4-
M$3X'8ZZ8K0;Q>?S]HAA/%RZ6\_R<?\NG?OPMO\AGET%,N\R__!'^?%C]-L^G
M^[ER9+<9#ZZZ15*&A3BLR,8%TYE7"[+D+9V(06[L=4NGM, ?R;@O?Q2K$7X(
MWO3+<:W_V9AE3;O*>/B/@=YS([U4%%L-;"D@XKAE&8L!GM+WQJN>H#Z62^'!
M?#6NP/LPQ&U<+_]9-*?5X;UF7 @8;$6"K(48*T.IEJ78C,"62^$ P]/[8UCO
MJ!])-E\L9ZOQ_7_Y;,_HXF\:4^W@/C.!K,.88HF0X1QZZD$U5S/8]H#AX+/Z
M-TRTOC$_EF9Q1'%X<<I],3)?S XE6//>,@@)!TPR((+]J4T0TU9B"NE:AM@>
M?&#_EJG5&]K)=P;>-[CAM:-%!J1&'DC'+5/42X#%X_Z)D:8N_?K;.7+J;_.H
M+9@)>/+4>3WL$*FF94:"5-!1!J05V$JNL:]L1VA\R[*&;V _H86V7]4K[!+:
MQ"QJ2)E, 608D=Q82P%#F&%4[HP@)7FJ>>6M\^- '),O/15_&R\]58M,,60-
M]0R$OP!-(#88EJ(%MS25I_\6*=(-I"<[='YQ&/MV#YTEA,!PBX/M()RW-L;N
MK6N.6.:(K#/#^Q'T\^5M?K6<Y!^ORS@8=?FOY7@^CFJ<ZX<G_[8C*J;NH+JC
M-V0P0 8]-\@QJXC@X;]V Q]'"J>ZJGKBP^W&)'I9G/ D6DB;QZ^G-+A&<H%D
MO(N.+3%6$LIQ)3+!+8\O!DB\Y!QID03W,&6DY%]_27"IB_7EN#.(<TLXIMB5
M(A/Y@R7!;:S_-DEP#P+Z1-SJ.@FNCR>$FCK#J77.2 TT+(76$*6*]1A,$MRF
M'&B3!/<PK!-&L=?/[$VV#5OTEB%J R)$ XFLC3ZJI:4]PR5EYFRV%$^]N/:O
MG!_BUH54,7+"4!Z395#D-,>DA(1+DLH8O%]5%O^\&,T6O;*V5]9T<!'C,'6<
M:,G^YWAQ^RIGX?QYTL)/+[)@;02\6,XN;T?SO<E0^GIEYA23D @E'%7>4 C@
MYG@T*A*(EMOV@]R63<GS@>CK[7T,?PL&VOMB/G\WO9PLK_*K=U,WFDW#8PF_
MCMUCR#PS*B /+';.$@*\XZJ$'T#>\EY\\RUJN?Y<IOG-:)%??>G=HGG#WTQG
M6GQ[']'G?+&8/*\*W_]7\^2E&=3.*X?#XLP!=8YY BH/WM&VVQG-(^J>?R9_
M?B%=:^R'< ,@4-0#01'ET8\WE.!JJ56V[7'DP=%Z:S? 3<^'QOTKXV0'F5_R
M[XOE:/)\-&_W.#,JEW#"F, $.DR(Q71]9YD K33Y\SAS[SX.DL%:C_=2B1+&
MQ:KVUI7P*5][&OP&=_6/(E%/QYF':>$-W._57&-BD32:0JJ0X+@L4TH81?Q\
M3LF3,Z#^3O!AV+^Q.\$^+JQ 2>.]T\9Q BPKA3/&I"K"=)([P8T5V_1.\&%@
MGM%54"T((QQ!8!&4"GHJH2X%EPR<3Q6YXU7?Y470PV!_@Q=!-<?!_B>862Z@
M\Q!A@DH!7>LB20,\1NR-5SU!?387037EPDNKH+'Q @B/R3VK-8"HWG=WSX!A
MO:-^%A=!H360Q_++1!.J.-48^E)DY7F=7WT&-XZ/)5K?F+_9BZ!,<"8@D-0@
M)X1S5#/^**9N&>OUENX8'TVMWM#^(:*](-4!#LV =9"%65VP,EMVK)W(VT=[
MG><>0_\0)V#=*L7UN[O[T7@6/T9S.YK=["_NL[5!#/7!1CGA$!", ,/#1ZP=
M-98X1!TXGPV(7K6^+0W]L5B?*A(ZC#9@,G\WC;]9?V[YY>UT_*_EP?%2>_O*
M! -:&FDM@XQ"C@+,I?O,28#W;+S+E-3K6PW)]U??38."\OGBTVB1?U[$X(*-
MA3"Z:7[C=5\G6?""B.1,AJ\2\/"!&@)+ZX5#0%HNGP/T05/RL#?\AQD(\:&8
M7JY2[^\[^#VJWTQB;@'6P$H3,QLBC 0N8>*&M'0S!EG.*B514RHE?9#$RE*>
M/Q_%VPV.X(2%]<DIJHA@4AC"G5F%I"CL@7-U:>/Z#HYH57]FI:$8Q*+#\'YO
M%"+1P7LR@[S'@:4&>A:<="JXPB640H!4&:N37E [BE([0R72:R/!$O@HGAG-
M9@]AV"L1HW1NOAC?Q26\$GS^\?KY<M^&U!V\)\-04*R)E59YZI&!9).9-<!H
M5%MG=I!7*WHF=7IMI'1W&WR@KP)\G\?W-N%V'Z_+B(?0>@ <A]8X*"#SM 25
M2]WR]M @,_;T0O$!**5?*S#8L&&(H\F3[_(4YM^3,L5QEH@S2+#E8P1\6?6Z
M@3'8O)/,.*R0I]@Q#8DV%F.'5BK02@0EU(6.]P-"K!S_HGI\D.'7T>SW?!%)
M]2A'D_FD16\9!4A9Y+SGC@L #"4<E+ 025L>>P[2S.N#+$5J#22?&S91]#_"
M% &Q0<(ZZ 7@1I)@8)O-<32@"JFZI;-_0WM^&X;_@E_- ^?WM \DA$!@QJ25
MTAD2]T9H*3HS\'P"!/N@PQXCN2O$$QB_C\A\":^L"8%__7 6CU1C(F_!"3(^
M_%<P4PH4XXC.AD(=Z[?H&-GD5#'!Z[LI9N/_7NFN-CU2?>/,(^(4@<%&)D@C
MZJVQU9>G/4R5N#CE;'2XLO?RI@-8$_#(%'=W^2P:'!>C^WQ62YVMSV=*QSAK
MZA1FF%F /$2\%,L1G2I16UH3]G@EOS1=.\ V 64^Y?>;Q!OJ9I:OSS!J>;.[
M469XD! #'.^R:J:X0]*5 L;-J#/:$>R1/)T!G(!!OQ;3_&'MDOGE]*J>/=L;
M9,1C0H0#!ENL!,4<4%(*9GS;-#T#C KHD3>=0)LHXN310ZAES+;',PXU%@!J
MY+$VGC AG"B% I:UO"(ZR./Y'AG3 ;0I#)NMCL'[!N&]-2TS@ T&1@!!*%!$
M6B58]6EH)UH&>0PP)JY?+ZM;F!,QZNFNXN+9 5R#?;!F'6222>P0D8QI 0SW
MQC%="FX-:ED39)#&=&<<V,*MSI$^.<5:4RM37",DH#%(.\V]X)14.$J0;&,H
M%:6Z5/U!S#H0Z%.=)+P8QID>)0!!/4+8>L:HQ5C&='8K54!E_,F/$M2WH(E5
M;:MB]GGT[%RJ\7%"31_9_]_>ES:YD2-9?M\_,[@/L[4UPUDF,Y6D+:EG=_8+
MC)49F>(TDY%#,E6E^?4+D SF248$&%=2/4=W214 X<\?' Z'PV$U \I9ZHQ5
M5GD&J0,5!$S1RRF)T@<MCAXI=(OZ$-OMV7^6J[0-V*<#O07/Z;.&ACT$0;61
M$ !I@48$(6\5KD37UEW.3:4>V/!R7]X+Y--@6VTMGL9]! Z\4(YHBICQ'G'E
M^'[?";4$X'+.*3KG0WN^94&><V7<E*O[<C7;%,]##6:7T'_Z@GB3MH%C!+TR
M$@E'$13IX<"#"!"P2]IB]:#7LE^X.V3,IW)Y#FE>-@_1G8>&16/NO8:*<HF-
MJ02QBND+.JH8AS=G(IY#G=_*".<R^8XM+4UMPZ!47.J-X%!9AE3< #HMJ\%C
M(3./12>9"-PS7;K&NBNB-#4P3=H&Q1U,H7@F/(*&*,UPM371@J',PJB3/)X8
M@2YGPIW#F-_+U>9V=EM$Z3YOOA>K[>TC/;OZ9W'=TM:T[RD8X34S""'-N0'$
M*JU0)9XC-)--K4O>7 ";>@>_-VXU-4]9G07B)9><Q@T&9]ZEY )'*R&58IE[
M+_8OAO6"_P!;_Y>0U)[2O]T@.&P0@5(P$2&4<=M*'V>/QRPS(XC_6L3J%.-!
MK[,>#ZDU.;YOU4^@%&,DG7#&2)8*?'+VB"I#0[WT=0D1RSZ!'Z):U]%!-SB7
MJF\<F$!I[QK]3:8DIA(1X \;%"4R2]A,,N;4$Q->5O#J&O-1299%KKCKI988
M)E,]/<F9<1H>]C# \Z$>Y1R"5%VJNS&36@(\KIFZNGJX>UBD @"_K<KU^A_+
M53%;S/\[_C'Z#[JX*5?%M]G?>5:L6=^!4.^LC6JP&L5IS;@T![CB+CMSTSG!
MY704-O:CA8F2-KU2V!=IG_4==-Q!P;@$(10GN:&>0J(/<YRK3-+F/E_Y*]'V
M'#V,2]N[N&-/$IARG>D7/NTA($X0P 1SJY1T5C -\4'TZ!@-%/K=E)O9X@()
M> ;68^7HO4C<N,P</>N85YIRAQ7ET$!MI=T57H@J9[7%H(:>]4F<WV>;+K:%
M;W<5G#,L5<FFAA#CF.12R@H0J 6^('^^#YHTM@B=P#_J"O1<@O3>[7SY>5G\
M1S%;'>HG=<#,MSL.A%D-*(J&%%FGF<5"Z0HH;^!0F:7C[CO/)5$F6SM1R52Y
M>[YCU;3S8)6C).[J4S%C!!@RB!ZL"E.Y!5<FF<PS;0Z?HY8)\5C=;(I5%.G;
M]U7Y</L]O8>2I%MW:8YK?R,@H3RAQDN,-4>$(&E)!1_VIO?-[*_,ZJZU\P[(
MW;6];O0[P3"/.;9".PF@9<@;[0^*%"3339YDIM2[(?DY&LI)@&DUWD;&N(MN
M ^'1[:(R+EX<4TT P^HPPR6$F5=@)IEVU3LU1U#(<$RLLYQ==1T@ ,((YC0'
M1"$!@#:X L#9W/<[)YFF-65&GJ.4=W@R[2"A1#C!J'98>YL*+A^F'0"953):
MYW"-&=$>;(%N"?8(;'I^R^/95-B6\6[!L;JN@B1.I 1N E+-",<E( =\D3&9
ME[O$OYC7EPK&.F)YX81>YA%+5+92-*XUE")/H'+ PJTJN#/2V+I(;3\@?%F5
M5T5QO?:1TXE0VPK=6[K^/)4S=@*1S!Z#I5@Q[+TR&FD X@3!MH*'$SW4@<ND
M2B0TIDPYA@Y&]86V^0M_/$FZR?..7G<3(")($X&LL0Q&8ZD)U14( O&AJHI-
M[.0OEXH]0C\=_J7LF4SW_(U^ K4(J2BZ!T0CH/BVY.,>!FA0YG-CDTR#F@X#
ML[ ?RV%*+V8\S!:_@MLDHT&PC%#%J8N>K.)B__( B/\A3-O,E".1H\_IFNK\
M]OMF5?Q('L#J4,1W=BCB>[][A;6\V6XH9ML'[(Z%BW+["YX)3QV)>T<!X^X
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MA\%P1>,RBG'<C@OF)?=:5X,CP&7>A'PG>L_44]DAH@.F3GUL4,'DU;>!*4R
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MI4WO.FY TMZC/9V.MPY>&H6B>P2) G'?8J1 \B"RR'WP<)+[Q'[HU!FV.>F
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MQ1918U?S_2MQ]XMB'W=2=^5JLX])U894WBYMTLE/!$")<1HXP!6E'"@&M*C
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M/"/L((R%['+N#?:FY6,EN'/P'6 EV=N9K]^+8O,QJ3-I[G1&S[$F 2NAE.+
MD52644,J.*R$X]AFUMF9(GDRE?KR%?1N@!R));7).,<;!281CI-)"Z:YP8Y
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M^O_Z'_\?4$L! A0#%     @ 6H>52#'G6.H)IP$  1\? !$
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M !4              ( ![RT# &)I:6(M,C Q-C S,S%?<')E+GAM;%!+!08
1    !@ & (H!   UO@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
